Unnamed: 0 stringlengths 3 8 | Date stringlengths 23 23 | Article_title stringlengths 1 250 | Stock_symbol stringlengths 1 5 | Url stringlengths 44 135 | Publisher stringclasses 1 value | Author stringclasses 1 value | Article stringlengths 1 343k | Lsa_summary stringlengths 3 53.9k | Luhn_summary stringlengths 1 53.9k | Textrank_summary stringlengths 1 53.9k | Lexrank_summary stringlengths 1 53.9k |
|---|---|---|---|---|---|---|---|---|---|---|---|
28100.0 | 2017-09-25 00:00:00 UTC | Here's Why These 3 Biotech Stocks Might Stop Rallying (Revised) | ABEO | https://www.nasdaq.com/articles/heres-why-these-3-biotech-stocks-might-stop-rallying-revised-2017-09-25 | nan | nan | Biotech stocks have bounced back strongly this year after a poor show last year despite challenges like rising competition, slowdown in growth of mature products and generic competition for certain key drugs. Strong clinical results, faster FDA approvals, success of new products and significant contributions from established drugs have led to the rally in the biotech sector.
The NASDAQ Biotechnology Index gained 24.6% so far this year. This is in sharp contrast to last year's performance when the index was down 22%.
However, despite the strong performance, investors are keen to know whether the rally will continue and what factors will drive the same.
These companies are likely to see continued demand for their products, given an accelerated increase in aging population and the proportionate increase in diseases.
Moreover, the FDA has approved far more drugs so far in 2017 than it did in the whole of 2016. Hence, a faster drug approval process along with strong pipelines, innovative treatments, impressive results, and increased health care spending should support further growth in the sector.
Though the momentum in the biotech sector is likely to continue, it's a good idea to avoid a few stocks that will possibly lose their momentum soon despite significant year-to-date gains.
3 Small Biotech Stocks to Avoid
Avoiding stocks that have represented significant share price gain could be a bit tricky. However, we have taken the help of the Zacks Stock Screener to identify stocks, which may stop rallying in the near term. To shortlist the stocks from the vast universe of biotech sector, we have picked stocks that carry a Zacks Rank #4 (Sell) or 5 (Strong Sell).
Moreover, we have also taken into consideration stocks that witnessed negative estimate revisions for the current year over the last 60 days as these are likely to plunge further and should be dumped.
Keryx Biopharmaceuticals Inc. KERX : This Boston-based biopharmaceutical company focuses on treating patients suffering from renal disease. The company's shares have risen 20.1% so far this year. However, it currently carries a Zacks Rank #4. Further, over the last 60 days, the loss per share estimates widened by 33% for 2017. Though the company's label expansion efforts for its only marketed drug, Auryxia bode well for growth, the company's sole dependence on the product for revenue is concerning.
Keryx Biopharmaceuticals, Inc. Price
Keryx Biopharmaceuticals, Inc. Price | Keryx Biopharmaceuticals, Inc. Quote
Juno Therapeutics, Inc. JUNO : This Washington-based biopharmaceutical company focuses on the development of immuno-oncology treatments. The company's shares have gained a significant 139.5% so far this year. Shares of the company mainly rose in September this year on the speculation that it will be acquired soon after the acquisition of Kite Pharma by Gilead. However, it currently carries a Zacks Rank #4 and has a VGM Score of D. Further, over the last 60 days, its loss per share estimates widened almost 3% for 2017.
Although Juno is among the major players in the field of T-cell-based immunotherapy, there are several other companies that are looking to develop and bring immunotherapy treatments to market. The CAR space has many companies including Novartis, Kite Pharma, bluebird bio, Intrexon, and Johnson & Johnson JNJ working on treatments. We note that Juno lags Kite Pharma and Novartis in the race to bring a CAR T product to the market. Hence, competition in the immunotherapy space may weigh heavily on the stock in the near term.
Juno Therapeutics, Inc. Price
Juno Therapeutics, Inc. Price | Juno Therapeutics, Inc. Quote
Abeona Therapeutics Inc. ABEO : This Delaware-based biopharmaceutical company focuses on developing gene therapies for life-threatening rare genetic diseases. The company's shares showed a significant gain of 245.3% so far this year. However, it currently carries a Zacks Rank #4 and has a VGM Score of F.
Further, over the last 60 days, its loss per share estimates widened by 24.5% for 2017. The company's lead gene therapies EB-101 and ABO-201 recently received breakthrough therapy and orphan drug designation, respectively from the FDA. Abeona's share significantly rose in July 2017 after the company announced that it has received guidance from the FDA to commence pivotal phase III for EB-101. However, many companies are working on bringing gene therapies to the market. Therefore, these candidates may face intense competition in the targeted space, if approved.
Abeona Therapeutics Inc. Price
Abeona Therapeutics Inc. Price | Abeona Therapeutics Inc. Quote
(We are reissuing this article to correct a mistake. The original article, issued on Sep 20, should no longer be relied upon.)
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Johnson & Johnson (JNJ): Free Stock Analysis Report
Abeona Therapeutics Inc. (ABEO): Free Stock Analysis Report
Juno Therapeutics, Inc. (JUNO): Free Stock Analysis Report
Keryx Biopharmaceuticals, Inc. (KERX): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abeona's share significantly rose in July 2017 after the company announced that it has received guidance from the FDA to commence pivotal phase III for EB-101. Juno Therapeutics, Inc. Price Juno Therapeutics, Inc. Price | Juno Therapeutics, Inc. Quote Abeona Therapeutics Inc. ABEO : This Delaware-based biopharmaceutical company focuses on developing gene therapies for life-threatening rare genetic diseases. Abeona Therapeutics Inc. Price Abeona Therapeutics Inc. Price | Abeona Therapeutics Inc. Quote (We are reissuing this article to correct a mistake. | Juno Therapeutics, Inc. Price Juno Therapeutics, Inc. Price | Juno Therapeutics, Inc. Quote Abeona Therapeutics Inc. ABEO : This Delaware-based biopharmaceutical company focuses on developing gene therapies for life-threatening rare genetic diseases. Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Abeona Therapeutics Inc. (ABEO): Free Stock Analysis Report Juno Therapeutics, Inc. (JUNO): Free Stock Analysis Report Keryx Biopharmaceuticals, Inc. (KERX): Free Stock Analysis Report To read this article on Zacks.com click here. Abeona's share significantly rose in July 2017 after the company announced that it has received guidance from the FDA to commence pivotal phase III for EB-101. | Juno Therapeutics, Inc. Price Juno Therapeutics, Inc. Price | Juno Therapeutics, Inc. Quote Abeona Therapeutics Inc. ABEO : This Delaware-based biopharmaceutical company focuses on developing gene therapies for life-threatening rare genetic diseases. Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Abeona Therapeutics Inc. (ABEO): Free Stock Analysis Report Juno Therapeutics, Inc. (JUNO): Free Stock Analysis Report Keryx Biopharmaceuticals, Inc. (KERX): Free Stock Analysis Report To read this article on Zacks.com click here. Abeona's share significantly rose in July 2017 after the company announced that it has received guidance from the FDA to commence pivotal phase III for EB-101. | Juno Therapeutics, Inc. Price Juno Therapeutics, Inc. Price | Juno Therapeutics, Inc. Quote Abeona Therapeutics Inc. ABEO : This Delaware-based biopharmaceutical company focuses on developing gene therapies for life-threatening rare genetic diseases. Abeona's share significantly rose in July 2017 after the company announced that it has received guidance from the FDA to commence pivotal phase III for EB-101. Abeona Therapeutics Inc. Price Abeona Therapeutics Inc. Price | Abeona Therapeutics Inc. Quote (We are reissuing this article to correct a mistake. |
28101.0 | 2017-09-20 00:00:00 UTC | Here's Why These 3 Biotech Stocks Might Stop Rallying | ABEO | https://www.nasdaq.com/articles/heres-why-these-3-biotech-stocks-might-stop-rallying-2017-09-20 | nan | nan | Biotech stocks bounced back strongly this year after a poor show last year despite challenges like rising competition, slowdown in growth of mature products and generic competition for certain key drugs. Strong clinical results, faster FDA approvals, success of new products and significant contributions from established drugs have led to the rally in the biotech sector.
The NASDAQ Biotechnology Index gained 24.6% so far this year. This is in sharp contrast to last year's performance when the index was down 22%.
However, despite the strong performance, investors are keen to know whether the rally will continue and what factors will drive the same.
These companies are likely to see continued demand for their products, given an accelerated increase in aging population and the proportionate increase in diseases.
Moreover, the FDA has approved far more drugs so far in 2017 than it did in the whole of 2016. Hence, a faster drug approval process along with strong pipelines, innovative treatments, impressive results, and increased health care spending should support further growth in the sector.
Though the momentum in the biotech sector is likely to continue, it's a good idea to avoid a few stocks that will possibly lose their momentum soon despite significant year-to-date gains.
3 Small Biotech Stocks to Avoid
Avoiding stocks that have represented significant share price gain could be a bit tricky. However, we have taken the help of the Zacks Stock Screener to identify stocks, which may stop rallying in the near term. To shortlist the stocks from the vast universe of biotech sector, we have picked stocks that carry a Zacks Rank #4 (Sell) or 5 (Strong Sell).
Moreover, we have also taken into consideration stocks that witnessed negative estimate revisions for the current year over the last 60 days as these are likely to plunge further and should be dumped.
Keryx Biopharmaceuticals Inc. KERX : This New York-based biopharmaceutical company focuses on treating patients suffering from renal disease. The company's shares have risen 20.1% so far this year. However, it currently carries a Zacks Rank #4. Further, over the last 60 days, the loss per share estimates widened by 92.5% for 2017. Though the company's label expansion efforts for its only marketed drug, Auryxia bode well for growth, supply interruption of Auryxia, may hurt sales in future quarter.
Keryx Biopharmaceuticals, Inc. Price
Keryx Biopharmaceuticals, Inc. Price | Keryx Biopharmaceuticals, Inc. Quote
Juno Therapeutics, Inc. JUNO : This Washington-based biopharmaceutical company focuses on the development of immuno-oncology treatments. The company's shares have gained a significant 132.4% so far this year. Shares of the company mainly rose in September this year on the speculation that it will be acquired soon after the acquisition of Kite Pharma by Gilead. However, it currently carries a Zacks Rank #4 and has a VGM Score of D. Further, over the last 60 days, its loss per share estimates widened almost 3% for 2017.
Although Juno is among the major players in the field of T-cell-based immunotherapy, there are several other companies that are looking to develop and bring immunotherapy treatments to market. The CAR space has many companies including Novartis, Kite Pharma, bluebird bio, Intrexon, and Johnson & Johnson JNJ working on treatments. We note that Juno lags Kite Pharma and Novartis in the race to bring a CAR T product to the market. Hence, competition in the immunotherapy space may weigh heavily on the stock in the near term.
Juno Therapeutics, Inc. Price
Juno Therapeutics, Inc. Price | Juno Therapeutics, Inc. Quote
Abeona Therapeutics Inc. ABEO : This Delaware-based biopharmaceutical company focuses on developing gene therapies for life-threatening rare genetic diseases. The company's shares showed a significant gain of 245.3% so far this year. However, it currently carries a Zacks Rank #4 and has a VGM Score of F.
Further, over the last 60 days, its loss per share estimates widened by 24.5% for 2017. The company's lead gene therapies EB-101 and ABO-201 recently received breakthrough therapy and orphan drug designation, respectively from the FDA. Abeona's share significantly rose in July 2017 after the company announced that it has received guidance from the FDA to commence pivotal phase III for EB-101. However, many companies are working on bringing gene therapies to the market. Therefore, these candidates may face intense competition in the targeted space, if approved.
Abeona Therapeutics Inc. Price
Abeona Therapeutics Inc. Price | Abeona Therapeutics Inc. Quote
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Johnson & Johnson (JNJ): Free Stock Analysis Report
Abeona Therapeutics Inc. (ABEO): Free Stock Analysis Report
Juno Therapeutics, Inc. (JUNO): Free Stock Analysis Report
Keryx Biopharmaceuticals, Inc. (KERX): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abeona's share significantly rose in July 2017 after the company announced that it has received guidance from the FDA to commence pivotal phase III for EB-101. Juno Therapeutics, Inc. Price Juno Therapeutics, Inc. Price | Juno Therapeutics, Inc. Quote Abeona Therapeutics Inc. ABEO : This Delaware-based biopharmaceutical company focuses on developing gene therapies for life-threatening rare genetic diseases. Abeona Therapeutics Inc. Price Abeona Therapeutics Inc. Price | Abeona Therapeutics Inc. Quote More Stock News: This Is Bigger than the iPhone! | Juno Therapeutics, Inc. Price Juno Therapeutics, Inc. Price | Juno Therapeutics, Inc. Quote Abeona Therapeutics Inc. ABEO : This Delaware-based biopharmaceutical company focuses on developing gene therapies for life-threatening rare genetic diseases. Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Abeona Therapeutics Inc. (ABEO): Free Stock Analysis Report Juno Therapeutics, Inc. (JUNO): Free Stock Analysis Report Keryx Biopharmaceuticals, Inc. (KERX): Free Stock Analysis Report To read this article on Zacks.com click here. Abeona's share significantly rose in July 2017 after the company announced that it has received guidance from the FDA to commence pivotal phase III for EB-101. | Juno Therapeutics, Inc. Price Juno Therapeutics, Inc. Price | Juno Therapeutics, Inc. Quote Abeona Therapeutics Inc. ABEO : This Delaware-based biopharmaceutical company focuses on developing gene therapies for life-threatening rare genetic diseases. Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Abeona Therapeutics Inc. (ABEO): Free Stock Analysis Report Juno Therapeutics, Inc. (JUNO): Free Stock Analysis Report Keryx Biopharmaceuticals, Inc. (KERX): Free Stock Analysis Report To read this article on Zacks.com click here. Abeona's share significantly rose in July 2017 after the company announced that it has received guidance from the FDA to commence pivotal phase III for EB-101. | Juno Therapeutics, Inc. Price Juno Therapeutics, Inc. Price | Juno Therapeutics, Inc. Quote Abeona Therapeutics Inc. ABEO : This Delaware-based biopharmaceutical company focuses on developing gene therapies for life-threatening rare genetic diseases. Abeona's share significantly rose in July 2017 after the company announced that it has received guidance from the FDA to commence pivotal phase III for EB-101. Abeona Therapeutics Inc. Price Abeona Therapeutics Inc. Price | Abeona Therapeutics Inc. Quote More Stock News: This Is Bigger than the iPhone! |
28102.0 | 2017-09-18 00:00:00 UTC | Abeona Therapeutics (ABEO) Surges: Stock Moves 22.9% Higher | ABEO | https://www.nasdaq.com/articles/abeona-therapeutics-abeo-surges%3A-stock-moves-22.9-higher-2017-09-18 | nan | nan | Abeona Therapeutics Inc.ABEO was a big mover last session, as the company saw its shares rise nearly 23% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company-as the stock is now up 102.4% in the past one-month time frame.
The stock gained after an analyst from RBC Capital initiated coverage of the gene therapy company with an outperform rating.
The company has seen no estimate revisions over the past few weeks, while its Zacks Consensus Estimate for the current quarter has also moved lower over the past few weeks, suggesting there may be trouble down the road. So make sure to keep an eye on this stock going forward, to see if this recent move higher can last.
Abeona Therapeutics currently has a Zacks Rank #4 (Sell) while its Earnings ESP is negative.
Abeona Therapeutics Inc. Price
Abeona Therapeutics Inc. Price | Abeona Therapeutics Inc. Quote
A better-ranked stock in the Medical - Biomedical and Genetics industry is Alexion Pharmaceuticals, Inc. ALXN , which currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here .
Is ABEO going up? Or down? Predict to see what others think: Up or Down
New Report: An Investor's Guide to Cybersecurity
Cyberattacks have become more frequent and destructive than ever. In fact, they're expected to cause $6 trillion per year in damage by 2020.
The cybersecurity industry is expanding quickly in response to these threats. In fact, a projected $170 billion per year will be spent to protect consumer and corporate assets. Zacks has just released Cybersecurity: An Investor's Guide to Locking Down Profits which reveals 4 promising investment candidates.
Download the new report now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Alexion Pharmaceuticals, Inc. (ALXN): Free Stock Analysis Report
Abeona Therapeutics Inc. (ABEO): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abeona Therapeutics Inc.ABEO was a big mover last session, as the company saw its shares rise nearly 23% on the day. Abeona Therapeutics currently has a Zacks Rank #4 (Sell) while its Earnings ESP is negative. Abeona Therapeutics Inc. Price Abeona Therapeutics Inc. Price | Abeona Therapeutics Inc. Quote A better-ranked stock in the Medical - Biomedical and Genetics industry is Alexion Pharmaceuticals, Inc. ALXN , which currently carries a Zacks Rank #1 (Strong Buy). | Abeona Therapeutics Inc. Price Abeona Therapeutics Inc. Price | Abeona Therapeutics Inc. Quote A better-ranked stock in the Medical - Biomedical and Genetics industry is Alexion Pharmaceuticals, Inc. ALXN , which currently carries a Zacks Rank #1 (Strong Buy). Click to get this free report Alexion Pharmaceuticals, Inc. (ALXN): Free Stock Analysis Report Abeona Therapeutics Inc. (ABEO): Free Stock Analysis Report To read this article on Zacks.com click here. Abeona Therapeutics Inc.ABEO was a big mover last session, as the company saw its shares rise nearly 23% on the day. | Abeona Therapeutics Inc. Price Abeona Therapeutics Inc. Price | Abeona Therapeutics Inc. Quote A better-ranked stock in the Medical - Biomedical and Genetics industry is Alexion Pharmaceuticals, Inc. ALXN , which currently carries a Zacks Rank #1 (Strong Buy). Click to get this free report Alexion Pharmaceuticals, Inc. (ALXN): Free Stock Analysis Report Abeona Therapeutics Inc. (ABEO): Free Stock Analysis Report To read this article on Zacks.com click here. Abeona Therapeutics Inc.ABEO was a big mover last session, as the company saw its shares rise nearly 23% on the day. | Abeona Therapeutics Inc.ABEO was a big mover last session, as the company saw its shares rise nearly 23% on the day. Click to get this free report Alexion Pharmaceuticals, Inc. (ALXN): Free Stock Analysis Report Abeona Therapeutics Inc. (ABEO): Free Stock Analysis Report To read this article on Zacks.com click here. Abeona Therapeutics currently has a Zacks Rank #4 (Sell) while its Earnings ESP is negative. |
28103.0 | 2017-09-15 00:00:00 UTC | Midday Update: Soft Economic Data Overshadows Geopolitical Risks | ABEO | https://www.nasdaq.com/articles/midday-update-soft-economic-data-overshadows-geopolitical-risks-2017-09-15 | nan | nan | The major U.S. market averages were higher at midday on Friday with the Dow, S&P 500 and Nasdaq Composite all setting record highs as Wall Street overlooked another provocative missile test from North Korea and terrorist attack in a London subway station, focusing instead on downbeat U.S. economic data that could preclude another interest rate hike.
As the financial impact from Hurricane Harvey begins to permeate the economy, weakness in key economic indicators might persuade the Federal Reserve to sideline efforts to normalize monetary policy. Retail sales were down 0.2% last month, missing estimates for a slight gain, while sales excluding autos and gas fell 0.1% versus +0.3% expectations. Excluding auto sales only, retail sales were up 0.2%, but this was well below +0.5% estimates.
Storm-related impact on manufacturing was evident in a 0.9% decline in industrial production, the biggest monthly drop since May 2009, and significantly below estimates for a 0.1% increase. As a result, capacity utilization dropped to 76.1% from July's 76.9%.
Accordingly, consumer sentiment deteriorated as measured by the Univ of Michigan. The preliminary September index dropped to 95.3 from 96.8 in August.
Friday's other data was mixed as the Empire State manufacturing index dropped to 24.4 from 25.2 in August, but business inventories and sales were both up by 0.2%.
European equities came under early pressure by North Korea's latest missile test and the London bombing, but failed to regain its momentum, leaving all the major market averages lower. The UK's FTSE-100 took the brunt of risk aversion with losses compounded by another 15-month high in the pound.
Crude oil was down $0.15 to $49.74 per barrel. Natural gas was down $0.05 to $3.02 per 1 million BTU. Gold was down $3.00 to $1,326.50 an ounce, while silver was down $0.069 to $17.72 an ounce. Copper was unchanged at $2.96 per pound.
Among energy ETFs, the United States Oil Fund was up 0.35% to 10.16 with the United States Natural Gas Fund was down 1.91% to $6.69. Amongst precious-metal funds, the Market Vectors Gold Miners ETF was down 0.25% to 24.25 while SPDR Gold Shares were down 0.38% to $125.68. The iShares Silver Trust was down 0.48% to 16.69.
Here's where the markets stand at mid-day:
US MARKETS
NYSE Composite Index was up 1.18 points (+0.02%) to 12,064.68
Dow Jones Industrial Index was up 52.42 points (+0.24%) to 22,255.90
S&P 500 was up 2.83 points (+0.11%) to 2,498.45
Nasdaq Composite Index was up 24.04 points (+0.37%) to 6,452.91
GLOBAL SENTIMENT
FTSE 100 was down 79.92 points (-1.10%) to 7,215.47
DAX was down 21.64 points (-0.17%) to 12,518.81
CAC 40 was down 11.29 points (-0.22%) to 5,213.91
Nikkei 225 was up 102.06 (+0.52%) to 19,909.50
Hang Seng Index was up 30.39 points (+0.11%) to 27,807.59
Shanghai China Composite Index was down 17.76 points (-0.53%) to 3,353.67
NYSE SECTOR INDICES
NYSE Energy Sector Index was down 30.33 points (-0.29%) to 10,470.65
NYSE Financial Sector Index was unchanged at 7,582.67
NYSE Healthcare Sector Index was down 28.41 points (-0.20%) to 14,060.65
UPSIDE MOVERS
(+) MRTX (+128.42%) Reports positive preliminary data from two ongoing studies of non-small cell lung cancer treatment
(+) ABEO (+14.36%) Initiated at outperform, $23 price target by RBC Capital
(+) LPTH (+9.54%) Reported better-than-expected Q4 results
DOWNSIDE MOVERS
(-) TTOO (-27.63%) Prices stock offering at $4 per share
(-) ORCL (-6.65%) Beat Q1 estimates but issued weak profit guidance for Q2
(-) NUE (-1.30%) Issued Q3 guidance below analyst's estimates
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | (+) MRTX (+128.42%) Reports positive preliminary data from two ongoing studies of non-small cell lung cancer treatment (+) ABEO (+14.36%) Initiated at outperform, $23 price target by RBC Capital (+) LPTH (+9.54%) Reported better-than-expected Q4 results The major U.S. market averages were higher at midday on Friday with the Dow, S&P 500 and Nasdaq Composite all setting record highs as Wall Street overlooked another provocative missile test from North Korea and terrorist attack in a London subway station, focusing instead on downbeat U.S. economic data that could preclude another interest rate hike. As the financial impact from Hurricane Harvey begins to permeate the economy, weakness in key economic indicators might persuade the Federal Reserve to sideline efforts to normalize monetary policy. | (+) MRTX (+128.42%) Reports positive preliminary data from two ongoing studies of non-small cell lung cancer treatment (+) ABEO (+14.36%) Initiated at outperform, $23 price target by RBC Capital (+) LPTH (+9.54%) Reported better-than-expected Q4 results Among energy ETFs, the United States Oil Fund was up 0.35% to 10.16 with the United States Natural Gas Fund was down 1.91% to $6.69. NYSE Energy Sector Index was down 30.33 points (-0.29%) to 10,470.65 NYSE Financial Sector Index was unchanged at 7,582.67 NYSE Healthcare Sector Index was down 28.41 points (-0.20%) to 14,060.65 | (+) MRTX (+128.42%) Reports positive preliminary data from two ongoing studies of non-small cell lung cancer treatment (+) ABEO (+14.36%) Initiated at outperform, $23 price target by RBC Capital (+) LPTH (+9.54%) Reported better-than-expected Q4 results NYSE Composite Index was up 1.18 points (+0.02%) to 12,064.68 Dow Jones Industrial Index was up 52.42 points (+0.24%) to 22,255.90 S&P 500 was up 2.83 points (+0.11%) to 2,498.45 Nasdaq Composite Index was up 24.04 points (+0.37%) to 6,452.91 FTSE 100 was down 79.92 points (-1.10%) to 7,215.47 DAX was down 21.64 points (-0.17%) to 12,518.81 CAC 40 was down 11.29 points (-0.22%) to 5,213.91 Nikkei 225 was up 102.06 (+0.52%) to 19,909.50 Hang Seng Index was up 30.39 points (+0.11%) to 27,807.59 Shanghai China Composite Index was down 17.76 points (-0.53%) to 3,353.67 | (+) MRTX (+128.42%) Reports positive preliminary data from two ongoing studies of non-small cell lung cancer treatment (+) ABEO (+14.36%) Initiated at outperform, $23 price target by RBC Capital (+) LPTH (+9.54%) Reported better-than-expected Q4 results The preliminary September index dropped to 95.3 from 96.8 in August. Friday's other data was mixed as the Empire State manufacturing index dropped to 24.4 from 25.2 in August, but business inventories and sales were both up by 0.2%. |
28104.0 | 2017-09-15 00:00:00 UTC | Noteworthy Friday Option Activity: IGT, ABEO, TRUE | ABEO | https://www.nasdaq.com/articles/noteworthy-friday-option-activity-igt-abeo-true-2017-09-15 | nan | nan | Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in International Game Technology PLC (Symbol: IGT), where a total of 8,701 contracts have traded so far, representing approximately 870,100 underlying shares. That amounts to about 56.1% of IGT's average daily trading volume over the past month of 1.6 million shares. Particularly high volume was seen for the $22.50 strike call option expiring September 15, 2017 , with 4,041 contracts trading so far today, representing approximately 404,100 underlying shares of IGT. Below is a chart showing IGT's trailing twelve month trading history, with the $22.50 strike highlighted in orange:
Abeona Therapeutics Inc (Symbol: ABEO) options are showing a volume of 6,615 contracts thus far today. That number of contracts represents approximately 661,500 underlying shares, working out to a sizeable 54.4% of ABEO's average daily trading volume over the past month, of 1.2 million shares. Especially high volume was seen for the $20 strike call option expiring December 15, 2017 , with 3,191 contracts trading so far today, representing approximately 319,100 underlying shares of ABEO. Below is a chart showing ABEO's trailing twelve month trading history, with the $20 strike highlighted in orange:
And TrueCar Inc (Symbol: TRUE) options are showing a volume of 4,516 contracts thus far today. That number of contracts represents approximately 451,600 underlying shares, working out to a sizeable 52.1% of TRUE's average daily trading volume over the past month, of 867,615 shares. Particularly high volume was seen for the $17.50 strike call option expiring October 20, 2017 , with 2,262 contracts trading so far today, representing approximately 226,200 underlying shares of TRUE. Below is a chart showing TRUE's trailing twelve month trading history, with the $17.50 strike highlighted in orange:
For the various different available expirations for IGT options , ABEO options , or TRUE options , visit StockOptionsChannel.com.
Today's Most Active Call & Put Options of the S&P 500 »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Especially high volume was seen for the $20 strike call option expiring December 15, 2017 , with 3,191 contracts trading so far today, representing approximately 319,100 underlying shares of ABEO. Below is a chart showing IGT's trailing twelve month trading history, with the $22.50 strike highlighted in orange: Abeona Therapeutics Inc (Symbol: ABEO) options are showing a volume of 6,615 contracts thus far today. That number of contracts represents approximately 661,500 underlying shares, working out to a sizeable 54.4% of ABEO's average daily trading volume over the past month, of 1.2 million shares. | Below is a chart showing IGT's trailing twelve month trading history, with the $22.50 strike highlighted in orange: Abeona Therapeutics Inc (Symbol: ABEO) options are showing a volume of 6,615 contracts thus far today. That number of contracts represents approximately 661,500 underlying shares, working out to a sizeable 54.4% of ABEO's average daily trading volume over the past month, of 1.2 million shares. Below is a chart showing ABEO's trailing twelve month trading history, with the $20 strike highlighted in orange: And TrueCar Inc (Symbol: TRUE) options are showing a volume of 4,516 contracts thus far today. | Below is a chart showing IGT's trailing twelve month trading history, with the $22.50 strike highlighted in orange: Abeona Therapeutics Inc (Symbol: ABEO) options are showing a volume of 6,615 contracts thus far today. That number of contracts represents approximately 661,500 underlying shares, working out to a sizeable 54.4% of ABEO's average daily trading volume over the past month, of 1.2 million shares. Especially high volume was seen for the $20 strike call option expiring December 15, 2017 , with 3,191 contracts trading so far today, representing approximately 319,100 underlying shares of ABEO. | Below is a chart showing TRUE's trailing twelve month trading history, with the $17.50 strike highlighted in orange: For the various different available expirations for IGT options , ABEO options , or TRUE options , visit StockOptionsChannel.com. Below is a chart showing IGT's trailing twelve month trading history, with the $22.50 strike highlighted in orange: Abeona Therapeutics Inc (Symbol: ABEO) options are showing a volume of 6,615 contracts thus far today. That number of contracts represents approximately 661,500 underlying shares, working out to a sizeable 54.4% of ABEO's average daily trading volume over the past month, of 1.2 million shares. |
28105.0 | 2017-09-15 00:00:00 UTC | Why Abeona Therapeutics Inc Stock Jumped Higher Today | ABEO | https://www.nasdaq.com/articles/why-abeona-therapeutics-inc-stock-jumped-higher-today-2017-09-15 | nan | nan | What happened
Shares of Abeona Therapeutics (NASDAQ: ABEO) are up 18% as of 2:50 p.m. EDT after an analyst from RBC Capital initiated coverage of the gene therapy company with an outperform rating and assigned a $23 price target, more than 35% higher than it is right now.
So what
Abeona Therapeutics has been on fire lately, up more than 250% over the last six months, but much of the higher stock price has come from increasing positive investor sentiment off of a fairly low market cap rather than any fundamental change in Abeona's valuation.
Last month, for instance, Abeona jumped 18% in one day after announcing that its EB-101 gene therapy program was given breakthrough therapy designation by the Food and Drug Administration. Sure, it's a nice thing to have, since the designation can speed up interactions with the FDA and is a bit of an endorsement from the agency, but it shouldn't make Abeona worth substantially more to any investor who already believed in EB-101's potential.
The same thing is going on here with the new analyst coverage. Abeona isn't actually worth more because an analyst assigns a high price target on the biotech, but the increasing positive sentiment from the added endorsement has investors feeling better about the risk-reward profile of Abeona.
Now what
Long-term investors don't really have to follow the momentum caused by changes in sentiment -- or be worried about when it might shift back. Abeona's eventual value will be determined by the results of its phase 3 trial that will start next year testing EB-101 in patients with recessive dystrophic epidermolysis bullosa, a genetic skin disorder.
Investors will get a rundown of the trial during Abeona's research and development day next month, which could help keep the bullish sentiment going for a little while longer.
10 stocks we like better than Abeona Therapeutics
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Abeona Therapeutics wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of September 5, 2017
Brian Orelli and The Motley Fool have no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | What happened Shares of Abeona Therapeutics (NASDAQ: ABEO) are up 18% as of 2:50 p.m. EDT after an analyst from RBC Capital initiated coverage of the gene therapy company with an outperform rating and assigned a $23 price target, more than 35% higher than it is right now. Sure, it's a nice thing to have, since the designation can speed up interactions with the FDA and is a bit of an endorsement from the agency, but it shouldn't make Abeona worth substantially more to any investor who already believed in EB-101's potential. Abeona's eventual value will be determined by the results of its phase 3 trial that will start next year testing EB-101 in patients with recessive dystrophic epidermolysis bullosa, a genetic skin disorder. | So what Abeona Therapeutics has been on fire lately, up more than 250% over the last six months, but much of the higher stock price has come from increasing positive investor sentiment off of a fairly low market cap rather than any fundamental change in Abeona's valuation. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. What happened Shares of Abeona Therapeutics (NASDAQ: ABEO) are up 18% as of 2:50 p.m. EDT after an analyst from RBC Capital initiated coverage of the gene therapy company with an outperform rating and assigned a $23 price target, more than 35% higher than it is right now. | So what Abeona Therapeutics has been on fire lately, up more than 250% over the last six months, but much of the higher stock price has come from increasing positive investor sentiment off of a fairly low market cap rather than any fundamental change in Abeona's valuation. Abeona isn't actually worth more because an analyst assigns a high price target on the biotech, but the increasing positive sentiment from the added endorsement has investors feeling better about the risk-reward profile of Abeona. * David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Abeona Therapeutics wasn't one of them! | What happened Shares of Abeona Therapeutics (NASDAQ: ABEO) are up 18% as of 2:50 p.m. EDT after an analyst from RBC Capital initiated coverage of the gene therapy company with an outperform rating and assigned a $23 price target, more than 35% higher than it is right now. So what Abeona Therapeutics has been on fire lately, up more than 250% over the last six months, but much of the higher stock price has come from increasing positive investor sentiment off of a fairly low market cap rather than any fundamental change in Abeona's valuation. Abeona isn't actually worth more because an analyst assigns a high price target on the biotech, but the increasing positive sentiment from the added endorsement has investors feeling better about the risk-reward profile of Abeona. |
28106.0 | 2017-09-15 00:00:00 UTC | Health Care Sector Update for 09/15/2017: ABEO,MRTX,TTOO | ABEO | https://www.nasdaq.com/articles/health-care-sector-update-09152017-abeomrtxttoo-2017-09-15 | nan | nan | Top Health Care Stocks
JNJ +0.09%
PFE -0.87%
ABT +0.02%
MRK -0.39%
AMGN -1.37%
Health care stocks were trending lower, with the NYSE Health Care Index sinking more than 0.2% while shares of health care companies in the S&P 500 were down almost 0.3% as a group.
In company news, Abeona Therapeutics ( ABEO ) rallied to a best-ever $17.25 a share on Friday after analysts at RBC Capital Markets began coverage of the biotech working to develop treatments for rare genetic diseases, assigning an Outperform Speculative Risk investment recommendation with a $23 price target.
In other sector news,
(+) MRTX, (+129.5%) Said a combination of the company's sitravatinib drug candidate with nivolumab, anFDA-approved monoclonal antibody, confirmed some partial responses in evaluable patients with non-small cell lung cancer patients during a pair of ongoing Phase II clinical studies.
(-) TTOO, (-25.8%) Prices a $17.5 mln public offering of nearly 4.4 mln shares of its common stock at $4 apiece, a 34.3% discount to Thursday's closing price.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In company news, Abeona Therapeutics ( ABEO ) rallied to a best-ever $17.25 a share on Friday after analysts at RBC Capital Markets began coverage of the biotech working to develop treatments for rare genetic diseases, assigning an Outperform Speculative Risk investment recommendation with a $23 price target. In other sector news, (+) MRTX, (+129.5%) Said a combination of the company's sitravatinib drug candidate with nivolumab, anFDA-approved monoclonal antibody, confirmed some partial responses in evaluable patients with non-small cell lung cancer patients during a pair of ongoing Phase II clinical studies. (-) TTOO, (-25.8%) Prices a $17.5 mln public offering of nearly 4.4 mln shares of its common stock at $4 apiece, a 34.3% discount to Thursday's closing price. | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. In company news, Abeona Therapeutics ( ABEO ) rallied to a best-ever $17.25 a share on Friday after analysts at RBC Capital Markets began coverage of the biotech working to develop treatments for rare genetic diseases, assigning an Outperform Speculative Risk investment recommendation with a $23 price target. Health care stocks were trending lower, with the NYSE Health Care Index sinking more than 0.2% while shares of health care companies in the S&P 500 were down almost 0.3% as a group. | In company news, Abeona Therapeutics ( ABEO ) rallied to a best-ever $17.25 a share on Friday after analysts at RBC Capital Markets began coverage of the biotech working to develop treatments for rare genetic diseases, assigning an Outperform Speculative Risk investment recommendation with a $23 price target. Health care stocks were trending lower, with the NYSE Health Care Index sinking more than 0.2% while shares of health care companies in the S&P 500 were down almost 0.3% as a group. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In company news, Abeona Therapeutics ( ABEO ) rallied to a best-ever $17.25 a share on Friday after analysts at RBC Capital Markets began coverage of the biotech working to develop treatments for rare genetic diseases, assigning an Outperform Speculative Risk investment recommendation with a $23 price target. Top Health Care Stocks Health care stocks were trending lower, with the NYSE Health Care Index sinking more than 0.2% while shares of health care companies in the S&P 500 were down almost 0.3% as a group. |
28107.0 | 2017-09-02 00:00:00 UTC | 3 Biotech Stocks That Skyrocketed This Week | ABEO | https://www.nasdaq.com/articles/3-biotech-stocks-skyrocketed-week-2017-09-02 | nan | nan | If you like excitement, biotech stocks provided plenty of it over the last several days. And most of the buzz stemmed from the $11.9 billion buyout of Kite Pharma (NASDAQ: KITE) announced by Gilead Sciences (NASDAQ: GILD) on Monday.
But while Kite Pharma stock shot up nearly 30% on the acquisition news and Gilead stock jumped more than 10%, neither company ranked among the best-performing biotech stocks this week. Instead, three smaller biotechs made even greater leaps -- Abeona Therapeutics (NASDAQ: ABEO) , Sangamo Therapeutics (NASDAQ: SGMO) , and Juno Therapeutics (NASDAQ: JUNO) . Here's why these biotech stocks skyrocketed.
Abeona Therapeutics
Shares of Abeona Therapeutics soared around 50% higher this week. That huge gain resulted primarily from the U.S. Food and Drug Administration (FDA) granting breakthrough therapy designation for the biotech's EB-101 gene therapy program for treating patients with recessive dystrophic epidermolysis bullosa. This rare genetic disease causes the skin to blister easily and can lead to serious medical problems.
Breakthrough therapy designation is certainly good news, since it can speed up the drug development and approval process. The designation is especially helpful to Abeona right now, as the company is working with the FDA to finalize the design of a phase 3 study of EB-101. Abeona hopes to begin that study in early 2018.
While EB-101 is Abeona's lead candidate, its experimental treatment for another rare genetic disease isn't too far behind. ABO-102 is in a phase 1/2 study for treating Sanfilippo syndrome type A. Abeona's pipeline also includes one other clinical gene therapy program and seven pre-clinical programs.
Sangamo Therapeutics
Sangamo Therapeutics didn't report huge news this week, although the biotech did announce the first patient received treatment in the phase 1/2 clinical trial of SB-525, its gene therapy for patients with Hemophilia A. But Sangamo stock's performance was huge, with shares surging more than 35% over the past five days.
What was the catalyst for Sangamo? I suspect the biotech is surfing the wave of investors' excitement about cell therapy spurred by Gilead's acquisition of Kite. The company could have also benefited from Abeona's good news from the FDA.
Sangamo is a pioneer in zinc finger nuclease (ZFN) gene editing. The biotech has four clinical programs in its pipeline and three pre-clinical programs, several of which are partnered with larger drugmakers. This interest from big pharma helped make Sangamo one of the best-performing biotech stocks of the first half of 2017 .
Juno Therapeutics
Juno Therapeutics had no news at all this week -- other than announcing that it would present at a couple of investor conferences in September. Yet the biotech stock shot up nearly 40% during the week.
You can definitely chalk up Juno's big increase to Gilead's buyout of Kite . Both Juno and Kite are developing chimeric antigen receptor T cell (CAR-T) and T cell receptor (TCR) therapies for treating cancer. With Kite no longer available, Juno is one of the most attractive acquisition targets for bigger companies looking to add cell therapy to their oncology portfolio.
Probably the most likely suitor for Juno is its partner, Celgene (NASDAQ: CELG) . The two companies are teamed up on development of experimental CAR-T drug JCAR017 in treating non-Hodgkin lymphoma.
Best pick?
All three of these biotechs could see tremendous success in the future. It's a hard choice as to which is the best pick right now. My nod, though, goes to Abeona Therapeutics.
Despite its massive gains this week, Abeona has the lowest market cap of any of the three biotechs discussed. The company isn't tightly linked to a larger biopharmaceutical company yet, either. That could make it more appealing to big drugmakers that don't have a strong gene therapy focus yet.
10 stocks we like better than Abeona Therapeutics
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Abeona Therapeutics wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of August 1, 2017
Keith Speights owns shares of Celgene and Gilead Sciences. The Motley Fool owns shares of and recommends Celgene and Gilead Sciences. The Motley Fool recommends Juno Therapeutics. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Instead, three smaller biotechs made even greater leaps -- Abeona Therapeutics (NASDAQ: ABEO) , Sangamo Therapeutics (NASDAQ: SGMO) , and Juno Therapeutics (NASDAQ: JUNO) . Abeona Therapeutics Shares of Abeona Therapeutics soared around 50% higher this week. The designation is especially helpful to Abeona right now, as the company is working with the FDA to finalize the design of a phase 3 study of EB-101. | Instead, three smaller biotechs made even greater leaps -- Abeona Therapeutics (NASDAQ: ABEO) , Sangamo Therapeutics (NASDAQ: SGMO) , and Juno Therapeutics (NASDAQ: JUNO) . Abeona Therapeutics Shares of Abeona Therapeutics soared around 50% higher this week. The designation is especially helpful to Abeona right now, as the company is working with the FDA to finalize the design of a phase 3 study of EB-101. | Instead, three smaller biotechs made even greater leaps -- Abeona Therapeutics (NASDAQ: ABEO) , Sangamo Therapeutics (NASDAQ: SGMO) , and Juno Therapeutics (NASDAQ: JUNO) . Abeona Therapeutics Shares of Abeona Therapeutics soared around 50% higher this week. The designation is especially helpful to Abeona right now, as the company is working with the FDA to finalize the design of a phase 3 study of EB-101. | Instead, three smaller biotechs made even greater leaps -- Abeona Therapeutics (NASDAQ: ABEO) , Sangamo Therapeutics (NASDAQ: SGMO) , and Juno Therapeutics (NASDAQ: JUNO) . Abeona Therapeutics Shares of Abeona Therapeutics soared around 50% higher this week. The designation is especially helpful to Abeona right now, as the company is working with the FDA to finalize the design of a phase 3 study of EB-101. |
28108.0 | 2017-08-30 00:00:00 UTC | 3 Biotechs Among Our 4 Top Charts to Watch | ABEO | https://www.nasdaq.com/articles/3-biotechs-among-our-4-top-charts-watch-2017-08-30 | nan | nan | By Harry Boxer, TheTechTrader.com
Our top charts to watch this week feature three biotechs and one online insurance stock moving on strong technicals and news.
Abeona Therapeutics Inc. (ABEO) rocketed $1.75, or 18%, to close at $11.25 on very heavy volume of 2.7 million shares traded Tuesday. The move came on news that the FDA granted breakthrough therapy status to the company's skin healing therapy. The stock had been pulling back in a flag pattern after its July high at $10.26, and recently broke out of the flag, with Tuesday's move thrusting the stock through that July high. In the short term, price may reach $14-$15, and may well climb to $17.50 in the longer term. Short interest of 10.8 times its average volume could fuel the move as shorts cover on a rally.
Health Insurance Innovations, Inc. (HIIQ) reached an all-time high of $36.70 on Tuesday before settling to close at $35.95, up by $1.10, on heavy volume of 874,532 shares traded and no news. The online insurance stock has risen more than 150% since March 27 and 33% since its positive earnings announcement on August 3. Price broke out of a bull flag consolidation pattern August 24. Next target range: $39-$40.
ImmunoGen, Inc. (IMGN) popped 17% to close at $7.58 on a whopping 12 million shares traded -- that is more than four times its average volume and the largest volume the stock has seen since January. The move came on news that the cancer drug company will collaborate with Jazz Pharmaceuticals on the development of blood cancer therapies. If price can move through the prior high of $8.04 from July 6, the next targets will be $9.50 and $12.50.
Sangamo Therapeutics, Inc. (SGMO) rose 11%, or $1.30, and closed at $12.80 on heavy volume of 3.3 million shares traded. Price broke above the prior high of $12.05 from August 14. The gene therapy company recently began a clinical trial with Pfizer for a hemophilia treatment. Price is up 250% year to date. The near-term target is $13 and the possibility for acceleration up to $17 in the coming weeks.
See Harry's video chart analysis on these stocks.
No holdings.
Harry Boxer is founder of TheTechTrader.com, a live trading room featuring his stock picks, technical market analysis, and live chart presentations.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abeona Therapeutics Inc. (ABEO) rocketed $1.75, or 18%, to close at $11.25 on very heavy volume of 2.7 million shares traded Tuesday. By Harry Boxer, TheTechTrader.com Our top charts to watch this week feature three biotechs and one online insurance stock moving on strong technicals and news. Health Insurance Innovations, Inc. (HIIQ) reached an all-time high of $36.70 on Tuesday before settling to close at $35.95, up by $1.10, on heavy volume of 874,532 shares traded and no news. | Abeona Therapeutics Inc. (ABEO) rocketed $1.75, or 18%, to close at $11.25 on very heavy volume of 2.7 million shares traded Tuesday. The stock had been pulling back in a flag pattern after its July high at $10.26, and recently broke out of the flag, with Tuesday's move thrusting the stock through that July high. Harry Boxer is founder of TheTechTrader.com, a live trading room featuring his stock picks, technical market analysis, and live chart presentations. | Abeona Therapeutics Inc. (ABEO) rocketed $1.75, or 18%, to close at $11.25 on very heavy volume of 2.7 million shares traded Tuesday. The stock had been pulling back in a flag pattern after its July high at $10.26, and recently broke out of the flag, with Tuesday's move thrusting the stock through that July high. Health Insurance Innovations, Inc. (HIIQ) reached an all-time high of $36.70 on Tuesday before settling to close at $35.95, up by $1.10, on heavy volume of 874,532 shares traded and no news. | Abeona Therapeutics Inc. (ABEO) rocketed $1.75, or 18%, to close at $11.25 on very heavy volume of 2.7 million shares traded Tuesday. By Harry Boxer, TheTechTrader.com Our top charts to watch this week feature three biotechs and one online insurance stock moving on strong technicals and news. If price can move through the prior high of $8.04 from July 6, the next targets will be $9.50 and $12.50. |
28109.0 | 2017-07-10 00:00:00 UTC | Monday Sector Leaders: Biotechnology, Sporting Goods & Activities | ABEO | https://www.nasdaq.com/articles/monday-sector-leaders-biotechnology-sporting-goods-activities-2017-07-10 | nan | nan | In trading on Monday, biotechnology shares were relative leaders, up on the day by about 3.3%. Leading the group were shares of Abeona Therapeutics Incorporated ( ABEO ) up about 9% on the day.
Also showing relative strength are sporting goods & activities shares, up on the day by about 2.1% as a group, led by Clubcorp Holdings ( MYCC ), trading up by about 30.5% and Drive Shack ( DS ), trading higher by about 1.7% on Monday.
VIDEO: Monday Sector Leaders: Biotechnology, Sporting Goods & Activities
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Leading the group were shares of Abeona Therapeutics Incorporated ( ABEO ) up about 9% on the day. Also showing relative strength are sporting goods & activities shares, up on the day by about 2.1% as a group, led by Clubcorp Holdings ( MYCC ), trading up by about 30.5% and Drive Shack ( DS ), trading higher by about 1.7% on Monday. VIDEO: Monday Sector Leaders: Biotechnology, Sporting Goods & Activities The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Leading the group were shares of Abeona Therapeutics Incorporated ( ABEO ) up about 9% on the day. In trading on Monday, biotechnology shares were relative leaders, up on the day by about 3.3%. VIDEO: Monday Sector Leaders: Biotechnology, Sporting Goods & Activities The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Leading the group were shares of Abeona Therapeutics Incorporated ( ABEO ) up about 9% on the day. Also showing relative strength are sporting goods & activities shares, up on the day by about 2.1% as a group, led by Clubcorp Holdings ( MYCC ), trading up by about 30.5% and Drive Shack ( DS ), trading higher by about 1.7% on Monday. VIDEO: Monday Sector Leaders: Biotechnology, Sporting Goods & Activities The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Leading the group were shares of Abeona Therapeutics Incorporated ( ABEO ) up about 9% on the day. In trading on Monday, biotechnology shares were relative leaders, up on the day by about 3.3%. VIDEO: Monday Sector Leaders: Biotechnology, Sporting Goods & Activities The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. |
28110.0 | 2017-07-06 00:00:00 UTC | Abeona Therapeutics (ABEO) Catches Eye: Stock Jumps 10.6% | ABEO | https://www.nasdaq.com/articles/abeona-therapeutics-abeo-catches-eye%3A-stock-jumps-10.6-2017-07-06 | nan | nan | Abeona Therapeutics Inc.ABEO was a big mover last session, as the company saw its shares rise over 10% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company as the stock is now up over 45% in the past one-month time frame.
The company has seen two positive estimate revisions in the last 30 days, while its Zacks Consensus Estimate moved higher over the same time frame, suggesting solid trading ahead. So make sure to keep an eye on this stock going forward to see if yesterday's jump can turn into more strength down the road.
Abeona Therapeutics currently carries a Zacks Rank #3 (Hold), while its Earnings ESP is 0.00%.
Abeona Therapeutics Inc. Price
Abeona Therapeutics Inc. Price | Abeona Therapeutics Inc. Quote
A better-ranked stock worth considering from the Medical - Biomedical and Genetics space Enzo Biochem, Inc. ENZ , sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here.
Is ABEO going up? Or down? Predict to see what others think: Up or Down
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation. See Them Free>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Enzo Biochem, Inc. (ENZ): Free Stock Analysis Report
Abeona Therapeutics Inc. (ABEO): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abeona Therapeutics Inc.ABEO was a big mover last session, as the company saw its shares rise over 10% on the day. Abeona Therapeutics currently carries a Zacks Rank #3 (Hold), while its Earnings ESP is 0.00%. Abeona Therapeutics Inc. Price Abeona Therapeutics Inc. Price | Abeona Therapeutics Inc. Quote A better-ranked stock worth considering from the Medical - Biomedical and Genetics space Enzo Biochem, Inc. ENZ , sporting a Zacks Rank #1 (Strong Buy). | Abeona Therapeutics Inc. Price Abeona Therapeutics Inc. Price | Abeona Therapeutics Inc. Quote A better-ranked stock worth considering from the Medical - Biomedical and Genetics space Enzo Biochem, Inc. ENZ , sporting a Zacks Rank #1 (Strong Buy). Click to get this free report Enzo Biochem, Inc. (ENZ): Free Stock Analysis Report Abeona Therapeutics Inc. (ABEO): Free Stock Analysis Report To read this article on Zacks.com click here. Abeona Therapeutics Inc.ABEO was a big mover last session, as the company saw its shares rise over 10% on the day. | Abeona Therapeutics Inc. Price Abeona Therapeutics Inc. Price | Abeona Therapeutics Inc. Quote A better-ranked stock worth considering from the Medical - Biomedical and Genetics space Enzo Biochem, Inc. ENZ , sporting a Zacks Rank #1 (Strong Buy). Click to get this free report Enzo Biochem, Inc. (ENZ): Free Stock Analysis Report Abeona Therapeutics Inc. (ABEO): Free Stock Analysis Report To read this article on Zacks.com click here. Abeona Therapeutics Inc.ABEO was a big mover last session, as the company saw its shares rise over 10% on the day. | Abeona Therapeutics Inc.ABEO was a big mover last session, as the company saw its shares rise over 10% on the day. Click to get this free report Enzo Biochem, Inc. (ENZ): Free Stock Analysis Report Abeona Therapeutics Inc. (ABEO): Free Stock Analysis Report To read this article on Zacks.com click here. Abeona Therapeutics currently carries a Zacks Rank #3 (Hold), while its Earnings ESP is 0.00%. |
28111.0 | 2017-06-22 00:00:00 UTC | Thursday Sector Leaders: Hospital & Medical Practitioners, Biotechnology Stocks | ABEO | https://www.nasdaq.com/articles/thursday-sector-leaders-hospital-medical-practitioners-biotechnology-stocks-2017-06-22 | nan | nan | In trading on Thursday, hospital & medical practitioners shares were relative leaders, up on the day by about 3.3%. Leading the group were shares of Quorum Health ( QHC ), up about 9.1% and shares of Tenet Healthcare ( THC ) up about 8% on the day.
Also showing relative strength are biotechnology shares, up on the day by about 2.4% as a group, led by Abeona Therapeutics ( ABEO ), trading up by about 14.9% and Sangamo Therapeutics ( SGMO ), trading higher by about 13.5% on Thursday.
VIDEO: Thursday Sector Leaders: Hospital & Medical Practitioners, Biotechnology Stocks
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Also showing relative strength are biotechnology shares, up on the day by about 2.4% as a group, led by Abeona Therapeutics ( ABEO ), trading up by about 14.9% and Sangamo Therapeutics ( SGMO ), trading higher by about 13.5% on Thursday. In trading on Thursday, hospital & medical practitioners shares were relative leaders, up on the day by about 3.3%. VIDEO: Thursday Sector Leaders: Hospital & Medical Practitioners, Biotechnology Stocks The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Also showing relative strength are biotechnology shares, up on the day by about 2.4% as a group, led by Abeona Therapeutics ( ABEO ), trading up by about 14.9% and Sangamo Therapeutics ( SGMO ), trading higher by about 13.5% on Thursday. In trading on Thursday, hospital & medical practitioners shares were relative leaders, up on the day by about 3.3%. VIDEO: Thursday Sector Leaders: Hospital & Medical Practitioners, Biotechnology Stocks The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Also showing relative strength are biotechnology shares, up on the day by about 2.4% as a group, led by Abeona Therapeutics ( ABEO ), trading up by about 14.9% and Sangamo Therapeutics ( SGMO ), trading higher by about 13.5% on Thursday. VIDEO: Thursday Sector Leaders: Hospital & Medical Practitioners, Biotechnology Stocks The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Also showing relative strength are biotechnology shares, up on the day by about 2.4% as a group, led by Abeona Therapeutics ( ABEO ), trading up by about 14.9% and Sangamo Therapeutics ( SGMO ), trading higher by about 13.5% on Thursday. In trading on Thursday, hospital & medical practitioners shares were relative leaders, up on the day by about 3.3%. Leading the group were shares of Quorum Health ( QHC ), up about 9.1% and shares of Tenet Healthcare ( THC ) up about 8% on the day. |
28112.0 | 2017-02-15 00:00:00 UTC | Abeona Therapeutics (ABEO) Catches Eye: Stock Jumps 5.8% | ABEO | https://www.nasdaq.com/articles/abeona-therapeutics-abeo-catches-eye%3A-stock-jumps-5.8-2017-02-15 | nan | nan | Abeona Therapeutics Inc.ABEO was a big mover last session, as the company saw its shares rise nearly 6% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $4.60 to $5.35 in the past one-month time frame.
The company has seen one positive revision in the past one month, while its Zacks Consensus Estimate moved higher over the same time frame, suggesting that more solid trading could be ahead for this stock. So make sure to keep an eye on this stock going forward to see if yesterday's jump can turn into more strength down the road.
Abeona Therapeutics currently carries a Zacks Rank #3 (Hold), while its Earnings ESP is negative.
Abeona Therapeutics Inc. Price
Abeona Therapeutics Inc. Price | Abeona Therapeutics Inc. Quote
A better-ranked Medical - Biomedical and Genetics stock is Cellectis S.A. CLLS , sporting a Zacks Rank #1 (Strong Buy).You can see the complete list of today's Zacks #1 Rank stocks here .
Is ABEO going up? Or down? Predict to see what others think: Up or Down
Zacks' Top Investment Ideas for Long-Term Profit
How would you like to see our best recommendations to help you find today's most promising long-term stocks? Starting now, you can look inside our portfolios featuring stocks under $10, income stocks, value investments and more. These picks, which have double and triple-digit profit potential, are rarely available to the public. But you can see them now. Click here >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Cellectis S.A. (CLLS): Free Stock Analysis Report
Abeona Therapeutics Inc. (ABEO): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abeona Therapeutics currently carries a Zacks Rank #3 (Hold), while its Earnings ESP is negative. Abeona Therapeutics Inc.ABEO was a big mover last session, as the company saw its shares rise nearly 6% on the day. Abeona Therapeutics Inc. Price Abeona Therapeutics Inc. Price | Abeona Therapeutics Inc. Quote A better-ranked Medical - Biomedical and Genetics stock is Cellectis S.A. CLLS , sporting a Zacks Rank #1 (Strong Buy).You can see the complete list of today's Zacks #1 Rank stocks here . | Abeona Therapeutics Inc. Price Abeona Therapeutics Inc. Price | Abeona Therapeutics Inc. Quote A better-ranked Medical - Biomedical and Genetics stock is Cellectis S.A. CLLS , sporting a Zacks Rank #1 (Strong Buy).You can see the complete list of today's Zacks #1 Rank stocks here . Click to get this free report Cellectis S.A. (CLLS): Free Stock Analysis Report Abeona Therapeutics Inc. (ABEO): Free Stock Analysis Report To read this article on Zacks.com click here. Abeona Therapeutics Inc.ABEO was a big mover last session, as the company saw its shares rise nearly 6% on the day. | Abeona Therapeutics Inc. Price Abeona Therapeutics Inc. Price | Abeona Therapeutics Inc. Quote A better-ranked Medical - Biomedical and Genetics stock is Cellectis S.A. CLLS , sporting a Zacks Rank #1 (Strong Buy).You can see the complete list of today's Zacks #1 Rank stocks here . Click to get this free report Cellectis S.A. (CLLS): Free Stock Analysis Report Abeona Therapeutics Inc. (ABEO): Free Stock Analysis Report To read this article on Zacks.com click here. Abeona Therapeutics Inc.ABEO was a big mover last session, as the company saw its shares rise nearly 6% on the day. | Abeona Therapeutics Inc.ABEO was a big mover last session, as the company saw its shares rise nearly 6% on the day. Click to get this free report Cellectis S.A. (CLLS): Free Stock Analysis Report Abeona Therapeutics Inc. (ABEO): Free Stock Analysis Report To read this article on Zacks.com click here. Abeona Therapeutics currently carries a Zacks Rank #3 (Hold), while its Earnings ESP is negative. |
28113.0 | 2017-02-14 00:00:00 UTC | Abeona: Preparing For Liftoff - The Next Avexis? | ABEO | https://www.nasdaq.com/articles/abeona-preparing-liftoff-next-avexis-2017-02-14 | nan | nan | By World's Greatest :
Executive Summary and Investment Thesis
Abeona Therapeutics ( ABEO ) is a biotechnology company with a number of early- and late-stage assets. This week the company will present initial data on its lead compound, ABO102 for Sanfilippo Syndrome at the WORLD Symposium (We're Organizing Research on Lysosomal Diseases) in San Diego (Feb 13-17).
The validation of a biotechnology company's key technology is usually a defining moment in the evolution of that company and usually creates significant value for the company's shareholders. Like other gene therapy companies with unproven technology, Abeona trades at a substantial discount to those companies with validated technology, and I believe that validation of Abeona's lead technology could drive the company's share price toward $30/share, which would put the company's valuation in line with those companies that have validated technology - e.g., AveXis ( AVXS ), Spark Therapeutics ( ONCE ), and Ultragenyx Pharmaceutical ( RARE ).
Longer-term, I believe the company has technologies that could be worth more than $100 per share but the purpose of this report is to preview the imminent clinical catalyst and readers should refer to previous work for the full company background and the longer-term investment thesis.
I note that a number of highly sophisticated biotech hedge funds have recently appeared on the shareholder register, there has been considerable insider buying over the past 18 months and in recent weeks a substantial number of March call options have traded.
As with all biotech investments, the outcome of an investment is very dependent on clinical trial outcomes which is speculative and the key company specific risk in Abeona is the failure to commercialize any of their clinical programs. Cash on balance sheet of $72m will provide support for the shares at $1.75 if clinical trials fail. That said, this company is investigating drugs for ultra rare terminal diseases where there is currently no approved agent and this means the hurdle for approval at the FDA is very low and the clinical trial data to date is highly encouraging. With cash burn of about $1m per month the company has over three years of cash burn on balance sheet so there is no need for near term funding.
Clinical Validation of a Biotech company's lead product typically creates substantial upside for shareholders
One of the most defining points of time in a biotechnology company's evolution is the moment that proof of concept is demonstrated with clinical trial data in humans. As shown in the exhibit below, gene therapy companies with clinical candidates that have been validated with human clinical trial data trade at market caps seven fold and enterprise values eleven fold greater than those companies that have yet to validate their technology in humans. Indeed, Avexis has seen its share price increase 230% during the past twelve months as the company has generated additional human data that supports the company's technology. I would argue that Abeona is perhaps 6-12 months behind AVXS in its evolution and it is therefore likely that the presentation of human clinical trial data for ABO 102 at the WORLD Symposium on Thursday Feb 16 (at 4:30 EST) will likely be a transforming event for Abeona and its shareholders.
AVXS: + 230% since IPO, now a $ 1.6B Market Cap Company
(click to enlarge)
In this report I will review the science, suggest what I believe will be required for FDA approval and successful commercialization and the approximate valuation for ABO 102.
The Science
ABO-102 is a next generation adeno-associated viral ( AAV )-based gene therapy for MPS III (Sanfilippo syndrome), which involves a one-time delivery of a normal copy of the defective gene to cells of the central nervous system with the aim of reversing the effects of the genetic errors that cause the disease.
Understanding AAV
Adeno-associated virus is a non-enveloped virus with a single-strand linear DNA genome (4.7kb), which has not been associated with any human/animal diseases (reviewed in Samulski et al, Annu Rev Virol, 2014, 1:427 ). Transgenes delivered by AAV were able to achieve long term in vivo expression in multiple organs (eye, brain, spinal cord, muscle and liver) in preclinical models. AAV enters cells through a series of steps including cell surface binding, intracellular trafficking, second-strand synthesis and persistence as episomes.
There is a great video here to help explain how the technology works.
As the first step of the cell entry, AAV binds to cell surface sugars (such as heparin sulfate, sialic acid and galactose) on proteoglycans and cell surface receptors (such as fibroblast growth factor receptor, integrin and hepatocyte growth factor receptor). It has been shown that the use of different cell surface sugars/receptors could lead to different tropism. The best-studied serotype AAV2 binds to heparin sulfate and fibroblast growth factor receptor 1 (FGFR1) and demonstrated a broad tropism with efficient transduction in liver, kidney, muscle and central nervous system. In comparison, AAV4/5/6 bind to sialic acid and co-receptors other than FGFR1 and showed tropism in tissues including retina, lung and heart ( Nonnenmacher et al, Gene Ther 2012, 19: 649 ).
Upon binding to cell surface sugars/receptors, AAV is internalized through endocytosis of clathrin-coated vesicles and disseminated to nearly every cytoplasmic compartment. In 2 hrs post-infection, most of the AAVs localize around the nucleus, where they escape from the endosomal compartments in response to the acidic environment. The exposure to the acidic environment was shown to be essential for subsequent AAV transduction, (at least partly) through the activation of the phospholipase A2 activity and nuclear localization signals of the minor capsid protein VP1 (N-terminal end). The AAV capsids eventually enter the nucleus and release its DNA through unknown mechanism.
As a double-stranded DNA is required for transcription and gene expression of AAV vectors, the second-strand synthesis is essential to enable effective gene expression (the hypothesis of annealing positive and negative strands was invalidated as AAV particles containing only one-strand is equally infectious). It has been shown that in vivo AAV transgene expression took weeks to months after infection to reach the highest level ( Flotte et al, Hum Gene Ther 2011, 22:1239 ).
With the inactivation of one of the AAV inverted terminal repeats (ITRs), the AAV genome could replicated as inverted dimer and self-anneal after the release of the DNA in the nucleus. The self-complementary AAV vector has been applied successfully in clinical studies including scAAV2/8-LP1-hFIXco in hemophilia B, which showed immediate transgene expression ( Nathwani et al, N Engl J Med 2011, 365:2357 ). The self-complementary AAV vector, however, has only half of the packaging capacity.
Preclinical studies have demonstrated that most AAV vectors are converted into circles to form episomes (DNA that can be replicated independently of the host), which contain several copies of the transgene (ligated in the order of head-to-tail). There is a low frequency (up to 1% in liver, lower in brain/muscle) that the AAV vectors can integrate into the host genome. The transgene expression is maintained mainly through the persistence of episomes, therefore AAV vectors are particularly suitable for gene delivery in non-dividing somatic tissues such as eye, brain, muscle and liver (adult).
Abeona is using AAV9 (double stranded) for its vector
Sanfilippo syndrome has a significant CNS component to the disease and it is imperative that the virus is able to penetrate the blood brain barrier, persist in the central nervous system and deliver its genetic payload to the patients' cells. As shown belowAAV9 appears to have the greatest ability to enter and persist in the central nervous system. The diagram below shows the results of a brain-directed injection of AAV vectors encoding green fluorescent protein gene (AAV/GFP). In this particular experiment approximately 2.0x10 ^10 vg of AAV/GFP vectors (serotypes 1,2,5,8,9 and 10) were injected into the right striatum over a period of 5 mins and expression of GFP was analyzed using fluorescent microscopy at 2 weeks.
To further enhance the potency of their vector, Abeona are using a double stranded (self-complementary) AAV as opposed to a single stranded AAV. Self-complementary vectors can facilitate gene transcription and translation without relying on the infected host's replication machinery, which could hinder therapeutic efficacy. The prime limitation of scAAV vectors is their size. They can carry DNA pieces up to ~2.4kb^9. scAAV vectors are 10-100 fold more efficient than traditional single stranded (ss) AAV vectors, as demonstrated in the pictures below.
Preclinical trial data supports mechanism and validates the science
There is a substantial amount of pre clinical trial data on Abeona's AAV9 gene therapy approach to treating MPS IIIA and B. As shown below and originally recorded in Fu H. et al., Molecular Therapy (2011) 19(6):1025-1033 , untreated MPS IIIB mice have a limited 8-12 month life span. Treatment of 4- to 6-week-old animals with either low (AAV9-L) or high dose (AAV9-H) gene therapy resulted in 16-28 months of survival. Wild type mice live on average 24 months.
(click to enlarge)
The results below are for mice with MPS IIIA.
(click to enlarge)
Abeona has already presented very preliminary data in October 2016. Low-dose ABO-102 (5E+12vg/kg) led to 58/26% reductions in urine/CSF GAG levels and 18% reductions in liver/spleen volumes at 30 day follow-up. Of note, the urinary and CSF GAG reductions appear comparable to other ERT data (57-75% urinary GAG reduction and 26% CSF GAG reduction). Since liver/spleen volumes remained 2x normal size over 1yr in natural history studies, the 18% reduction observed in ABO-102 Ph1/2 study looks encouraging. The safety profile appears good with no treatment related AEs or SAEs (all 3 pts received 3mon prophylactic tapering-dose steroid) and the Data Safety Monitoring Board has allowed enrollment of the high-dose cohort. The table below shows the magnitude of GAG changes seen in currently approved drugs for other MPS diseases that are currently marketed by Shire (SHPG), Sanofi (SNY), Biomarin (BMRN) and Ultragenyx.
(click to enlarge)
What data might we expect on Thursday Feb 16?
The presenter is likely to present three month follow up data from the three initial subjects and six month follow up data from the first two subjects. This will allow investors to gauge the durability of the response seen at one month and to gauge the clinical outcomes at six months.
During the presentation of the initial two subjects at six months it is likely that the presenter will report neurocognitive data which is likely to be the primary clinical endpoint upon which the FDA will review the BLA (that said, changes in GAG, and liver and spleen size are also clinically relevant). It may be possible to compare this data to the results of the natural history study.
The principle investigator has conducted a natural history study (see K.V. Truxal, et al., A prospective one-year natural history study of mucopolysaccharidosis types IIIA and IIIB: Implications for clinical trial design, Mol. Genet. Metab . (2016)) so it will be possible to compare the neurocognitive data to the untreated population in the natural history study. It is likely that there will be three main neurocognitive tests analyzed.
Leiter - 3 International Performance Scale
For cognitive assessment, the Leiter-3 has several features that are useful in this population. As it measures nonverbal IQ, it does not require participants to comprehend auditory instructions or provide any verbal responses - critical test characteristics for assessing this population. In the natural history study, two subjects between 2 and 3 years of age began the study with a Leiter-3 (or converted Leiter-R) NVIQ score N85, which is within the normal range. Consistent with the understanding of disease pathogenesis, this observation suggests that an earlier successful treatment could result in preservation of normal cognition. However, with the Leiter, subjects tended to score at the floor of the measure starting around 6 to 8 years, which limits the utility of this measure to detect further decline at this stage of disease progression. In addition, and particularly near the test floor, fluctuations in attention and cooperation affected scores if a subject was unable on that particular day to attend to the test long enough to receive a score.
In the natural history study, a majority of subjects (N=16)were able to receive a NVIQ standard score at two consecutive visits, allowing for assessment of change over a 6-month interval. For statistical analysis, mean change was assessed in these 16 subjects using the first 6-month interval for which a subject was able to be scored at both time points (i.e., either baseline to Month 6 or Month 6 to Month 12). The mean decline in Leiter-3 NVIQ score over 6 months was 8.625 points (N = 16, p = 0.002). The mean decline in NVIQ score over 6months of 8.625 points is considered a reliable change beyond what can be explained by measurement error alone, as the Reliable Change Index in the normative population is ≥6.43 for children 3 to 6 years old or ≥6.76 for children 7 to 11 years old, using a significance level of p b 0.05
Intra-subject change in Leiter-3 nonverbal IQ over 6month intervals (N=21). Normal range (shaded, partially shown on graph) is 85 to 115. The lowest score possible is 30. Blue circle(s) connected by line(s) = subject with MPS IIIA, red square(s) connected by line(s) = subject with MPS IIIB
Other Neurocognitive Tests
In the natural history study, the Mullen Scales of Early Learning also demonstrated significant change in age-equivalence scores over the course of the study in 3 of 5 domains (Visual Reception, Fine Motor, and Expressive Language), and the decline neared significance in the Receptive Language domain.
For behavioral assessment, the investigators of the natural history study found the Vineland Adaptive Behavior Scale to be measurable across the entire subject population, as expected from a parental interview that measures adaptive living skills. A decline in the Vineland composite standard score correlated strongly with chronological age in this entire cohort, with a significant mean decline of 5.09 points over a 6-month interval (p = 0.0004) that notably does not differ for those below versus above 7 years old, in contrast to the Leiter NVIQ standard score.
Below are the results of the Intra-subject change in Vineland composite standard score over 6 month intervals (N = 25) found during the natural history study. Due to late addition of the test and subject withdrawals: three subjects were assessed at one, 16 subjects at two, and six subjects at three time points. Normal range (shaded, partially shown on graph) is 85 to 115. The lowest score possible is 20. Blue circle(s) connected by line(s) = subject with MPS IIIA, red square(s) connected by line(s) = subject with MPS IIIB.
Anecdotal evidence suggests that ABO 102 may have an effect on neurocognitive function but we await data on Feb 16
As I mentioned in a previous report, it is possible to track the first patient in real time. The family keep a facebook page (Saving Eliza O'Neill) and the family have appeared on numerous television shows and in various newspapers and journals. Eliza's story is pretty incredible. In order to ensure that Eliza was eligible for enrollment into the clinical trial the entire family had to isolate themselves for 726 days (they could not allow Eliza to come into contact with the virus that is being used to deliver the gene). Her nine year old brother, Beckham had to be home schooled so that he wouldn't come into contact with other people.
Eliza received the first treatment in the clinical trial in May 2016 and has just passed her six month follow up and we hope to hear about six month results in 1Q 2017. Anecdotal evidence from the facebook page suggests that she is doing very well. In fact, Eliza had lost the ability to speak in April 2016 but now she appears to be able to say basic words. The family have also been on numerous television shows and in magazines and journals - it really is an amazing story. She appears to have had a great seventh birthday, is enjoying her first year at school (she is attending a special school for autistic children) and Beckham (who should be awarded "the best big brother in the world" award spends much time talking about how Eliza has changed following treatment and how she no longer grabs his ipad from him! Based on this anecdotal evidence, perhaps ABO-102 is having an effect on Eliza's neurocognitive function.
The path forwards and the approval process
The current clinical trial has already enrolled three patients that have received the low dose formulation. An additional six patients will receive the higher dose with the first patient receiving treatment on or around Jan 24, 2017. This will therefore be viewed as a multicenter clinical trial.
It is likely that the company will have >20 patients of data with six month follow up by the end of 2017. At this time point there will also be three patients with >12 months follow up. As shown in a previous exhibit, most BLA submissions for other MPS diseases have involved trial populations of around twenty patients and we would be surprised if the FDA did not accept such a data package for regulatory review and subsequent approval. It therefore appears likely that Abeona will receive approval around mid year 2018 for ABO 102.
There have been two gene therapy products approved in Europe.
Strimvelis is the first ex-vivo stem cell gene therapy to treat patients with a very rare disease called ADA-SCID (Severe Combined Immunodeficiency due to Adenosine Deaminase deficiency), a rare disorder caused by the absence of an essential protein called adenosine deaminase (ADA), which is required for the production of lymphocytes. Children born with ADA-SCID do not develop a healthy immune system so cannot fight off everyday infections, which results in severe and life-threatening illness. Without prompt treatment, the disorder often proves fatal within the child's first year of life. ADA-SCID is estimated to occur in approximately 15 patients per year in Europe. Strimvelis was approved in 1H 2016 following a clinical trial involving 22 children.
Glybera is a gene therapy that is designed to restore the LPL enzyme activity required to enable the processing, or clearance, of fat-carrying chylomicron particles formed in the intestine after a fat-containing meal. The product consists of an engineered copy of the human LPL gene packaged with a tissue-specific promoter in a non-replicating AAV1 vector, which has a particular affinity for muscle cells. Ahead of EMEA approval, Glybera was studied in 27 patients with lipoprotein lipase deficiency on a low-fat diet. The majority of patients who received Glybera also received immunosuppressive treatment. The main measures of effectiveness were the reduction in blood fat levels after meals and the reduction in the number of pancreatitis attacks.
The Commercial Opportunity
The incidence of MPS III is estimated to be ~1/70,000 births ( Meikle et al, JAMA 1999, 281: 249 ; Heron et al, Am J Med Genet 2010, 155: 58 ). It is also estimated that there are approximately 2000 Sanfilippo type A patients in the world with approximately 60 births in the US each year and about 100 in the developed rest of world (source: wikipedia and industry websites). Unlike primary care illnesses such as cardiovascular illnesses, these rare genetic diseases have very high levels of penetration and reimbursement and it is quite likely that c. 80% of patients will receive treatment. The company has not disclosed the price it intends to charge however other gene therapy companies such as Biomarin have suggested a gene therapy treatment cost of $1.5m per treatment is where they intend to price their gene therapy products for similar diseases and this appears to be a sensible assumption, in my view. This is also considerably lower than lifetime treatment costs for diseases such as Gaucher's disease (c. $5m), Hemophilia (c. $3m) and Hunter Syndrome (c. $5m). Glybera (the first ever gene therapy product approved) was launched in Europe at $1.4m per patient.
Based on these assumptions, this product could potentially generate $4.4bn of revenues in its first ten years. On their recent Q3 conference call, the company suggested that the cost of each dose will be approximately $25k and the company is in the process of constructing a manufacturing facility in Cleveland. Abeona will also need to finalize the financial terms with RegenXBio (RGNX) who own the rights to the AVV9 vector. RegenXBio's patent that protects the AAV9 vector expires in the early part of next decade (c. 2023). Looking at precedent transactions suggests that Abeona will have to pay a royalty in the low double digit area. Lysogene (private) received exclusive licensing from RGNX for AAVrh10-based gene therapy in MPS IIIA in Dec '13, with financial terms including 1) $0.5M initial fee, 2) an annual maintenance fee, 3) up to $7.75M milestones per product and 4) mid-single to high-single digit % royalty. Esteve (private) received non-exclusive licensing from RGNX for AAV9-based gene therapy in MPS IIIA in Mar '14, with financial terms including 1) $0.5M initial fee, 2) an annual maintenance fee, 3) up to $8.5M in milestones per product, 4) mid-single to low double-digit % royalty.
This suggests that gross profit derived from ABO102 during its first ten years will be over $4bn. There are minimal selling and marketing costs associated with this disease because it is so rare and patients are very aware of the disease. If we discount this $4bn of cumulative profit back a few years then $3bn probably isn't far from the correct number of where fair value will reside, once the product has been approved. Take a 50% haircut for an unapproved product and it isn't unreasonable to think that the mkt cap should reside in the $1.5bn region fairly soon ($30/share). This is also close to the value where other gene therapy companies with validated clinical data trade (Spark Therapeutics ( ONCE ), Blubird Bio (BLUE), Avexis , Ultragenyx (NASDAQ:) and Alexion (ALXN)).
Valuation and target price
As with all early stage biotech companies it is very easy to get carried away with potential valuation etc. under blue sky outcomes. However giving the company $3bn of value for ABO 102 when fully commercialized. In addition, as we have previously written there are a number of other technologies that may provide upside to >$100 per share over the next several years, however this report focuses on ABO 102 and Abeona's SanFilippo gene therapy franchise.
This is an unprofitable biotechnology company with cash on balance sheet of $72m. The key risks to an investment in Abeona is clearly the failure of the company to commercialize any of their clinical programs. Under such a scenario, cash on balance sheet is approx $1.75/share.
See also Northern Dynasty Minerals Ltd.: The Pebble Deposit Isn't Commercially Viable on seekingalpha.com
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abeona is using AAV9 (double stranded) for its vector Sanfilippo syndrome has a significant CNS component to the disease and it is imperative that the virus is able to penetrate the blood brain barrier, persist in the central nervous system and deliver its genetic payload to the patients' cells. By World's Greatest : Executive Summary and Investment Thesis Abeona Therapeutics ( ABEO ) is a biotechnology company with a number of early- and late-stage assets. Like other gene therapy companies with unproven technology, Abeona trades at a substantial discount to those companies with validated technology, and I believe that validation of Abeona's lead technology could drive the company's share price toward $30/share, which would put the company's valuation in line with those companies that have validated technology - e.g., AveXis ( AVXS ), Spark Therapeutics ( ONCE ), and Ultragenyx Pharmaceutical ( RARE ). | By World's Greatest : Executive Summary and Investment Thesis Abeona Therapeutics ( ABEO ) is a biotechnology company with a number of early- and late-stage assets. Like other gene therapy companies with unproven technology, Abeona trades at a substantial discount to those companies with validated technology, and I believe that validation of Abeona's lead technology could drive the company's share price toward $30/share, which would put the company's valuation in line with those companies that have validated technology - e.g., AveXis ( AVXS ), Spark Therapeutics ( ONCE ), and Ultragenyx Pharmaceutical ( RARE ). As with all biotech investments, the outcome of an investment is very dependent on clinical trial outcomes which is speculative and the key company specific risk in Abeona is the failure to commercialize any of their clinical programs. | Like other gene therapy companies with unproven technology, Abeona trades at a substantial discount to those companies with validated technology, and I believe that validation of Abeona's lead technology could drive the company's share price toward $30/share, which would put the company's valuation in line with those companies that have validated technology - e.g., AveXis ( AVXS ), Spark Therapeutics ( ONCE ), and Ultragenyx Pharmaceutical ( RARE ). By World's Greatest : Executive Summary and Investment Thesis Abeona Therapeutics ( ABEO ) is a biotechnology company with a number of early- and late-stage assets. As with all biotech investments, the outcome of an investment is very dependent on clinical trial outcomes which is speculative and the key company specific risk in Abeona is the failure to commercialize any of their clinical programs. | Like other gene therapy companies with unproven technology, Abeona trades at a substantial discount to those companies with validated technology, and I believe that validation of Abeona's lead technology could drive the company's share price toward $30/share, which would put the company's valuation in line with those companies that have validated technology - e.g., AveXis ( AVXS ), Spark Therapeutics ( ONCE ), and Ultragenyx Pharmaceutical ( RARE ). By World's Greatest : Executive Summary and Investment Thesis Abeona Therapeutics ( ABEO ) is a biotechnology company with a number of early- and late-stage assets. As with all biotech investments, the outcome of an investment is very dependent on clinical trial outcomes which is speculative and the key company specific risk in Abeona is the failure to commercialize any of their clinical programs. |
28114.0 | 2017-01-06 00:00:00 UTC | Friday Sector Leaders: Trucking, Biotechnology Stocks | ABEO | https://www.nasdaq.com/articles/friday-sector-leaders-trucking-biotechnology-stocks-2017-01-06 | nan | nan | In trading on Friday, trucking shares were relative leaders, up on the day by about 1.3%. Leading the group were shares of Celadon Group ( CGI ), up about 5.7% and shares of USA Truck ( USAK ) up about 5.1% on the day.
Also showing relative strength are biotechnology shares, up on the day by about 1.3% as a group, led by Abeona Therapeutics ( ABEO ), trading higher by about 8.6% and Puma Biotechnology ( PBYI ), trading up by about 7.1% on Friday.
VIDEO: Friday Sector Leaders: Trucking, Biotechnology Stocks
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Also showing relative strength are biotechnology shares, up on the day by about 1.3% as a group, led by Abeona Therapeutics ( ABEO ), trading higher by about 8.6% and Puma Biotechnology ( PBYI ), trading up by about 7.1% on Friday. In trading on Friday, trucking shares were relative leaders, up on the day by about 1.3%. VIDEO: Friday Sector Leaders: Trucking, Biotechnology Stocks The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Also showing relative strength are biotechnology shares, up on the day by about 1.3% as a group, led by Abeona Therapeutics ( ABEO ), trading higher by about 8.6% and Puma Biotechnology ( PBYI ), trading up by about 7.1% on Friday. In trading on Friday, trucking shares were relative leaders, up on the day by about 1.3%. VIDEO: Friday Sector Leaders: Trucking, Biotechnology Stocks The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Also showing relative strength are biotechnology shares, up on the day by about 1.3% as a group, led by Abeona Therapeutics ( ABEO ), trading higher by about 8.6% and Puma Biotechnology ( PBYI ), trading up by about 7.1% on Friday. Leading the group were shares of Celadon Group ( CGI ), up about 5.7% and shares of USA Truck ( USAK ) up about 5.1% on the day. VIDEO: Friday Sector Leaders: Trucking, Biotechnology Stocks The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Also showing relative strength are biotechnology shares, up on the day by about 1.3% as a group, led by Abeona Therapeutics ( ABEO ), trading higher by about 8.6% and Puma Biotechnology ( PBYI ), trading up by about 7.1% on Friday. In trading on Friday, trucking shares were relative leaders, up on the day by about 1.3%. Leading the group were shares of Celadon Group ( CGI ), up about 5.7% and shares of USA Truck ( USAK ) up about 5.1% on the day. |
28115.0 | 2017-01-03 00:00:00 UTC | Abeona Therapeutics (ABEO): Strong Industry, Solid Earnings Estimate Revisions | ABEO | https://www.nasdaq.com/articles/abeona-therapeutics-abeo%3A-strong-industry-solid-earnings-estimate-revisions-2017-01-03 | nan | nan | One stock that might be an intriguing choice for investors right now is Abeona Therapeutics Inc.ABEO . This is because this security in the Medical-Biomedical/Genetics space is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.
This is important because, often times, a rising tide will lift all boats in an industry, as there can be broad trends taking place in a segment that are boosting securities across the board. This is arguably taking place in the Medical-Biomedical/Genetics space as it currently has a Zacks Industry Rank of 59 out of more than 250 industries, suggesting it is well-positioned from this perspective, especially when compared to other segments out there.
Meanwhile, Abeona Therapeutics is actually looking pretty good on its own too. The firm has seen solid earnings estimate revision activity over the past month, suggesting analysts are becoming a bit more bullish on the firm's prospects in both the short and long term.
ABEONA THERAPTC Price and Consensus
ABEONA THERAPTC Price and Consensus | ABEONA THERAPTC Quote
In fact, over the last 60 days, current quarter estimates have narrowed from a loss of 15 cents per share to a loss of 12 cents per share, while current year estimates have narrowed from a loss of 72 cents per share to a loss of 66 cents per share. The company currently carries a Zacks Rank #3 (Hold), which is also a favorable signal.You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
So, if you are looking for a decent pick in a strong industry, consider Abeona Therapeutics. Not only is its industry currently in the top third, but it is seeing solid estimate revisions as of late, suggesting it could be a very interesting choice for investors seeking a name in this great industry segment.
Zacks' Top 10 Stocks for 2017
In addition to the stocks discussed above, would you like to know about our 10 finest tickers for the entirety of 2017?
Who wouldn't? These 10 are painstakingly hand-picked from 4,400 companies covered by the Zacks Rank. They are our primary picks to buy and hold. Be among the very first to see them >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ABEONA THERAPTC (ABEO): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ABEONA THERAPTC Price and Consensus ABEONA THERAPTC Price and Consensus | ABEONA THERAPTC Quote In fact, over the last 60 days, current quarter estimates have narrowed from a loss of 15 cents per share to a loss of 12 cents per share, while current year estimates have narrowed from a loss of 72 cents per share to a loss of 66 cents per share. One stock that might be an intriguing choice for investors right now is Abeona Therapeutics Inc.ABEO . Meanwhile, Abeona Therapeutics is actually looking pretty good on its own too. | ABEONA THERAPTC Price and Consensus ABEONA THERAPTC Price and Consensus | ABEONA THERAPTC Quote In fact, over the last 60 days, current quarter estimates have narrowed from a loss of 15 cents per share to a loss of 12 cents per share, while current year estimates have narrowed from a loss of 72 cents per share to a loss of 66 cents per share. One stock that might be an intriguing choice for investors right now is Abeona Therapeutics Inc.ABEO . Meanwhile, Abeona Therapeutics is actually looking pretty good on its own too. | ABEONA THERAPTC Price and Consensus ABEONA THERAPTC Price and Consensus | ABEONA THERAPTC Quote In fact, over the last 60 days, current quarter estimates have narrowed from a loss of 15 cents per share to a loss of 12 cents per share, while current year estimates have narrowed from a loss of 72 cents per share to a loss of 66 cents per share. One stock that might be an intriguing choice for investors right now is Abeona Therapeutics Inc.ABEO . Meanwhile, Abeona Therapeutics is actually looking pretty good on its own too. | One stock that might be an intriguing choice for investors right now is Abeona Therapeutics Inc.ABEO . Meanwhile, Abeona Therapeutics is actually looking pretty good on its own too. ABEONA THERAPTC Price and Consensus ABEONA THERAPTC Price and Consensus | ABEONA THERAPTC Quote In fact, over the last 60 days, current quarter estimates have narrowed from a loss of 15 cents per share to a loss of 12 cents per share, while current year estimates have narrowed from a loss of 72 cents per share to a loss of 66 cents per share. |
28116.0 | 2016-10-20 00:00:00 UTC | Health Care Sector Update for 10/20/2016: MDGL,ABEO,RIGL | ABEO | https://www.nasdaq.com/articles/health-care-sector-update-10202016-mdglabeorigl-2016-10-20 | nan | nan | Top Health Care Stocks
JNJ +0.29%
PFE -0.03%
MRK +1.95%
ABT +0.15%
AMGN +0.49%
Health care stocks were significantly higher this afternoon and helping to limit declines for the broader markets today, with the NYSE Health Care Index rising over 0.4% while shares of health care companies in the S&P 500 also were up 0.6% as a group.
In company news, Madrigal Pharmaceuticals ( MDGL ) was lower in late Thursday trading and the early-stage biotech company receiving little apparent help from the start of Phase II testing of its MGL-3196 drug candidate in patients with liver inflammation caused by an accumulation of fat in the organ.
The study expects to enroll 117 adults with biopsy-confirmed nonalcoholic steatohepatitis, with the patients randomized to have twice as many of the patients receiving MGL-3196 compared with the placebo group. The primary target for the trial will be a reduction in symptoms as measured by a biopsy after 36 weeks with secondary endpoints including changes in clinically relevant biomarkers after 12 and 36 weeks as well as a reduction in fibrosis with increase in their steatohepatitis.
MDGL shares were down about 0.3% at $15.26 each, recovering somewhat from an early slide to a session low of $14.50 a share.
In other sector news,
(+) ABEO, Presents Phase I/II data indicating all subjects with mucopolysaccharidosis receiving small dosages of its ABO-102 gene therapy saw protein levels in their urine and spinal fluid decline.
(-) RIGL, Fostamatinib drug candidate fails to meet primary endpoint of a stable platelet response during Phase III testing.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In other sector news, (+) ABEO, Presents Phase I/II data indicating all subjects with mucopolysaccharidosis receiving small dosages of its ABO-102 gene therapy saw protein levels in their urine and spinal fluid decline. In company news, Madrigal Pharmaceuticals ( MDGL ) was lower in late Thursday trading and the early-stage biotech company receiving little apparent help from the start of Phase II testing of its MGL-3196 drug candidate in patients with liver inflammation caused by an accumulation of fat in the organ. (-) RIGL, Fostamatinib drug candidate fails to meet primary endpoint of a stable platelet response during Phase III testing. | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. In other sector news, (+) ABEO, Presents Phase I/II data indicating all subjects with mucopolysaccharidosis receiving small dosages of its ABO-102 gene therapy saw protein levels in their urine and spinal fluid decline. Health care stocks were significantly higher this afternoon and helping to limit declines for the broader markets today, with the NYSE Health Care Index rising over 0.4% while shares of health care companies in the S&P 500 also were up 0.6% as a group. | In other sector news, (+) ABEO, Presents Phase I/II data indicating all subjects with mucopolysaccharidosis receiving small dosages of its ABO-102 gene therapy saw protein levels in their urine and spinal fluid decline. Health care stocks were significantly higher this afternoon and helping to limit declines for the broader markets today, with the NYSE Health Care Index rising over 0.4% while shares of health care companies in the S&P 500 also were up 0.6% as a group. In company news, Madrigal Pharmaceuticals ( MDGL ) was lower in late Thursday trading and the early-stage biotech company receiving little apparent help from the start of Phase II testing of its MGL-3196 drug candidate in patients with liver inflammation caused by an accumulation of fat in the organ. | In other sector news, (+) ABEO, Presents Phase I/II data indicating all subjects with mucopolysaccharidosis receiving small dosages of its ABO-102 gene therapy saw protein levels in their urine and spinal fluid decline. Top Health Care Stocks Health care stocks were significantly higher this afternoon and helping to limit declines for the broader markets today, with the NYSE Health Care Index rising over 0.4% while shares of health care companies in the S&P 500 also were up 0.6% as a group. |
28117.0 | 2016-10-20 00:00:00 UTC | Health Care Sector Update for 10/20/2016: ONVO,ABEO,RIGL | ABEO | https://www.nasdaq.com/articles/health-care-sector-update-10202016-onvoabeorigl-2016-10-20 | nan | nan | Top Health Care Stocks
JNJ +0.23%
PFE +0.22%
MRK +1.65%
ABT +0.09%
AMGN +0.46%
Health care stocks were significantly higher this afternoon, helping to limit declines for the broader markets. The NYSE Health Care Index is up more than 0.6% while shares of health care companies in the S&P 500 are up 0.6% as a group.
In company news, Organovo Holdings ( ONVO ) retreated Thursday after the tissue and organ manufacturing company priced a $25 million public offering of 9 million shares at $2.75 each, a 21% discount compared with Wednesday's closing price.
The company expects to use net proceeds from the deal, after first paying underwriter discounts and other offering expenses, to fund general corporate activities, including research and development as well as development and commercialization of new products in addition to administrative expenses and working capital.
ONVO shares were down about 16% at $2.93 each, earlier sliding to a session low of $2.76 a share.
In other sector news,
(+) ABEO, (+13.3%) Presents Phase I/II data indicating all subjects with mucopolysaccharidosis receiving small dosages of its ABO-102 gene therapy saw protein levels in their urine and spinal fluid decline.
(-) RIGL, (-22.4%) Fostamatinib drug candidate fails to meet primary endpoint of a stable platelet response during Phase III testing.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In other sector news, (+) ABEO, (+13.3%) Presents Phase I/II data indicating all subjects with mucopolysaccharidosis receiving small dosages of its ABO-102 gene therapy saw protein levels in their urine and spinal fluid decline. Health care stocks were significantly higher this afternoon, helping to limit declines for the broader markets. (-) RIGL, (-22.4%) Fostamatinib drug candidate fails to meet primary endpoint of a stable platelet response during Phase III testing. | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. In other sector news, (+) ABEO, (+13.3%) Presents Phase I/II data indicating all subjects with mucopolysaccharidosis receiving small dosages of its ABO-102 gene therapy saw protein levels in their urine and spinal fluid decline. In company news, Organovo Holdings ( ONVO ) retreated Thursday after the tissue and organ manufacturing company priced a $25 million public offering of 9 million shares at $2.75 each, a 21% discount compared with Wednesday's closing price. | In other sector news, (+) ABEO, (+13.3%) Presents Phase I/II data indicating all subjects with mucopolysaccharidosis receiving small dosages of its ABO-102 gene therapy saw protein levels in their urine and spinal fluid decline. The NYSE Health Care Index is up more than 0.6% while shares of health care companies in the S&P 500 are up 0.6% as a group. In company news, Organovo Holdings ( ONVO ) retreated Thursday after the tissue and organ manufacturing company priced a $25 million public offering of 9 million shares at $2.75 each, a 21% discount compared with Wednesday's closing price. | In other sector news, (+) ABEO, (+13.3%) Presents Phase I/II data indicating all subjects with mucopolysaccharidosis receiving small dosages of its ABO-102 gene therapy saw protein levels in their urine and spinal fluid decline. The NYSE Health Care Index is up more than 0.6% while shares of health care companies in the S&P 500 are up 0.6% as a group. The company expects to use net proceeds from the deal, after first paying underwriter discounts and other offering expenses, to fund general corporate activities, including research and development as well as development and commercialization of new products in addition to administrative expenses and working capital. |
28118.0 | 2016-10-18 00:00:00 UTC | Why Abeona Therapeutics Inc. Is Surging Today | ABEO | https://www.nasdaq.com/articles/why-abeona-therapeutics-inc-surging-today-2016-10-18 | nan | nan | Image source: Getty Images.
What happened
Shares of Abeona Therapeutics (NASDAQ: ABEO) , a clinical-stage biotech focused on rare diseases, rose by 16% as of 3:55 p.m. EDT on Tuesday.
So what
The company announced that the European Medicines Agency has granted its lead gene therapy compound, ABO-102, orphan-drug status. ABO-102 is currently in phase 1/2 testing as a hopeful treatment for Sanfilippo syndrome type A, a potentially deadly rare autosomal disease that results in abnormal accumulation of sugars in the body.
Receiving orphan-drug designation provides the company with a number of potential benefits, including lower regulatory fees, increased guidance from regulatory agencies, and a longer protection period from competition if it wins approval.
The news caused a handful of analysts to reaffirm their "buy" rating on the company, which is why shares are moving higher today.
Now what
Abeona currently has two product candidates in development -- ABO-101 and ABO-102 -- for Sanfilippo syndromes, and the FDA has already granted an orphan-product and rare pediatric disease designation to both. If the company manages to win approval for either, then it could earn pediatric disease priority review vouchers, allowing the company to cut the review time of another one of its drugs to six months from the standard 10-month period. Another option could be to sell the voucher on the open market, which could be a great way to raise capital without diluting shareholders.
There's no doubt that Abeona's future is looking bright if either one of its product candidates can find its way to market, but it's important to remember that both of them are still in early clinical development. That means there are still plenty of hurdles for the company to clear before it can start to generate product revenue. For that reason, only investors with an extremely high tolerance for risk should consider making an investment today.
A secret billion-dollar stock opportunity
The world's biggest tech company forgot to show you something, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early in-the-know investors! To be one of them, just click here .
Brian Feroldi has no position in any stocks mentioned.Like this article? Follow him on Twitter, where he goes by the handle@Longtermmindset, or connect with him onLinkedInto see more articles like this.
The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | What happened Shares of Abeona Therapeutics (NASDAQ: ABEO) , a clinical-stage biotech focused on rare diseases, rose by 16% as of 3:55 p.m. EDT on Tuesday. Now what Abeona currently has two product candidates in development -- ABO-101 and ABO-102 -- for Sanfilippo syndromes, and the FDA has already granted an orphan-product and rare pediatric disease designation to both. There's no doubt that Abeona's future is looking bright if either one of its product candidates can find its way to market, but it's important to remember that both of them are still in early clinical development. | Now what Abeona currently has two product candidates in development -- ABO-101 and ABO-102 -- for Sanfilippo syndromes, and the FDA has already granted an orphan-product and rare pediatric disease designation to both. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. What happened Shares of Abeona Therapeutics (NASDAQ: ABEO) , a clinical-stage biotech focused on rare diseases, rose by 16% as of 3:55 p.m. EDT on Tuesday. | What happened Shares of Abeona Therapeutics (NASDAQ: ABEO) , a clinical-stage biotech focused on rare diseases, rose by 16% as of 3:55 p.m. EDT on Tuesday. Now what Abeona currently has two product candidates in development -- ABO-101 and ABO-102 -- for Sanfilippo syndromes, and the FDA has already granted an orphan-product and rare pediatric disease designation to both. There's no doubt that Abeona's future is looking bright if either one of its product candidates can find its way to market, but it's important to remember that both of them are still in early clinical development. | Now what Abeona currently has two product candidates in development -- ABO-101 and ABO-102 -- for Sanfilippo syndromes, and the FDA has already granted an orphan-product and rare pediatric disease designation to both. What happened Shares of Abeona Therapeutics (NASDAQ: ABEO) , a clinical-stage biotech focused on rare diseases, rose by 16% as of 3:55 p.m. EDT on Tuesday. There's no doubt that Abeona's future is looking bright if either one of its product candidates can find its way to market, but it's important to remember that both of them are still in early clinical development. |
28119.0 | 2016-10-18 00:00:00 UTC | Health Care Sector Update for 10/18/2016: JNJ,PFE,ABEO,ICCC | ABEO | https://www.nasdaq.com/articles/health-care-sector-update-10182016-jnjpfeabeoiccc-2016-10-18 | nan | nan | Top Health Care Stocks
JNJ -2.70%
PFE +0.58%
MRK +0.93%
ABT +1.43%
AMGN +0.11%
Health care stocks were broadly higher in afternoon trade, with the NYSE Health Care Index climbing almost 1.2% while shares of health care companies in the S&P 500 also were up 1.2% as a group.
In company news, Johnson & Johnson ( JNJ ) remained underwater deep into Tuesday trading, with shares of the health care conglomerate still holding near their session low after rival Pfizer ( PFE ) late yesterday said it will begin selling a biosimilar medication to J&J's Remicade arthritis treatment late next month.
Remicade generated around $1.22 billion in sales for Johnson & Johnson during the three months ended Sept. 30, up 9.4% over the same quarter last year, and is projected to produce over $5 billion in sales this year. Pfizer plans to market its Inflectra medication as a treatment for Crohn's disease, ulcerative colitis and severe plaque psoriasis in addition to certain forms of arthritis.
Worries over the new competition for Remicade upstaged better-than-expected Q3 financial results at Johnson & Johnson earlier today, with the company reporting net income of $1.68 per share on $17.82 in revenue. That beat a year-ago profit of $1.49 a share on $17.1 billion in revenue and topping the Capital IQ consensus expecting earnings of $1.66 per share and revenue of $17.74 billion.
JNJ shares finished 2.7% lower at $115.30 apiece, recovering slightly from a session low of $115.16 a share. PFE shares rose nearly 1% at $32.69 each, easing from a prior advance to $32.87 a share.
In other sector news,
(+) ABEO, Receives orphan drug designation by European regulators for its ABO-102 gene therapy in patients with Sanfilippo syndrome type A.
(-) ICCC, Launches $3.5 mln private placement of 659,880 shares of its common stock at $5.25 each.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In other sector news, (+) ABEO, Receives orphan drug designation by European regulators for its ABO-102 gene therapy in patients with Sanfilippo syndrome type A. In company news, Johnson & Johnson ( JNJ ) remained underwater deep into Tuesday trading, with shares of the health care conglomerate still holding near their session low after rival Pfizer ( PFE ) late yesterday said it will begin selling a biosimilar medication to J&J's Remicade arthritis treatment late next month. Pfizer plans to market its Inflectra medication as a treatment for Crohn's disease, ulcerative colitis and severe plaque psoriasis in addition to certain forms of arthritis. | In other sector news, (+) ABEO, Receives orphan drug designation by European regulators for its ABO-102 gene therapy in patients with Sanfilippo syndrome type A. Top Health Care Stocks In company news, Johnson & Johnson ( JNJ ) remained underwater deep into Tuesday trading, with shares of the health care conglomerate still holding near their session low after rival Pfizer ( PFE ) late yesterday said it will begin selling a biosimilar medication to J&J's Remicade arthritis treatment late next month. | In other sector news, (+) ABEO, Receives orphan drug designation by European regulators for its ABO-102 gene therapy in patients with Sanfilippo syndrome type A. Health care stocks were broadly higher in afternoon trade, with the NYSE Health Care Index climbing almost 1.2% while shares of health care companies in the S&P 500 also were up 1.2% as a group. In company news, Johnson & Johnson ( JNJ ) remained underwater deep into Tuesday trading, with shares of the health care conglomerate still holding near their session low after rival Pfizer ( PFE ) late yesterday said it will begin selling a biosimilar medication to J&J's Remicade arthritis treatment late next month. | In other sector news, (+) ABEO, Receives orphan drug designation by European regulators for its ABO-102 gene therapy in patients with Sanfilippo syndrome type A. Top Health Care Stocks In company news, Johnson & Johnson ( JNJ ) remained underwater deep into Tuesday trading, with shares of the health care conglomerate still holding near their session low after rival Pfizer ( PFE ) late yesterday said it will begin selling a biosimilar medication to J&J's Remicade arthritis treatment late next month. |
28120.0 | 2016-10-18 00:00:00 UTC | Health Care Sector Update for 10/18/2016: CCXI,ABEO,ICCC | ABEO | https://www.nasdaq.com/articles/health-care-sector-update-10182016-ccxiabeoiccc-2016-10-18 | nan | nan | Top Health Care Stocks
JNJ -2.60%
PFE +0.98%
MRK +1.04%
ABT +1.53%
AMGN +0.30%
Health care stocks were broadly higher in afternoon trade, with the NYSE Health Care Index climbing more than 1.2% while shares of health care companies in the S&P 500 were up 1.3% as a group.
In company news, ChemoCentryx ( CCXI ) advanced Tuesday after the biopharmaceutical company said its CCX872 drug candidate outperformed a placebo as well as another prospective treatment for non-alcoholic steatohepatitis also in development during in vivo testing.
CCX872 demonstrated significant reductions in fibrosis and scarring in patients with the fatty liver disease caused by chronic inflammation, according to data presented at American College of Gastroenterology annual meeting that began on Friday, Oct. 14 and extending through Wednesday.
CCXI shares were up more than 7% at $6.22 each, easing slightly from a recent session high of $6.38 a share.
In other sector news,
(+) ABEO, (+14.2%) Receives orphan drug designation by European regulators for its ABO-102 gene therapy in patients with Sanfilippo syndrome type A.
(-) ICCC, (-16.0%) Launches $3.5 mln private placement of 659,880 shares of its common stock at $5.25 each. Also said it expects lower Q3 results from the year-ago period.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In other sector news, (+) ABEO, (+14.2%) Receives orphan drug designation by European regulators for its ABO-102 gene therapy in patients with Sanfilippo syndrome type A. CCX872 demonstrated significant reductions in fibrosis and scarring in patients with the fatty liver disease caused by chronic inflammation, according to data presented at American College of Gastroenterology annual meeting that began on Friday, Oct. 14 and extending through Wednesday. (-) ICCC, (-16.0%) Launches $3.5 mln private placement of 659,880 shares of its common stock at $5.25 each. | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. In other sector news, (+) ABEO, (+14.2%) Receives orphan drug designation by European regulators for its ABO-102 gene therapy in patients with Sanfilippo syndrome type A. Health care stocks were broadly higher in afternoon trade, with the NYSE Health Care Index climbing more than 1.2% while shares of health care companies in the S&P 500 were up 1.3% as a group. | In other sector news, (+) ABEO, (+14.2%) Receives orphan drug designation by European regulators for its ABO-102 gene therapy in patients with Sanfilippo syndrome type A. Health care stocks were broadly higher in afternoon trade, with the NYSE Health Care Index climbing more than 1.2% while shares of health care companies in the S&P 500 were up 1.3% as a group. In company news, ChemoCentryx ( CCXI ) advanced Tuesday after the biopharmaceutical company said its CCX872 drug candidate outperformed a placebo as well as another prospective treatment for non-alcoholic steatohepatitis also in development during in vivo testing. | In other sector news, (+) ABEO, (+14.2%) Receives orphan drug designation by European regulators for its ABO-102 gene therapy in patients with Sanfilippo syndrome type A. Top Health Care Stocks Health care stocks were broadly higher in afternoon trade, with the NYSE Health Care Index climbing more than 1.2% while shares of health care companies in the S&P 500 were up 1.3% as a group. |
28121.0 | 2016-10-06 00:00:00 UTC | Abeona Therapeutics (ABEO) Surges: Stock Rises 11.3% | ABEO | https://www.nasdaq.com/articles/abeona-therapeutics-abeo-surges%3A-stock-rises-11.3-2016-10-06 | nan | nan | Abeona Therapeutics Inc.ABEO was a big mover last session, as its shares rose a little over 11% on the day. The move came on the back of Data Safety Monitoring Board's approval of ABO-102 dose escalation for second cohort in Phase 1/2 clinical trial for Sanfilippo Syndrome Type A. This led to far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $4.69 to $6.57 in the past one-month time frame.
None of the estimates for this stock were revised over the past 30 days while the Zacks Consensus Estimate moved lower over the same time frame, suggesting there may be trouble down the road. So make sure to keep an eye on this stock going forward to see if this recent move higher can last.
Abeona Therapeutics currently carries a Zacks Rank #4 (Sell) while its Earnings ESP is 0.00%.
ABEONA THERAPTC Price
ABEONA THERAPTC Price | ABEONA THERAPTC Quote
A better-ranked stock in the med-biomed/gene space is Geron Corporation GERN , which sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here.
Is ABEO going up? Or down? Predict to see what others think: Up or Down
Confidential from Zacks
Beyond this Tale of the Tape, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
GERON CORP (GERN): Free Stock Analysis Report
ABEONA THERAPTC (ABEO): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abeona Therapeutics Inc.ABEO was a big mover last session, as its shares rose a little over 11% on the day. Abeona Therapeutics currently carries a Zacks Rank #4 (Sell) while its Earnings ESP is 0.00%. ABEONA THERAPTC Price ABEONA THERAPTC Price | ABEONA THERAPTC Quote A better-ranked stock in the med-biomed/gene space is Geron Corporation GERN , which sports a Zacks Rank #1 (Strong Buy). | ABEONA THERAPTC Price ABEONA THERAPTC Price | ABEONA THERAPTC Quote A better-ranked stock in the med-biomed/gene space is Geron Corporation GERN , which sports a Zacks Rank #1 (Strong Buy). Click to get this free report GERON CORP (GERN): Free Stock Analysis Report ABEONA THERAPTC (ABEO): Free Stock Analysis Report To read this article on Zacks.com click here. Abeona Therapeutics Inc.ABEO was a big mover last session, as its shares rose a little over 11% on the day. | ABEONA THERAPTC Price ABEONA THERAPTC Price | ABEONA THERAPTC Quote A better-ranked stock in the med-biomed/gene space is Geron Corporation GERN , which sports a Zacks Rank #1 (Strong Buy). Click to get this free report GERON CORP (GERN): Free Stock Analysis Report ABEONA THERAPTC (ABEO): Free Stock Analysis Report To read this article on Zacks.com click here. Abeona Therapeutics Inc.ABEO was a big mover last session, as its shares rose a little over 11% on the day. | Abeona Therapeutics Inc.ABEO was a big mover last session, as its shares rose a little over 11% on the day. Abeona Therapeutics currently carries a Zacks Rank #4 (Sell) while its Earnings ESP is 0.00%. ABEONA THERAPTC Price ABEONA THERAPTC Price | ABEONA THERAPTC Quote A better-ranked stock in the med-biomed/gene space is Geron Corporation GERN , which sports a Zacks Rank #1 (Strong Buy). |
28122.0 | 2016-09-21 00:00:00 UTC | Health Care Sector Update for 09/21/2016: NWBO,ABEO,MIRN | ABEO | https://www.nasdaq.com/articles/health-care-sector-update-09212016-nwboabeomirn-2016-09-21 | nan | nan | Top Health Care Stocks
JNJ +0.82%
PFE +1.30%
MRK +0.85%
ABT +1.25%
AMGN +0.28%
Health care stocks were ending broadly higher this afternoon, with the NYSE Health Care Index rising about 0.8% while shares of health care companies in the S&P 500 were ahead 1.1% as a group.
In company news, shares of Northwest Biotherapeutics ( NWBO ) fell Wednesday after the specialty drugmaker updated data from Phase I testing of its prospective treatment for inoperable solid tumors.
The company said the top 20% of the trial's patients have so far exceeded more than two years of survival, with the longest survivor now reaching nearly three years. The top 30% of patients were surviving 26.7 months, on average, compared with expected survival period of about 12.3 months.
NWBO share lost almost 11% today, closing at 63 cents each after earlier sinking to a session low of 55 cents a share.
In other sector news,
(+) ABEO, Receives exclusive global license from the University of North Carolina to a next-generation gene therapy platform of Adeno-associated viruses that do not make people sick but still can trigger a mild immune response.
(-) MIRN, Voluntarily ends enrollment in Phase I trial of MRX34 drug candidate after the prospective anti-tumor treatment caused a fifth immune-related adverse reaction.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In other sector news, (+) ABEO, Receives exclusive global license from the University of North Carolina to a next-generation gene therapy platform of Adeno-associated viruses that do not make people sick but still can trigger a mild immune response. In company news, shares of Northwest Biotherapeutics ( NWBO ) fell Wednesday after the specialty drugmaker updated data from Phase I testing of its prospective treatment for inoperable solid tumors. (-) MIRN, Voluntarily ends enrollment in Phase I trial of MRX34 drug candidate after the prospective anti-tumor treatment caused a fifth immune-related adverse reaction. | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. In other sector news, (+) ABEO, Receives exclusive global license from the University of North Carolina to a next-generation gene therapy platform of Adeno-associated viruses that do not make people sick but still can trigger a mild immune response. Top Health Care Stocks | In other sector news, (+) ABEO, Receives exclusive global license from the University of North Carolina to a next-generation gene therapy platform of Adeno-associated viruses that do not make people sick but still can trigger a mild immune response. Health care stocks were ending broadly higher this afternoon, with the NYSE Health Care Index rising about 0.8% while shares of health care companies in the S&P 500 were ahead 1.1% as a group. In company news, shares of Northwest Biotherapeutics ( NWBO ) fell Wednesday after the specialty drugmaker updated data from Phase I testing of its prospective treatment for inoperable solid tumors. | In other sector news, (+) ABEO, Receives exclusive global license from the University of North Carolina to a next-generation gene therapy platform of Adeno-associated viruses that do not make people sick but still can trigger a mild immune response. Top Health Care Stocks Health care stocks were ending broadly higher this afternoon, with the NYSE Health Care Index rising about 0.8% while shares of health care companies in the S&P 500 were ahead 1.1% as a group. |
28123.0 | 2016-08-12 00:00:00 UTC | FormFactor, Palo Alto Networks, Concordia International, Abeona Therapeutics and Proteostasis Therapeutics highlighted as Zacks Bull and Bear of the Day | ABEO | https://www.nasdaq.com/articles/formfactor-palo-alto-networks-concordia-international-abeona-therapeutics-and-proteostasis | nan | nan | For Immediate Release
Chicago, IL - August 12, 2016 - Zacks Equity Research highlights FormFactor ( FORM ) as the Bull of the Day and Palo Alto Networks ( PANW ) as the Bear of the Day. In addition, Zacks Equity Research provides analysis on Concordia International Corp. ( CXRX ), Abeona Therapeutics Inc. ( ABEO ) and Proteostasis Therapeutics, Inc. ( PTI ).
Here is a synopsis of all five stocks:
Bull of the Day:
FormFactor ( FORM ) designs, develops, manufactures, sells and supports precision, high performance advanced semiconductor wafer probe cards. The California based company was founded in 1993 and has almost 1000 employees. FormFactor is ZacksRank #1 (Strong Buy) and todays Bull of the Day after an impressive earnings beat and multiple price upgrades.
FORM has a market cap of $700 Million with a Forward PE of 38. The stock has Zacks Style Scores of "D" in Value, but "A" in Momentum. The high PE is the reason for the Value score, but recent earnings momentum justifies the valuation.
In addition, the company also sits in an industry that is ranked 56 out of 265 (Top 21%) in the Zacks Industry Rank.
Industry strength
Looking at how the stock has performed against its peers we see that FormFactor has a way to go to catch its competitors. Although it has outperformed the S&P 500 over the last two years with a 47% gain versus 12.63% for the index.
Bear of the Day :
Palo Alto Networks ( PANW ) offers a network security platform that allows enterprises, service providers, and government entities to secure their networks. The stock is aZacks Rank #5 (Strong Sell) and the Bear of the Day after peers reported poor earnings over the last week.
Palo Alto has a market cap of $11 Billion and has a PE of negative 49. The stock sports a Zacks Style Score of "F" in Value and "B" in Growth. The valuation is concerning as recanting earnings from peers FireEye and CyberArk disappointed investors.
Palo Alto is the best in breed of the network security space, but that can't bring a stock higher when the rest of the space is headed lower. FireEye reported earnings on august 4 th and cut Q3 guidance to -$0.32 to -$0.30 verse the -$0.24 expected. The company's lower outlook was a result of weaker than expected Q2 billings.
CyberHawk actually bet by 9 cents, beat in revenue, and raised fiscal year guidance. CEO Ehud Mokady had some comments on the quarter: "As we move into the second half of the year, we plan to continue making thoughtful investments including enhancing our technology platform and expanding market presence ."
Investors sold the news and the stock 7% lower.
PANW reaction
Before FireEye and CyberArk reported Palo Alto was trading over $132. Now after the earnings news has settled in the stock is at $125, 5% lower. We won't the company report till August 30 th and estimate revisions are not looking good.
Estimate Revisions
For fiscal year 2016 estimates have come down % over the last 90 days. However, the real concern is fiscal year 2017, as estimate revisions have come down almost 20%, from -$0.94 to -$1.17. be on the lookout for a cut to guidance and more pressure on the stock.
Additional content:
Drug Stock Earnings to Watch for Friday
The Q2 earnings season is almost over with as many as 92.1% S&P 500 members having reported results as of Aug 10. What does the Q2 earnings season scorecard look like so far? Both earnings and revenue growth was negative with the quarter on track to be the fifth in a row to record an earnings decline for the S&P 500 index.
Of the 454 S&P 500 members that have declared quarterly numbers as of Aug 10, an impressive 71.1% were able to top earnings estimates while 52.9% surpassed top-line expectations.
Notably, the Technology and Medical sectors recorded the highest proportion of positive surprises. In fact, results of the Medical sector have been particularly strong so far.
Our Q2 scorecard for the Medical sector shows that 96.2% have reported results with a blended beat of 74% (the percentage of companies that have beaten both earnings and revenue estimates), with the sector registering 5% earnings growth on 9.2% higher revenues.
Note that per our Earnings Trends report, Medical is one of the nine sectors expected to record positive earnings growth (4.7%) this quarter.
While the majority of pharma and biotech companies have already released quarterly results, quite a few companies in the sector are yet to declare the same. Let's see what's in store for these three drug stocks.
Can These Drug Stocks Surprise?
Headquartered in Oakville, Canada, Concordia International Corp. ( CXRX ) is a pharmaceutical company focused on legacy pharmaceutical products and orphan drugs. The company markets orphan drugs through its Orphan Drug Division, consisting of Photofrin for the treatment of certain rare forms of cancer, which is currently being evaluated for additional indications.
CONCORDIA INTL Price and EPS Surprise | CONCORDIA INTL Quote
Concordia has missed earnings expectations in each of the past four quarters, with an average negative earnings surprise of 8.56%. Given its track record, will the stock disappoint again? Concordia currently carries a Zacks Rank #3 (Hold). Though the stock's Zacks Rank #3 increases the predictive power of the ESP, its 0.00% Earnings ESP makes a surprise prediction difficult this quarter. The company is scheduled to release Q2 results on Aug 12.
Abeona Therapeutics Inc. ( ABEO ) is a development-stage company focused on the development of gene therapy and plasma-based treatments for severe and life-threatening rare genetic diseases. This Dallas, TX-based company's performance has been far from encouraging, having missed estimates consistently. Overall, the company has clocked an average negative surprise of 62.43%. Its Zacks Rank #3, when combined with a 0.00% ESP, makes surprise prediction difficult for this quarter.
Abeona is expected to report Q2 results on Aug 12.
ABEONA THERAPTC Price and EPS Surprise | ABEONA THERAPTC Quote
Based in Cambridge, MA, Proteostasis Therapeutics, Inc. ( PTI ) is a development-stage biopharmaceutical company focused on the discovery and development of novel therapeutics targeting diseases caused by an imbalance in the proteostasis network with an initial therapeutic focus on cystic fibrosis. Proteostasis started trading from Feb 2016. Last quarter, the company posted a negative surprise of 85.11%. Proteostasis' Zacks Rank #3, when combined with an ESP of 0.00%, makes surprise prediction difficult for this quarter. It is expected to release Q2 results on Aug 12.
PROTEOSTASIS Price and EPS Surprise | PROTEOSTASIS Quote
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>
Get today's Zacks #1 Stock of the Day with your free subscription to Profit from the Pros newsletter:
About the Bull and Bear of the Day
Every day, the analysts at Zacks Equity Research select two stocks that are likely to outperform (Bull) or underperform (Bear) the markets over the next 3-6 months.
About the Analyst Blog
Updated throughout every trading day, the Analyst Blog provides analysis from Zacks Equity Research about the latest news and events impacting stocks and the financial markets.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous analyst coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Click here to subscribe to this free newsletter today .
About Zacks
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978. The later formation of the Zacks Rank, a proprietary stock picking system; continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros .
Follow us on Twitter: https://twitter.com/zacksresearch
Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Zacks.com provides investment resources and informs you of these resources, which you may choose to use in making your own investment decisions. Zacks is providing information on this resource to you subject to the Zacks "Terms and Conditions of Service" disclaimer. www.zacks.com/disclaimer .
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
FORMFACTOR INC (FORM): Free Stock Analysis Report
PALO ALTO NETWK (PANW): Free Stock Analysis Report
CONCORDIA INTL (CXRX): Free Stock Analysis Report
ABEONA THERAPTC (ABEO): Free Stock Analysis Report
PROTEOSTASIS (PTI): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abeona Therapeutics Inc. ( ABEO ) is a development-stage company focused on the development of gene therapy and plasma-based treatments for severe and life-threatening rare genetic diseases. In addition, Zacks Equity Research provides analysis on Concordia International Corp. ( CXRX ), Abeona Therapeutics Inc. ( ABEO ) and Proteostasis Therapeutics, Inc. ( PTI ). Abeona is expected to report Q2 results on Aug 12. | In addition, Zacks Equity Research provides analysis on Concordia International Corp. ( CXRX ), Abeona Therapeutics Inc. ( ABEO ) and Proteostasis Therapeutics, Inc. ( PTI ). Click to get this free report FORMFACTOR INC (FORM): Free Stock Analysis Report PALO ALTO NETWK (PANW): Free Stock Analysis Report CONCORDIA INTL (CXRX): Free Stock Analysis Report ABEONA THERAPTC (ABEO): Free Stock Analysis Report PROTEOSTASIS (PTI): Free Stock Analysis Report To read this article on Zacks.com click here. Abeona Therapeutics Inc. ( ABEO ) is a development-stage company focused on the development of gene therapy and plasma-based treatments for severe and life-threatening rare genetic diseases. | Click to get this free report FORMFACTOR INC (FORM): Free Stock Analysis Report PALO ALTO NETWK (PANW): Free Stock Analysis Report CONCORDIA INTL (CXRX): Free Stock Analysis Report ABEONA THERAPTC (ABEO): Free Stock Analysis Report PROTEOSTASIS (PTI): Free Stock Analysis Report To read this article on Zacks.com click here. In addition, Zacks Equity Research provides analysis on Concordia International Corp. ( CXRX ), Abeona Therapeutics Inc. ( ABEO ) and Proteostasis Therapeutics, Inc. ( PTI ). Abeona Therapeutics Inc. ( ABEO ) is a development-stage company focused on the development of gene therapy and plasma-based treatments for severe and life-threatening rare genetic diseases. | In addition, Zacks Equity Research provides analysis on Concordia International Corp. ( CXRX ), Abeona Therapeutics Inc. ( ABEO ) and Proteostasis Therapeutics, Inc. ( PTI ). Abeona Therapeutics Inc. ( ABEO ) is a development-stage company focused on the development of gene therapy and plasma-based treatments for severe and life-threatening rare genetic diseases. Abeona is expected to report Q2 results on Aug 12. |
28124.0 | 2016-08-11 00:00:00 UTC | Drug Stocks' Earnings to Watch on Aug 12: CXRX, PTI & ABEO | ABEO | https://www.nasdaq.com/articles/drug-stocks-earnings-to-watch-on-aug-12%3A-cxrx-pti-abeo-2016-08-11 | nan | nan | The Q2 earnings season is almost over with as many as 92.1% S&P 500 members having reported results as of Aug 10. What does the Q2 earnings season scorecard look like so far? Both earnings and revenue growth was negative with the quarter on track to be the fifth in a row to record an earnings decline for the S&P 500 index.
Of the 454 S&P 500 members that have declared quarterly numbers as of Aug 10, an impressive 71.1% were able to top earnings estimates while 52.9% surpassed top-line expectations.
Notably, the Technology and Medical sectors recorded the highest proportion of positive surprises. In fact, results of the Medical sector have been particularly strong so far.
Our Q2 scorecard for the Medical sector shows that 96.2% have reported results with a blended beat of 74% (the percentage of companies that have beaten both earnings and revenue estimates), with the sector registering 5% earnings growth on 9.2% higher revenues.
Note that per our Earnings Trends report, Medical is one of the nine sectors expected to record positive earnings growth (4.7%) this quarter.
While the majority of pharma and biotech companies have already released quarterly results, quite a few companies in the sector are yet to declare the same. Let's see what's in store for these three drug stocks.
Can these Drug Stocks Surprise?
Headquartered in Oakville, Canada, Concordia International Corp.CXRX is a pharmaceutical company focused on legacy pharmaceutical products and orphan drugs. The company markets orphan drugs through its Orphan Drug Division, consisting of Photofrin for the treatment of certain rare forms of cancer, which is currently being evaluated for additional indications.
CONCORDIA INTL Price and EPS Surprise
CONCORDIA INTL Price and EPS Surprise | CONCORDIA INTL Quote
Concordia has missed earnings expectations in each of the past four quarters, with an average negative earnings surprise of 8.56%. Given its track record, will the stock disappoint again? Concordia currently carries a Zacks Rank #3 (Hold). Though the stock's Zacks Rank #3 increases the predictive power of the ESP, its 0.00% Earnings ESP makes a surprise prediction difficult this quarter. The company is scheduled to release Q2 results on Aug 12.
Abeona Therapeutics Inc.ABEO is a development-stage company focused on the development of gene therapy and plasma-based treatments for severe and life-threatening rare genetic diseases. This Dallas, TX-based company's performance has been far from encouraging, having missed estimates consistently. Overall, the company has clocked an average negative surprise of 62.43%. Its Zacks Rank #3, when combined with a 0.00% ESP, makes surprise prediction difficult for this quarter.
Abeona is expected to report Q2 results on Aug 12.
ABEONA THERAPTC Price and EPS Surprise
ABEONA THERAPTC Price and EPS Surprise | ABEONA THERAPTC Quote
Based in Cambridge, MA, Proteostasis Therapeutics, Inc.PTI is a development-stage biopharmaceutical company focused on the discovery and development of novel therapeutics targeting diseases caused by an imbalance in the proteostasis network with an initial therapeutic focus on cystic fibrosis. Proteostasis started trading from Feb 2016. Last quarter, the company posted a negative surprise of 85.11%. Proteostasis' Zacks Rank #3, when combined with an ESP of 0.00%, makes surprise prediction difficult for this quarter. It is expected to release Q2 results on Aug 12.
PROTEOSTASIS Price and EPS Surprise
PROTEOSTASIS Price and EPS Surprise | PROTEOSTASIS Quote
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
CONCORDIA INTL (CXRX): Free Stock Analysis Report
ABEONA THERAPTC (ABEO): Free Stock Analysis Report
PROTEOSTASIS (PTI): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abeona Therapeutics Inc.ABEO is a development-stage company focused on the development of gene therapy and plasma-based treatments for severe and life-threatening rare genetic diseases. Abeona is expected to report Q2 results on Aug 12. ABEONA THERAPTC Price and EPS Surprise ABEONA THERAPTC Price and EPS Surprise | ABEONA THERAPTC Quote Based in Cambridge, MA, Proteostasis Therapeutics, Inc.PTI is a development-stage biopharmaceutical company focused on the discovery and development of novel therapeutics targeting diseases caused by an imbalance in the proteostasis network with an initial therapeutic focus on cystic fibrosis. | ABEONA THERAPTC Price and EPS Surprise ABEONA THERAPTC Price and EPS Surprise | ABEONA THERAPTC Quote Based in Cambridge, MA, Proteostasis Therapeutics, Inc.PTI is a development-stage biopharmaceutical company focused on the discovery and development of novel therapeutics targeting diseases caused by an imbalance in the proteostasis network with an initial therapeutic focus on cystic fibrosis. Click to get this free report CONCORDIA INTL (CXRX): Free Stock Analysis Report ABEONA THERAPTC (ABEO): Free Stock Analysis Report PROTEOSTASIS (PTI): Free Stock Analysis Report To read this article on Zacks.com click here. Abeona Therapeutics Inc.ABEO is a development-stage company focused on the development of gene therapy and plasma-based treatments for severe and life-threatening rare genetic diseases. | ABEONA THERAPTC Price and EPS Surprise ABEONA THERAPTC Price and EPS Surprise | ABEONA THERAPTC Quote Based in Cambridge, MA, Proteostasis Therapeutics, Inc.PTI is a development-stage biopharmaceutical company focused on the discovery and development of novel therapeutics targeting diseases caused by an imbalance in the proteostasis network with an initial therapeutic focus on cystic fibrosis. Click to get this free report CONCORDIA INTL (CXRX): Free Stock Analysis Report ABEONA THERAPTC (ABEO): Free Stock Analysis Report PROTEOSTASIS (PTI): Free Stock Analysis Report To read this article on Zacks.com click here. Abeona Therapeutics Inc.ABEO is a development-stage company focused on the development of gene therapy and plasma-based treatments for severe and life-threatening rare genetic diseases. | Abeona is expected to report Q2 results on Aug 12. Abeona Therapeutics Inc.ABEO is a development-stage company focused on the development of gene therapy and plasma-based treatments for severe and life-threatening rare genetic diseases. ABEONA THERAPTC Price and EPS Surprise ABEONA THERAPTC Price and EPS Surprise | ABEONA THERAPTC Quote Based in Cambridge, MA, Proteostasis Therapeutics, Inc.PTI is a development-stage biopharmaceutical company focused on the discovery and development of novel therapeutics targeting diseases caused by an imbalance in the proteostasis network with an initial therapeutic focus on cystic fibrosis. |
28125.0 | 2016-08-03 00:00:00 UTC | Abeona Therapeutics (ABEO) in Focus: Stock Up 5.7% in Session | ABEO | https://www.nasdaq.com/articles/abeona-therapeutics-abeo-in-focus%3A-stock-up-5.7-in-session-2016-08-03 | nan | nan | Abeona Therapeutics Inc.ABEO was a big mover last session, as the company saw its shares rise around 6% on the day. Shares gained after the company announced encouraging data from its ongoing Phase I/II trial for ABO-102, a single treatment gene therapy strategy for patients with Sanfilippo syndrome type A. The news led to far more shares changing hands than in a normal session resulting in solid volume. This continues the recent uptrend for the company as the stock is now up 23.1% in the past one-month time frame.
None of the estimates for this stock were revised over the past 30 days. The Zacks Consensus Estimate also remained unchanged over the same time frame. Yesterday's price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Abeona Therapeutics currently carries a Zacks Rank #3 (Hold), while its Earnings ESP is 0.00%.
ABEONA THERAPTC Price
ABEONA THERAPTC Price | ABEONA THERAPTC Quote
A better-ranked stock in the same industry is Agenus Inc. AGEN , sporting a Zacks Rank #1 (Strong Buy).
Is ABEO going up? Or down? Predict to see what others think: Up or Down
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AGENUS INC (AGEN): Free Stock Analysis Report
ABEONA THERAPTC (ABEO): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abeona Therapeutics Inc.ABEO was a big mover last session, as the company saw its shares rise around 6% on the day. Abeona Therapeutics currently carries a Zacks Rank #3 (Hold), while its Earnings ESP is 0.00%. ABEONA THERAPTC Price ABEONA THERAPTC Price | ABEONA THERAPTC Quote A better-ranked stock in the same industry is Agenus Inc. AGEN , sporting a Zacks Rank #1 (Strong Buy). | ABEONA THERAPTC Price ABEONA THERAPTC Price | ABEONA THERAPTC Quote A better-ranked stock in the same industry is Agenus Inc. AGEN , sporting a Zacks Rank #1 (Strong Buy). Click to get this free report AGENUS INC (AGEN): Free Stock Analysis Report ABEONA THERAPTC (ABEO): Free Stock Analysis Report To read this article on Zacks.com click here. Abeona Therapeutics Inc.ABEO was a big mover last session, as the company saw its shares rise around 6% on the day. | Abeona Therapeutics Inc.ABEO was a big mover last session, as the company saw its shares rise around 6% on the day. ABEONA THERAPTC Price ABEONA THERAPTC Price | ABEONA THERAPTC Quote A better-ranked stock in the same industry is Agenus Inc. AGEN , sporting a Zacks Rank #1 (Strong Buy). Click to get this free report AGENUS INC (AGEN): Free Stock Analysis Report ABEONA THERAPTC (ABEO): Free Stock Analysis Report To read this article on Zacks.com click here. | Abeona Therapeutics Inc.ABEO was a big mover last session, as the company saw its shares rise around 6% on the day. ABEONA THERAPTC Price ABEONA THERAPTC Price | ABEONA THERAPTC Quote A better-ranked stock in the same industry is Agenus Inc. AGEN , sporting a Zacks Rank #1 (Strong Buy). Abeona Therapeutics currently carries a Zacks Rank #3 (Hold), while its Earnings ESP is 0.00%. |
28126.0 | 2016-05-17 00:00:00 UTC | Health Care Sector Update for 05/17/2016: FATE, ABEO | ABEO | https://www.nasdaq.com/articles/health-care-sector-update-05172016-fate-abeo-2016-05-17 | nan | nan | Top Health-care stocks:
JNJ: -0.2%
PFE: -0.1%
ABT: flat
MRK: flat
AMGN: flat
Health-care shares were mixed in pre-market trade on Tuesday.
In health-care stocks news, Fate Therapeutics ( FATE ), a biopharmaceutical company, hired Chris Storgard, M.D., to become its Chief Medical Officer.
Shares in the company were unchanged at $1.54 pre-bell. The stock has traded between $1.46 and $8.37 over the past 52 weeks.
And biopharmaceutical company Abeona Therapeutics ( ABEO ) has begun dosing patients in a Phase 1/2 trial for ABO-102 to treat Sanfilippo syndrome type A.
Shares in the company were unchanged at $2.41 pre-bell. The stock has traded between $2.05 and $10.85 over the past 52 weeks.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | And biopharmaceutical company Abeona Therapeutics ( ABEO ) has begun dosing patients in a Phase 1/2 trial for ABO-102 to treat Sanfilippo syndrome type A. In health-care stocks news, Fate Therapeutics ( FATE ), a biopharmaceutical company, hired Chris Storgard, M.D., to become its Chief Medical Officer. The stock has traded between $1.46 and $8.37 over the past 52 weeks. | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. And biopharmaceutical company Abeona Therapeutics ( ABEO ) has begun dosing patients in a Phase 1/2 trial for ABO-102 to treat Sanfilippo syndrome type A. In health-care stocks news, Fate Therapeutics ( FATE ), a biopharmaceutical company, hired Chris Storgard, M.D., to become its Chief Medical Officer. | And biopharmaceutical company Abeona Therapeutics ( ABEO ) has begun dosing patients in a Phase 1/2 trial for ABO-102 to treat Sanfilippo syndrome type A. ABT: flat MRK: flat AMGN: flat Health-care shares were mixed in pre-market trade on Tuesday. In health-care stocks news, Fate Therapeutics ( FATE ), a biopharmaceutical company, hired Chris Storgard, M.D., to become its Chief Medical Officer. | And biopharmaceutical company Abeona Therapeutics ( ABEO ) has begun dosing patients in a Phase 1/2 trial for ABO-102 to treat Sanfilippo syndrome type A. Top Health-care stocks: ABT: flat MRK: flat AMGN: flat Health-care shares were mixed in pre-market trade on Tuesday. |
28127.0 | 2016-05-04 00:00:00 UTC | Abeona Therapeutics (ABEO) Sees Hammer Chart Pattern: Time to Buy? | ABEO | https://www.nasdaq.com/articles/abeona-therapeutics-abeo-sees-hammer-chart-pattern%3A-time-to-buy-2016-05-04 | nan | nan | Abeona Therapeutics Inc.ABEO has been struggling lately, but the selling pressure may be coming to an end soon. That is because ABEO recently saw a Hammer Chart Pattern which can signal that the stock is nearing a bottom.
What is a Hammer Chart Pattern?
A hammer chart pattern is a popular technical indicator that is used in candlestick charting. The hammer appears when a stock tumbles during the day, but then finds strength at some point in the session to close near or above its opening price. This forms a candlestick that resembles a hammer, and it can suggest that the market has found a low point in the stock, and that better days are ahead.
Other Factors
Plus, earnings estimates have been rising for this company, even despite the sluggish trading lately. In just the past 60 days alone 1 estimate has gone higher, compared to none lower, while the consensus estimate has also moved in the right direction.
Estimates have actually risen so much that the stock now has a Zacks Rank #2 (Buy) suggesting this relatively unloved stock could be due for a breakout soon. This will be especially true if ABEO stock can build momentum from here and find a way to continue higher of off this encouraging trading development.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ABEONA THERAPTC (ABEO): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | This will be especially true if ABEO stock can build momentum from here and find a way to continue higher of off this encouraging trading development. Abeona Therapeutics Inc.ABEO has been struggling lately, but the selling pressure may be coming to an end soon. That is because ABEO recently saw a Hammer Chart Pattern which can signal that the stock is nearing a bottom. | Click to get this free report ABEONA THERAPTC (ABEO): Free Stock Analysis Report To read this article on Zacks.com click here. Abeona Therapeutics Inc.ABEO has been struggling lately, but the selling pressure may be coming to an end soon. That is because ABEO recently saw a Hammer Chart Pattern which can signal that the stock is nearing a bottom. | That is because ABEO recently saw a Hammer Chart Pattern which can signal that the stock is nearing a bottom. Click to get this free report ABEONA THERAPTC (ABEO): Free Stock Analysis Report To read this article on Zacks.com click here. Abeona Therapeutics Inc.ABEO has been struggling lately, but the selling pressure may be coming to an end soon. | Abeona Therapeutics Inc.ABEO has been struggling lately, but the selling pressure may be coming to an end soon. That is because ABEO recently saw a Hammer Chart Pattern which can signal that the stock is nearing a bottom. This will be especially true if ABEO stock can build momentum from here and find a way to continue higher of off this encouraging trading development. |
28128.0 | 2016-04-05 00:00:00 UTC | Abeona Therapeutics (ABEO) Jumps: Stock Rises 6.4% | ABEO | https://www.nasdaq.com/articles/abeona-therapeutics-abeo-jumps%3A-stock-rises-6.4-2016-04-05 | nan | nan | Abeona Therapeutics Inc.ABEO was a big mover last session, as the company saw its shares rise above 6% on the day. The move came on solid volume with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $2.56-$2.95 in the past one-month time frame.
In the last 30 days, the company has seen no estimate revision and the Zacks Consensus Estimate also remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Abeona Therapeutics currently carries a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
A better-ranked Bio-medical/Gene stock is Actelion Ltd. ALIOF , which sports a Zacks Rank #1 (Strong Buy).
Is ABEO going up? Or down? Predict to see what others think: Up or Down
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ACTELION LTD (ALIOF): Free Stock Analysis Report
ABEONA THERAPTC (ABEO): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Abeona Therapeutics Inc.ABEO was a big mover last session, as the company saw its shares rise above 6% on the day. Abeona Therapeutics currently carries a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%. Is ABEO going up? | Click to get this free report ACTELION LTD (ALIOF): Free Stock Analysis Report ABEONA THERAPTC (ABEO): Free Stock Analysis Report To read this article on Zacks.com click here. Abeona Therapeutics Inc.ABEO was a big mover last session, as the company saw its shares rise above 6% on the day. Abeona Therapeutics currently carries a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%. | Abeona Therapeutics Inc.ABEO was a big mover last session, as the company saw its shares rise above 6% on the day. Click to get this free report ACTELION LTD (ALIOF): Free Stock Analysis Report ABEONA THERAPTC (ABEO): Free Stock Analysis Report To read this article on Zacks.com click here. Abeona Therapeutics currently carries a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%. | Abeona Therapeutics Inc.ABEO was a big mover last session, as the company saw its shares rise above 6% on the day. Click to get this free report ACTELION LTD (ALIOF): Free Stock Analysis Report ABEONA THERAPTC (ABEO): Free Stock Analysis Report To read this article on Zacks.com click here. Abeona Therapeutics currently carries a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%. |
28129.0 | 2016-04-01 00:00:00 UTC | Friday Sector Leaders: Drugs, Biotechnology Stocks | ABEO | https://www.nasdaq.com/articles/friday-sector-leaders-drugs-biotechnology-stocks-2016-04-01 | nan | nan | In trading on Friday, drugs shares were relative leaders, up on the day by about 2.4%. Leading the group were shares of Cormedix ( CRMD ), up about 17% and shares of Colucid Pharmaceuticals ( CLCD ) up about 11.9% on the day.
Also showing relative strength are biotechnology shares, up on the day by about 1.9% as a group, led by Regeneron Pharmaceutical ( REGN ), trading higher by about 13.4% and Abeona Therapeutics ( ABEO ), trading up by about 10.6% on Friday.
VIDEO: Friday Sector Leaders: Drugs, Biotechnology Stocks
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Also showing relative strength are biotechnology shares, up on the day by about 1.9% as a group, led by Regeneron Pharmaceutical ( REGN ), trading higher by about 13.4% and Abeona Therapeutics ( ABEO ), trading up by about 10.6% on Friday. In trading on Friday, drugs shares were relative leaders, up on the day by about 2.4%. VIDEO: Friday Sector Leaders: Drugs, Biotechnology Stocks The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Also showing relative strength are biotechnology shares, up on the day by about 1.9% as a group, led by Regeneron Pharmaceutical ( REGN ), trading higher by about 13.4% and Abeona Therapeutics ( ABEO ), trading up by about 10.6% on Friday. In trading on Friday, drugs shares were relative leaders, up on the day by about 2.4%. VIDEO: Friday Sector Leaders: Drugs, Biotechnology Stocks The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Also showing relative strength are biotechnology shares, up on the day by about 1.9% as a group, led by Regeneron Pharmaceutical ( REGN ), trading higher by about 13.4% and Abeona Therapeutics ( ABEO ), trading up by about 10.6% on Friday. VIDEO: Friday Sector Leaders: Drugs, Biotechnology Stocks The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Also showing relative strength are biotechnology shares, up on the day by about 1.9% as a group, led by Regeneron Pharmaceutical ( REGN ), trading higher by about 13.4% and Abeona Therapeutics ( ABEO ), trading up by about 10.6% on Friday. In trading on Friday, drugs shares were relative leaders, up on the day by about 2.4%. Leading the group were shares of Cormedix ( CRMD ), up about 17% and shares of Colucid Pharmaceuticals ( CLCD ) up about 11.9% on the day. |
28130.0 | 2015-11-09 00:00:00 UTC | What's in Store for Voxeljet (VJET) This Earnings Season? | ABEO | https://www.nasdaq.com/articles/whats-in-store-for-voxeljet-vjet-this-earnings-season-2015-11-09 | nan | nan | Voxeljet AGVJET is slated to report third-quarter 2015 results on Nov 12, 2015, after the closing bell.
Last quarter, the company posted a positive earnings surprise of 23.53%.
Let us see how things are shaping up for this announcement.
Factors to Consider
Voxeljet witnessed sluggish earnings results in the first half of 2015 owing to high operating expenses. Especially, the company has been suffering due to rise in its Long Term Cash Incentive Plan (LTCIP) related expenses. Apart from this, foreign currency exchange costs acted as the headwinds. If this problem persists, Voxeljet might report meek results this earnings season.
Nevertheless, Voxeljet's revenues have been seeing an upward trend fueled by strong demand for both systems and on-demand printed parts. Especially, sand and plastic parts of Voxeljet generated record revenues. This could continue to help the company tide over in third-quarter 2015.
Management has cited certain key drivers, which are expected to benefit its earnings in the third quarter and fourth quarter of 2015. These are - rise in global Systems sales; high contribution from its Services facility in Michigan, Voxeljet of America; continual Services revenue growth at its German facility; and a strong revenue contribution from its Services facility outside England, Voxeljet UK.
Earnings Whispers?
Our proven model does not conclusively show that Voxeljet will beat earnings this season. This is because a stock needs to have both a positive Earnings ESP (Expected Surprise Prediction) and a Zacks Rank #1(Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. This is not the case here, as you will see below.
Zacks ESP: Both the Most Accurate estimate and the Zacks Consensus Estimate stand at a loss of 14 cents. Hence, the difference is 0.00%.
Zacks Rank: Voxeljet's Zacks Rank #3 (Hold) when combined with 0.00% Earnings ESP makes surprise prediction difficult. Note that stocks with a Zacks Rank #1, 2 or 3 have a significantly higher chance of beating earnings.
We caution against stocks with a Zacks Rank #4 or 5 (Sell-rated stocks) going into the earnings announcement, especially when the company is seeing negative estimate revisions momentum.
Stocks to Consider
Here are some companies you may want to consider as our model shows they have the right combination of elements to post an earnings beat this quarter:
Abeona Therapeutics Inc.ABEO has an Earnings ESP of +36.36% and a Zacks Rank #3.
Aurinia Pharmaceuticals Inc.AUPH has an Earnings ESP of +21.74% and a Zacks Rank #2.
Ryerson Holding Corp.RYI has an Earnings ESP of +44.44% and a Zacks Rank #3.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
VOXELJET AG-ADR (VJET): Free Stock Analysis Report
RYERSON HOLDING (RYI): Free Stock Analysis Report
AURINIA PHARMA (AUPH): Free Stock Analysis Report
ABEONA THERAPTC (ABEO): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Stocks to Consider Here are some companies you may want to consider as our model shows they have the right combination of elements to post an earnings beat this quarter: Abeona Therapeutics Inc.ABEO has an Earnings ESP of +36.36% and a Zacks Rank #3. Click to get this free report VOXELJET AG-ADR (VJET): Free Stock Analysis Report RYERSON HOLDING (RYI): Free Stock Analysis Report AURINIA PHARMA (AUPH): Free Stock Analysis Report ABEONA THERAPTC (ABEO): Free Stock Analysis Report To read this article on Zacks.com click here. Factors to Consider Voxeljet witnessed sluggish earnings results in the first half of 2015 owing to high operating expenses. | Click to get this free report VOXELJET AG-ADR (VJET): Free Stock Analysis Report RYERSON HOLDING (RYI): Free Stock Analysis Report AURINIA PHARMA (AUPH): Free Stock Analysis Report ABEONA THERAPTC (ABEO): Free Stock Analysis Report To read this article on Zacks.com click here. Stocks to Consider Here are some companies you may want to consider as our model shows they have the right combination of elements to post an earnings beat this quarter: Abeona Therapeutics Inc.ABEO has an Earnings ESP of +36.36% and a Zacks Rank #3. This is because a stock needs to have both a positive Earnings ESP (Expected Surprise Prediction) and a Zacks Rank #1(Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. | Stocks to Consider Here are some companies you may want to consider as our model shows they have the right combination of elements to post an earnings beat this quarter: Abeona Therapeutics Inc.ABEO has an Earnings ESP of +36.36% and a Zacks Rank #3. Click to get this free report VOXELJET AG-ADR (VJET): Free Stock Analysis Report RYERSON HOLDING (RYI): Free Stock Analysis Report AURINIA PHARMA (AUPH): Free Stock Analysis Report ABEONA THERAPTC (ABEO): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Rank: Voxeljet's Zacks Rank #3 (Hold) when combined with 0.00% Earnings ESP makes surprise prediction difficult. | Stocks to Consider Here are some companies you may want to consider as our model shows they have the right combination of elements to post an earnings beat this quarter: Abeona Therapeutics Inc.ABEO has an Earnings ESP of +36.36% and a Zacks Rank #3. Click to get this free report VOXELJET AG-ADR (VJET): Free Stock Analysis Report RYERSON HOLDING (RYI): Free Stock Analysis Report AURINIA PHARMA (AUPH): Free Stock Analysis Report ABEONA THERAPTC (ABEO): Free Stock Analysis Report To read this article on Zacks.com click here. If this problem persists, Voxeljet might report meek results this earnings season. |
28131.0 | 2015-11-04 00:00:00 UTC | Is Humana (HUM) Poised to Beat Q3 Earnings Estimates? | ABEO | https://www.nasdaq.com/articles/is-humana-hum-poised-to-beat-q3-earnings-estimates-2015-11-04 | nan | nan | We expect Humana, Inc . HUM to beat expectations when it reports third-quarter 2015 earnings on Nov 6, 2015.
Why a Likely Positive Surprise?
Our proven model shows that Humana is likely to beat on earnings because it has the right combination of two key components.
Zacks ESP:Earnings ESP , which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate, is +0.47%. This is very meaningful and a leading indicator of a likely positive earnings surprise for shares.
Zacks Rank: Humana carries a Zacks Rank #3 (Hold). Note that stocks with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 have a significantly higher chance of beating earnings.
Conversely, the Sell-rated stocks (Zacks Ranks #4 and 5) should never be considered going into an earnings announcement, especially when the company is witnessing negative estimate revisions.
The combination of Humana's Zacks Rank #3 and +0.47% ESP makes us confident of an earnings beat this season.
What is Driving the Better-Than-Expected Earnings?
Humana has been upfront in engaging itself in Accountable Care arrangements with eminent names to boost its care delivery capacities and make way for a steady stream of revenue generation. This should boost the bottom line as well.
The company's notable ACO arrangements include the ones with Partners in Primary Care, Doylestown Health Partners, King's Daughters' Health, Premier Health, Oak Street Health and Iora Health. These agreements expanded and strengthened Humana's foothold across San Antonio, South Texas, Bucks and Montgomery counties, Madison county, Southwest Ohio, greater Chicago area, Arizona, Colorado and Washington. Also, the insurer's strategies to boost core operations and generate profits from these deals raise optimism.
Other Stocks to Consider
Humana is not the only stock looking up this earnings season. We expect these three companies from the healthcare sector to beat on earnings as well:
Abeona Therapeutics Inc. ABEO has an Earnings ESP of +36.36% and a Zacks Rank #3. The company is expected to release third-quarter earnings on Nov 13.
Aurinia Pharmaceuticals Inc. AUPH has an Earnings ESP of +21.74% and a Zacks Rank #2. The company is scheduled to release third-quarter earnings on Nov 11.
Kindred Healthcare Inc. KND has an Earnings ESP of +3.85% and a Zacks Rank #3. The company is scheduled to report third-quarter earnings on Nov 4.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
HUMANA INC NEW (HUM): Free Stock Analysis Report
KINDRED HLTHCR (KND): Free Stock Analysis Report
AURINIA PHARMA (AUPH): Free Stock Analysis Report
ABEONA THERAPTC (ABEO): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | We expect these three companies from the healthcare sector to beat on earnings as well: Abeona Therapeutics Inc. ABEO has an Earnings ESP of +36.36% and a Zacks Rank #3. Click to get this free report HUMANA INC NEW (HUM): Free Stock Analysis Report KINDRED HLTHCR (KND): Free Stock Analysis Report AURINIA PHARMA (AUPH): Free Stock Analysis Report ABEONA THERAPTC (ABEO): Free Stock Analysis Report To read this article on Zacks.com click here. Conversely, the Sell-rated stocks (Zacks Ranks #4 and 5) should never be considered going into an earnings announcement, especially when the company is witnessing negative estimate revisions. | We expect these three companies from the healthcare sector to beat on earnings as well: Abeona Therapeutics Inc. ABEO has an Earnings ESP of +36.36% and a Zacks Rank #3. Click to get this free report HUMANA INC NEW (HUM): Free Stock Analysis Report KINDRED HLTHCR (KND): Free Stock Analysis Report AURINIA PHARMA (AUPH): Free Stock Analysis Report ABEONA THERAPTC (ABEO): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | We expect these three companies from the healthcare sector to beat on earnings as well: Abeona Therapeutics Inc. ABEO has an Earnings ESP of +36.36% and a Zacks Rank #3. Click to get this free report HUMANA INC NEW (HUM): Free Stock Analysis Report KINDRED HLTHCR (KND): Free Stock Analysis Report AURINIA PHARMA (AUPH): Free Stock Analysis Report ABEONA THERAPTC (ABEO): Free Stock Analysis Report To read this article on Zacks.com click here. The combination of Humana's Zacks Rank #3 and +0.47% ESP makes us confident of an earnings beat this season. | We expect these three companies from the healthcare sector to beat on earnings as well: Abeona Therapeutics Inc. ABEO has an Earnings ESP of +36.36% and a Zacks Rank #3. Click to get this free report HUMANA INC NEW (HUM): Free Stock Analysis Report KINDRED HLTHCR (KND): Free Stock Analysis Report AURINIA PHARMA (AUPH): Free Stock Analysis Report ABEONA THERAPTC (ABEO): Free Stock Analysis Report To read this article on Zacks.com click here. The combination of Humana's Zacks Rank #3 and +0.47% ESP makes us confident of an earnings beat this season. |
28132.0 | 2021-05-03 00:00:00 UTC | Stock ETFs Start May on the Front Foot | ABEQ | https://www.nasdaq.com/articles/stock-etfs-start-may-on-the-front-foot-2021-05-03 | nan | nan | Stocks and index ETFs started the first trading day of May on an upswing, as investors drove most sectors higher in Monday morning trading.
The Dow Jones Industrial Average added almost 1%, while the S&P 500 climbed 0.6%. The Nasdaq Composite advanced 0.4% before slipping back into negative territory amid losses from Amazon, Tesla, Facebook, and Netflix.
Major stock ETFs are mixed to higher on Monday as well. The SPDR Dow Jones Industrial Average ETF (DIA) and SPDR S&P 500 ETF Trust (SPY), are both climbing, while the Invesco QQQ Trust (QQQ) is off on the day, as of noon EST.
Earnings are still on investors' minds, and Berkshire Hathaway stock gained 1% after Warren Buffett’s enterprise said it captured a 20% increase in operating earnings and continued to repurchase significant portions of its own shares. Buffett also revealed that when he steps down, Greg Abel, vice chairman of all non-insurance operations, will take over the reigns. The move helped fuel the Absolute Core Strategy ETF(ABEQ), which holds an almost 9% position in Berkshire, higher.
Investors also championed reopening stocks, driving Disney and Royal Caribbean more than 1% higher apiece. The move helped the First Trust Consumer Discretionary AlphaDEX Fund (FXD) gain some ground Monday.
Despite Friday’s stock decline, the S&P 500 managed to score its third straight month of gains in April, adding over 5% to the index as investors remain sanguine about the economic recovery process. The key benchmark is now up 11% for the year. Meanwhile, the Dow added about 2.7% last month, while the Nasdaq Composite soared 5.4% in April.
"Sell in May and Go Away?"
Yet, with stocks close to all-time highs, some investors are leery that the new month may lead to the old adage “sell in May and go away."
Data going back to 1928 shows that the May-October period has the lowest average and median returns of any six-month period of the year, with the S&P 500 up 66% of the time on an average return of 2.2%, according to Bank of America.
“This is a small number of observations, but May-October has lackluster average and median returns after a November-April rally of at least 20%,” Stephen Suttmeier, technical research strategist at Bank of America, said in a note.
Other analysts agree, adding that stocks are priced well, but that earnings may have peaked.
"I think the market is priced almost to perfection, right? We've priced in a good vaccine rollout. We've priced in a strong reopening to the economy. I'm a little concerned about the second half of the year," Allan Boomer, Momentum Advisors Chief Investment Officer, told Yahoo! Finance. "I think it's possible that in the short term, earnings have basically peaked and ... this is a great quarter, but I don't know that the rest of the year will be quite as strong."
"One of the things that I think you'll start to see is that we've got a labor shortage in the United States. We talk about the jobs that were lost. We don't really talk about the fact that there's a lot of companies that have a lot of vacancies that are outstanding," he added. "So I think you'll start to see in the second half particularly companies that rely on labor, you'll start to see some issues around a labor shortage for sure."
There may be reason to look for more gains however, as IHS Markit data revealed that U.S. manufacturing activity increased at a record-high speed last month, with April’s Manufacturing Business Activity PMI Index climbing to 60.5, meeting predictions from economists polled by Dow Jones.
However, a separate gauge from Institute for Supply Management signaled a slowdown in manufacturing activities. The ISM Manufacturing PMI for April came in at 60.7, compared to the projected 65.0 and March’s level of 64.7.
“Investors are gearing up for another busy earnings week capped off with a widely watched jobs report. Given the positive economic and earnings news, the path of least resistance appears higher,” said Jack Ablin, chief investment officer at Cresset Capital.
For more market trends, visit ETF Trends.
Read more on ETFtrends.com.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The move helped fuel the Absolute Core Strategy ETF(ABEQ), which holds an almost 9% position in Berkshire, higher. Despite Friday’s stock decline, the S&P 500 managed to score its third straight month of gains in April, adding over 5% to the index as investors remain sanguine about the economic recovery process. “This is a small number of observations, but May-October has lackluster average and median returns after a November-April rally of at least 20%,” Stephen Suttmeier, technical research strategist at Bank of America, said in a note. | The move helped fuel the Absolute Core Strategy ETF(ABEQ), which holds an almost 9% position in Berkshire, higher. The Dow Jones Industrial Average added almost 1%, while the S&P 500 climbed 0.6%. The SPDR Dow Jones Industrial Average ETF (DIA) and SPDR S&P 500 ETF Trust (SPY), are both climbing, while the Invesco QQQ Trust (QQQ) is off on the day, as of noon EST. | The move helped fuel the Absolute Core Strategy ETF(ABEQ), which holds an almost 9% position in Berkshire, higher. Stocks and index ETFs started the first trading day of May on an upswing, as investors drove most sectors higher in Monday morning trading. Earnings are still on investors' minds, and Berkshire Hathaway stock gained 1% after Warren Buffett’s enterprise said it captured a 20% increase in operating earnings and continued to repurchase significant portions of its own shares. | The move helped fuel the Absolute Core Strategy ETF(ABEQ), which holds an almost 9% position in Berkshire, higher. The Dow Jones Industrial Average added almost 1%, while the S&P 500 climbed 0.6%. Other analysts agree, adding that stocks are priced well, but that earnings may have peaked. |
28133.0 | 2023-11-15 00:00:00 UTC | ABEV Factor-Based Stock Analysis - Peter Lynch | ABEV | https://www.nasdaq.com/articles/abev-factor-based-stock-analysis-peter-lynch | nan | nan | Below is Validea's guru fundamental report for AMBEV SA (ADR) (ABEV). Of the 22 guru strategies we follow, ABEV rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. This strategy looks for stocks trading at a reasonable price relative to earnings growth that also possess strong balance sheets.
AMBEV SA (ADR) (ABEV) is a large-cap value stock in the Beverages (Alcoholic) industry. The rating using this strategy is 91% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
SALES: PASS
INVENTORY TO SALES: PASS
YIELD COMPARED TO THE S&P 500: PASS
YIELD ADJUSTED P/E/GROWTH (PEG) RATIO: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
Detailed Analysis of AMBEV SA (ADR)
ABEV Guru Analysis
ABEV Fundamental Analysis
More Information on Peter Lynch
Peter Lynch Portfolio
Top Peter Lynch Stocks
About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Lynch's common sense approach and quick wit made him one of the most quoted investors on Wall Street. ("Go for a business that any idiot can run -- because sooner or later, any idiot probably is going to run it," is one of his many pearls of wisdom.) Lynch's bestseller One Up on Wall Street is something of a "stocks for the everyman/everywoman", breaking his approach down into easy-to-understand concepts.
Additional Research Links
Top Large-Cap Growth Stocks
Factor-Based Stock Portfolios
Dividend Aristocrats 2023
High Insider Ownership Stocks
Top S&P 500 Stocks
About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Below is Validea's guru fundamental report for AMBEV SA (ADR) (ABEV). Of the 22 guru strategies we follow, ABEV rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. AMBEV SA (ADR) (ABEV) is a large-cap value stock in the Beverages (Alcoholic) industry. | Below is Validea's guru fundamental report for AMBEV SA (ADR) (ABEV). Of the 22 guru strategies we follow, ABEV rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. Detailed Analysis of AMBEV SA (ADR) ABEV Guru Analysis ABEV Fundamental Analysis More Information on Peter Lynch Peter Lynch Portfolio Top Peter Lynch Stocks About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. | Of the 22 guru strategies we follow, ABEV rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. Detailed Analysis of AMBEV SA (ADR) ABEV Guru Analysis ABEV Fundamental Analysis More Information on Peter Lynch Peter Lynch Portfolio Top Peter Lynch Stocks About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Below is Validea's guru fundamental report for AMBEV SA (ADR) (ABEV). | Below is Validea's guru fundamental report for AMBEV SA (ADR) (ABEV). Of the 22 guru strategies we follow, ABEV rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. Detailed Analysis of AMBEV SA (ADR) ABEV Guru Analysis ABEV Fundamental Analysis More Information on Peter Lynch Peter Lynch Portfolio Top Peter Lynch Stocks About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. |
28134.0 | 2023-11-07 00:00:00 UTC | Forget the Magnificent 7. Jump Into Brazilian Stocks Instead. | ABEV | https://www.nasdaq.com/articles/forget-the-magnificent-7.-jump-into-brazilian-stocks-instead. | nan | nan | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
One of the nice things about interviewing over 500 thought leaders in the realm of investing and finance on my podcast Lead-Lag Live is getting exposure to new investment ideas and tracking really smart people’s arguments for where to turn attention to next. On X, Tavi Costa, who I had on not too long ago, showed an interesting chart of the MSCI Brazil index. He argued that it makes no sense to buy Magnificent 7 stocks with insane valuations when there are stocks in Brazil that trade at 5 times earnings and are clearly tied to the commodity cycle.
Tavi is fundamentally right.
Brazil IS cheap and is a comparatively more stable part of the emerging market space. Brazilian stocks and ETFs like the MSCI Brazil ETF (NYSEARCA:EWZ) have gone nowhere for well over a decade. Oddly enough, I like that. I believe in mean reversion and cycles. I believe valuations do matter in the very long term. And that’s why I believe Brazil may actually be a really good place to allocate to right now.
Using EWZ’s portfolio as a proxy for Brazil’s market, we can clearly see that it’s heavily exposed to the commodities sector, with materials and energy making up more than a third of its portfolio. The ETF’s largest holdings include Petrobras (NYSE:PBR), Vale (NYSE:VALE) and Ambev (NYSE:ABEV). Investing in Brazil isn’t some tech play. It’s a commodity and value play.
It’s also apparently a high dividend play, with many of these stocks yielding around 8%. When you combine high dividends with low valuation, what’s not to like? Even on a forward P/E basis, Brazil continues to look undervalued. The forward P/E ratio for the MSCI Brazil index currently stands at 8.3x, making it an intriguing option for value investors in the long run.
It’s more than that though. The Brazilian central bank’s monetary policy and its decisions on interest rates significantly impact the Brazilian stock market. Historically, a decline in interest rates has correlated positively with the performance of Brazilian equities. And that central bank is in a cutting rate cycle now, way before the Federal Reserve here in the U.S.
The Bottom Line on Brazilian Stocks
Yes, I know Brazil is volatile. Yes, I know it has currency risk (and that by the way is important to emphasize). The Brazilian real has historically depreciated against stronger currencies like the U.S. dollar, euro, and the pound. This depreciation can impact the returns for investors who live and spend in these stronger currencies. But that can be hedged, and if the dollar were to fall, unhedged exposure to Brazil becomes even more interesting.
Momentum may not be fully there, but I really do think Brazil is worth keeping an eye on. Valuations should matter again and it’s only a matter of time until the investor love affair with U.S. tech ends. This would favor emerging markets like Brazil, and cheap commodity-linked plays.
On the date of publication, Michael Gayed did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.
The Lead-Lag Report is provided by Lead-Lag Publishing, LLC. All opinions and views mentioned in this report constitute our judgments as of the date of writing and are subject to change at any time. Information within this material is not intended to be used as a primary basis for investment decisions and should also not be construed as advice meeting the particular investment needs of any individual investor. Trading signals produced by the Lead-Lag Report are independent of other services provided by Lead-Lag Publishing, LLC or its affiliates, and positioning of accounts under their management may differ. Please remember that investing involves risk, including loss of principal, and past performance may not be indicative of future results. Lead-Lag Publishing, LLC, its members, officers, directors and employees expressly disclaim all liability in respect to actions taken based on any or all of the information on this writing. Michael A. Gayed is the Publisher of The Lead-Lag Report, and Portfolio Manager at Tidal Financial Group, an investment management company specializing in ETF-focused research, investment strategies and services designed for financial advisors, RIAs, family offices and investment managers. InvestorPlace readers that are new subscribers to the The Lead-Lag Report can receive a 30% discount.
More From InvestorPlace
ChatGPT IPO Could Shock the World, Make This Move Before the Announcement
Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In.
The Rich Use This Income Secret (NOT Dividends) Far More Than Regular Investors
The post Forget the Magnificent 7. Jump Into Brazilian Stocks Instead. appeared first on InvestorPlace.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The ETF’s largest holdings include Petrobras (NYSE:PBR), Vale (NYSE:VALE) and Ambev (NYSE:ABEV). Please remember that investing involves risk, including loss of principal, and past performance may not be indicative of future results. Lead-Lag Publishing, LLC, its members, officers, directors and employees expressly disclaim all liability in respect to actions taken based on any or all of the information on this writing. | The ETF’s largest holdings include Petrobras (NYSE:PBR), Vale (NYSE:VALE) and Ambev (NYSE:ABEV). InvestorPlace - Stock Market News, Stock Advice & Trading Tips One of the nice things about interviewing over 500 thought leaders in the realm of investing and finance on my podcast Lead-Lag Live is getting exposure to new investment ideas and tracking really smart people’s arguments for where to turn attention to next. The Brazilian central bank’s monetary policy and its decisions on interest rates significantly impact the Brazilian stock market. | The ETF’s largest holdings include Petrobras (NYSE:PBR), Vale (NYSE:VALE) and Ambev (NYSE:ABEV). InvestorPlace - Stock Market News, Stock Advice & Trading Tips One of the nice things about interviewing over 500 thought leaders in the realm of investing and finance on my podcast Lead-Lag Live is getting exposure to new investment ideas and tracking really smart people’s arguments for where to turn attention to next. He argued that it makes no sense to buy Magnificent 7 stocks with insane valuations when there are stocks in Brazil that trade at 5 times earnings and are clearly tied to the commodity cycle. | The ETF’s largest holdings include Petrobras (NYSE:PBR), Vale (NYSE:VALE) and Ambev (NYSE:ABEV). On X, Tavi Costa, who I had on not too long ago, showed an interesting chart of the MSCI Brazil index. He argued that it makes no sense to buy Magnificent 7 stocks with insane valuations when there are stocks in Brazil that trade at 5 times earnings and are clearly tied to the commodity cycle. |
28135.0 | 2023-10-31 00:00:00 UTC | Consumer Sector Update for 10/31/2023: BUD, VFC, ABEV, XLP, XLY | ABEV | https://www.nasdaq.com/articles/consumer-sector-update-for-10-31-2023%3A-bud-vfc-abev-xlp-xly | nan | nan | Consumer stocks were gaining premarket Tuesday with the Consumer Staples Select Sector SPDR Fund (XLP) up 0.2% and the Consumer Discretionary Select Sector SPDR Fund (XLY) advancing 0.9% recently.
Anheuser-Busch Inbev (BUD) was over 4% higher after it reported Q3 underlying earnings of $0.86 per share, up from $0.84 a year earlier. Three analysts polled by Capital IQ expected $0.81.
VF (VFC) was 11% lower after it reported fiscal Q2 adjusted earnings of $0.63 per diluted share, down from $0.73 a year ago. Analysts polled by Capital IQ expected $0.65.
Ambev (ABEV) was climbing nearly 3% after it reported Q3 normalized EPS of 0.25 Brazilian real ($0.05), up from 0.20 real a year earlier. An analyst polled by Capital IQ expected 0.22 real.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Ambev (ABEV) was climbing nearly 3% after it reported Q3 normalized EPS of 0.25 Brazilian real ($0.05), up from 0.20 real a year earlier. Anheuser-Busch Inbev (BUD) was over 4% higher after it reported Q3 underlying earnings of $0.86 per share, up from $0.84 a year earlier. VF (VFC) was 11% lower after it reported fiscal Q2 adjusted earnings of $0.63 per diluted share, down from $0.73 a year ago. | Ambev (ABEV) was climbing nearly 3% after it reported Q3 normalized EPS of 0.25 Brazilian real ($0.05), up from 0.20 real a year earlier. Consumer stocks were gaining premarket Tuesday with the Consumer Staples Select Sector SPDR Fund (XLP) up 0.2% and the Consumer Discretionary Select Sector SPDR Fund (XLY) advancing 0.9% recently. Three analysts polled by Capital IQ expected $0.81. | Ambev (ABEV) was climbing nearly 3% after it reported Q3 normalized EPS of 0.25 Brazilian real ($0.05), up from 0.20 real a year earlier. Consumer stocks were gaining premarket Tuesday with the Consumer Staples Select Sector SPDR Fund (XLP) up 0.2% and the Consumer Discretionary Select Sector SPDR Fund (XLY) advancing 0.9% recently. An analyst polled by Capital IQ expected 0.22 real. | Ambev (ABEV) was climbing nearly 3% after it reported Q3 normalized EPS of 0.25 Brazilian real ($0.05), up from 0.20 real a year earlier. Consumer stocks were gaining premarket Tuesday with the Consumer Staples Select Sector SPDR Fund (XLP) up 0.2% and the Consumer Discretionary Select Sector SPDR Fund (XLY) advancing 0.9% recently. Anheuser-Busch Inbev (BUD) was over 4% higher after it reported Q3 underlying earnings of $0.86 per share, up from $0.84 a year earlier. |
28136.0 | 2023-10-28 00:00:00 UTC | 3 Dividend Growth Stocks to Buy With Yields Between 4% and 8% | ABEV | https://www.nasdaq.com/articles/3-dividend-growth-stocks-to-buy-with-yields-between-4-and-8 | nan | nan | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Wagering on dividend growth stocks offering yields of 4% to 8% can harmonize income with capital appreciation potential. However, the tempo of sustainability is imperative to consider as you look to scrutinize the payout ratio, growth prospects, and the firm’s financial health.
A high yield might be a false crescendo, signaling deeper issues in earnings or cash flows. Market rhythms and sector trends compose more layers of complexity, influencing dividend stability. Herein lies the charm of dividend growth stocks. They provide robust regular income with appreciation potential, appealing to those seeking consistency and lower risk. Established with profitable encores, these companies don’t just return cash dividends, they are increasing payouts on a yearly basis.
Ambev (ABEV)
Source: rafapress / Shutterstock.com
3-Year Dividend Growth Rate (10y Median): 11.55%
Dividend Yield: 5.90%
Ambev (NYSE:ABEV) isn’t a beverage-only company, as it offers a bubbling fountain of diverse offerings, from beers and soft drinks to food products.
Despite a 10% dip in ABEV stock this year, its second-quarter results pour a refreshing glass of resilience. Its proven so with its non-GAAP EPS of R$16 cents and revenue hitting R$18.9 billion, a 5.1% increase year-over-year (YOY). And it particularly impressed with a normalized EBITDA surge of 34.2%. Also, margins are fizzing, with gross margin swelling 170 basis points and EBITDA margin rising 300 basis points.
Looking ahead, Ambev has set the bar high, thirsting for greater robust organic normalized EBITDA growth in 2023 than the 17.1% bump witnessed last year. Moreover, it stands out in terms of profitability, with its net income and EBITDA growth rising to 17.5% and 27%, respectively. Finally, its free cash flow margin remains at an impressive 13% YOY, powering its near 6% yield.
Stellantis (STLA)
Source: Antonello Marangi / Shutterstock.com
3-Year Dividend Growth Rate (10y Median): 15.10%
Dividend Yield: 7.90%
Stellantis (NYSE:STLA), the powerhouse behind Chrysler and a member of Detroit’s Big Three, is more than weathering the recent United Auto Workers’ strike. In fact, it’s cruising with confidence. Despite the industry’s rumblings, STLA stock remains remarkably resilient.
The first half of the year saw Stellantis shift gears, revving up its transition to electrified, software-defined models across its fleet of 14 legendary brands. Revenues accelerated 12% YOY to €98.4 billion, fueled by burgeoning shipments. At the same time, adjusted operating income advanced 11% to €14.1 billion, flaunting a robust 14.4% margin.
On the innovation speedway, Stellantis isn’t tapping the brakes either. Its Pro One initiative, spotlighting commercial vehicles from six brands, promises a turbocharged future. With expected reported earnings today, projected revenue of $46.3 billion might seem a softer purr compared to last year. But savvy investors hear a potential buy-the-dip roar for this 8% yielder.
Cheniere Energy Partners (CQP)
Source: Shutterstock
3-Year Dividend Growth Rate (10y Median): 12.50%
Dividend Yield: 7.60%
Cheniere Energy Partners (NYSEAMERICAN:CQP) stands as a compelling tale in the high-voltage world of energy. Amid the dazzle of renewables and EVs, this titan of the liquid natural gas (LNG) industry holds its ground with aplomb.
Sprawling across the Gulf Coast, Cheniere’s operations showcase a network that is nothing short of astounding. It’s a stronghold in infrastructure that remains unmatched and formidable. More than just muscle, the firm rewards shareholders with stability, with it recently announcing a $1.03 per share quarterly dividend, consistent with its history. It currently yields a solid 7.60%, with a track record of dividend growth stretching over six impressive years.
A glance at the books reveals resilience. Despite the price-induced sales slump, net income is robust, up by 31%. More encouraging is that free cash flow margins have climbed a noteworthy 20% YOY. Cheniere isn’t just surviving. It’s thriving, demonstrating that there’s substantial energy in LNG’s reality.
On the date of publication, Muslim Farooque did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.
More From InvestorPlace
ChatGPT IPO Could Shock the World, Make This Move Before the Announcement
Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In.
The Rich Use This Income Secret (NOT Dividends) Far More Than Regular Investors
The post 3 Dividend Growth Stocks to Buy With Yields Between 4% and 8% appeared first on InvestorPlace.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Ambev (ABEV) Source: rafapress / Shutterstock.com 3-Year Dividend Growth Rate (10y Median): 11.55% Dividend Yield: 5.90% Ambev (NYSE:ABEV) isn’t a beverage-only company, as it offers a bubbling fountain of diverse offerings, from beers and soft drinks to food products. Despite a 10% dip in ABEV stock this year, its second-quarter results pour a refreshing glass of resilience. Looking ahead, Ambev has set the bar high, thirsting for greater robust organic normalized EBITDA growth in 2023 than the 17.1% bump witnessed last year. | Ambev (ABEV) Source: rafapress / Shutterstock.com 3-Year Dividend Growth Rate (10y Median): 11.55% Dividend Yield: 5.90% Ambev (NYSE:ABEV) isn’t a beverage-only company, as it offers a bubbling fountain of diverse offerings, from beers and soft drinks to food products. Despite a 10% dip in ABEV stock this year, its second-quarter results pour a refreshing glass of resilience. Stellantis (STLA) Source: Antonello Marangi / Shutterstock.com 3-Year Dividend Growth Rate (10y Median): 15.10% Dividend Yield: 7.90% Stellantis (NYSE:STLA), the powerhouse behind Chrysler and a member of Detroit’s Big Three, is more than weathering the recent United Auto Workers’ strike. | Ambev (ABEV) Source: rafapress / Shutterstock.com 3-Year Dividend Growth Rate (10y Median): 11.55% Dividend Yield: 5.90% Ambev (NYSE:ABEV) isn’t a beverage-only company, as it offers a bubbling fountain of diverse offerings, from beers and soft drinks to food products. Despite a 10% dip in ABEV stock this year, its second-quarter results pour a refreshing glass of resilience. InvestorPlace - Stock Market News, Stock Advice & Trading Tips Wagering on dividend growth stocks offering yields of 4% to 8% can harmonize income with capital appreciation potential. | Ambev (ABEV) Source: rafapress / Shutterstock.com 3-Year Dividend Growth Rate (10y Median): 11.55% Dividend Yield: 5.90% Ambev (NYSE:ABEV) isn’t a beverage-only company, as it offers a bubbling fountain of diverse offerings, from beers and soft drinks to food products. Despite a 10% dip in ABEV stock this year, its second-quarter results pour a refreshing glass of resilience. Finally, its free cash flow margin remains at an impressive 13% YOY, powering its near 6% yield. |
28137.0 | 2023-10-18 00:00:00 UTC | Validea Peter Lynch Strategy Daily Upgrade Report - 10/18/2023 | ABEV | https://www.nasdaq.com/articles/validea-peter-lynch-strategy-daily-upgrade-report-10-18-2023 | nan | nan | The following are today's upgrades for Validea's P/E/Growth Investor model based on the published strategy of Peter Lynch. This strategy looks for stocks trading at a reasonable price relative to earnings growth that also possess strong balance sheets.
TALOS ENERGY INC (TALO) is a small-cap value stock in the Oil & Gas Operations industry. The rating according to our strategy based on Peter Lynch changed from 56% to 74% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Talos Energy Inc. is a technically driven independent exploration and production company. The Company has its operations in the United States and offshore Mexico, both through upstream oil and gas exploration and production and the development of carbon capture and sequestration (CCS) opportunities. The Company operates through the exploration and production of oil, natural gas and natural gas liquid (NGLs) segment (Upstream Segment). It has operations across a range of Deepwater and shallow water assets in both the United States and Mexico. Its area of focus in the United States is the Gulf of Mexico Deepwater and its core areas are Green Canyon, Mississippi Canyon and Shelf and Gulf Coast. Green Canyon is a Deepwater region in the Central United States, Gulf of Mexico. Mississippi Canyon is a Deepwater region in the eastern portion of the Central United States, Gulf of Mexico. Its CCS portfolio includes multiple future project sites along the United States Gulf Coast.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: PASS
INVENTORY TO SALES: FAIL
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
Detailed Analysis of TALOS ENERGY INC
TALO Guru Analysis
TALO Fundamental Analysis
AMBEV SA (ADR) (ABEV) is a large-cap value stock in the Beverages (Alcoholic) industry. The rating according to our strategy based on Peter Lynch changed from 0% to 91% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Ambev SA, formerly Inbev Participacoes Societarias SA, is a Brazil-based company engaged in the brewing sector. The Company produces, distributes and sells beer, carbonated soft drinks (CSDs) and other non-alcoholic and non-carbonated (NANC) beverages across the Americas. The Company's activities are divided into three segments: Latin America North, including sell of beer, CSD and NANC drinks in Brazil, as well as operations in the Dominican Republic, Saint Vincent, Antigua, Dominica, Cuba, Guatemala, El Salvador, Honduras, Nicaragua, Barbados and Panama; Latin America South, distributing products in Argentina, Bolivia, Paraguay, Uruguay, Chile; and Canada, represented by Labatt's operations, which comprises sales in Canada and some exports to the U.S. market. The Company markets products under various brand names, such as Adriatica, Brahma, Leffe, Budweiser, Corona, PepsiCo and Lipton. It is a subsidiary of Interbrew International BV.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
SALES: PASS
INVENTORY TO SALES: PASS
YIELD COMPARED TO THE S&P 500: PASS
YIELD ADJUSTED P/E/GROWTH (PEG) RATIO: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
Detailed Analysis of AMBEV SA (ADR)
ABEV Guru Analysis
ABEV Fundamental Analysis
Peter Lynch Portfolio
Top Peter Lynch Stocks
About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Lynch's common sense approach and quick wit made him one of the most quoted investors on Wall Street. ("Go for a business that any idiot can run -- because sooner or later, any idiot probably is going to run it," is one of his many pearls of wisdom.) Lynch's bestseller One Up on Wall Street is something of a "stocks for the everyman/everywoman", breaking his approach down into easy-to-understand concepts.
About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Detailed Analysis of TALOS ENERGY INC TALO Guru Analysis TALO Fundamental Analysis AMBEV SA (ADR) (ABEV) is a large-cap value stock in the Beverages (Alcoholic) industry. Detailed Analysis of AMBEV SA (ADR) ABEV Guru Analysis ABEV Fundamental Analysis Peter Lynch Portfolio Top Peter Lynch Stocks About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. The Company has its operations in the United States and offshore Mexico, both through upstream oil and gas exploration and production and the development of carbon capture and sequestration (CCS) opportunities. | Detailed Analysis of TALOS ENERGY INC TALO Guru Analysis TALO Fundamental Analysis AMBEV SA (ADR) (ABEV) is a large-cap value stock in the Beverages (Alcoholic) industry. Detailed Analysis of AMBEV SA (ADR) ABEV Guru Analysis ABEV Fundamental Analysis Peter Lynch Portfolio Top Peter Lynch Stocks About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. The Company operates through the exploration and production of oil, natural gas and natural gas liquid (NGLs) segment (Upstream Segment). | Detailed Analysis of TALOS ENERGY INC TALO Guru Analysis TALO Fundamental Analysis AMBEV SA (ADR) (ABEV) is a large-cap value stock in the Beverages (Alcoholic) industry. Detailed Analysis of AMBEV SA (ADR) ABEV Guru Analysis ABEV Fundamental Analysis Peter Lynch Portfolio Top Peter Lynch Stocks About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. The Company's activities are divided into three segments: Latin America North, including sell of beer, CSD and NANC drinks in Brazil, as well as operations in the Dominican Republic, Saint Vincent, Antigua, Dominica, Cuba, Guatemala, El Salvador, Honduras, Nicaragua, Barbados and Panama; Latin America South, distributing products in Argentina, Bolivia, Paraguay, Uruguay, Chile; and Canada, represented by Labatt's operations, which comprises sales in Canada and some exports to the U.S. market. | Detailed Analysis of TALOS ENERGY INC TALO Guru Analysis TALO Fundamental Analysis AMBEV SA (ADR) (ABEV) is a large-cap value stock in the Beverages (Alcoholic) industry. Detailed Analysis of AMBEV SA (ADR) ABEV Guru Analysis ABEV Fundamental Analysis Peter Lynch Portfolio Top Peter Lynch Stocks About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. The following are today's upgrades for Validea's P/E/Growth Investor model based on the published strategy of Peter Lynch. |
28138.0 | 2023-09-28 00:00:00 UTC | Thursday's ETF with Unusual Volume: KXI | ABEV | https://www.nasdaq.com/articles/thursdays-etf-with-unusual-volume%3A-kxi | nan | nan | The iShares Global Consumer Staples ETF is seeing unusually high volume in afternoon trading Thursday, with over 2.7 million shares traded versus three month average volume of about 98,000. Shares of KXI were up about 0.6% on the day.
Components of that ETF with the highest volume on Thursday were Ambev, trading up about 2% with over 8.5 million shares changing hands so far this session, and Kenvue, off about 0.1% on volume of over 7.7 million shares. Philip Morris International is the component faring the best Thursday, higher by about 2.5% on the day, while The Kraft Heinz is lagging other components of the iShares Global Consumer Staples ETF, trading lower by about 0.9%.
VIDEO: Thursday's ETF with Unusual Volume: KXI
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The iShares Global Consumer Staples ETF is seeing unusually high volume in afternoon trading Thursday, with over 2.7 million shares traded versus three month average volume of about 98,000. Components of that ETF with the highest volume on Thursday were Ambev, trading up about 2% with over 8.5 million shares changing hands so far this session, and Kenvue, off about 0.1% on volume of over 7.7 million shares. Philip Morris International is the component faring the best Thursday, higher by about 2.5% on the day, while The Kraft Heinz is lagging other components of the iShares Global Consumer Staples ETF, trading lower by about 0.9%. | The iShares Global Consumer Staples ETF is seeing unusually high volume in afternoon trading Thursday, with over 2.7 million shares traded versus three month average volume of about 98,000. Philip Morris International is the component faring the best Thursday, higher by about 2.5% on the day, while The Kraft Heinz is lagging other components of the iShares Global Consumer Staples ETF, trading lower by about 0.9%. VIDEO: Thursday's ETF with Unusual Volume: KXI The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | The iShares Global Consumer Staples ETF is seeing unusually high volume in afternoon trading Thursday, with over 2.7 million shares traded versus three month average volume of about 98,000. Components of that ETF with the highest volume on Thursday were Ambev, trading up about 2% with over 8.5 million shares changing hands so far this session, and Kenvue, off about 0.1% on volume of over 7.7 million shares. Philip Morris International is the component faring the best Thursday, higher by about 2.5% on the day, while The Kraft Heinz is lagging other components of the iShares Global Consumer Staples ETF, trading lower by about 0.9%. | The iShares Global Consumer Staples ETF is seeing unusually high volume in afternoon trading Thursday, with over 2.7 million shares traded versus three month average volume of about 98,000. Philip Morris International is the component faring the best Thursday, higher by about 2.5% on the day, while The Kraft Heinz is lagging other components of the iShares Global Consumer Staples ETF, trading lower by about 0.9%. VIDEO: Thursday's ETF with Unusual Volume: KXI The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. |
28139.0 | 2023-09-07 00:00:00 UTC | FEMSA (FMX) Stock Rallies 65% in the Past Year: What's Ahead? | ABEV | https://www.nasdaq.com/articles/femsa-fmx-stock-rallies-65-in-the-past-year%3A-whats-ahead | nan | nan | Fomento Economico Mexicano S.A.B. de C.V. FMX, alias FEMSA, appears to be a lucrative pick with solid growth prospects. The company has been in investors’ good books due to gains from growth across all business units, a solid online show and continued strength in OXXO Mexico and OXXO Gas. It has been on track with its strategy of creating a distribution platform in the United States by expanding its footprint in the specialized distribution industry.
The company is also poised for growth through investments in digital and technology-driven initiatives. Moreover, FEMSA displays solid financial flexibility.
FEMSA reported top and bottom line beat for the second consecutive quarter in second-quarter 2023. The company’s adjusted net majority earnings per ADS benefited from robust sales growth, improved gross margin and lower interest expenses. FEMSA's revenues improved 18.3% year over year in the local currency. Gains across its business units drove revenue growth. On an organic basis, total revenues rose 9.5%.
Shares of this Zacks Rank #1 (Strong Buy) company have rallied 64.5% in the past year compared with the industry’s growth of 6.1%. The FMX stock also compared favorably with the sector’s decline of 3.2% and the S&P 500’s 12.4% rise. You can see the complete list of today’s Zacks #1 Rank stocks here.
Image Source: Zacks Investment Research
Factors Likely to Drive Growth
FEMSA will likely continue witnessing momentum driven by strength across business units resulting from effective growth strategies and robust market demand.
FEMSA has been gaining pace in the digital space through its tech and innovation business unit — Digital@FEMSA. The unit is focused on building a value-added digital and financial ecosystem for end customers and businesses. It is also inclined toward enabling and leveraging the strategic assets of FEMSA’s core business verticals.
The company’s Coca-Cola FEMSA is leading the way with its omni-channel business, while the Proximity division is progressing with the adoption of digital initiatives for the OXXO stores. Within its OXXO store chains, the company is on track with investing in digital offerings, loyalty programs and fintech platforms, to evolve stronger over the long term. Its OXXO digital wallet, OXXO Premia and loyalty program have been performing well. The company made progress on its digital efforts, with the continued addition of Spin Premia and Spin by OXXO customers at an accelerated Pace.
Spin by OXXO received its definitive authorization to operate as a fintech in Mexico. Spin by OXXO reached 7.6 million users in second-quarter 2023, suggesting a 142.1% growth year over year. Active users at Spin by OXXO currently represent 75.8% of the acquired user base. Meanwhile, Spin Premia reached 32.7 million users in the second quarter, reflecting a year-over-year growth of 115%. Active users at Spin Premia represented 48.3% of the total acquired user base.
FEMSA’s venture in the specialized distribution industry relates to its plan of investing in adjacent businesses, which can leverage capabilities across different markets, providing an opportunity for attractive growth and risk-adjusted returns.
With the presence of its OXXO business and other retail operations, the company has become an expert in the organization and management of supply chains and distribution systems. FEMSA serves several businesses and retail customers through millions of interactions in different industries.
Key Picks
We have highlighted three top-ranked stocks from the Consumer Staple sector, namely PepsiCo Inc. PEP, McCormick & Company MKC and Ambev ABEV.
PepsiCo has a trailing four-quarter earnings surprise of 6.3%, on average. It currently carries a Zacks Rank #2. Shares of PEP have gained 1.2% in the past year.
The Zacks Consensus Estimate for PepsiCo’s current financial-year sales and earnings suggests growth of 6.7% and 10.2%, respectively, from the year-ago period's reported figures. PEP has an expected EPS growth rate of 8.1% for three to five years.
McCormick currently sports a Zacks Rank #2. The company has an expected EPS growth rate of 7.5% for three to five years. Shares of MKC have risen 1% in the past year.
The Zacks Consensus Estimate for McCormick’s current financial year’s sales and earnings per share suggests 6.4% and 5.1% growth, respectively, from the year-ago period’s reported figures. MKC has a trailing four-quarter negative earnings surprise of 4.2% on average.
Ambev has a trailing four-quarter earnings surprise of 20.8% on average. It currently carries a Zacks Rank #2. Shares of ABEV have declined 5.1% in the past year.
The Zacks Consensus Estimate for Ambev’s current financial-year sales suggests growth of 4.5% from the year-ago period's reported figure. Meanwhile, the consensus estimate for earnings indicates a decline of 5.6% from the year-ago quarter’s reported figure. ABEV has an expected EPS growth rate of 7% for three to five years.
Zacks Names #1 Semiconductor Stock
It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom.
With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028.
See This Stock Now for Free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Fomento Economico Mexicano S.A.B. de C.V. (FMX) : Free Stock Analysis Report
PepsiCo, Inc. (PEP) : Free Stock Analysis Report
McCormick & Company, Incorporated (MKC) : Free Stock Analysis Report
Ambev S.A. (ABEV) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | PEP, McCormick & Company MKC and Ambev ABEV. Shares of ABEV have declined 5.1% in the past year. ABEV has an expected EPS growth rate of 7% for three to five years. | de C.V. (FMX) : Free Stock Analysis Report PepsiCo, Inc. (PEP) : Free Stock Analysis Report McCormick & Company, Incorporated (MKC) : Free Stock Analysis Report Ambev S.A. (ABEV) : Free Stock Analysis Report To read this article on Zacks.com click here. PEP, McCormick & Company MKC and Ambev ABEV. Shares of ABEV have declined 5.1% in the past year. | de C.V. (FMX) : Free Stock Analysis Report PepsiCo, Inc. (PEP) : Free Stock Analysis Report McCormick & Company, Incorporated (MKC) : Free Stock Analysis Report Ambev S.A. (ABEV) : Free Stock Analysis Report To read this article on Zacks.com click here. PEP, McCormick & Company MKC and Ambev ABEV. Shares of ABEV have declined 5.1% in the past year. | PEP, McCormick & Company MKC and Ambev ABEV. Shares of ABEV have declined 5.1% in the past year. ABEV has an expected EPS growth rate of 7% for three to five years. |
28140.0 | 2023-09-01 00:00:00 UTC | Energy Drink Demand to Aid Monster Beverage's (MNST) Sales | ABEV | https://www.nasdaq.com/articles/energy-drink-demand-to-aid-monster-beverages-mnst-sales | nan | nan | Monster Beverage Corporation MNST is a stock to watch, given the robust demand trends for its energy drinks, effective pricing actions, product innovations and a healthy balance sheet. The company’s steady lineup of product launches is likely to help retain its business momentum. It is anticipated to reap gains from its strong distribution network in international markets and investments in growth opportunities.
Backed by these trends, Monster Beverage’s top and bottom lines improved year over year in second-quarter 2023. Monster Beverage’s earnings advanced 50% year over year, while sales improved 12%. Results gained from the expansion of the energy drinks category and product launches.
The Zacks Rank #3 (Hold) company has a market capitalization of $60.9 billion. In the past year, shares of the company have gained 29.9% compared with the industry’s growth of 12.4%. The stock also outpaced the sector and the S&P 500’s growth of 0.5% and 15.1%, respectively, in the same period.
The Zacks Consensus Estimate for Monster Beverage’s 2023 sales and earnings suggests growth of 13.7% and 37.5%, respectively, from the year-ago period’s reported numbers.
Image Source: Zacks Investment Research
Factors Driving Growth
Monster Beverage’s continued momentum in the energy drinks category remains a key growth driver. We note that the company offers a wide range of energy drink brands, such as Monster Energy, Java Monster, Cafe Monster, Espresso Monster, Monster Energy Mule, Juice Monster Pipeline Punch, Juice Monster Pacific Punch, Juice Monster Mango Loco, Monster Ultra Paradise, and Monster Hydra Sport. In second-quarter 2023, the Monster Energy Drinks segment's net sales increased 9.7% year over year to $1.7 billion.
Product innovation plays a significant role in the company's success. Monster Beverage remains committed to product launches and innovation to boost growth. In second-quarter 2023, the company launched many products and expanded distribution in the international markets.
In the second quarter, Monster Beverage continued with the roll-out of its first flavored malt beverage alcohol product, The Beast Unleashed, in the United States and received positive feedback. Consequently, MNST is on track with the expansion of the distribution of The Beast Unleashed into additional markets, with plans for nationwide distribution by the end of the year. It intends to launch a hard iced tea extension of The Beast Unleashed, named Nasty Beast Hardcore Tea, later this year or early next year, with a target of nationwide distribution in the first half of 2024. The brand will be available in four flavors — Original, Half & Half, Razzleberry and Green.
Moreover, Monster Energy is on track with price increases to wean the ongoing cost pressures. It has been implementing price hikes from the first half of 2022. It continued to implement price hikes in the second quarter of 2023, with additional price hikes planned in many other markets through the remainder of 2023. In some markets, this rise was in addition to price increases implemented in 2022.
In the United States, management implemented an additional price increase on its 18.6 oz and 24 oz energy drinks, effective Apr 1, 2023.
The company’s pricing actions, along with reduced freight costs, have been aiding the gross and operating margins. In second-quarter 2023, Monster Beverage’s gross margin expanded 540 basis points (bps) to 52.5%, driven by pricing actions, lower freight-in costs and reduced aluminum can costs. The operating margin expanded 570 bps to 28.2% on an improved gross margin. The persistence of this trend may contribute to the company’s profitability.
What Holds MNST Back?
Monster Beverage has been witnessing rising SG&A expenses due to increased payroll expenses. Also, the persistence of certain supply-chain headwinds has been a deterrent. Operating expenses grew 10.7% year over year in the second quarter mainly due to increased payroll expenses. Selling expenses, as a percentage of net sales, expanded 20 bps year over year to 9.3%. General and administrative expenses, as a percentage of net sales, expanded 40 bps year over year to 10.6%.
Stocks to Consider
We have highlighted three better-ranked stocks from the Consumer Staple sector, namely Fomento Economico Mexicano FMX, Ambev ABEV and PepsiCo Inc. PEP.
Fomento Economico Mexicano, alias FEMSA, currently sports a Zacks Rank #1 (Strong Buy). The company has an expected EPS growth rate of 22.4% for three to five years. Shares of FMX have rallied 72.6% in the past year. You can see the complete list of today's Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for FEMSA’s current financial year’s sales and earnings per share suggests growth of 31.9% and 58.3%, respectively, from the year-ago period’s reported figures. FMX has a trailing four-quarter earnings surprise of 6.1%, on average.
Ambev has a trailing four-quarter earnings surprise of 20.8%, on average. It currently carries a Zacks Rank #2 (Buy). Shares of ABEV have declined 5.4% in the past year.
The Zacks Consensus Estimate for Ambev’s current financial-year sales suggests growth of 4.5% from the year-ago period's reported figure. Meanwhile, the consensus estimate for earnings indicates a decline of 5.6% from the year-ago quarter’s reported figure. ABEV has an expected EPS growth rate of 7% for three to five years.
PepsiCo has a trailing four-quarter earnings surprise of 6.3%, on average. It currently carries a Zacks Rank #2. Shares of PEP have gained 4.2% in the past year.
The Zacks Consensus Estimate for PepsiCo’s current financial-year sales and earnings suggests growth of 6.7% and 10.2%, respectively, from the year-ago period's reported figures. PEP has an expected EPS growth rate of 8.1% for three to five years.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Fomento Economico Mexicano S.A.B. de C.V. (FMX) : Free Stock Analysis Report
PepsiCo, Inc. (PEP) : Free Stock Analysis Report
Monster Beverage Corporation (MNST) : Free Stock Analysis Report
Ambev S.A. (ABEV) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Stocks to Consider We have highlighted three better-ranked stocks from the Consumer Staple sector, namely Fomento Economico Mexicano FMX, Ambev ABEV and PepsiCo Inc. Shares of ABEV have declined 5.4% in the past year. ABEV has an expected EPS growth rate of 7% for three to five years. | de C.V. (FMX) : Free Stock Analysis Report PepsiCo, Inc. (PEP) : Free Stock Analysis Report Monster Beverage Corporation (MNST) : Free Stock Analysis Report Ambev S.A. (ABEV) : Free Stock Analysis Report To read this article on Zacks.com click here. Stocks to Consider We have highlighted three better-ranked stocks from the Consumer Staple sector, namely Fomento Economico Mexicano FMX, Ambev ABEV and PepsiCo Inc. Shares of ABEV have declined 5.4% in the past year. | de C.V. (FMX) : Free Stock Analysis Report PepsiCo, Inc. (PEP) : Free Stock Analysis Report Monster Beverage Corporation (MNST) : Free Stock Analysis Report Ambev S.A. (ABEV) : Free Stock Analysis Report To read this article on Zacks.com click here. Stocks to Consider We have highlighted three better-ranked stocks from the Consumer Staple sector, namely Fomento Economico Mexicano FMX, Ambev ABEV and PepsiCo Inc. Shares of ABEV have declined 5.4% in the past year. | Stocks to Consider We have highlighted three better-ranked stocks from the Consumer Staple sector, namely Fomento Economico Mexicano FMX, Ambev ABEV and PepsiCo Inc. Shares of ABEV have declined 5.4% in the past year. ABEV has an expected EPS growth rate of 7% for three to five years. |
28141.0 | 2023-08-31 00:00:00 UTC | Thursday's ETF Movers: IHAK, ILF | ABEV | https://www.nasdaq.com/articles/thursdays-etf-movers%3A-ihak-ilf | nan | nan | In trading on Thursday, the iShares Cybersecurity and Tech ETF is outperforming other ETFs, up about 2% on the day. Components of that ETF showing particular strength include shares of Okta, up about 12.2% and shares of Crowdstrike Holdings, up about 9.6% on the day.
And underperforming other ETFs today is the iShares Latin America 40 ETF, down about 1.8% in Thursday afternoon trading. Among components of that ETF with the weakest showing on Thursday were shares of NU Holdings, lower by about 2.3%, and shares of Ambev, lower by about 2.3% on the day.
VIDEO: Thursday's ETF Movers: IHAK, ILF
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Components of that ETF showing particular strength include shares of Okta, up about 12.2% and shares of Crowdstrike Holdings, up about 9.6% on the day. Among components of that ETF with the weakest showing on Thursday were shares of NU Holdings, lower by about 2.3%, and shares of Ambev, lower by about 2.3% on the day. VIDEO: Thursday's ETF Movers: IHAK, ILF The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In trading on Thursday, the iShares Cybersecurity and Tech ETF is outperforming other ETFs, up about 2% on the day. Among components of that ETF with the weakest showing on Thursday were shares of NU Holdings, lower by about 2.3%, and shares of Ambev, lower by about 2.3% on the day. VIDEO: Thursday's ETF Movers: IHAK, ILF The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In trading on Thursday, the iShares Cybersecurity and Tech ETF is outperforming other ETFs, up about 2% on the day. And underperforming other ETFs today is the iShares Latin America 40 ETF, down about 1.8% in Thursday afternoon trading. Among components of that ETF with the weakest showing on Thursday were shares of NU Holdings, lower by about 2.3%, and shares of Ambev, lower by about 2.3% on the day. | In trading on Thursday, the iShares Cybersecurity and Tech ETF is outperforming other ETFs, up about 2% on the day. Components of that ETF showing particular strength include shares of Okta, up about 12.2% and shares of Crowdstrike Holdings, up about 9.6% on the day. And underperforming other ETFs today is the iShares Latin America 40 ETF, down about 1.8% in Thursday afternoon trading. |
28142.0 | 2023-08-30 00:00:00 UTC | Growth Efforts to Aid Diageo (DEO) Amid Inflationary Pressures | ABEV | https://www.nasdaq.com/articles/growth-efforts-to-aid-diageo-deo-amid-inflationary-pressures | nan | nan | Diageo Plc DEO has been benefiting from its diversified footprint, advantaged portfolio, strong brands and favorable industry trends of premiumization. The company has been witnessing a solid business momentum, strong consumer demand and market share gains, which have been boosting its performance. Effective marketing and exceptional commercial execution bode well.
Robust sales growth, organic operating margin expansion, productivity savings and favorable currency impact aided Diageo’s fiscal 2023 results. The price/mix gained from a positive mix due to robust growth in super-premium-plus brands, particularly scotch, tequila and beer.
The Zacks Consensus Estimate for DEO’s fiscal 2024 sales and earnings suggests growth of 9.9% and 1.2%, respectively, from the year-ago period’s reported numbers.
However, continued inflationary pressures from increased glass, paper, metal, and transportation costs have been headwinds. Also, currency headwinds are concerning.
Shares of the Zacks Rank #3 (Hold) company have lost 4.1% in the past year against the industry’s growth of 2.8%.
Image Source: Zacks Investment Research
What Keeps Diageo Strong?
DEO is anticipated to retain the strength in its business through constant premiumization efforts, recovery across markets, pricing actions and supply productivity savings. The company’s premium-plus brands contributed 63% to reported sales growth and 57% to total organic sales growth for fiscal 2023.
Diageo is confident about the long-term growth potential of the beverage alcohol sector. It expects to expand its value share by 50% in the sector to 6% by 2030. DEO is on track to deliver on its medium-term guidance for fiscal 2023-2025 of 5-7% organic sales growth and 6-9% organic operating profit growth. Diageo expects to invest strongly in marketing and innovation, and leverage its revenue growth management capabilities, including strategic pricing actions.
Although the company predicts a challenging operating environment for fiscal 2024, it predicts a gradual improvement in year-over-year comparisons in the second half of fiscal 2024. The company expects net sales to improve in the first half of fiscal 2024 from the second half of fiscal 2023. It also expects accelerated sales growth in the second half of fiscal 2024 due to easy comparisons from fiscal 2023.
DEO is well-poised for growth from effective marketing and extraordinary commercial execution. It is likely to invest strongly in marketing and innovation, and leverage its revenue growth management capabilities, including strategic pricing actions. This is likely to support DEO in the near and long terms.
DEO’s margin trends were favorable in fiscal 2023, thanks to its premiumization efforts, recovery in markets, pricing actions and supply productivity savings, which mostly offset the cost inflation. Organic operating profit benefited from strong sales growth, revenue management initiatives, disciplined cost management and productivity savings. Productivity initiatives delivered £450 million of cost savings in fiscal 2023. Gains from price increases more than offset the impacts of cost inflation on the gross margin.
The company expects the operating margin in fiscal 2024 to benefit from a moderating inflationary environment and continued focus on revenue management initiatives, including improved pricing. Moreover, the organic operating margin is likely to benefit from premiumization trends and operating leverage with strong marketing investments.
Our model predicts a 5% rise in operating profit in the first half of fiscal 2024, with 7% growth in fiscal 2024. The operating margin is estimated to expand 50 basis points (bps) in the first half and 100 bps in fiscal 2024.
Hurdles to Overcome
Diageo suffers from persistent inflationary pressures from higher commodity costs, particularly agave, energy expenses and supply disruptions. The company’s organic gross margin declined 97 bps in fiscal 2023 mainly due to the cost pressures.
Price increases and supply productivity savings more than offset the absolute impact of cost inflation. The significant cost pressure in fiscal 2023 mainly came from increased glass, paper, metal and transportation costs. Additionally, the gross margin was impacted by lower beer volumes in Africa.
DEO expects to continue its revenue management initiatives, including pricing actions, throughout fiscal 2024 to overcome the challenging inflationary environment. In fiscal 2024, the company expects cost inflation pressure to persist and is committed to investing in its brands to deliver sustainable growth.
We expect its cost of sales to increase 1.5% in the first half of fiscal 2024, owing to continued cost inflation. Our model estimates marketing investments to increase 4% year over year in the first half of fiscal 2024, with a 20-bps increase as a percentage of sales.
As a substantial portion of the company’s business comes from international operations, exchange rate fluctuations have been hampering its sales for a while.
Stocks to Consider
We have highlighted three better-ranked stocks from the Consumer Staple sector, namely Fomento Economico Mexicano FMX, Ambev ABEV and PepsiCo Inc. PEP.
Fomento Economico Mexicano, alias FEMSA, currently sports a Zacks Rank #1 (Strong Buy). The company has an expected EPS growth rate of 22.4% for three to five years. Shares of FMX have rallied 89.3% in the past year. You can see the complete list of today's Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for FEMSA’s current financial year’s sales and earnings per share suggests growth of 31.9% and 58.3%, respectively, from the year-ago period’s reported figures. FMX has a trailing four-quarter earnings surprise of 6.1%, on average.
Ambev has a trailing four-quarter earnings surprise of 20.8%, on average. It currently carries a Zacks Rank #2 (Buy). Shares of ABEV have gained 6.4% in the year-to-date period.
The Zacks Consensus Estimate for Ambev’s current financial-year sales suggests growth of 4.5% from the year-ago period's reported figure. Meanwhile, the consensus estimate for earnings indicates a decline of 5.6% from the year-ago quarter’s reported figure. ABEV has an expected EPS growth rate of 7% for three to five years.
PepsiCo has a trailing four-quarter earnings surprise of 6.3%, on average. It currently carries a Zacks Rank #2. Shares of PEP have gained 5.1% in the past year.
The Zacks Consensus Estimate for PepsiCo’s current financial-year sales and earnings suggests growth of 6.7% and 10.2%, respectively, from the year-ago period's reported figures. PEP has an expected EPS growth rate of 8.1% for three to five years.
Zacks Reveals ChatGPT "Sleeper" Stock
One little-known company is at the heart of an especially brilliant Artificial Intelligence sector. By 2030, the AI industry is predicted to have an internet and iPhone-scale economic impact of $15.7 Trillion.
As a service to readers, Zacks is providing a bonus report that names and explains this explosive growth stock and 4 other "must buys." Plus more.
Download Free ChatGPT Stock Report Right Now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Fomento Economico Mexicano S.A.B. de C.V. (FMX) : Free Stock Analysis Report
PepsiCo, Inc. (PEP) : Free Stock Analysis Report
Diageo plc (DEO) : Free Stock Analysis Report
Ambev S.A. (ABEV) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Stocks to Consider We have highlighted three better-ranked stocks from the Consumer Staple sector, namely Fomento Economico Mexicano FMX, Ambev ABEV and PepsiCo Inc. Shares of ABEV have gained 6.4% in the year-to-date period. ABEV has an expected EPS growth rate of 7% for three to five years. | de C.V. (FMX) : Free Stock Analysis Report PepsiCo, Inc. (PEP) : Free Stock Analysis Report Diageo plc (DEO) : Free Stock Analysis Report Ambev S.A. (ABEV) : Free Stock Analysis Report To read this article on Zacks.com click here. Stocks to Consider We have highlighted three better-ranked stocks from the Consumer Staple sector, namely Fomento Economico Mexicano FMX, Ambev ABEV and PepsiCo Inc. Shares of ABEV have gained 6.4% in the year-to-date period. | de C.V. (FMX) : Free Stock Analysis Report PepsiCo, Inc. (PEP) : Free Stock Analysis Report Diageo plc (DEO) : Free Stock Analysis Report Ambev S.A. (ABEV) : Free Stock Analysis Report To read this article on Zacks.com click here. Stocks to Consider We have highlighted three better-ranked stocks from the Consumer Staple sector, namely Fomento Economico Mexicano FMX, Ambev ABEV and PepsiCo Inc. Shares of ABEV have gained 6.4% in the year-to-date period. | Stocks to Consider We have highlighted three better-ranked stocks from the Consumer Staple sector, namely Fomento Economico Mexicano FMX, Ambev ABEV and PepsiCo Inc. Shares of ABEV have gained 6.4% in the year-to-date period. ABEV has an expected EPS growth rate of 7% for three to five years. |
28143.0 | 2023-08-30 00:00:00 UTC | Brown-Forman (BF.B) Q1 Earnings & Sales Miss on Soft Trends | ABEV | https://www.nasdaq.com/articles/brown-forman-bf.b-q1-earnings-sales-miss-on-soft-trends | nan | nan | Brown-Forman Corporation (BF.B) has reported dismal first-quarter fiscal 2024 results, wherein sales and earnings missed the Zacks Consensus Estimate. Meanwhile, sales improved year over year, while earnings declined.
In the fiscal first quarter, earnings per share (EPS) of 48 cents declined 7% year over year and lagged the Zacks Consensus Estimate of 52 cents.
Net sales of $1,038 million missed the Zacks Consensus Estimate of $1,053 million. The top line increased 3% year over year on a reported basis. On an organic basis, net sales were up 2% from the prior-year level. Lower-than-expected sales mainly resulted from the impacts of difficult shipment comparisons from the prior-year quarter, when the company rebuilt inventory to overcome the glass supply challenges.
Brown-Forman Corporation Price, Consensus and EPS Surprise
Brown-Forman Corporation price-consensus-eps-surprise-chart | Brown-Forman Corporation Quote
In the first quarter of fiscal 2024, Brown-Forman’s gross profit amounted to $651 million, up 5% year over year. On an organic basis, the gross profit rose 5%. Meanwhile, the gross margin expanded 90 basis points (bps) to 62.7%. The favorable gross margin resulted from improved price/mix and reduced supply-chain disruptions due to lower costs and lower tariff-related expenses. This was partly negated by higher input costs and adverse currency rates.
SG&A expenses of $200 million rose 14% year over year and 12% on an organic basis. The increase stemmed from higher compensation expenses. Advertising expenses increased 19% year over year to $131 million for the fiscal first quarter. On an organic basis, advertising expenses increased 14%. Elevated advertising costs mainly resulted from the launch of Jack Daniel’s and Coca-Cola RTDs, increased investments in Jack Daniel’s Tennessee Whiskey, and the acquisition of Gin Mare and Diplomatico.
We expected total operating expenses to increase 15.6% year over year to $322.5 million in the fiscal first quarter, driven by a 1.9% rise in advertising expenses and a 3.9% increase in selling, general and administrative expenses.
The operating income fell 4% year over year to $327 million on a reported basis due to the timing of higher operating expenses, offset by an improved gross margin. The organic operating income declined 6%. The operating margin of 31.5% contracted 250 bps from the 34% reported in the year-ago quarter.
Our model predicted an operating margin of 32.4%, suggesting a 170-bps contraction from the year-ago quarter’s actual.
The Zacks Rank #2 (Buy) company’s shares have rallied 11.8% in the past three months compared with the industry’s growth of 7.2%.
Image Source: Zacks Investment Research
Market-Wise Performance
In first-quarter fiscal 2024, net sales growth was mainly driven by broad-based growth across emerging and developed international markets, as well as the Travel Retail channel. However, sales growth was partly negated by a decline in the United States due to a decrease in distributor inventories resulting from last year’s significant inventory build.
The emerging markets registered 27% net sales growth, whereas organic sales improved 32%. This was backed by strong growth of New Mix and Jack Daniel’s Tennessee Whiskey in the United Arab Emirates and Poland.
The developed international market reported sales growth of 5%, with flat organic sales. The improvement can be attributed to Gin Mare and Diplomático in Italy, and the launch of Jack Daniel’s Tennessee Apple in South Korea. This was partly offset by lower volumes for Jack Daniel’s RTDs in the U.K. and Australia.
Net sales in the Travel Retail channel advanced 13% on a reported basis and 9% on an organic basis due to higher volumes for Woodford Reserve and Jack Daniel’s super-premium expressions like Jack Daniel’s Single Barrel Tennessee Whiskey.
The company’s overall sales in the United States declined 8% on a reported and 9% on an organic basis. The decline resulted from lower volumes reflected in reduced distributor inventories, offset by improved prices across the portfolio led by Jack Daniel’s Tennessee Whiskey.
Category-Wise Performance
Net sales for whiskey products declined 1% year over year and were flat on an organic basis. The decline was led by Woodford Reserve and Gentleman Jack due to the estimated decline in distributor inventories. This was partly offset by improvements in Jack Daniel’s Tennessee Apple and Jack Daniel’s super-premium expressions like Jack Daniel’s Sinatra and Jack Daniel’s Bonded. Net sales for Jack Daniel’s Tennessee Whiskey were flat year over year.
The company continued to witness growth in the Ready-to-Drink (RTD) category, owing to consumer preference for convenience and flavor. Sales for New Mix improved 52% on a reported basis and 32% on an organic basis, driven by elevated volumes and prices, as well as positive currency effects. Jack Daniel’s RTDs/Ready-to-Pours reported flat sales both on a reported and organic basis, driven by lower Jack Daniel’s & Cola volume due to the launch of Jack Daniel’s & Coca-Cola RTD.
Brown-Forman’s tequila portfolio reported year-over-year sales growth of 15% and 12% on an organic basis. This was driven by double-digit sales growth for the el Jimador brand. The el Jimador reported year-over-year sales growth of 27% on a reported basis and 26% on an organic basis, driven by higher pricing, mainly in the United States, as well as higher volumes in Colombia. Sales increased 1% on a reported and declined 3% on an organic basis for the Herradura brand, driven by lower volumes in the United States due to an estimated decline in distributor inventories, offset by positive currency effects.
The company’s newly acquired Gin Mare and Diplomático led significant growth in the rest of the portfolio, with reported sales growth of 97% and organic sales growth of 5%.
Our model had predicted the tequila category to register sales growth of 12.7% in the fiscal first quarter. Meanwhile, other key categories, including wine, vodka and whiskey, were expected to report sales growth of 10.2%, 6.2% and 1.8%, respectively.
Balance Sheet & Cash Flow
The company ended first-quarter fiscal 2024 with cash and cash equivalents of $426 million, and long-term debt of $2,687 million. Its total shareholders’ equity was $3,338 million. As of Jul 31, 2023, BF.B used about $44 million in cash for operating activities.
In first-quarter fiscal 2024, the company returned nearly $99 million to stockholders via dividends. It recently announced a quarterly dividend of 20.55 cents per share on its Class A and Class B shares. The dividend is payable on Oct 2 to shareholders of record as of Sep 5. It has paid out regular quarterly dividends for 79 consecutive years and raised the dividend for 39 consecutive years.
Outlook
Management has reiterated its view for fiscal 2024. It anticipates organic sales growth of 5-7% for fiscal 2024, driven by its strong portfolio of brands, pricing strategy and robust consumer demand. The company remains optimistic about organic sales and organic operating income growth. BF.B predicts trends to normalize after two consecutive years of double-digit organic sales growth.
Brown-Forman expects the organic operating income to increase 6-8%, driven by lower supply-chain disruption costs, partly offset by continued input cost pressures. The effective tax rate is expected to be 21-23% for fiscal 2024. Capital expenditure is anticipated to be $250-$270 million.
Stocks to Consider
We have highlighted three better-ranked stocks from the Consumer Staples sector, namely Fomento Economico Mexicano FMX, Ambev ABEV and PepsiCo Inc. PEP.
Fomento Economico Mexicano, alias FEMSA, currently sports a Zacks Rank #1 (Strong Buy). The company has an expected EPS growth rate of 22.4% for three to five years. Shares of FMX have rallied 18% in the past three months. You can see the complete list of today's Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for FEMSA’s current financial year’s sales and earnings per share suggests growth of 31.9% and 58.3%, respectively, from the year-ago period’s reported figures. FMX has a trailing four-quarter earnings surprise of 6.1%, on average.
Ambev has a trailing four-quarter earnings surprise of 20.8%, on average. It currently carries a Zacks Rank #2 (Buy). Shares of ABEV have gained 3.9% in the past three months.
The Zacks Consensus Estimate for Ambev’s current financial-year sales suggests growth of 4.5% from the year-ago period's reported figure. Meanwhile, the consensus estimate for earnings indicates a decline of 5.6% from the year-ago quarter’s reported figure. ABEV has an expected EPS growth rate of 7% for three to five years.
PepsiCo has a trailing four-quarter earnings surprise of 6.3%, on average. It currently carries a Zacks Rank #2. Shares of PEP have declined 0.7% in the past three months.
The Zacks Consensus Estimate for PepsiCo’s current financial-year sales and earnings suggests growth of 6.7% and 10.2%, respectively, from the year-ago period's reported figures. PEP has an expected EPS growth rate of 8.1% for three to five years.
Zacks Reveals ChatGPT "Sleeper" Stock
One little-known company is at the heart of an especially brilliant Artificial Intelligence sector. By 2030, the AI industry is predicted to have an internet and iPhone-scale economic impact of $15.7 Trillion.
As a service to readers, Zacks is providing a bonus report that names and explains this explosive growth stock and 4 other "must buys." Plus more.
Download Free ChatGPT Stock Report Right Now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Brown-Forman Corporation (BF.B) : Free Stock Analysis Report
Fomento Economico Mexicano S.A.B. de C.V. (FMX) : Free Stock Analysis Report
PepsiCo, Inc. (PEP) : Free Stock Analysis Report
Ambev S.A. (ABEV) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Stocks to Consider We have highlighted three better-ranked stocks from the Consumer Staples sector, namely Fomento Economico Mexicano FMX, Ambev ABEV and PepsiCo Inc. Shares of ABEV have gained 3.9% in the past three months. ABEV has an expected EPS growth rate of 7% for three to five years. | de C.V. (FMX) : Free Stock Analysis Report PepsiCo, Inc. (PEP) : Free Stock Analysis Report Ambev S.A. (ABEV) : Free Stock Analysis Report To read this article on Zacks.com click here. Stocks to Consider We have highlighted three better-ranked stocks from the Consumer Staples sector, namely Fomento Economico Mexicano FMX, Ambev ABEV and PepsiCo Inc. Shares of ABEV have gained 3.9% in the past three months. | Stocks to Consider We have highlighted three better-ranked stocks from the Consumer Staples sector, namely Fomento Economico Mexicano FMX, Ambev ABEV and PepsiCo Inc. Shares of ABEV have gained 3.9% in the past three months. ABEV has an expected EPS growth rate of 7% for three to five years. | Stocks to Consider We have highlighted three better-ranked stocks from the Consumer Staples sector, namely Fomento Economico Mexicano FMX, Ambev ABEV and PepsiCo Inc. Shares of ABEV have gained 3.9% in the past three months. ABEV has an expected EPS growth rate of 7% for three to five years. |
28144.0 | 2023-08-29 00:00:00 UTC | Molson Coors (TAP) Stays on Growth Track Amid Inflation Woes | ABEV | https://www.nasdaq.com/articles/molson-coors-tap-stays-on-growth-track-amid-inflation-woes | nan | nan | Molson Coors Beverage Company TAP has been in a good spot, courtesy of gains from contributions of its revitalization plan, commitment toward innovation and the premiumization of its global portfolio. The impacts of these initiatives were seen in the second quarter of 2023, wherein revenues and earnings increased year over year, and the bottom line surpassed the Zacks Consensus Estimate. Results gained from the strong performance across its portfolio and both business units.
The company’s adjusted earnings improved 50% year over year, while net sales grew 12%. On a constant-currency basis, net sales rose 12.1%, driven by a favorable price and sales mix, and higher financial volume. Net sales per hectoliter increased 8.7% on a reported basis and 9% on a constant-currency basis, driven by strong net pricing, and a favorable sales mix stemming from the premiumization and geographic mix.
Shares of this Zacks Rank #3 (Hold) company have rallied 20.4% in the past year compared with the industry’s growth of 0.7%. The stock also fared better than the sector’s fall of 2.5% and the S&P 500’s growth of 10.5% in the same period.
The Zacks Consensus Estimate for TAP’s 2023 sales and earnings suggests growth of 9.1% and 23.2%, respectively, from the year-ago period’s reported numbers.
Image Source: Zacks Investment Research
Let’s Delve Deeper
Molson Coors, one of the largest brewers in the world, is on track with its revitalization plan. The plan is focused on achieving sustainable top and bottom-line growth by streamlining the organization and reinvesting resources into its brands and capabilities.
The company intends to invest in iconic brands and growth opportunities in the above-premium beer space. It also plans to develop digital competencies for employees, supply-chain-related system capabilities and commercial functions. As part of the plan, the company has been expanding in adjacencies and beyond beer without hampering the support for its existing large brands.
To facilitate these investments, Molson Coors plans to generate savings of $150 million by simplifying its structure. The company is also building on the strength of its iconic core brands. Additionally, its cost-saving program, announced in 2020, targets delivering cost savings of $600 million over three years.
Additionally, Molson Coors is committed to growing its market shares through innovation and premiumization. The company has been rapidly expanding its above-premium portfolio over the past few years to accelerate portfolio premiumization.
The company has emphasized that it has been working to reshape its product portfolio and grow in emerging markets. Sales of its U.S. above-premium portfolio have been outperforming those of its U.S. economy portfolio on strength in core brands.
Management raised its 2023 view. Net sales, on a constant-currency basis, are projected to grow year over year in the high-single digits, up from low-single-digit growth mentioned earlier. Constant-currency underlying EBT is likely to grow 23-26% year over year compared with earlier stated low-single-digit growth.
The company plans to increase investment in C-store shopper marketing in the second half of 2023. Also, favorable volume leverage is expected to partly offset cost increases. This, along with premiumization and lower contract brewing volumes, is anticipated to drive gross margin expansion for 2023.
What Holds Molson Coors Back?
Molson Coors has been witnessing cost inflation, with respect to materials and manufacturing expenses, and an unfavorable mix. The cost inflation resulted in about 80% of the rise in COGS in the second quarter, driven by higher materials and manufacturing costs.
Management continues to anticipate the inflation impacts on COGS for 2023. However, it is likely to moderate in the second half. Underlying MG&A expenses are projected to be $100 million higher in the second half than the first half and rise 15% year over year. This will be driven by elevated marketing spend, which is likely to increase $100 million, coupled with increased people-related costs.
Also, TAP has been witnessing weakened consumer demand across the beer industry due to pricing actions. On its second-quarterearnings call management highlighted the softness in the beer industry. This is likely to affect the company’s performance in the near term. The company’s business in EMEA and APAC is likely to continue witnessing relatively high inflationary pressures.
Management further expected a headwind in relation to the large U.S. contract brewing agreement. The agreement has started to wind down ahead of its termination at the end of 2024. Hence, it anticipates volume declines under this contract to be higher in the fourth quarter, with an impact of 2-3% of America's financial volume.
Key Picks
We have highlighted three better-ranked stocks from the Consumer Staple sector, namely Fomento Economico Mexicano FMX, Ambev ABEV and PepsiCo Inc. PEP.
Fomento Economico Mexicano, alias FEMSA, currently sports a Zacks Rank #1 (Strong Buy). The company has an expected EPS growth rate of 22.4% for three to five years. Shares of FMX have rallied 82.1% in the past year. You can see the complete list of today's Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for FEMSA’s current financial year’s sales and earnings per share suggests growth of 31.9% and 58.3%, respectively, from the year-ago period’s reported figures. FMX has a trailing four-quarter negative earnings surprise of 6.1%, on average.
Ambev has a trailing four-quarter earnings surprise of 20.8%, on average. It currently carries a Zacks Rank #2 (Buy). Shares of ABEV have declined 2.4% in the past year.
The Zacks Consensus Estimate for Ambev’s current financial-year sales suggests growth of 4.5% from the year-ago period's reported figure. Meanwhile, the consensus estimate for earnings indicates a decline of 5.6% from the year-ago quarter’s reported figure. ABEV has an expected EPS growth rate of 7% for three to five years.
PepsiCo has a trailing four-quarter earnings surprise of 6.3%, on average. It currently carries a Zacks Rank #2. Shares of PEP have gained 4.2% in the past year.
The Zacks Consensus Estimate for PepsiCo’s current financial-year sales and earnings suggests growth of 6.7% and 10.2%, respectively, from the year-ago period's reported figures. PEP has an expected EPS growth rate of 8.1% for three to five years.
Zacks Names #1 Semiconductor Stock
It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom.
With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028.
See This Stock Now for Free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Fomento Economico Mexicano S.A.B. de C.V. (FMX) : Free Stock Analysis Report
PepsiCo, Inc. (PEP) : Free Stock Analysis Report
Molson Coors Beverage Company (TAP) : Free Stock Analysis Report
Ambev S.A. (ABEV) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Key Picks We have highlighted three better-ranked stocks from the Consumer Staple sector, namely Fomento Economico Mexicano FMX, Ambev ABEV and PepsiCo Inc. Shares of ABEV have declined 2.4% in the past year. ABEV has an expected EPS growth rate of 7% for three to five years. | de C.V. (FMX) : Free Stock Analysis Report PepsiCo, Inc. (PEP) : Free Stock Analysis Report Molson Coors Beverage Company (TAP) : Free Stock Analysis Report Ambev S.A. (ABEV) : Free Stock Analysis Report To read this article on Zacks.com click here. Key Picks We have highlighted three better-ranked stocks from the Consumer Staple sector, namely Fomento Economico Mexicano FMX, Ambev ABEV and PepsiCo Inc. Shares of ABEV have declined 2.4% in the past year. | de C.V. (FMX) : Free Stock Analysis Report PepsiCo, Inc. (PEP) : Free Stock Analysis Report Molson Coors Beverage Company (TAP) : Free Stock Analysis Report Ambev S.A. (ABEV) : Free Stock Analysis Report To read this article on Zacks.com click here. Key Picks We have highlighted three better-ranked stocks from the Consumer Staple sector, namely Fomento Economico Mexicano FMX, Ambev ABEV and PepsiCo Inc. Shares of ABEV have declined 2.4% in the past year. | de C.V. (FMX) : Free Stock Analysis Report PepsiCo, Inc. (PEP) : Free Stock Analysis Report Molson Coors Beverage Company (TAP) : Free Stock Analysis Report Ambev S.A. (ABEV) : Free Stock Analysis Report To read this article on Zacks.com click here. Key Picks We have highlighted three better-ranked stocks from the Consumer Staple sector, namely Fomento Economico Mexicano FMX, Ambev ABEV and PepsiCo Inc. Shares of ABEV have declined 2.4% in the past year. |
28145.0 | 2023-08-21 00:00:00 UTC | Validea Detailed Fundamental Analysis - ABEV | ABEV | https://www.nasdaq.com/articles/validea-detailed-fundamental-analysis-abev-1 | nan | nan | Below is Validea's guru fundamental report for AMBEV SA (ADR) (ABEV). Of the 22 guru strategies we follow, ABEV rates highest using our Multi-Factor Investor model based on the published strategy of Pim van Vliet. This multi-factor model seeks low volatility stocks that also have strong momentum and high net payout yields.
AMBEV SA (ADR) (ABEV) is a large-cap growth stock in the Beverages (Alcoholic) industry. The rating using this strategy is 81% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
MARKET CAP: PASS
STANDARD DEVIATION: PASS
TWELVE MINUS ONE MOMENTUM: NEUTRAL
NET PAYOUT YIELD: NEUTRAL
FINAL RANK: FAIL
Detailed Analysis of AMBEV SA (ADR)
ABEV Guru Analysis
ABEV Fundamental Analysis
More Information on Pim van Vliet
Pim van Vliet Portfolio
About Pim van Vliet: In investing, you typically need to take more risk to get more return. There is one major exception to this in the factor investing world, though. Low volatility stocks have been proven to outperform their high volatility counterparts, and do so with less risk. Pim van Vliet is the head of Conservative Equities at Robeco Asset Management. His research into conservative factor investing led to the creation of this strategy and the publication of the book "High Returns From Low Risk: A Remarkable Stock Market Paradox". Van Vliet holds a PhD in Financial and Business Economics from Erasmus University Rotterdam.
Additional Research Links
Top Large-Cap Growth Stocks
Factor-Based Stock Portfolios
Dividend Aristocrats 2023
High Insider Ownership Stocks
Top S&P 500 Stocks
Excess Returns Investing Podcast
About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Below is Validea's guru fundamental report for AMBEV SA (ADR) (ABEV). Of the 22 guru strategies we follow, ABEV rates highest using our Multi-Factor Investor model based on the published strategy of Pim van Vliet. AMBEV SA (ADR) (ABEV) is a large-cap growth stock in the Beverages (Alcoholic) industry. | Detailed Analysis of AMBEV SA (ADR) ABEV Guru Analysis ABEV Fundamental Analysis More Information on Pim van Vliet Pim van Vliet Portfolio About Pim van Vliet: In investing, you typically need to take more risk to get more return. Below is Validea's guru fundamental report for AMBEV SA (ADR) (ABEV). Of the 22 guru strategies we follow, ABEV rates highest using our Multi-Factor Investor model based on the published strategy of Pim van Vliet. | Of the 22 guru strategies we follow, ABEV rates highest using our Multi-Factor Investor model based on the published strategy of Pim van Vliet. Detailed Analysis of AMBEV SA (ADR) ABEV Guru Analysis ABEV Fundamental Analysis More Information on Pim van Vliet Pim van Vliet Portfolio About Pim van Vliet: In investing, you typically need to take more risk to get more return. Below is Validea's guru fundamental report for AMBEV SA (ADR) (ABEV). | Of the 22 guru strategies we follow, ABEV rates highest using our Multi-Factor Investor model based on the published strategy of Pim van Vliet. Detailed Analysis of AMBEV SA (ADR) ABEV Guru Analysis ABEV Fundamental Analysis More Information on Pim van Vliet Pim van Vliet Portfolio About Pim van Vliet: In investing, you typically need to take more risk to get more return. Below is Validea's guru fundamental report for AMBEV SA (ADR) (ABEV). |
28146.0 | 2023-08-17 00:00:00 UTC | ABEV vs. DEO: Which Stock Is the Better Value Option? | ABEV | https://www.nasdaq.com/articles/abev-vs.-deo%3A-which-stock-is-the-better-value-option-2 | nan | nan | Investors interested in stocks from the Beverages - Alcohol sector have probably already heard of Ambev (ABEV) and Diageo (DEO). But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look.
There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns. The proven Zacks Rank puts an emphasis on earnings estimates and estimate revisions, while our Style Scores work to identify stocks with specific traits.
Ambev and Diageo are sporting Zacks Ranks of #2 (Buy) and #3 (Hold), respectively, right now. Investors should feel comfortable knowing that ABEV likely has seen a stronger improvement to its earnings outlook than DEO has recently. However, value investors will care about much more than just this.
Value investors analyze a variety of traditional, tried-and-true metrics to help find companies that they believe are undervalued at their current share price levels.
Our Value category highlights undervalued companies by looking at a variety of key metrics, including the popular P/E ratio, as well as the P/S ratio, earnings yield, cash flow per share, and a variety of other fundamentals that have been used by value investors for years.
ABEV currently has a forward P/E ratio of 17.21, while DEO has a forward P/E of 20.21. We also note that ABEV has a PEG ratio of 2.45. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. DEO currently has a PEG ratio of 2.98.
Another notable valuation metric for ABEV is its P/B ratio of 2.56. The P/B ratio is used to compare a stock's market value with its book value, which is defined as total assets minus total liabilities. For comparison, DEO has a P/B of 8.50.
These are just a few of the metrics contributing to ABEV's Value grade of B and DEO's Value grade of C.
ABEV has seen stronger estimate revision activity and sports more attractive valuation metrics than DEO, so it seems like value investors will conclude that ABEV is the superior option right now.
The New Gold Rush: How Lithium Batteries Will Make Millionaires
As the electric vehicle revolution expands, investors have a chance to target huge gains. Millions of lithium batteries are being made & demand is expected to increase 889%.
Download the brand-new FREE report revealing 5 EV battery stocks set to soar.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Ambev S.A. (ABEV) : Free Stock Analysis Report
Diageo plc (DEO) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Investors interested in stocks from the Beverages - Alcohol sector have probably already heard of Ambev (ABEV) and Diageo (DEO). Investors should feel comfortable knowing that ABEV likely has seen a stronger improvement to its earnings outlook than DEO has recently. ABEV currently has a forward P/E ratio of 17.21, while DEO has a forward P/E of 20.21. | These are just a few of the metrics contributing to ABEV's Value grade of B and DEO's Value grade of C. ABEV has seen stronger estimate revision activity and sports more attractive valuation metrics than DEO, so it seems like value investors will conclude that ABEV is the superior option right now. Click to get this free report Ambev S.A. (ABEV) : Free Stock Analysis Report Diageo plc (DEO) : Free Stock Analysis Report To read this article on Zacks.com click here. Investors interested in stocks from the Beverages - Alcohol sector have probably already heard of Ambev (ABEV) and Diageo (DEO). | These are just a few of the metrics contributing to ABEV's Value grade of B and DEO's Value grade of C. ABEV has seen stronger estimate revision activity and sports more attractive valuation metrics than DEO, so it seems like value investors will conclude that ABEV is the superior option right now. Click to get this free report Ambev S.A. (ABEV) : Free Stock Analysis Report Diageo plc (DEO) : Free Stock Analysis Report To read this article on Zacks.com click here. Investors interested in stocks from the Beverages - Alcohol sector have probably already heard of Ambev (ABEV) and Diageo (DEO). | These are just a few of the metrics contributing to ABEV's Value grade of B and DEO's Value grade of C. ABEV has seen stronger estimate revision activity and sports more attractive valuation metrics than DEO, so it seems like value investors will conclude that ABEV is the superior option right now. Investors interested in stocks from the Beverages - Alcohol sector have probably already heard of Ambev (ABEV) and Diageo (DEO). Investors should feel comfortable knowing that ABEV likely has seen a stronger improvement to its earnings outlook than DEO has recently. |
28147.0 | 2023-08-10 00:00:00 UTC | Is Ambev (ABEV) Outperforming Other Consumer Staples Stocks This Year? | ABEV | https://www.nasdaq.com/articles/is-ambev-abev-outperforming-other-consumer-staples-stocks-this-year-0 | nan | nan | For those looking to find strong Consumer Staples stocks, it is prudent to search for companies in the group that are outperforming their peers. Ambev (ABEV) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? By taking a look at the stock's year-to-date performance in comparison to its Consumer Staples peers, we might be able to answer that question.
Ambev is a member of the Consumer Staples sector. This group includes 194 individual stocks and currently holds a Zacks Sector Rank of #12. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Ambev is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for ABEV's full-year earnings has moved 3.1% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Based on the most recent data, ABEV has returned 7% so far this year. At the same time, Consumer Staples stocks have lost an average of 1.3%. This means that Ambev is outperforming the sector as a whole this year.
Another stock in the Consumer Staples sector, Coty (COTY), has outperformed the sector so far this year. The stock's year-to-date return is 36.7%.
In Coty's case, the consensus EPS estimate for the current year increased 3.9% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Ambev belongs to the Beverages - Alcohol industry, which includes 18 individual stocks and currently sits at #83 in the Zacks Industry Rank. On average, stocks in this group have gained 2.6% this year, meaning that ABEV is performing better in terms of year-to-date returns.
On the other hand, Coty belongs to the Cosmetics industry. This 14-stock industry is currently ranked #165. The industry has moved -18.2% year to date.
Going forward, investors interested in Consumer Staples stocks should continue to pay close attention to Ambev and Coty as they could maintain their solid performance.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."
Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.3% per year. So be sure to give these hand-picked 7 your immediate attention.
See them now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Ambev S.A. (ABEV) : Free Stock Analysis Report
Coty (COTY) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | On average, stocks in this group have gained 2.6% this year, meaning that ABEV is performing better in terms of year-to-date returns. Ambev (ABEV) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Over the past three months, the Zacks Consensus Estimate for ABEV's full-year earnings has moved 3.1% higher. | Click to get this free report Ambev S.A. (ABEV) : Free Stock Analysis Report Coty (COTY) : Free Stock Analysis Report To read this article on Zacks.com click here. Ambev (ABEV) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Over the past three months, the Zacks Consensus Estimate for ABEV's full-year earnings has moved 3.1% higher. | Click to get this free report Ambev S.A. (ABEV) : Free Stock Analysis Report Coty (COTY) : Free Stock Analysis Report To read this article on Zacks.com click here. Ambev (ABEV) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Over the past three months, the Zacks Consensus Estimate for ABEV's full-year earnings has moved 3.1% higher. | Ambev (ABEV) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Over the past three months, the Zacks Consensus Estimate for ABEV's full-year earnings has moved 3.1% higher. Based on the most recent data, ABEV has returned 7% so far this year. |
28148.0 | 2023-07-25 00:00:00 UTC | ABEV vs. DEO: Which Stock Is the Better Value Option? | ABEV | https://www.nasdaq.com/articles/abev-vs.-deo%3A-which-stock-is-the-better-value-option-1 | nan | nan | Investors interested in Beverages - Alcohol stocks are likely familiar with Ambev (ABEV) and Diageo (DEO). But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out.
There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns. The Zacks Rank favors stocks with strong earnings estimate revision trends, and our Style Scores highlight companies with specific traits.
Right now, Ambev is sporting a Zacks Rank of #2 (Buy), while Diageo has a Zacks Rank of #4 (Sell). This system places an emphasis on companies that have seen positive earnings estimate revisions, so investors should feel comfortable knowing that ABEV is likely seeing its earnings outlook improve to a greater extent. But this is just one piece of the puzzle for value investors.
Value investors analyze a variety of traditional, tried-and-true metrics to help find companies that they believe are undervalued at their current share price levels.
Our Value category highlights undervalued companies by looking at a variety of key metrics, including the popular P/E ratio, as well as the P/S ratio, earnings yield, cash flow per share, and a variety of other fundamentals that have been used by value investors for years.
ABEV currently has a forward P/E ratio of 19.09, while DEO has a forward P/E of 20.64. We also note that ABEV has a PEG ratio of 2.65. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. DEO currently has a PEG ratio of 2.81.
Another notable valuation metric for ABEV is its P/B ratio of 2.98. Investors use the P/B ratio to look at a stock's market value versus its book value, which is defined as total assets minus total liabilities. By comparison, DEO has a P/B of 8.69.
These metrics, and several others, help ABEV earn a Value grade of B, while DEO has been given a Value grade of D.
ABEV is currently sporting an improving earnings outlook, which makes it stick out in our Zacks Rank model. And, based on the above valuation metrics, we feel that ABEV is likely the superior value option right now.
Zacks Reveals ChatGPT "Sleeper" Stock
One little-known company is at the heart of an especially brilliant Artificial Intelligence sector. By 2030, the AI industry is predicted to have an internet and iPhone-scale economic impact of $15.7 Trillion.
As a service to readers, Zacks is providing a bonus report that names and explains this explosive growth stock and 4 other "must buys." Plus more.
Download Free ChatGPT Stock Report Right Now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Ambev S.A. (ABEV) : Free Stock Analysis Report
Diageo plc (DEO) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Investors interested in Beverages - Alcohol stocks are likely familiar with Ambev (ABEV) and Diageo (DEO). This system places an emphasis on companies that have seen positive earnings estimate revisions, so investors should feel comfortable knowing that ABEV is likely seeing its earnings outlook improve to a greater extent. ABEV currently has a forward P/E ratio of 19.09, while DEO has a forward P/E of 20.64. | Click to get this free report Ambev S.A. (ABEV) : Free Stock Analysis Report Diageo plc (DEO) : Free Stock Analysis Report To read this article on Zacks.com click here. Investors interested in Beverages - Alcohol stocks are likely familiar with Ambev (ABEV) and Diageo (DEO). This system places an emphasis on companies that have seen positive earnings estimate revisions, so investors should feel comfortable knowing that ABEV is likely seeing its earnings outlook improve to a greater extent. | These metrics, and several others, help ABEV earn a Value grade of B, while DEO has been given a Value grade of D. ABEV is currently sporting an improving earnings outlook, which makes it stick out in our Zacks Rank model. Click to get this free report Ambev S.A. (ABEV) : Free Stock Analysis Report Diageo plc (DEO) : Free Stock Analysis Report To read this article on Zacks.com click here. Investors interested in Beverages - Alcohol stocks are likely familiar with Ambev (ABEV) and Diageo (DEO). | Another notable valuation metric for ABEV is its P/B ratio of 2.98. Investors interested in Beverages - Alcohol stocks are likely familiar with Ambev (ABEV) and Diageo (DEO). This system places an emphasis on companies that have seen positive earnings estimate revisions, so investors should feel comfortable knowing that ABEV is likely seeing its earnings outlook improve to a greater extent. |
28149.0 | 2023-07-24 00:00:00 UTC | Validea Detailed Fundamental Analysis - ABEV | ABEV | https://www.nasdaq.com/articles/validea-detailed-fundamental-analysis-abev-0 | nan | nan | Below is Validea's guru fundamental report for AMBEV SA (ADR) (ABEV). Of the 22 guru strategies we follow, ABEV rates highest using our Multi-Factor Investor model based on the published strategy of Pim van Vliet. This multi-factor model seeks low volatility stocks that also have strong momentum and high net payout yields.
AMBEV SA (ADR) (ABEV) is a large-cap growth stock in the Beverages (Alcoholic) industry. The rating using this strategy is 93% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
MARKET CAP: PASS
STANDARD DEVIATION: PASS
TWELVE MINUS ONE MOMENTUM: NEUTRAL
NET PAYOUT YIELD: NEUTRAL
FINAL RANK: PASS
Detailed Analysis of AMBEV SA (ADR)
ABEV Guru Analysis
ABEV Fundamental Analysis
More Information on Pim van Vliet
Pim van Vliet Portfolio
About Pim van Vliet: In investing, you typically need to take more risk to get more return. There is one major exception to this in the factor investing world, though. Low volatility stocks have been proven to outperform their high volatility counterparts, and do so with less risk. Pim van Vliet is the head of Conservative Equities at Robeco Asset Management. His research into conservative factor investing led to the creation of this strategy and the publication of the book "High Returns From Low Risk: A Remarkable Stock Market Paradox". Van Vliet holds a PhD in Financial and Business Economics from Erasmus University Rotterdam.
Additional Research Links
Top Large-Cap Growth Stocks
Factor-Based Stock Portfolios
Dividend Aristocrats 2023
High Insider Ownership Stocks
Top S&P 500 Stocks
Excess Returns Investing Podcast
About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Below is Validea's guru fundamental report for AMBEV SA (ADR) (ABEV). Of the 22 guru strategies we follow, ABEV rates highest using our Multi-Factor Investor model based on the published strategy of Pim van Vliet. AMBEV SA (ADR) (ABEV) is a large-cap growth stock in the Beverages (Alcoholic) industry. | Detailed Analysis of AMBEV SA (ADR) ABEV Guru Analysis ABEV Fundamental Analysis More Information on Pim van Vliet Pim van Vliet Portfolio About Pim van Vliet: In investing, you typically need to take more risk to get more return. Below is Validea's guru fundamental report for AMBEV SA (ADR) (ABEV). Of the 22 guru strategies we follow, ABEV rates highest using our Multi-Factor Investor model based on the published strategy of Pim van Vliet. | Of the 22 guru strategies we follow, ABEV rates highest using our Multi-Factor Investor model based on the published strategy of Pim van Vliet. Detailed Analysis of AMBEV SA (ADR) ABEV Guru Analysis ABEV Fundamental Analysis More Information on Pim van Vliet Pim van Vliet Portfolio About Pim van Vliet: In investing, you typically need to take more risk to get more return. Below is Validea's guru fundamental report for AMBEV SA (ADR) (ABEV). | Of the 22 guru strategies we follow, ABEV rates highest using our Multi-Factor Investor model based on the published strategy of Pim van Vliet. Detailed Analysis of AMBEV SA (ADR) ABEV Guru Analysis ABEV Fundamental Analysis More Information on Pim van Vliet Pim van Vliet Portfolio About Pim van Vliet: In investing, you typically need to take more risk to get more return. Below is Validea's guru fundamental report for AMBEV SA (ADR) (ABEV). |
28150.0 | 2023-07-11 00:00:00 UTC | Are Consumer Staples Stocks Lagging Ambev (ABEV) This Year? | ABEV | https://www.nasdaq.com/articles/are-consumer-staples-stocks-lagging-ambev-abev-this-year | nan | nan | For those looking to find strong Consumer Staples stocks, it is prudent to search for companies in the group that are outperforming their peers. Ambev (ABEV) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the stock's year-to-date performance to find out.
Ambev is one of 194 individual stocks in the Consumer Staples sector. Collectively, these companies sit at #4 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Ambev is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for ABEV's full-year earnings has moved 3.1% higher within the past quarter. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
According to our latest data, ABEV has moved about 12.1% on a year-to-date basis. In comparison, Consumer Staples companies have returned an average of -1.9%. This shows that Ambev is outperforming its peers so far this year.
Another Consumer Staples stock, which has outperformed the sector so far this year, is Beyond Meat (BYND). The stock has returned 20.7% year-to-date.
In Beyond Meat's case, the consensus EPS estimate for the current year increased 4.8% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Ambev belongs to the Beverages - Alcohol industry, a group that includes 18 individual stocks and currently sits at #101 in the Zacks Industry Rank. On average, stocks in this group have gained 0.2% this year, meaning that ABEV is performing better in terms of year-to-date returns.
Beyond Meat, however, belongs to the Food - Meat Products industry. Currently, this 6-stock industry is ranked #106. The industry has moved -12.9% so far this year.
Going forward, investors interested in Consumer Staples stocks should continue to pay close attention to Ambev and Beyond Meat as they could maintain their solid performance.
4 Oil Stocks with Massive Upsides
Global demand for oil is through the roof... and oil producers are struggling to keep up. So even though oil prices are well off their recent highs, you can expect big profits from the companies that supply the world with "black gold."
Zacks Investment Research has just released an urgent special report to help you bank on this trend.
In Oil Market on Fire, you'll discover 4 unexpected oil and gas stocks positioned for big gains in the coming weeks and months. You don't want to miss these recommendations.
Download your free report now to see them.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Ambev S.A. (ABEV) : Free Stock Analysis Report
Beyond Meat, Inc. (BYND) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Ambev (ABEV) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? The Zacks Consensus Estimate for ABEV's full-year earnings has moved 3.1% higher within the past quarter. According to our latest data, ABEV has moved about 12.1% on a year-to-date basis. | Click to get this free report Ambev S.A. (ABEV) : Free Stock Analysis Report Beyond Meat, Inc. (BYND) : Free Stock Analysis Report To read this article on Zacks.com click here. Ambev (ABEV) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? The Zacks Consensus Estimate for ABEV's full-year earnings has moved 3.1% higher within the past quarter. | Click to get this free report Ambev S.A. (ABEV) : Free Stock Analysis Report Beyond Meat, Inc. (BYND) : Free Stock Analysis Report To read this article on Zacks.com click here. Ambev (ABEV) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? The Zacks Consensus Estimate for ABEV's full-year earnings has moved 3.1% higher within the past quarter. | Ambev (ABEV) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? The Zacks Consensus Estimate for ABEV's full-year earnings has moved 3.1% higher within the past quarter. According to our latest data, ABEV has moved about 12.1% on a year-to-date basis. |
28151.0 | 2023-07-06 00:00:00 UTC | ABEV or CABGY: Which Is the Better Value Stock Right Now? | ABEV | https://www.nasdaq.com/articles/abev-or-cabgy%3A-which-is-the-better-value-stock-right-now | nan | nan | Investors interested in Beverages - Alcohol stocks are likely familiar with Ambev (ABEV) and Carlsberg AS (CABGY). But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look.
Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The Zacks Rank favors stocks with strong earnings estimate revision trends, and our Style Scores highlight companies with specific traits.
Ambev and Carlsberg AS are sporting Zacks Ranks of #2 (Buy) and #4 (Sell), respectively, right now. This means that ABEV's earnings estimate revision activity has been more impressive, so investors should feel comfortable with its improving analyst outlook. But this is only part of the picture for value investors.
Value investors also tend to look at a number of traditional, tried-and-true figures to help them find stocks that they believe are undervalued at their current share price levels.
Our Value category grades stocks based on a number of key metrics, including the tried-and-true P/E ratio, the P/S ratio, earnings yield, and cash flow per share, as well as a variety of other fundamentals that value investors frequently use.
ABEV currently has a forward P/E ratio of 18.97, while CABGY has a forward P/E of 19.14. We also note that ABEV has a PEG ratio of 2.69. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. CABGY currently has a PEG ratio of 2.74.
Another notable valuation metric for ABEV is its P/B ratio of 2.96. Investors use the P/B ratio to look at a stock's market value versus its book value, which is defined as total assets minus total liabilities. By comparison, CABGY has a P/B of 4.49.
Based on these metrics and many more, ABEV holds a Value grade of B, while CABGY has a Value grade of C.
ABEV sticks out from CABGY in both our Zacks Rank and Style Scores models, so value investors will likely feel that ABEV is the better option right now.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."
Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.2% per year. So be sure to give these hand-picked 7 your immediate attention.
See them now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Ambev S.A. (ABEV) : Free Stock Analysis Report
Carlsberg AS (CABGY) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Investors interested in Beverages - Alcohol stocks are likely familiar with Ambev (ABEV) and Carlsberg AS (CABGY). This means that ABEV's earnings estimate revision activity has been more impressive, so investors should feel comfortable with its improving analyst outlook. ABEV currently has a forward P/E ratio of 18.97, while CABGY has a forward P/E of 19.14. | Click to get this free report Ambev S.A. (ABEV) : Free Stock Analysis Report Carlsberg AS (CABGY) : Free Stock Analysis Report To read this article on Zacks.com click here. Investors interested in Beverages - Alcohol stocks are likely familiar with Ambev (ABEV) and Carlsberg AS (CABGY). This means that ABEV's earnings estimate revision activity has been more impressive, so investors should feel comfortable with its improving analyst outlook. | Based on these metrics and many more, ABEV holds a Value grade of B, while CABGY has a Value grade of C. ABEV sticks out from CABGY in both our Zacks Rank and Style Scores models, so value investors will likely feel that ABEV is the better option right now. Click to get this free report Ambev S.A. (ABEV) : Free Stock Analysis Report Carlsberg AS (CABGY) : Free Stock Analysis Report To read this article on Zacks.com click here. Investors interested in Beverages - Alcohol stocks are likely familiar with Ambev (ABEV) and Carlsberg AS (CABGY). | Based on these metrics and many more, ABEV holds a Value grade of B, while CABGY has a Value grade of C. ABEV sticks out from CABGY in both our Zacks Rank and Style Scores models, so value investors will likely feel that ABEV is the better option right now. Investors interested in Beverages - Alcohol stocks are likely familiar with Ambev (ABEV) and Carlsberg AS (CABGY). This means that ABEV's earnings estimate revision activity has been more impressive, so investors should feel comfortable with its improving analyst outlook. |
28152.0 | 2023-06-29 00:00:00 UTC | 3 Reasons Boston Beer Stock Could Finally Hop Higher | ABEV | https://www.nasdaq.com/articles/3-reasons-boston-beer-stock-could-finally-hop-higher | nan | nan | For The Boston Beer Company, Inc. (NYSE: SAM) shareholders, the last two years have been far from a Boston Tea Party. Maybe it relates to the Bruins, Celtics, Patriots and Red Sox teams’ collective failure to bring home a sports championship. More likely, it's because the brewer has missed Wall Street profit estimates in seven of the last eight quarters.
Last time at bat, Boston Beer struck out in embarrassing fashion. Higher inventory obsolescence and brewery processing costs drove a $0.73 share net loss that was more than double what analysts expected. The stock has since gone flat, while the S&P 500 has hit 2023 highs.
Boston Beer isn’t the only one experiencing margin pressures. Other brewers are being forced to juggle cost inflation, inventory build-ups and pricing. But with consumers trading down to cheaper alcoholic beverages, craft brewers like Boston Beer that depend heavily on the Sam Adams and Dogfish Head brands are getting hit harder.
SAM shares are down about 3% year-to-date. The Dow Jones U.S. Brewers Index is up 20%.
Of course, recent beer stock returns largely relate to the backlash from Bud Light’s support of transgender influencer Dylan Mulvaney. While Molson Coors Brewing and Ambev S.A. are winners, Boston Beer’s lack of strong value brands has caused it to lose out.
But with the Bud Light fiasco likely to fade in the second half of the year, investors’ attention should shift back to industry fundamentals by 2024. This could make Boston Beer an interesting ‘comeback brewer of the year candidate.
#1 - Seltzer Has Been Canned
Boston Beer’s recent financial woes have much to do with a slowdown in hard seltzer demand. With the novelty of the beverage wearing off, the company has turned to Truly Vodka Soda in an attempt to refresh the brand. Partly a marketing trick, a product reformulation, plus the introduction of new flavors and real fruit juice just could work. The timing alongside a ramp in summer concerts and other activities could prove particularly effective.
While the jury is out on the Truly reboot, the company’s Twisted Tea is a clear winner. As a result of effective media campaigns, including Super Bowl promos, Twisted Tea sales jumped 34% in the first quarter. And with further investments being made, America’s best-selling hard iced tea could remain a growth driver well into 2024. In time for 4th of July celebrations, the brand recently launched three Rocket Pop flavors.
Despite getting crushed by the seltzer downturn, Boston Beer’s track record of innovation (including Angry Orchard hard cider) makes it hard to dismiss. And with the category likely to be less of a drag on future financial performances, the outlook is improving. Analysts are anticipating 50% EPS growth in 2024, which would mark the highest level of profitability since 2021, when the stock price soared to a record $1,350.
#2 - Institutional Money Is Pouring In
Even with a profit recovery ahead, Boston Beer shares are trading at 31x next year’s EPS estimate. Molson Coors, Ambev and Anheuser-Busch have 2024 P/E ratios that are roughly half that.
Hedge funds, however, seem to feel the premium beverage portfolio justifies SAM’s premium valuation. As the stock has fallen off the cliff over the last two years, the so-called smart money investors have been loading up. Dating back to the fourth quarter of 2021, hedge fund managers have increased their Boston Beer holdings for six consecutive quarters. In the first quarter of 2023, Southeastern Asset Management initiated a $35.7 million position.
Besides banking on a craft beer comeback and non-beer innovation, fundamentally-focused hedge funds are likely attracted to Boston Beer’s financial strength. Despite the recent losses, the balance sheet is in good shape, with $122.6 million in cash and no debt. An active buyback program with $62.8 million remaining also bodes well for downside stock price protection.
#3 - Technicals Are Ice Cold
Boston Beer’s technical picture looks good too. With $1,000 gashed from the share price over the last couple of years, several indicators are naturally at depressed levels.
The daily 31 relative strength indicator (RSI) reading is teetering on oversold territory. Over the last 12 months, this level has repeatedly served as the launchpad for a near-term bounce. If the stock can hang on to long-term support around $318, the upside-to-downside tradeoff looks favorable.
The company’s second-quarter report on July 27th could be an important step in the recovery. The Street is projecting a 2% sales decline. But given the strength in Twisted Tea and multiple product rollouts during the period, SAM’s top line could get ‘twisted’ to growth.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | But with consumers trading down to cheaper alcoholic beverages, craft brewers like Boston Beer that depend heavily on the Sam Adams and Dogfish Head brands are getting hit harder. Of course, recent beer stock returns largely relate to the backlash from Bud Light’s support of transgender influencer Dylan Mulvaney. #2 - Institutional Money Is Pouring In Even with a profit recovery ahead, Boston Beer shares are trading at 31x next year’s EPS estimate. | But with consumers trading down to cheaper alcoholic beverages, craft brewers like Boston Beer that depend heavily on the Sam Adams and Dogfish Head brands are getting hit harder. Despite getting crushed by the seltzer downturn, Boston Beer’s track record of innovation (including Angry Orchard hard cider) makes it hard to dismiss. #2 - Institutional Money Is Pouring In Even with a profit recovery ahead, Boston Beer shares are trading at 31x next year’s EPS estimate. | For The Boston Beer Company, Inc. (NYSE: SAM) shareholders, the last two years have been far from a Boston Tea Party. But with consumers trading down to cheaper alcoholic beverages, craft brewers like Boston Beer that depend heavily on the Sam Adams and Dogfish Head brands are getting hit harder. Besides banking on a craft beer comeback and non-beer innovation, fundamentally-focused hedge funds are likely attracted to Boston Beer’s financial strength. | But with consumers trading down to cheaper alcoholic beverages, craft brewers like Boston Beer that depend heavily on the Sam Adams and Dogfish Head brands are getting hit harder. #2 - Institutional Money Is Pouring In Even with a profit recovery ahead, Boston Beer shares are trading at 31x next year’s EPS estimate. Besides banking on a craft beer comeback and non-beer innovation, fundamentally-focused hedge funds are likely attracted to Boston Beer’s financial strength. |
28153.0 | 2023-06-26 00:00:00 UTC | Ambev S.A. - ADR Shares Approach 52-Week High - Market Mover | ABEV | https://www.nasdaq.com/articles/ambev-s.a.-adr-shares-approach-52-week-high-market-mover-0 | nan | nan | Ambev S.A. - ADR (ABEV) shares closed today at 1.2% below its 52 week high of $3.23, giving the company a market cap of $50B. The stock is currently up 17.3% year-to-date, up 30.8% over the past 12 months, and down 21.2% over the past five years. This week, the Dow Jones Industrial Average fell 1.7%, and the S&P 500 fell 1.8%.
Trading Activity
Trading volume this week was 18.4% lower than the 20-day average.
Beta, a measure of the stock’s volatility relative to the overall market stands at 0.0.
Technical Indicators
The Relative Strength Index (RSI) on the stock was between 30 and 70.
MACD, a trend-following momentum indicator, indicates an upward trend.
The stock closed below its Bollinger band, indicating it may be oversold.
Market Comparative Performance
The company's share price is the same as the S&P 500 Index , beats it on a 1-year basis, and lags it on a 5-year basis
The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and lags it on a 5-year basis
Per Group Comparative Performance
The company's stock price performance year-to-date beats the peer average by -991.4%
The company's stock price performance over the past 12 months beats the peer average by -1638.0%
The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is -33.9% lower than the average peer.
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Ambev S.A. - ADR (ABEV) shares closed today at 1.2% below its 52 week high of $3.23, giving the company a market cap of $50B. Beta, a measure of the stock’s volatility relative to the overall market stands at 0.0. Market Comparative Performance The company's share price is the same as the S&P 500 Index , beats it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -991.4% The company's stock price performance over the past 12 months beats the peer average by -1638.0% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is -33.9% lower than the average peer. | Ambev S.A. - ADR (ABEV) shares closed today at 1.2% below its 52 week high of $3.23, giving the company a market cap of $50B. This week, the Dow Jones Industrial Average fell 1.7%, and the S&P 500 fell 1.8%. Trading Activity Trading volume this week was 18.4% lower than the 20-day average. | Ambev S.A. - ADR (ABEV) shares closed today at 1.2% below its 52 week high of $3.23, giving the company a market cap of $50B. Market Comparative Performance The company's share price is the same as the S&P 500 Index , beats it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -991.4% The company's stock price performance over the past 12 months beats the peer average by -1638.0% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is -33.9% lower than the average peer. This story was produced by the Kwhen Automated News Generator. | Ambev S.A. - ADR (ABEV) shares closed today at 1.2% below its 52 week high of $3.23, giving the company a market cap of $50B. This week, the Dow Jones Industrial Average fell 1.7%, and the S&P 500 fell 1.8%. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70. |
28154.0 | 2023-06-25 00:00:00 UTC | Ambev S.A. - ADR Shares Close in on 52-Week High - Market Mover | ABEV | https://www.nasdaq.com/articles/ambev-s.a.-adr-shares-close-in-on-52-week-high-market-mover-0 | nan | nan | Ambev S.A. - ADR (ABEV) shares closed today at 1.2% below its 52 week high of $3.23, giving the company a market cap of $50B. The stock is currently up 17.6% year-to-date, up 31.2% over the past 12 months, and down 22.4% over the past five years. This week, the Dow Jones Industrial Average fell 1.7%, and the S&P 500 fell 1.4%.
Trading Activity
Trading volume this week was 32.6% lower than the 20-day average.
Beta, a measure of the stock’s volatility relative to the overall market stands at 0.0.
Technical Indicators
The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.
MACD, a trend-following momentum indicator, indicates an upward trend.
The stock closed below its Bollinger band, indicating it may be oversold.
Market Comparative Performance
The company's share price is the same as the S&P 500 Index , beats it on a 1-year basis, and lags it on a 5-year basis
The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and lags it on a 5-year basis
Per Group Comparative Performance
The company's stock price performance year-to-date beats the peer average by -878.9%
The company's stock price performance over the past 12 months beats the peer average by -1478.1%
The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is -33.0% lower than the average peer.
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Ambev S.A. - ADR (ABEV) shares closed today at 1.2% below its 52 week high of $3.23, giving the company a market cap of $50B. Beta, a measure of the stock’s volatility relative to the overall market stands at 0.0. Market Comparative Performance The company's share price is the same as the S&P 500 Index , beats it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -878.9% The company's stock price performance over the past 12 months beats the peer average by -1478.1% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is -33.0% lower than the average peer. | Ambev S.A. - ADR (ABEV) shares closed today at 1.2% below its 52 week high of $3.23, giving the company a market cap of $50B. This week, the Dow Jones Industrial Average fell 1.7%, and the S&P 500 fell 1.4%. Trading Activity Trading volume this week was 32.6% lower than the 20-day average. | Ambev S.A. - ADR (ABEV) shares closed today at 1.2% below its 52 week high of $3.23, giving the company a market cap of $50B. Market Comparative Performance The company's share price is the same as the S&P 500 Index , beats it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -878.9% The company's stock price performance over the past 12 months beats the peer average by -1478.1% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is -33.0% lower than the average peer. This story was produced by the Kwhen Automated News Generator. | Ambev S.A. - ADR (ABEV) shares closed today at 1.2% below its 52 week high of $3.23, giving the company a market cap of $50B. This week, the Dow Jones Industrial Average fell 1.7%, and the S&P 500 fell 1.4%. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought. |
28155.0 | 2023-06-19 00:00:00 UTC | Ambev S.A. - ADR Shares Close in on 52-Week High - Market Mover | ABEV | https://www.nasdaq.com/articles/ambev-s.a.-adr-shares-close-in-on-52-week-high-market-mover | nan | nan | Ambev S.A. - ADR (ABEV) shares closed today at 1.6% below its 52 week high of $3.16, giving the company a market cap of $48B. The stock is currently up 13.6% year-to-date, up 30.8% over the past 12 months, and down 27.5% over the past five years. This week, the Dow Jones Industrial Average rose 1.0%, and the S&P 500 rose 2.1%.
Trading Activity
Trading volume this week was 34.9% higher than the 20-day average.
Beta, a measure of the stock’s volatility relative to the overall market stands at 0.0.
Technical Indicators
The Relative Strength Index (RSI) on the stock was between 30 and 70.
MACD, a trend-following momentum indicator, indicates an upward trend.
The stock closed below its Bollinger band, indicating it may be oversold.
Market Comparative Performance
The company's share price is the same as the S&P 500 Index , beats it on a 1-year basis, and lags it on a 5-year basis
The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and lags it on a 5-year basis
Per Group Comparative Performance
The company's stock price performance year-to-date beats the peer average by -9812.2%
The company's stock price performance over the past 12 months beats the peer average by 379.5%
The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is -39.3% lower than the average peer.
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Ambev S.A. - ADR (ABEV) shares closed today at 1.6% below its 52 week high of $3.16, giving the company a market cap of $48B. Beta, a measure of the stock’s volatility relative to the overall market stands at 0.0. Market Comparative Performance The company's share price is the same as the S&P 500 Index , beats it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -9812.2% The company's stock price performance over the past 12 months beats the peer average by 379.5% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is -39.3% lower than the average peer. | Ambev S.A. - ADR (ABEV) shares closed today at 1.6% below its 52 week high of $3.16, giving the company a market cap of $48B. This week, the Dow Jones Industrial Average rose 1.0%, and the S&P 500 rose 2.1%. Market Comparative Performance The company's share price is the same as the S&P 500 Index , beats it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -9812.2% The company's stock price performance over the past 12 months beats the peer average by 379.5% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is -39.3% lower than the average peer. | Ambev S.A. - ADR (ABEV) shares closed today at 1.6% below its 52 week high of $3.16, giving the company a market cap of $48B. Market Comparative Performance The company's share price is the same as the S&P 500 Index , beats it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -9812.2% The company's stock price performance over the past 12 months beats the peer average by 379.5% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is -39.3% lower than the average peer. This story was produced by the Kwhen Automated News Generator. | Ambev S.A. - ADR (ABEV) shares closed today at 1.6% below its 52 week high of $3.16, giving the company a market cap of $48B. This week, the Dow Jones Industrial Average rose 1.0%, and the S&P 500 rose 2.1%. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70. |
28156.0 | 2023-06-16 00:00:00 UTC | 3 Under-the-Radar Penny Stocks That May Be Sleeping Giants | ABEV | https://www.nasdaq.com/articles/3-under-the-radar-penny-stocks-that-may-be-sleeping-giants | nan | nan | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
While there are few stocks trading under $5 that I would consider investing in, promising penny stocks are still available.
According to Finviz.com, 3,674 stocks have a market capitalization of $300 million or higher. Of these, 304 have a share price of less than $5, the definition of a penny stock.
Sirius XM Holdings (NASDAQ:SIRI), a penny stock, stands out as a relatively large company. Despite trading at $3.77 at the time of writing, this satellite radio network boasts a market cap of $14.6 billion.
Among the 304 penny stocks, 12 boast a market cap exceeding $10 billion, while another 25 fall between $2 billion and $10 billion.
For this article, I plan to choose one from the above $10 billion group and two from the $2 billion to $10 billion range. Importantly, each selection should be profitable. Consistent with my approach, I’ll ensure they represent three distinct sectors.
Here goes.
Ambev (ABEV)
Source: Master1305/ShutterStock.com
Ambev (NYSE:ABEV) is a Brazilian beer company controlled by Anheuser-Busch InBev (NYSE:BUD), who own nearly 62% of its stock, and control another 10% through a voting agreement with Fundação Antonio e Helena Zerrenner Instituição Nacional de Beneficência, or FAHZ, the brewer’s second-largest shareholder.
The company, known for beers like Brahma, Skol, and Antarctica, formed from a 1999 merger. A 2004 merger with Belgium’s Interbrew led to InBev, which later merged with Anheuser-Busch in 2008, creating Anheuser-Busch InBev.
Since August 2019, Ambev’s stock has remained under $5. It peaked near $10 in 2013. To profit from capital appreciation, careful timing is crucial. An entry point below $3.25 is ideal.
However, the real draw is the dividend. Typically, a single payment occurs in January. This year, shareholders received $0.1443 per share, yielding 4.6% based on the current share price. For income investors, it’s a great option for allocating some risk-off funds.
Olaplex Holdings (OLPX)
Source: Gorodenkoff / Shutterstock
Olaplex Holdings (NASDAQ:OLPX) is a California-based hair care company founded in 2014. Its 15 products provide a holistic regimen for hair health. The company started in the professional market but has since broadened its scope to a more omnichannel business model, adding specialty retail, and direct-to-consumer, to its repertoire.
The company’s stock has plummeted 31% year-to-date and 76% over the past year. A significant factor in its 2023 losses is a lawsuit claiming its products cause hair loss and bald spots, a damaging allegation for a company promoting hair health.
In response, the company released independent third-party laboratory test results, as reported by CNN Business in February. The company stated, “We have full confidence in the safety and efficacy of our products,” attributing hair loss to various factors including lifestyle, medical conditions, and medications.
Despite a significant drop in Q1 2023 results compared to the previous year – with revenue and adjusted net income falling 38.9% and 65.7% respectively – the company remains optimistic about the rest of the year and, crucially, into 2024.
Given its 2023 guidance, the company’s stock trades at 3.9x sales and 11.8x earnings. This valuation is quite low for a brand that has boosted its sales by 150% over the past two fiscal years. By 2025, it aims to reach or approach $1 billion in revenue.
For aggressive investors, this presents an intriguing opportunity.
Baytex Energy (BTE)
Source: stockwars / Shutterstock.com
Baytex Energy (NYSE:BTE) is a Calgary-based energy company with crude oil and natural gas production in Canada and the U.S.
In February, the company announced it would acquire Ranger Oil (NASDAQ:ROCC) for $2.5 billion, including the assumption of net debt. The company is a pure-play operator in Texas’s Eagle Ford shale basin. It is paying for the acquisition with a combination of stock (70%) and cash (30%).
Baytex is acquiring Ranger for 2.9 times its EBITDA, calculated on $50,000 per barrel of daily production and a $75 barrel of West Texas Intermediate (WTI).
The merger will result in a combined daily production of at least 155,000 barrels of oil equivalent (Mboe/d), 1.7 million net acres, and adjusted funds flow of $2.2 billion.
Upon finalizing the acquisition, which is imminent, Baytex plans to return 50% of annual free cash flow to shareholders. This includes a new quarterly dividend of $0.0225, yielding 2.7% at the current price, and increased share repurchases.
Once Baytex reduces its total debt to $1.5 billion, it aims to boost the free cash flow returned to shareholders to 75%.
On the date of publication, Will Ashworth did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.
Will Ashworth has written about investments full-time since 2008. Publications where he’s appeared include InvestorPlace, The Motley Fool Canada, Investopedia, Kiplinger, and several others in both the U.S. and Canada. He particularly enjoys creating model portfolios that stand the test of time. He lives in Halifax, Nova Scotia.
More From InvestorPlace
Buy This $5 Stock BEFORE This Apple Project Goes Live
Wall Street Titan: Here’s My #1 Stock for 2023
The $1 Investment You MUST Take Advantage of Right Now
It doesn’t matter if you have $500 or $5 million. Do this now.
The post 3 Under-the-Radar Penny Stocks That May Be Sleeping Giants appeared first on InvestorPlace.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Ambev (ABEV) Source: Master1305/ShutterStock.com Ambev (NYSE:ABEV) is a Brazilian beer company controlled by Anheuser-Busch InBev (NYSE:BUD), who own nearly 62% of its stock, and control another 10% through a voting agreement with Fundação Antonio e Helena Zerrenner Instituição Nacional de Beneficência, or FAHZ, the brewer’s second-largest shareholder. The company started in the professional market but has since broadened its scope to a more omnichannel business model, adding specialty retail, and direct-to-consumer, to its repertoire. In February, the company announced it would acquire Ranger Oil (NASDAQ:ROCC) for $2.5 billion, including the assumption of net debt. | Ambev (ABEV) Source: Master1305/ShutterStock.com Ambev (NYSE:ABEV) is a Brazilian beer company controlled by Anheuser-Busch InBev (NYSE:BUD), who own nearly 62% of its stock, and control another 10% through a voting agreement with Fundação Antonio e Helena Zerrenner Instituição Nacional de Beneficência, or FAHZ, the brewer’s second-largest shareholder. Olaplex Holdings (OLPX) Source: Gorodenkoff / Shutterstock Olaplex Holdings (NASDAQ:OLPX) is a California-based hair care company founded in 2014. Baytex Energy (BTE) Source: stockwars / Shutterstock.com Baytex Energy (NYSE:BTE) is a Calgary-based energy company with crude oil and natural gas production in Canada and the U.S. | Ambev (ABEV) Source: Master1305/ShutterStock.com Ambev (NYSE:ABEV) is a Brazilian beer company controlled by Anheuser-Busch InBev (NYSE:BUD), who own nearly 62% of its stock, and control another 10% through a voting agreement with Fundação Antonio e Helena Zerrenner Instituição Nacional de Beneficência, or FAHZ, the brewer’s second-largest shareholder. InvestorPlace - Stock Market News, Stock Advice & Trading Tips While there are few stocks trading under $5 that I would consider investing in, promising penny stocks are still available. Among the 304 penny stocks, 12 boast a market cap exceeding $10 billion, while another 25 fall between $2 billion and $10 billion. | Ambev (ABEV) Source: Master1305/ShutterStock.com Ambev (NYSE:ABEV) is a Brazilian beer company controlled by Anheuser-Busch InBev (NYSE:BUD), who own nearly 62% of its stock, and control another 10% through a voting agreement with Fundação Antonio e Helena Zerrenner Instituição Nacional de Beneficência, or FAHZ, the brewer’s second-largest shareholder. InvestorPlace - Stock Market News, Stock Advice & Trading Tips While there are few stocks trading under $5 that I would consider investing in, promising penny stocks are still available. The merger will result in a combined daily production of at least 155,000 barrels of oil equivalent (Mboe/d), 1.7 million net acres, and adjusted funds flow of $2.2 billion. |
28157.0 | 2023-06-13 00:00:00 UTC | Ambev S.A. - ADR Shares Climb 0.3% Past Previous 52-Week High - Market Mover | ABEV | https://www.nasdaq.com/articles/ambev-s.a.-adr-shares-climb-0.3-past-previous-52-week-high-market-mover | nan | nan | Ambev S.A. - ADR (ABEV) shares closed 0.3% higher than its previous 52 week high, giving the company a market cap of $48B. The stock is currently up 14.0% year-to-date, up 28.1% over the past 12 months, and down 26.6% over the past five years. This week, the Dow Jones Industrial Average rose 1.9%, and the S&P 500 rose 2.0%.
Trading Activity
Trading volume this week was 6.2% lower than the 20-day average.
Beta, a measure of the stock’s volatility relative to the overall market stands at 0.5.
Technical Indicators
The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.
MACD, a trend-following momentum indicator, indicates an upward trend.
The stock closed below its Bollinger band, indicating it may be oversold.
Market Comparative Performance
The company's share price is the same as the S&P 500 Index , beats it on a 1-year basis, and lags it on a 5-year basis
The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and lags it on a 5-year basis
Per Group Comparative Performance
The company's stock price performance year-to-date beats the peer average by -1289.0%
The company's stock price performance over the past 12 months beats the peer average by 400.1%
The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is -38.8% lower than the average peer.
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Ambev S.A. - ADR (ABEV) shares closed 0.3% higher than its previous 52 week high, giving the company a market cap of $48B. Beta, a measure of the stock’s volatility relative to the overall market stands at 0.5. Market Comparative Performance The company's share price is the same as the S&P 500 Index , beats it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -1289.0% The company's stock price performance over the past 12 months beats the peer average by 400.1% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is -38.8% lower than the average peer. | Ambev S.A. - ADR (ABEV) shares closed 0.3% higher than its previous 52 week high, giving the company a market cap of $48B. This week, the Dow Jones Industrial Average rose 1.9%, and the S&P 500 rose 2.0%. Trading Activity Trading volume this week was 6.2% lower than the 20-day average. | Ambev S.A. - ADR (ABEV) shares closed 0.3% higher than its previous 52 week high, giving the company a market cap of $48B. Market Comparative Performance The company's share price is the same as the S&P 500 Index , beats it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -1289.0% The company's stock price performance over the past 12 months beats the peer average by 400.1% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is -38.8% lower than the average peer. This story was produced by the Kwhen Automated News Generator. | Ambev S.A. - ADR (ABEV) shares closed 0.3% higher than its previous 52 week high, giving the company a market cap of $48B. This week, the Dow Jones Industrial Average rose 1.9%, and the S&P 500 rose 2.0%. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought. |
28158.0 | 2023-06-11 00:00:00 UTC | Ambev S.A. - ADR Shares Approach 52-Week High - Market Mover | ABEV | https://www.nasdaq.com/articles/ambev-s.a.-adr-shares-approach-52-week-high-market-mover | nan | nan | Ambev S.A. - ADR (ABEV) shares closed today at 0.6% below its 52 week high of $3.10, giving the company a market cap of $48B. The stock is currently up 14.0% year-to-date, up 22.4% over the past 12 months, and down 27.7% over the past five years. This week, the Dow Jones Industrial Average rose 0.4%, and the S&P 500 rose 0.5%.
Trading Activity
Trading volume this week was 9.2% higher than the 20-day average.
Beta, a measure of the stock’s volatility relative to the overall market stands at 0.5.
Technical Indicators
The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.
MACD, a trend-following momentum indicator, indicates an upward trend.
The stock closed below its Bollinger band, indicating it may be oversold.
Market Comparative Performance
The company's share price is the same as the S&P 500 Index , beats it on a 1-year basis, and lags it on a 5-year basis
The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and lags it on a 5-year basis
Per Group Comparative Performance
The company's stock price performance year-to-date beats the peer average by -746.0%
The company's stock price performance over the past 12 months beats the peer average by 1250.3%
The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is -37.8% lower than the average peer.
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Ambev S.A. - ADR (ABEV) shares closed today at 0.6% below its 52 week high of $3.10, giving the company a market cap of $48B. Beta, a measure of the stock’s volatility relative to the overall market stands at 0.5. Market Comparative Performance The company's share price is the same as the S&P 500 Index , beats it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -746.0% The company's stock price performance over the past 12 months beats the peer average by 1250.3% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is -37.8% lower than the average peer. | Ambev S.A. - ADR (ABEV) shares closed today at 0.6% below its 52 week high of $3.10, giving the company a market cap of $48B. This week, the Dow Jones Industrial Average rose 0.4%, and the S&P 500 rose 0.5%. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought. | Ambev S.A. - ADR (ABEV) shares closed today at 0.6% below its 52 week high of $3.10, giving the company a market cap of $48B. Market Comparative Performance The company's share price is the same as the S&P 500 Index , beats it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -746.0% The company's stock price performance over the past 12 months beats the peer average by 1250.3% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is -37.8% lower than the average peer. This story was produced by the Kwhen Automated News Generator. | Ambev S.A. - ADR (ABEV) shares closed today at 0.6% below its 52 week high of $3.10, giving the company a market cap of $48B. This week, the Dow Jones Industrial Average rose 0.4%, and the S&P 500 rose 0.5%. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought. |
28159.0 | 2023-06-04 00:00:00 UTC | The 7 Best Stocks Under $20 to Buy in June 2023 | ABEV | https://www.nasdaq.com/articles/the-7-best-stocks-under-%2420-to-buy-in-june-2023 | nan | nan | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
With stubbornly high inflation hitting the pocketbook, you might believe that the concept of the best affordable stocks for June 2023 is a pipe dream. To be quite blunt, investors should avoid chasing cheap securities just because of their entry point. Many times – if not most of the time – cheap equities are that way for a reason (usually not a good one).
That said, you can’t make blanket statements for all circumstances. If you dig deep enough, you’ll find promising enterprises, even high-return stocks under $20. That’s right: for less than a Jackson, you can acquire an equity stake in some rather surprisingly popular ventures. Or you can take a potshot in a business enterprise of tomorrow. Of course, as with any endeavor in life, the higher the reward potential, (usually) the higher the risk. Before you proceed, you’ll want to conduct your due diligence. Nevertheless, for the smart speculator, below are the top stocks under $20 to buy.
Vipshop (VIPS)
Source: Vova Shevchuk / Shutterstock.com
To be clear upfront, I don’t want to keep milking the same cow over and over again. However, when you’re specifically targeting a narrow niche – such as high-return stocks under $20 – your options are limited. With Vipshop (NYSE:VIPS), investors enjoy exposure to a leading online discount retailer in China. Specifically, as the Chinese economy gradually recovers, Vipshop may be in a prime position to benefit.
However, following a skyrocket in Nov., VIPS incurred choppy trading so far this year. Since the January opener, VIPS gained only 5% of its market value. That said, the company provides great value under the hood. Notably, the company enjoys strong net income expansion, from $735 million in 2021 to just over $1 billion on a trailing-12-month basis.
Despite this magnitude of expanding profitability, VIPS trades at a forward multiple of 7.8. As a discount to projected earnings, Vipshop ranks better than 86.93% of companies listed in the cyclical retail industry. Thus, it makes a great case for the best stocks to buy on a budget. Finally, analysts peg VIPS as a consensus strong buy. Their average price target lands at $17, implying nearly 13% upside potential.
Ambev (ABEV)
Source: PX Media / Shutterstock
Hailing from Brazil, Ambev (NYSE:ABEV) is a major brewing company. Since the beginning of the year, ABEV managed to gain nearly 9% of equity value. Its performance slips just under the U.S. benchmark S&P 500, which gained over 10% during the same period. At the moment, Ambev commands a market capitalization of just over $45 billion. Shares trade hands below $3 at the time of writing.
Though seemingly a penny stock without any context, ABEV legitimately represents one of the best affordable stocks for June 2023. Sure, the price tag is low but that shouldn’t impugn the underlying value. Specifically, Ambev enjoys significant net income expansion, from $2.21 billion in 2020 to $2.84 billion on a TTM basis.
Even with that profitability growth, the market prices ABEV at a forward multiple of 15.45. As a discount to projected earnings, the brewing company ranks better than 77.27% of the competition. Lastly, covering analysts peg ABEV as a consensus strong buy. Their average price target hits $3.46, implying nearly 23% upside potential.
Stellantis (STLA)
Source: Zurijeta / Shutterstock.com
A multinational automotive manufacturing company, Stellantis (NYSE:STLA) itself might not be a household name. However, its 16 brands, including icons such as Alfa Romeo, Fiat, and Jeep have fans across the globe. Moving forward, Stellantis’ brand Dodge will make a splash in the electric vehicle market with a zero-emissions muscle car if you can believe it.
Trading at $15.48 at the last count, STLA gained over 6% of market value since the January opener. However, in the trailing month, STLA slipped more than 5%. The red ink might represent a great excuse to acquire one of the best affordable stocks for June 2023. From 2021 to 2022, the company’s net income expanded from $16 billion to $17.8 billion. As well, the enterprise posted a better-than-average three-year revenue growth rate of 14.6%.
Even with that, the market prices STLA at a forward multiple of only 3.23. As a discount to projected earnings, Stellantis ranks better than 97.69% of its peers. Thus, it’s a promising idea among top stocks under $20 to buy. Per analysts, STLA ranks as a strong buy. Their average price target clocks in at $22.35, implying over 44% upside potential.
Envela (ELA)
Source: Freedom365day / Shutterstock.com
Headquartered in Dallas, Texas, Envela (NYSEAMERICAN:ELA) engages in diverse business activities within the recommerce sector. This involves re-commercializing luxury hard assets, consumer electronics, and information technology equipment. As well, the company provides end-of-life recycling solutions. Put another way, it’s go-green capitalism at its finest. And it also happens to be one of the best affordable stocks for June 2023.
Priced at $7.41 at the time of writing, ELA gained nearly 41% of its equity value since the Jan. opener. However, even with this outperformance, the market prices ELA at a trailing multiple of 13. As a discount to earnings, Envela ranks better than 62.62% of the cyclical retail industry.
In addition, the company prints a three-year revenue growth rate of 30.6%, outflanking almost 90% of its peers. As well, its EBITDA growth rate during the same period impresses at 62.6%. Even with all the positives, ELA’s price-earnings-growth ratio sits at 0.2, well below the retail sector’s ratio of 1.14 times. Turning to Wall Street, Lake Street’s Mark Argento rates shares a buy. His price target stands at $11, implying over 48% upside potential.
Radiant Logistics (RLGT)
Source: Chompoo Suriyo / Shutterstock.com
Based in Bellevue, Washington, Radiant Logistics (NYSEAMERICAN:RLGT) is a comprehensive North American provider of third-party logistics and multimodal transportation services. Per its public profile, Radiant provides domestic and international freight forwarding services, truck, and rail brokerage services, and other value-added supply chain management services. Priced at $6.26, RLGT gained nearly 21% of equity value since the Jan. opener.
Even with the outperformance, RLGT ranks among the best affordable stocks for June 2023. It’s not just the price point that’s attractive here. Rather, the company benefits from decent stability in the balance sheet. Also, its Altman Z-Score pings at 4.59, indicating a low risk of bankruptcy.
Enticingly, Radiant’s three-year revenue growth rate clocks in at 18.2%, outpacing 79.31% of its peers. As well, its EBITDA growth rate during the same period impresses at 25.9%. Despite these stats, the market prices RLGT at a low multiple of 9.21. Thus, it’s a great candidate for the best stocks to buy on a budget. Looking to the Street, analysts peg RLGT as a moderate buy. Their average price target comes in at $10, implying nearly 60% upside potential.
Qifu Technology (QFIN)
Source: ImageFlow/Shutterstock.com
Hailing from China, Qifu Technology (NASDAQ:QFIN) is a data-driven, technology-empowered digital platform. From its corporate profile, Qifu enables financial institutions to provide better and more targeted products and services to a broader consumer base. The company also offers standardized risk management services, in the form of Software-as-a-Service (SaaS) modules to institutional clients. Priced at under $15, QFIN is an intriguing opportunity among the best affordable stocks for June 2023.
To be fair, though, it’s also one of the riskiest. Since the beginning of this year, QFIN tanked by almost 30%. Still, it’s possible that QFIN could become one of the high-return stocks under $20. Notably, the company’s three-year revenue growth rate is 22.5%, beating out 81.4% of sector players. Also, its book growth rate during the same period is 34.2%, above 93.42%. Despite the strong numbers, QFIN appears a bargain, priced at only 1.18 times trailing-year sales. Also, its price-earnings (PE) ratio sits at 4.34 times. Thus, it seems one of the top stocks under $20 to buy.
Lastly, analysts appear enthused about QFIN, pegging it a moderate buy. Their average price target lands at $26.12, implying over 78% upside potential.
Magic Software (MGIC)
Source: AdityaB. Photography/ShutterStock.com
If you really want to maximize the risk-reward framework of the best affordable stocks for June 2023, Magic Software (NASDAQ:MGIC) may be worth consideration, but probably only with pocket change. Based in Israel, Magic is a global provider of powerful and versatile end-to-end, on-premises, and cloud-based integration and low-code application development platforms. At the moment, shares trade at $11.40. So far, so good.
Unfortunately, shares fell almost 30% since the beginning of this year. That’s probably going to lose most investors reading this. However, if you still want to give it a chance as one of the affordable stocks with high growth potential, it’s fair to point out its operational strengths. Its three-year revenue growth rate pings at 20.2%. And its EBITDA growth rate is 20.5%. Both stats are well above the underlying sector median. Even with these numbers considered, the market prices MGIC at a trailing multiple of 13.9. As a discount to earnings, Magic ranks better than 75% of the competition.
On a final note, a Barclays analyst pegs MGIC a buy. The expert forecasts a $23 price target, implying nearly 102% upside potential.
VIPS Vipshop $15.94
ABEV Ambev $2.90
STLA Stellantis $15.87
ELA Envela $7.50
RLGT Radiant Logistics $6.45
QFIN Qifu Technology $14.97
MGIC Magic Software $11.38
On the date of publication, Josh Enomoto did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.
A former senior business analyst for Sony Electronics, Josh Enomoto has helped broker major contracts with Fortune Global 500 companies. Over the past several years, he has delivered unique, critical insights for the investment markets, as well as various other industries including legal, construction management, and healthcare.
The post The 7 Best Stocks Under $20 to Buy in June 2023 appeared first on InvestorPlace.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | VIPS Vipshop $15.94 ABEV Ambev $2.90 STLA Stellantis $15.87 ELA Envela $7.50 RLGT Radiant Logistics $6.45 QFIN Qifu Technology $14.97 MGIC Magic Software $11.38 On the date of publication, Josh Enomoto did not have (either directly or indirectly) any positions in the securities mentioned in this article. Ambev (ABEV) Source: PX Media / Shutterstock Hailing from Brazil, Ambev (NYSE:ABEV) is a major brewing company. Since the beginning of the year, ABEV managed to gain nearly 9% of equity value. | VIPS Vipshop $15.94 ABEV Ambev $2.90 STLA Stellantis $15.87 ELA Envela $7.50 RLGT Radiant Logistics $6.45 QFIN Qifu Technology $14.97 MGIC Magic Software $11.38 On the date of publication, Josh Enomoto did not have (either directly or indirectly) any positions in the securities mentioned in this article. Ambev (ABEV) Source: PX Media / Shutterstock Hailing from Brazil, Ambev (NYSE:ABEV) is a major brewing company. Since the beginning of the year, ABEV managed to gain nearly 9% of equity value. | Even with that profitability growth, the market prices ABEV at a forward multiple of 15.45. VIPS Vipshop $15.94 ABEV Ambev $2.90 STLA Stellantis $15.87 ELA Envela $7.50 RLGT Radiant Logistics $6.45 QFIN Qifu Technology $14.97 MGIC Magic Software $11.38 On the date of publication, Josh Enomoto did not have (either directly or indirectly) any positions in the securities mentioned in this article. Ambev (ABEV) Source: PX Media / Shutterstock Hailing from Brazil, Ambev (NYSE:ABEV) is a major brewing company. | Since the beginning of the year, ABEV managed to gain nearly 9% of equity value. Ambev (ABEV) Source: PX Media / Shutterstock Hailing from Brazil, Ambev (NYSE:ABEV) is a major brewing company. Though seemingly a penny stock without any context, ABEV legitimately represents one of the best affordable stocks for June 2023. |
28160.0 | 2023-05-28 00:00:00 UTC | Validea's Top 5 Consumer Staples Stocks Based On David Dreman - 5/28/2023 | ABEV | https://www.nasdaq.com/articles/valideas-top-5-consumer-staples-stocks-based-on-david-dreman-5-28-2023 | nan | nan | The following are the top rated Consumer Staples stocks according to Validea's Contrarian Investor model based on the published strategy of David Dreman. This contrarian strategy finds the most unpopular mid- and large-cap stocks in the market and looks for improving fundamentals.
COCA-COLA CO (KO) is a large-cap growth stock in the Beverages (Non-Alcoholic) industry. The rating according to our strategy based on David Dreman is 57% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: The Coca-Cola Company is a beverage company. The Company's segments include Europe, Middle East and Africa; Latin America; North America; Asia Pacific; Global Ventures; and Bottling Investments. It owns or licenses and markets various beverage brands, which are grouped into categories, such as Coca-Cola; sparkling flavors; water, sports, coffee and tea; juice, dairy and plant-based beverages; and emerging beverages. It owns and markets six nonalcoholic sparkling soft drink brands, such as Coca-Cola, Sprite, Fanta, Diet Coke /Coca-Cola Light, and Coca-Cola Zero Sugar. Its water, sports, coffee and tea brands include quarius, Ayataka, BODYARMOR, Ciel, Costa, dogadan, Dasani, FUZE TEA, Georgia, glaceau smartwater, glaceau vitaminwater, Gold Peak, Powerade and others. The Company's juice, dairy and plant-based beverages brands include AdeS, Del Valle, fairlife, innocent, Minute Maid, Minute Maid Pulpy and Simply. The Company products are available to consumers in more than 200 countries.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
MARKET CAP: PASS
EARNINGS TREND: PASS
EPS GROWTH RATE IN THE IMMEDIATE PAST AND FUTURE: PASS
P/E RATIO: FAIL
PRICE/CASH FLOW (P/CF) RATIO: FAIL
PRICE/BOOK (P/B) VALUE: FAIL
PRICE/DIVIDEND (P/D) RATIO: FAIL
CURRENT RATIO: FAIL
PAYOUT RATIO: PASS
RETURN ON EQUITY: PASS
PRE-TAX PROFIT MARGINS: PASS
YIELD: FAIL
LOOK AT THE TOTAL DEBT/EQUITY: FAIL
Detailed Analysis of COCA-COLA CO
KO Guru Analysis
KO Fundamental Analysis
AMBEV SA (ADR) (ABEV) is a large-cap growth stock in the Beverages (Alcoholic) industry. The rating according to our strategy based on David Dreman is 36% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Ambev SA, formerly Inbev Participacoes Societarias SA, is a Brazil-based company engaged in the brewing sector. The Company produces, distributes and sells beer, carbonated soft drinks (CSDs) and other non-alcoholic and non-carbonated (NANC) beverages across the Americas. The Company's activities are divided into three segments: Latin America North, including sell of beer, CSD and NANC drinks in Brazil, as well as operations in the Dominican Republic, Saint Vincent, Antigua, Dominica, Cuba, Guatemala, El Salvador, Honduras, Nicaragua, Barbados and Panama; Latin America South, distributing products in Argentina, Bolivia, Paraguay, Uruguay, Chile; and Canada, represented by Labatt's operations, which comprises sales in Canada and some exports to the U.S. market. The Company markets products under various brand names, such as Adriatica, Brahma, Leffe, Budweiser, Corona, PepsiCo and Lipton. It is a subsidiary of Interbrew International BV.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
MARKET CAP: PASS
EARNINGS TREND: FAIL
EPS GROWTH RATE IN THE IMMEDIATE PAST AND FUTURE: FAIL
P/E RATIO: FAIL
PRICE/CASH FLOW (P/CF) RATIO: FAIL
PRICE/BOOK (P/B) VALUE: FAIL
PRICE/DIVIDEND (P/D) RATIO: FAIL
CURRENT RATIO: FAIL
PAYOUT RATIO: FAIL
RETURN ON EQUITY: FAIL
PRE-TAX PROFIT MARGINS: PASS
YIELD: PASS
LOOK AT THE TOTAL DEBT/EQUITY: PASS
Detailed Analysis of AMBEV SA (ADR)
ABEV Guru Analysis
ABEV Fundamental Analysis
PHILIP MORRIS INTERNATIONAL INC. (PM) is a large-cap growth stock in the Tobacco industry. The rating according to our strategy based on David Dreman is 29% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Philip Morris International Inc. (PMI) is an international tobacco company. It focuses on delivering a smoke-free future and evolving its portfolio for the long term to include products outside of the tobacco and nicotine sector. Its product portfolio consists of cigarettes and smoke-free products, including heat-not-burn, vapor and oral nicotine products, which are sold in markets outside the United States. It is engaged in developing smoke-free products for adults along with building scientific assessment capabilities in the areas of pre-clinical systems toxicology, clinical and behavioral research, as well as post-market studies. The United States Food and Drug Administration (FDA) has authorized versions of its IQOS Platform 1 device and consumables, and Swedish Match's General snus, as Modified Risk Tobacco Products (MRTPs). Its portfolio consists of both international and local brands and is led by Marlboro. Its other cigarette brands include Chesterfield, L&M and Philip Morris.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
MARKET CAP: PASS
EARNINGS TREND: FAIL
EPS GROWTH RATE IN THE IMMEDIATE PAST AND FUTURE: FAIL
P/E RATIO: FAIL
PRICE/CASH FLOW (P/CF) RATIO: FAIL
PRICE/BOOK (P/B) VALUE: FAIL
PRICE/DIVIDEND (P/D) RATIO: FAIL
CURRENT RATIO: FAIL
PAYOUT RATIO: FAIL
RETURN ON EQUITY: FAIL
PRE-TAX PROFIT MARGINS: PASS
YIELD: PASS
LOOK AT THE TOTAL DEBT/EQUITY: FAIL
Detailed Analysis of PHILIP MORRIS INTERNATIONAL INC.
PM Guru Analysis
PM Fundamental Analysis
WALMART INC (WMT) is a large-cap growth stock in the Retail (Grocery) industry. The rating according to our strategy based on David Dreman is 29% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Walmart Inc. is a technology-powered omni-channel retailer. The Company provides the opportunity to shop in both retail stores and through e-commerce and to access its other service offerings. It offers an assortment of merchandise and services at everyday low prices (EDLP). It operates through three segments: Walmart U.S., Walmart International and Sam's Club. The Walmart U.S. segment is a mass merchandiser of consumer products, operating under the Walmart and Walmart Neighborhood Market brands, as well as walmart.com and other e-commerce brands. Walmart International segment includes various formats divided into two categories: retail and wholesale. These categories consist of many formats, including supercenters, supermarkets, hypermarkets, warehouse clubs (including Sam's Clubs) and cash & carry, as well as e-commerce through walmart.com.mx, walmart.ca, flipkart.com, walmart.cn and other sites. Sam's Club segment is a membership-only warehouse club that also operates samsclub.com.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
MARKET CAP: PASS
EARNINGS TREND: FAIL
EPS GROWTH RATE IN THE IMMEDIATE PAST AND FUTURE: FAIL
P/E RATIO: FAIL
PRICE/CASH FLOW (P/CF) RATIO: FAIL
PRICE/BOOK (P/B) VALUE: FAIL
PRICE/DIVIDEND (P/D) RATIO: FAIL
CURRENT RATIO: FAIL
PAYOUT RATIO: PASS
RETURN ON EQUITY: FAIL
PRE-TAX PROFIT MARGINS: FAIL
YIELD: FAIL
LOOK AT THE TOTAL DEBT/EQUITY: PASS
Detailed Analysis of WALMART INC
WMT Guru Analysis
WMT Fundamental Analysis
David Dreman Portfolio
About David Dreman: Dreman's Kemper-Dreman High Return Fund was one of the best-performing mutual funds ever, ranking as the best of 255 funds in its peer groups from 1988 to 1998, according to Lipper Analytical Services. At the time Dreman published Contrarian Investment Strategies: The Next Generation, the fund had been ranked number one in more time periods than any of the 3,175 funds in Lipper's database. In addition to managing money, Dreman is also a longtime Forbes magazine columnist.
About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Detailed Analysis of COCA-COLA CO KO Guru Analysis KO Fundamental Analysis AMBEV SA (ADR) (ABEV) is a large-cap growth stock in the Beverages (Alcoholic) industry. Detailed Analysis of AMBEV SA (ADR) ABEV Guru Analysis ABEV Fundamental Analysis PHILIP MORRIS INTERNATIONAL INC. (PM) is a large-cap growth stock in the Tobacco industry. The Company's activities are divided into three segments: Latin America North, including sell of beer, CSD and NANC drinks in Brazil, as well as operations in the Dominican Republic, Saint Vincent, Antigua, Dominica, Cuba, Guatemala, El Salvador, Honduras, Nicaragua, Barbados and Panama; Latin America South, distributing products in Argentina, Bolivia, Paraguay, Uruguay, Chile; and Canada, represented by Labatt's operations, which comprises sales in Canada and some exports to the U.S. market. | Detailed Analysis of COCA-COLA CO KO Guru Analysis KO Fundamental Analysis AMBEV SA (ADR) (ABEV) is a large-cap growth stock in the Beverages (Alcoholic) industry. Detailed Analysis of AMBEV SA (ADR) ABEV Guru Analysis ABEV Fundamental Analysis PHILIP MORRIS INTERNATIONAL INC. (PM) is a large-cap growth stock in the Tobacco industry. Detailed Analysis of WALMART INC WMT Guru Analysis WMT Fundamental Analysis David Dreman Portfolio About David Dreman: Dreman's Kemper-Dreman High Return Fund was one of the best-performing mutual funds ever, ranking as the best of 255 funds in its peer groups from 1988 to 1998, according to Lipper Analytical Services. | Detailed Analysis of COCA-COLA CO KO Guru Analysis KO Fundamental Analysis AMBEV SA (ADR) (ABEV) is a large-cap growth stock in the Beverages (Alcoholic) industry. Detailed Analysis of AMBEV SA (ADR) ABEV Guru Analysis ABEV Fundamental Analysis PHILIP MORRIS INTERNATIONAL INC. (PM) is a large-cap growth stock in the Tobacco industry. The Company's activities are divided into three segments: Latin America North, including sell of beer, CSD and NANC drinks in Brazil, as well as operations in the Dominican Republic, Saint Vincent, Antigua, Dominica, Cuba, Guatemala, El Salvador, Honduras, Nicaragua, Barbados and Panama; Latin America South, distributing products in Argentina, Bolivia, Paraguay, Uruguay, Chile; and Canada, represented by Labatt's operations, which comprises sales in Canada and some exports to the U.S. market. | Detailed Analysis of COCA-COLA CO KO Guru Analysis KO Fundamental Analysis AMBEV SA (ADR) (ABEV) is a large-cap growth stock in the Beverages (Alcoholic) industry. Detailed Analysis of AMBEV SA (ADR) ABEV Guru Analysis ABEV Fundamental Analysis PHILIP MORRIS INTERNATIONAL INC. (PM) is a large-cap growth stock in the Tobacco industry. Company Description: The Coca-Cola Company is a beverage company. |
28161.0 | 2023-04-30 00:00:00 UTC | Validea's Top 5 Consumer Staples Stocks Based On John Neff - 4/30/2023 | ABEV | https://www.nasdaq.com/articles/valideas-top-5-consumer-staples-stocks-based-on-john-neff-4-30-2023 | nan | nan | The following are the top rated Consumer Staples stocks according to Validea's Low PE Investor model based on the published strategy of John Neff. This strategy looks for firms with persistent earnings growth that trade at a discount relative to their earnings growth and dividend yield.
KEURIG DR PEPPER INC (KDP) is a large-cap growth stock in the Beverages (Non-Alcoholic) industry. The rating according to our strategy based on John Neff is 60% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Keurig Dr Pepper Inc. is a beverage company in North America. The Company has a diverse portfolio of flavored (non-cola) carbonated soft drinks (CSDs), non-carbonated beverages (NCBs), including water, ready-to-drink tea and coffee, juice, juice drinks, mixers, and specialty coffee, and is a producer of single serve brewing systems. The Company's segments include Coffee Systems, Packaged Beverages, Beverage Concentrates and Latin America Beverages. The Coffee Systems segment is a producer of single serve brewers and specialty coffee. Packaged Beverages and Latin America Beverages segment is principally a brand ownership, manufacturing, and distribution business of CSDs. The Company's brand portfolio includes CSD brands, such as Dr Pepper, Canada Dry, Schweppes, Crush, Sunkist, A&W, 7UP, SunDrop, Squirt, Big Red, Vernors and RC Cola, and NCB brands, which include Snapple, Mott's, Bai, Clamato, Hawaiian Punch, Core, Yoo-Hoo, ReaLemon, evian, Vita Coco, and Mr and Mrs T mixers.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: FAIL
EPS GROWTH: PASS
FUTURE EPS GROWTH: PASS
SALES GROWTH: PASS
TOTAL RETURN/PE: FAIL
FREE CASH FLOW: PASS
EPS PERSISTENCE: FAIL
Detailed Analysis of KEURIG DR PEPPER INC
KDP Guru Analysis
KDP Fundamental Analysis
AMBEV SA (ADR) (ABEV) is a large-cap growth stock in the Beverages (Alcoholic) industry. The rating according to our strategy based on John Neff is 42% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Ambev SA, formerly Inbev Participacoes Societarias SA, is a Brazil-based company engaged in the brewing sector. The Company produces, distributes and sells beer, carbonated soft drinks (CSDs) and other non-alcoholic and non-carbonated (NANC) beverages across the Americas. The Company's activities are divided into three segments: Latin America North, including sell of beer, CSD and NANC drinks in Brazil, as well as operations in the Dominican Republic, Saint Vincent, Antigua, Dominica, Cuba, Guatemala, El Salvador, Honduras, Nicaragua, Barbados and Panama; Latin America South, distributing products in Argentina, Bolivia, Paraguay, Uruguay, Chile; and Canada, represented by Labatt's operations, which comprises sales in Canada and some exports to the U.S. market. The Company markets products under various brand names, such as Adriatica, Brahma, Leffe, Budweiser, Corona, PepsiCo and Lipton. It is a subsidiary of Interbrew International BV.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: FAIL
EPS GROWTH: PASS
FUTURE EPS GROWTH: FAIL
SALES GROWTH: PASS
TOTAL RETURN/PE: FAIL
FREE CASH FLOW: PASS
EPS PERSISTENCE: PASS
Detailed Analysis of AMBEV SA (ADR)
ABEV Guru Analysis
ABEV Fundamental Analysis
John Neff Portfolio
About John Neff: While known as the manager with whom many top managers entrusted their own money, Neff was far from the smooth-talking, high-profile Wall Streeter you might expect. He was mild-mannered and low-key, and the same might be said of the Windsor Fund that he managed for more than three decades. In fact, Neff himself described the fund as "relatively prosaic, dull, [and] conservative." There was nothing dull about his results, however. From 1964 to 1995, Neff guided Windsor to a 13.7 percent average annual return, easily outpacing the S&P 500's 10.6 percent return during that time. That 3.1 percentage point difference is huge over time -- a $10,000 investment in Windsor (with dividends reinvested) at the start of Neff's tenure would have ended up as more than $564,000 by the time he retired, more than twice what the same investment in the S&P would have yielded (about $233,000). Considering the length of his tenure, that track record may be the best ever for a manager of such a large fund.
About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Detailed Analysis of KEURIG DR PEPPER INC KDP Guru Analysis KDP Fundamental Analysis AMBEV SA (ADR) (ABEV) is a large-cap growth stock in the Beverages (Alcoholic) industry. Detailed Analysis of AMBEV SA (ADR) ABEV Guru Analysis ABEV Fundamental Analysis John Neff Portfolio About John Neff: While known as the manager with whom many top managers entrusted their own money, Neff was far from the smooth-talking, high-profile Wall Streeter you might expect. The following are the top rated Consumer Staples stocks according to Validea's Low PE Investor model based on the published strategy of John Neff. | Detailed Analysis of KEURIG DR PEPPER INC KDP Guru Analysis KDP Fundamental Analysis AMBEV SA (ADR) (ABEV) is a large-cap growth stock in the Beverages (Alcoholic) industry. Detailed Analysis of AMBEV SA (ADR) ABEV Guru Analysis ABEV Fundamental Analysis John Neff Portfolio About John Neff: While known as the manager with whom many top managers entrusted their own money, Neff was far from the smooth-talking, high-profile Wall Streeter you might expect. The Company produces, distributes and sells beer, carbonated soft drinks (CSDs) and other non-alcoholic and non-carbonated (NANC) beverages across the Americas. | Detailed Analysis of KEURIG DR PEPPER INC KDP Guru Analysis KDP Fundamental Analysis AMBEV SA (ADR) (ABEV) is a large-cap growth stock in the Beverages (Alcoholic) industry. Detailed Analysis of AMBEV SA (ADR) ABEV Guru Analysis ABEV Fundamental Analysis John Neff Portfolio About John Neff: While known as the manager with whom many top managers entrusted their own money, Neff was far from the smooth-talking, high-profile Wall Streeter you might expect. The Company's segments include Coffee Systems, Packaged Beverages, Beverage Concentrates and Latin America Beverages. | Detailed Analysis of KEURIG DR PEPPER INC KDP Guru Analysis KDP Fundamental Analysis AMBEV SA (ADR) (ABEV) is a large-cap growth stock in the Beverages (Alcoholic) industry. Detailed Analysis of AMBEV SA (ADR) ABEV Guru Analysis ABEV Fundamental Analysis John Neff Portfolio About John Neff: While known as the manager with whom many top managers entrusted their own money, Neff was far from the smooth-talking, high-profile Wall Streeter you might expect. Company Description: Keurig Dr Pepper Inc. is a beverage company in North America. |
28162.0 | 2023-04-24 00:00:00 UTC | 7 Stocks Under $10 That Analysts Love | ABEV | https://www.nasdaq.com/articles/7-stocks-under-%2410-that-analysts-love | nan | nan | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Generally speaking, you get what you pay for, which on paper doesn’t bode well for these bargain stocks under $10. Nevertheless, with thousands upon thousands of tradable securities available to public investors, at least a few will go unnoticed. That’s a shame for those missing out because some of these enterprises also command positive analyst ratings.
Indeed, Wall Street’s top experts don’t just focus on blue chips with big price tags. Rather, cheap stocks to buy occasionally tickle the suits’ fancy. Moreover, some analysts’ top picks center on bargain market ideas because they want to make serious noise. You’re not going to do that by just following the crowd. So, if you’re looking for substantive profits at a great price, take a look at these bargain stocks under $10.
ABEV Ambev $2.82
NVTS Navitas Semiconductor $6.44
GGB Gerdau $4.95
SGHC SGHC. Limited $3.63
MOMO Hello Group $8.22
ARHS Arhaus $7.98
ABCL AbCellera Biologics $7.17
Stocks Under $10: Ambev (ABEV)
Source: Shutterstock
Brazilian brewing company Ambev (NYSE:ABEV) trades at one of the lowest levels possible before entering the too-cheap zone. At $2.83 a pop at the time of writing, it’s what most people would consider a penny stock. However, investors also need to consider one not-so-small detail: Ambev features a market capitalization of nearly $46 billion. Since the beginning of this year, ABEV gained over 9% of its equity value.
While it’s easily one of the stocks under $10, ABEV also ranks among analysts’ top picks for foreign, non-China public enterprises. At the time of writing, covering experts peg ABEV as a consensus moderate buy. Moreover, their average price target lands at $3.30, implying nearly 17% upside potential.
Financially, Ambev provides investors with plenty to appreciate. Perhaps most importantly at this juncture, the company hosts a relatively cash-rich balance sheet. Operationally, Ambev’s three-year revenue growth rate pings at 15.3%, which is quite impressive. Also, its net margin is equally impressive at 18.14%. Therefore, it’s one of the cheap stocks to buy.
Stocks Under $10: Navitas (NVTS)
Source: Shutterstock
Headquartered in Torrance, California, Navitas (NASDAQ:NVTS) is a pure-play, next-generation power semiconductor firm. Featuring proprietary technologies, Navitas offers relevancies across multiple industries, including mobile communications, data centers, solar energy infrastructures, and electric vehicles, among many others. Presently, Navitas carries a market cap of just over $1 billion. Thanks to its enormous relevancies, NVTS gained almost 91% of its equity value since the start of the year.
Not surprisingly, those in the know appreciate Navitas. One of the high-flying stocks under $10, Navitas without qualifiers ranks among analysts’ top picks. According to TipRanks, covering experts peg NVTS as a unanimous strong buy. Their average price target comes out to $8.70, implying over 26% upside potential.
Attractively, the market prices NVTS at a trailing multiple of 11.66. As a discount to earnings, Navitas ranks better than 74.05% of companies listed in the semiconductor space. Also, it enjoys a cash-rich balance sheet. Notably, its Altman Z-Score pings at 16.45, indicating high fiscal stability and low bankruptcy risk. Thus, it’s one of the bargain stocks to consider.
Stocks Under $10: Gerdau (GGB)
Source: Shutterstock
Standing as the largest producer of long steel in the Americas, Gerdau (NYSE:GGB) commands an enviable footprint, with steel mills in Brazil, Argentina, Canada, Colombia, Dominican Republic, Mexico, Peru, the U.S., Uruguay, and Venezuela. Per its public profile, Gerdau offers steel for the civil construction, automobile, industrial and agricultural sectors, among others. Presently, the company carries a market cap of $8.54 billion.
Trading hands at a few cents shy of five bucks, GGB naturally makes for one of the bargain stocks under $10. As well, Wall Street analysts like the opportunity, pegging shares a consensus moderate buy. Right now, their average price target stands at $6.26, implying nearly 27% upside potential.
Another factor that makes Gerdau one of the cheap stocks to buy centers on its financial performance. In 2022, despite the pressures impacting the global economy, the company posted revenue of $15.71 billion. That’s up over 13% against the prior year’s tally of $13.85 billion. As well, it posted a net income of $2.18 billion last year.
Super Group (SGHC)
Source: Shutterstock
An enticing idea among cheap stocks to buy, Super Group (NYSE:SGHC) is a global digital gaming company. Providing first-class entertainment to the worldwide betting and gaming community per its website, Super Group may see rising demand. Basically, as society enters a full normalization period, consumers may earnestly pick up activities they temporarily abandoned such as online sports betting.
Trading hands at $3.61, SGHC garnered conspicuous interest this year, popping up 15%. However, some Wall Street experts also got into the game over the past 11 months. Within the past 90 days, SGHC carries a consensus assessment of moderate buy. The average price target stands at $5, implying almost 39% upside potential. Therefore, Super Group legitimately ranks as one of the stocks under $10 that’s also among analysts’ top picks.
Financially, the gaming specialist will almost surely attract retail investors’ attention for its financial strengths. Specifically, Super Group features a cash-to-debt ratio of 13.68, above 83.89% of its peers. Further, the company enjoys a stout net margin of 20.53%.
Hello Group (MOMO)
Source: Shutterstock
Arguably the most interesting idea on this list of bargain stocks under $10, China-based Hello Group (NASDAQ:MOMO) carries significant fundamental potential. Billed as a leading player in China’s online social networking space, Hello Group allows people to make meaningful interactions. Since Hello’s website mentions social dynamics as well as dating applications, you can read between the lines.
Without getting too mixed up in the details, the Chinese government imposed some of the strictest restrictions on personal mobility. With the nation gradually normalizing, the need for social interactions has become particularly acute. Almost surely, analysts have thought about this in the past year. Right now, the consensus pings as a moderate buy. Also, the average price target comes out to $12.50, implying over 49% upside potential.
To be fair, Hello Group presents significant risks, such as a negative three-year revenue growth rate. However, that’s explainable due to China’s draconian Covid-19 policies. Enticingly, shares trade at only 6.63 times forward earnings, which Gurufocus labels as undervalued.
Arhaus (ARHS)
Source: Shutterstock
Based in Ohio, Arhaus (NASDAQ:ARHS) is a retail chain that designs and sells home furnishings online and through its retail stores and catalogs. Fundamentally, Arhaus represents one of the riskiest ideas among stocks under $10. Yes, ARHS is cheap at $8.16 a pop. However, with the residential real estate market presenting challenges, Arhaus may incur demand loss.
Not surprisingly (at least in my opinion), ARHS dipped over 13% since the start of the year. However, the suits on Wall Street peg ARHS as one of the cheap stocks to buy. According to data compiled by TipRanks, analysts peg ARHS as a consensus strong buy. Their average price target hits $13.08, implying over 60% upside potential. Thus, it easily justifies inclusion among analysts’ top picks.
Despite my personal hesitations, Arhaus offers solid financial metrics to ponder over. Operationally, the company features a three-year revenue growth rate of 35.6%, outpacing 91.32% of firms listed in the cyclical retail industry. Also, it trades at 8.33-times trailing earnings, which appears significantly undervalued.
AbCellera (ABCL)
Source: Shutterstock
An enterprise that I’ve mentioned a few times now, AbCellera Biologics (NASDAQ:ABCL) presents significant risks. At the same time, if you’re looking for stocks under $10 that can blow the roof off your portfolio, ABCL could be it. Based in western Canada, AbCellera researches and develops human antibodies. Currently, the company commands a market cap of just over $2 billion.
Despite its relevance, ABCL hasn’t performed well so far this year, dropping 24% since the Jan. opener. In the past year, it’s down almost 10%. However, Wall Street experts simply do not care, assigning ABCL a unanimous strong buy rating. Moreover, their average price target stands at $29.60, implying almost 311% upside potential. That’s what you call one of the analysts’ top picks.
Plus, ABCL offers other strong points. For instance, the company commands a solid balance sheet, with an Altman Z-Score of 5.92 implying low bankruptcy risk. Also, it prints a very impressive net margin of nearly 33%. Just be careful if you decide to roll the dice.
On Penny Stocks and Low-Volume Stocks: With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That’s because these “penny stocks” are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com’s writers disclose this fact and warn readers of the risks.
Read More: Penny Stocks — How to Profit Without Getting Scammed
On the date of publication, Josh Enomoto did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.
A former senior business analyst for Sony Electronics, Josh Enomoto has helped broker major contracts with Fortune Global 500 companies. Over the past several years, he has delivered unique, critical insights for the investment markets, as well as various other industries including legal, construction management, and healthcare.
The post 7 Stocks Under $10 That Analysts Love appeared first on InvestorPlace.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ABEV Ambev $2.82 NVTS Navitas Semiconductor $6.44 GGB Gerdau $4.95 SGHC SGHC. Limited $3.63 MOMO Hello Group $8.22 ARHS Arhaus $7.98 ABCL AbCellera Biologics $7.17 Stocks Under $10: Ambev (ABEV) Source: Shutterstock Brazilian brewing company Ambev (NYSE:ABEV) trades at one of the lowest levels possible before entering the too-cheap zone. Since the beginning of this year, ABEV gained over 9% of its equity value. | Limited $3.63 MOMO Hello Group $8.22 ARHS Arhaus $7.98 ABCL AbCellera Biologics $7.17 Stocks Under $10: Ambev (ABEV) Source: Shutterstock Brazilian brewing company Ambev (NYSE:ABEV) trades at one of the lowest levels possible before entering the too-cheap zone. ABEV Ambev $2.82 NVTS Navitas Semiconductor $6.44 GGB Gerdau $4.95 SGHC SGHC. Since the beginning of this year, ABEV gained over 9% of its equity value. | Limited $3.63 MOMO Hello Group $8.22 ARHS Arhaus $7.98 ABCL AbCellera Biologics $7.17 Stocks Under $10: Ambev (ABEV) Source: Shutterstock Brazilian brewing company Ambev (NYSE:ABEV) trades at one of the lowest levels possible before entering the too-cheap zone. ABEV Ambev $2.82 NVTS Navitas Semiconductor $6.44 GGB Gerdau $4.95 SGHC SGHC. Since the beginning of this year, ABEV gained over 9% of its equity value. | ABEV Ambev $2.82 NVTS Navitas Semiconductor $6.44 GGB Gerdau $4.95 SGHC SGHC. Limited $3.63 MOMO Hello Group $8.22 ARHS Arhaus $7.98 ABCL AbCellera Biologics $7.17 Stocks Under $10: Ambev (ABEV) Source: Shutterstock Brazilian brewing company Ambev (NYSE:ABEV) trades at one of the lowest levels possible before entering the too-cheap zone. Since the beginning of this year, ABEV gained over 9% of its equity value. |
28163.0 | 2023-04-20 00:00:00 UTC | ABEV June 16th Options Begin Trading | ABEV | https://www.nasdaq.com/articles/abev-june-16th-options-begin-trading | nan | nan | Investors in Ambev SA (Symbol: ABEV) saw new options become available today, for the June 16th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABEV options chain for the new June 16th contracts and identified the following call contract of particular interest.
The call contract at the $3.00 strike price has a current bid of 10 cents. If an investor was to purchase shares of ABEV stock at the current price level of $2.87/share, and then sell-to-open that call contract as a "covered call," they are committing to sell the stock at $3.00. Considering the call seller will also collect the premium, that would drive a total return (excluding dividends, if any) of 8.01% if the stock gets called away at the June 16th expiration (before broker commissions). Of course, a lot of upside could potentially be left on the table if ABEV shares really soar, which is why looking at the trailing twelve month trading history for Ambev SA, as well as studying the business fundamentals becomes important. Below is a chart showing ABEV's trailing twelve month trading history, with the $3.00 strike highlighted in red:
Considering the fact that the $3.00 strike represents an approximate 5% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 99%. On our website under the contract detail page for this contract, Stock Options Channel will track those odds over time to see how they change and publish a chart of those numbers (the trading history of the option contract will also be charted). Should the covered call contract expire worthless, the premium would represent a 3.48% boost of extra return to the investor, or 22.31% annualized, which we refer to as the YieldBoost.
Meanwhile, we calculate the actual trailing twelve month volatility (considering the last 251 trading day closing values as well as today's price of $2.87) to be 35%. For more put and call options contract ideas worth looking at, visit StockOptionsChannel.com.
Top YieldBoost Calls of the S&P 500 »
Also see:
Funds Holding FTEV
RCMT Average Annual Return
VRA Average Annual Return
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Of course, a lot of upside could potentially be left on the table if ABEV shares really soar, which is why looking at the trailing twelve month trading history for Ambev SA, as well as studying the business fundamentals becomes important. Below is a chart showing ABEV's trailing twelve month trading history, with the $3.00 strike highlighted in red: Considering the fact that the $3.00 strike represents an approximate 5% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Ambev SA (Symbol: ABEV) saw new options become available today, for the June 16th expiration. | Of course, a lot of upside could potentially be left on the table if ABEV shares really soar, which is why looking at the trailing twelve month trading history for Ambev SA, as well as studying the business fundamentals becomes important. Below is a chart showing ABEV's trailing twelve month trading history, with the $3.00 strike highlighted in red: Considering the fact that the $3.00 strike represents an approximate 5% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Ambev SA (Symbol: ABEV) saw new options become available today, for the June 16th expiration. | If an investor was to purchase shares of ABEV stock at the current price level of $2.87/share, and then sell-to-open that call contract as a "covered call," they are committing to sell the stock at $3.00. Below is a chart showing ABEV's trailing twelve month trading history, with the $3.00 strike highlighted in red: Considering the fact that the $3.00 strike represents an approximate 5% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Ambev SA (Symbol: ABEV) saw new options become available today, for the June 16th expiration. | At Stock Options Channel, our YieldBoost formula has looked up and down the ABEV options chain for the new June 16th contracts and identified the following call contract of particular interest. Below is a chart showing ABEV's trailing twelve month trading history, with the $3.00 strike highlighted in red: Considering the fact that the $3.00 strike represents an approximate 5% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Ambev SA (Symbol: ABEV) saw new options become available today, for the June 16th expiration. |
28164.0 | 2023-04-06 00:00:00 UTC | Unusual Call Option Trade in Ambev S.A (ABEV) Worth $234.32K | ABEV | https://www.nasdaq.com/articles/unusual-call-option-trade-in-ambev-s.a-abev-worth-%24234.32k | nan | nan | On April 6, 2023 at 10:58:50 ET an unusually large $234.32K block of Call contracts in Ambev S.A (ABEV) was bought, with a strike price of $2.50 / share, expiring in 288 days (on January 19, 2024). Fintel tracks all large options trades, and the premium spent on this trade was 3.82 sigmas above the mean, placing it in the 100.00 percentile of all recent large trades made in ABEV options.
This trade was first picked up on Fintel's real time Unusual Option Trades tool, where unusual option trades are highlighted.
Analyst Price Forecast Suggests 28.56% Upside
As of March 30, 2023, the average one-year price target for Ambev S.A is $3.63. The forecasts range from a low of $2.50 to a high of $4.54. The average price target represents an increase of 28.56% from its latest reported closing price of $2.82.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Ambev S.A is $89,176MM, an increase of 11.88%. The projected annual non-GAAP EPS is $0.92.
What is the Fund Sentiment?
There are 414 funds or institutions reporting positions in Ambev S.A. This is an increase of 23 owner(s) or 5.88% in the last quarter. Average portfolio weight of all funds dedicated to ABEV is 0.39%, a decrease of 7.78%. Total shares owned by institutions increased in the last three months by 1.56% to 1,776,940K shares. The put/call ratio of ABEV is 1.87, indicating a bearish outlook.
What are Large Shareholders Doing?
First Eagle Investment Management holds 285,756K shares representing 1.82% ownership of the company. In it's prior filing, the firm reported owning 282,312K shares, representing an increase of 1.21%. The firm decreased its portfolio allocation in ABEV by 10.72% over the last quarter.
SGENX - First Eagle Global Fund holds 135,882K shares representing 0.86% ownership of the company. No change in the last quarter.
Harding Loevner holds 121,085K shares representing 0.77% ownership of the company. In it's prior filing, the firm reported owning 129,457K shares, representing a decrease of 6.91%. The firm decreased its portfolio allocation in ABEV by 21.00% over the last quarter.
Westwood Global Investments holds 101,336K shares representing 0.64% ownership of the company. In it's prior filing, the firm reported owning 101,828K shares, representing a decrease of 0.49%. The firm decreased its portfolio allocation in ABEV by 52.56% over the last quarter.
Sprucegrove Investment Management holds 93,582K shares representing 0.59% ownership of the company. In it's prior filing, the firm reported owning 98,954K shares, representing a decrease of 5.74%. The firm decreased its portfolio allocation in ABEV by 12.27% over the last quarter.
Ambev Background Information
(This description is provided by the company.)
Ambev, formally Companhia de Bebidas das Américas, is a Brazilian brewing company now merged into Anheuser-Busch InBev. Its name translates to "Beverage Company of the Americas", hence the "Ambev" abbreviation. It was created on July 1, 1999, with the merger of two breweries, Brahma and Antarctica.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | On April 6, 2023 at 10:58:50 ET an unusually large $234.32K block of Call contracts in Ambev S.A (ABEV) was bought, with a strike price of $2.50 / share, expiring in 288 days (on January 19, 2024). Fintel tracks all large options trades, and the premium spent on this trade was 3.82 sigmas above the mean, placing it in the 100.00 percentile of all recent large trades made in ABEV options. Average portfolio weight of all funds dedicated to ABEV is 0.39%, a decrease of 7.78%. | On April 6, 2023 at 10:58:50 ET an unusually large $234.32K block of Call contracts in Ambev S.A (ABEV) was bought, with a strike price of $2.50 / share, expiring in 288 days (on January 19, 2024). Fintel tracks all large options trades, and the premium spent on this trade was 3.82 sigmas above the mean, placing it in the 100.00 percentile of all recent large trades made in ABEV options. Average portfolio weight of all funds dedicated to ABEV is 0.39%, a decrease of 7.78%. | On April 6, 2023 at 10:58:50 ET an unusually large $234.32K block of Call contracts in Ambev S.A (ABEV) was bought, with a strike price of $2.50 / share, expiring in 288 days (on January 19, 2024). Fintel tracks all large options trades, and the premium spent on this trade was 3.82 sigmas above the mean, placing it in the 100.00 percentile of all recent large trades made in ABEV options. Average portfolio weight of all funds dedicated to ABEV is 0.39%, a decrease of 7.78%. | On April 6, 2023 at 10:58:50 ET an unusually large $234.32K block of Call contracts in Ambev S.A (ABEV) was bought, with a strike price of $2.50 / share, expiring in 288 days (on January 19, 2024). Fintel tracks all large options trades, and the premium spent on this trade was 3.82 sigmas above the mean, placing it in the 100.00 percentile of all recent large trades made in ABEV options. Average portfolio weight of all funds dedicated to ABEV is 0.39%, a decrease of 7.78%. |
28165.0 | 2023-04-03 00:00:00 UTC | 7 Stocks to Buy as the Banking Sector Fallout Grows | ABEV | https://www.nasdaq.com/articles/7-stocks-to-buy-as-the-banking-sector-fallout-grows | nan | nan | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Although the fallout from the banking sector appears to have faded, investors still should consider stocks to buy that can weather storms. Understandably, this narrative runs counter to the apparently prevailing wisdom of the moment. For example, even legendary hedge-fund manager Michael Burry stated that he was “wrong to say sell.” Nevertheless, let’s look at the fundamentals.
While the U.S. government responded quickly and decisively to recent bank failures, here’s the deal: every action generates a reaction. For federal authorities to protect depositors suggests an inflationary framework, exactly the directive policymakers want to avoid. Besides, if government action was the correct response to every problem, why aren’t we asking the government to get involved in everything? Again, the answer is that every decision (particularly major ones) carries consequences. Essentially, we might not be out of the woods just yet. Therefore, below are the reliable or relevant stocks to buy.
KO Coca-Cola $62.40
SRE Sempra Energy $149.58
STM STMicroelectronics $52.89
VTRU Vitru $21.04
ABEV Ambev $2.81
ANDE Andersons $41.73
BG Bunge $96.66
Coca-Cola (KO)
Source: Epic Cure / Shutterstock
A business icon, beverage manufacturer Coca-Cola (NYSE:KO) symbolizes one of the brands of American free market capitalism. Just that status alone affords Coca-Cola significant social cachet, even during a potential downturn. Fundamentally, the company may benefit from the trade-down effect. Rather than purchase their caffeine fix from an overpriced café, consumers can always go to their local grocery stores and pick up a six-pack of Coke.
In terms of stability, Coca-Cola features an Altman Z-Score of 4.42, indicating low bankruptcy risk over the next two years. Also, it quietly gets the job done operationally. Its three-year revenue growth rate comes in at 4.6%, above 56.52% of the sector. As well, its book growth rate during the same period is 7.9%, above 64.13% of the competition. Perhaps most notably, Coca-Cola makes a name for itself in the profitability department. For example, its net margin pings at 22.19%, outpacing 93.46% of its peers.
Finally, Wall Street analysts peg KO as a consensus strong buy. Their average price target stands at $68.18, implying nearly 10% upside potential. Thus, it’s an intriguing case for stocks to buy.
Sempra Energy (SRE)
Source: Zurijeta / Shutterstock.com
A public utility holding firm, Sempra Energy (NYSE:SRE) is one of the largest such entities in the U.S. According to its public profile, Sempra serves nearly 40 million consumers. Given its massive reach – and the fact that utilities represent natural monopolies – SRE ranks among the stocks to buy amid banking sector concerns. That said, SRE is on a relative discount, losing almost 2% since the Jan. opener.
If that wasn’t compelling enough for speculators, SRE dipped more than 11% in the trailing year. To be fair, its financials don’t offer the greatest level of confidence. However, because Sempra serves large swathes of the economic engine known as Southern California, investors don’t have to worry as much about the print. Still, that’s not to say that Sempra can’t hold its own. For instance, its net margin pings at 14.81%.
And it benefits from consistent annual profitability. Lastly, covering analyst peg SRE as a consensus moderate buy. Their average price target comes out to $168.11, implying over 11% upside potential.
STMicroelectronics (STM)
Source: shutterstock.com/CC7
Based in Switzerland, STMicroelectronics (NYSE:STM) represents an unsung hero in the technology space. A semiconductor manufacturer, STM undergirds various innovations while staying in the background. Because of its tremendous relevance, STM easily ranks among the stocks to buy during banking troubles. Indeed, shares gained more than 51% since the Jan. opener, a simply blistering figure.
Nevertheless, STM may offer room to run. In particular, the market prices shares at a forward multiple of 12.65. As a discount to projected earnings, STM ranks better than 82.09% of the semiconductor industry. In addition, the company represents an operational powerhouse. Its three-year revenue growth rate pings at 19.1%, outpacing 68.54% of sector rivals. Further, its net margin comes in at 24.6%, blowing past 86.25% of the field. To top it off, the enterprise features an Altman Z-Score of 6.39, indicating very low bankruptcy risk.
In closing, analysts peg STM as a consensus moderate buy. Their average price target hits $61.20, implying over 14% upside potential.
Vitru (VTRU)
Source: Freedom365day / Shutterstock.com
Based in Brazil, Vitru (NASDAQ:VTRU) is the nation’s largest private education institution, per the company’s website. Given Brazil’s vast population and abundant natural resources, investing in its educational infrastructure could yield significant gains. Since the start of the year, VTRU moved up over 3%. In the trailing one-year period, it returned stakeholders 44%.
Despite its impressive performance, VTRU makes for an intriguing case for stocks to buy. Overall, the company owns a stable balance sheet. In particular, its Altman Z-Score hit triple digits. Also, its debt-to-EBITDA sits at 0.03 times, favorably below the sector median value of 2.15.
Operationally, Vitru’s three-year revenue growth rate clocks in at 21.3%, above 79.46% of its rivals. Its book growth rate during the same period pings at a lofty 37.2%. On the bottom line, Vitru’s net margin is almost 13%, above 72% of the competition. Turning to Wall Street, analyst peg VTRU as a consensus moderate buy. Their average price target stands at $27, implying nearly 19% upside potential.
Ambev (ABEV)
Source: Chompoo Suriyo / Shutterstock.com
Also based in Brazil, Ambev (NYSE:ABEV) is a powerhouse in the brewery business. Should the global economy struggle, Ambev might be an interesting idea for stocks to buy. Essentially, the stress of yet another hardship might accelerate alcohol sales due to consumers wanting to take the edge off. Notably, since the beginning of the year, ABEV gained nearly 9% of its equity value.
Against the trailing-year comparison, ABEV still has some work to do. Still, the red ink makes the beverage investment appealing to contrarians. For example, the market prices ABEV at a forward multiple of 16.38. As a discount to projected earnings, the company ranks better than 77.27% of the underlying industry. Operationally, Ambev commands a three-year revenue growth rate of 15.3%. Its book growth rate during the same period is a respectable 10.1%. Finally, its Altman Z-Score hits 3.47, indicating low bankruptcy risk.
Looking to the Street, analysts peg ABEV as a consensus moderate buy. Their average price target stands at $3.35, implying nearly 19% upside potential.
Andersons (ANDE)
Source: ImageFlow/Shutterstock.com
An American agribusiness, Andersons (NYSE:ANDE) is one of the stocks to buy for its critical relevancies. Per its corporate profile, Andersons conducts business in the commodity merchandising, renewables, and plant nutrient sectors. Not surprisingly, since the start of the year, ANDE gained nearly 22% of its equity value. However, it trades at a relative discount, down more than 17% in the past 365 days.
If you can handle choppy weather, ANDE deserves closer inspection. First, the market prices ANDE at a trailing multiple of 10.87. As a discount to earnings, Andersons ranks better than 74.57% of the competition. Second, it enjoys stability in the balance sheet, buoyed by an Altman Z-Score of 4.69.
Operationally, Andersons delivers a three-year revenue growth rate of 27.7%, an impressive performance. Also, its free cash flow (FCF) growth rate during the same period is 22%, above 66.15% of the field. Finally, analysts peg ANDE as a consensus moderate buy. Their average price target is $52.50, implying 27% upside potential.
Bunge (BG)
Source: Wright Studio/Shutterstock.com
Another agribusiness and food-focused enterprise, Bunge (NYSE:BG) deserves consideration as one of the stocks to buy for permanent relevance. No matter what happens in the economy, people have to eat. Since the start of the year, BG dipped a hair below parity. In the trailing one-year period, it gave up more than 15% of its equity value.
While that certainly sounds risky, Bunge shouldn’t be ignored because it’s also quite tempting. Perhaps most conspicuously, the market prices BG at a forward multiple of 7.99. As a discount to projected earnings, Bunge ranks better than 86.22% of the competition.
Also, the company delivers on the operational front. Its three-year revenue growth rate stands at a healthy 14.7%. As well, its book growth rate during the same period is 18.7%, outpacing nearly 83% of sector rivals. Lastly, analysts peg BG as a consensus strong buy. Their average price target stands at $123, implying nearly 29% upside potential.
On the date of publication, Josh Enomoto did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.
A former senior business analyst for Sony Electronics, Josh Enomoto has helped broker major contracts with Fortune Global 500 companies. Over the past several years, he has delivered unique, critical insights for the investment markets, as well as various other industries including legal, construction management, and healthcare.
The post 7 Stocks to Buy as the Banking Sector Fallout Grows appeared first on InvestorPlace.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | KO Coca-Cola $62.40 SRE Sempra Energy $149.58 STM STMicroelectronics $52.89 VTRU Vitru $21.04 ABEV Ambev $2.81 ANDE Andersons $41.73 BG Bunge $96.66 Coca-Cola (KO) Source: Epic Cure / Shutterstock A business icon, beverage manufacturer Coca-Cola (NYSE:KO) symbolizes one of the brands of American free market capitalism. Ambev (ABEV) Source: Chompoo Suriyo / Shutterstock.com Also based in Brazil, Ambev (NYSE:ABEV) is a powerhouse in the brewery business. Notably, since the beginning of the year, ABEV gained nearly 9% of its equity value. | KO Coca-Cola $62.40 SRE Sempra Energy $149.58 STM STMicroelectronics $52.89 VTRU Vitru $21.04 ABEV Ambev $2.81 ANDE Andersons $41.73 BG Bunge $96.66 Coca-Cola (KO) Source: Epic Cure / Shutterstock A business icon, beverage manufacturer Coca-Cola (NYSE:KO) symbolizes one of the brands of American free market capitalism. Ambev (ABEV) Source: Chompoo Suriyo / Shutterstock.com Also based in Brazil, Ambev (NYSE:ABEV) is a powerhouse in the brewery business. Notably, since the beginning of the year, ABEV gained nearly 9% of its equity value. | KO Coca-Cola $62.40 SRE Sempra Energy $149.58 STM STMicroelectronics $52.89 VTRU Vitru $21.04 ABEV Ambev $2.81 ANDE Andersons $41.73 BG Bunge $96.66 Coca-Cola (KO) Source: Epic Cure / Shutterstock A business icon, beverage manufacturer Coca-Cola (NYSE:KO) symbolizes one of the brands of American free market capitalism. Ambev (ABEV) Source: Chompoo Suriyo / Shutterstock.com Also based in Brazil, Ambev (NYSE:ABEV) is a powerhouse in the brewery business. Notably, since the beginning of the year, ABEV gained nearly 9% of its equity value. | KO Coca-Cola $62.40 SRE Sempra Energy $149.58 STM STMicroelectronics $52.89 VTRU Vitru $21.04 ABEV Ambev $2.81 ANDE Andersons $41.73 BG Bunge $96.66 Coca-Cola (KO) Source: Epic Cure / Shutterstock A business icon, beverage manufacturer Coca-Cola (NYSE:KO) symbolizes one of the brands of American free market capitalism. Ambev (ABEV) Source: Chompoo Suriyo / Shutterstock.com Also based in Brazil, Ambev (NYSE:ABEV) is a powerhouse in the brewery business. Notably, since the beginning of the year, ABEV gained nearly 9% of its equity value. |
28166.0 | 2023-04-02 00:00:00 UTC | Guru Fundamental Report for ABEV - Martin Zweig | ABEV | https://www.nasdaq.com/articles/guru-fundamental-report-for-abev-martin-zweig | nan | nan | Below is Validea's guru fundamental report for AMBEV SA (ADR) (ABEV). Of the 22 guru strategies we follow, ABEV rates highest using our Growth Investor model based on the published strategy of Martin Zweig. This strategy looks for growth stocks with persistent accelerating earnings and sales growth, reasonable valuations and low debt.
AMBEV SA (ADR) (ABEV) is a large-cap growth stock in the Beverages (Alcoholic) industry. The rating using this strategy is 69% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E RATIO: PASS
REVENUE GROWTH IN RELATION TO EPS GROWTH: PASS
SALES GROWTH RATE: FAIL
CURRENT QUARTER EARNINGS: PASS
QUARTERLY EARNINGS ONE YEAR AGO: PASS
POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: PASS
EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: FAIL
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: PASS
EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: PASS
EARNINGS PERSISTENCE: PASS
LONG-TERM EPS GROWTH: FAIL
TOTAL DEBT/EQUITY RATIO: PASS
INSIDER TRANSACTIONS: PASS
Detailed Analysis of AMBEV SA (ADR)
ABEV Guru Analysis
ABEV Fundamental Analysis
More Information on Martin Zweig
Martin Zweig Portfolio
About Martin Zweig: During the 15 years that it was monitored, Zweig's stock recommendation newsletter returned an average of 15.9 percent per year, during which time it was ranked number one based on risk-adjusted returns by Hulbert Financial Digest. Zweig has managed both mutual and hedge funds during his career, and he's put the fortune he's compiled to some interesting uses. He has owned what Forbes reported was the most expensive apartment in New York, a $70 million penthouse that sits atop Manhattan's Pierre Hotel, and he is a collector of all sorts of pop culture and historical memorabilia -- among his purchases are the gun used by Clint Eastwood in "Dirty Harry", a stock certificate signed by Commodore Vanderbilt, and even two old-fashioned gas pumps similar to those he'd seen at a nearby gas station while growing up in Cleveland, according to published reports.
Additional Research Links
Factor-Based Stock Portfolios
Factor-Based ETF Portfolios
Harry Browne Permanent Portfolio
Ray Dalio All Weather Portfolio
About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | AMBEV SA (ADR) (ABEV) is a large-cap growth stock in the Beverages (Alcoholic) industry. Below is Validea's guru fundamental report for AMBEV SA (ADR) (ABEV). Of the 22 guru strategies we follow, ABEV rates highest using our Growth Investor model based on the published strategy of Martin Zweig. | Below is Validea's guru fundamental report for AMBEV SA (ADR) (ABEV). Of the 22 guru strategies we follow, ABEV rates highest using our Growth Investor model based on the published strategy of Martin Zweig. Detailed Analysis of AMBEV SA (ADR) ABEV Guru Analysis ABEV Fundamental Analysis More Information on Martin Zweig Martin Zweig Portfolio About Martin Zweig: During the 15 years that it was monitored, Zweig's stock recommendation newsletter returned an average of 15.9 percent per year, during which time it was ranked number one based on risk-adjusted returns by Hulbert Financial Digest. | Of the 22 guru strategies we follow, ABEV rates highest using our Growth Investor model based on the published strategy of Martin Zweig. Detailed Analysis of AMBEV SA (ADR) ABEV Guru Analysis ABEV Fundamental Analysis More Information on Martin Zweig Martin Zweig Portfolio About Martin Zweig: During the 15 years that it was monitored, Zweig's stock recommendation newsletter returned an average of 15.9 percent per year, during which time it was ranked number one based on risk-adjusted returns by Hulbert Financial Digest. Below is Validea's guru fundamental report for AMBEV SA (ADR) (ABEV). | Below is Validea's guru fundamental report for AMBEV SA (ADR) (ABEV). Of the 22 guru strategies we follow, ABEV rates highest using our Growth Investor model based on the published strategy of Martin Zweig. AMBEV SA (ADR) (ABEV) is a large-cap growth stock in the Beverages (Alcoholic) industry. |
28167.0 | 2023-03-23 00:00:00 UTC | 7 Strong Buy Stocks Under $10 to Snap Up Now | ABEV | https://www.nasdaq.com/articles/7-strong-buy-stocks-under-%2410-to-snap-up-now | nan | nan | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Investors looking for a bargain and potential upside have strong buy stocks under $10 to consider. Investors should snap up companies that have value without sacrificing quality or growth.
A stock may trade at a deep discount because sellers are dumping it at the same time. A company’s quality does not change when the stock price falls to $10 or less.
Mutual fund managers may avoid stocks at that price. This gives retail investors an advantage. We may snap up those companies and wait for the stock market to recognize their worth.
For example, the market may not recognize its profit margin. The balance sheet may have favorably low debt/equity, all of those metrics matter to the investor. When the economy rebounds, those companies will post strong results sooner than their peers.
ABEV Ambev $2.64
ERIC Ericsson $5.38
HIMX Himax Technologies $7.86
NOK Nokia $4.64
PBI Pitney Bowes $3.75
SIRI Sirius XM Holdings $3.72
TEVA Teva Pharmaceutical $8.84
Ambev (ABEV)
Source: rafapress / Shutterstock.com
Ambev (NYSE:ABEV) is a Brazilian brewing company. In the last quarter, it reported revenue growing by 3.3%.
Looking ahead, Ambev expects net revenue will grow from net revenue per hectoliter performance to volumes. Profits should rise as the brewer contains input costs, thanks mostly to hedges.
Ambev will drive its growth by spending on marketing efforts. For example, it will promote its premium brands in Canada. Chief Financial Officer Lucas Lira said that the industry declined in the last few years, yet Ambev’s market share grew.
The company is betting that Beyond Beer will resonate with customers. Despite a weak performance in that brand last year, it saw a slight recovery toward the end of 2022. Expect momentum to speed up from there as advertisements drive demand higher.
In Q4/2022, Ambev set higher prices for its beers. For 2023, it will benefit from the resilient demand. Further efforts to reconnect with customers after the Covid pandemic will strengthen sales volumes.
Ericsson (ERIC)
Source: rafapress / Shutterstock.com
Ericsson (NASDAQ:ERIC) fell slightly after paying a $206.7 million fine to the U.S. Department of Justice.
In 2019, the company violated the Foreign Corrupt Practices Act. The firm pleaded guilty regarding previously deferred charges. Though the amount could have been higher, investors did not get behind ERIC stock by bidding shares higher.
The beaten-down company is transforming its culture and its business efficiency. It has visibility on customer demand, project rollouts, and its cost situation. CFO Carl Mellander said that the company is confident that it will meet project targets this quarter.
It is controlling costs. Reuters reported that according to a memo, it will cut 8,500 staff. The move aligns with its plans announced in Dec. 2022 to lower costs by $880 million by the end of this year.
Ericsson’s profit margins might rise from around 40%. It will depend on the size of its inventory adjustment this quarter. Expect modest write-downs in each of the next two quarters, which may hold the stock back. After that, when the macro-environment improves in around six months, profitability will rise.
Himax Technologies (HIMX)
Source: Mamat Suryadi / Shutterstock
Himax Technologies (NASDAQ:HIMX) is a sensor developer. HIMX stock dipped slightly after it posted a 42% drop in revenue to $262.2 million.
The firm also guided its revenue range to a 12% to 17% Q/Q decline. Q1 is a seasonally weak period for Himax. After that slow quarter, its business will re-accelerate.
CEO Jordan Wu discussed the large-sized driver integrated circuit demand weakness. He said that automotive exposure is nothing new.
It hurt results for a few quarters as the industry managed through the supply chain disruption. The sudden stop in output for components in China hurt its results in the last quarter. Fortunately, China ended its Covid lockdown in late 2022.
Demand for in-cell Touch and Display Driver Integration (TDDI) single-chip solutions appear promising. This is a relatively new product that new automobiles require, especially in the electric vehicle market. Thanks to more EV models coming to market, Himax has a winning revenue growth catalyst with TDDI.
Nokia (NOK)
Source: rafapress / Shutterstock.com
Nokia (NYSE:NOK) is a long-forgotten wireless phone supplier from nearly two decades ago.
Today, it is pivoting as the largest 5G network company. While its logo update will not catch investor attention, its many contracts win in wireless networking hardware will.
On Feb. 22, Nokia won a 10-year 5G deal with Antina in Singapore. The press release included no financial terms. However, the contract shows that customers are confident in Nokia as a long-term supplier. Nokia supplies premium 5G solutions that expand Antina’s coverage and capacity. The demand for low latency and high-speed wireless will keep growing.
Nokia announced that along with its partners NTT Docomo and NTT achieved a technology milestone. The companies paired an AI-based learning waveform in a transmitter with a deep-learning receiver. This sets a 6G path where the radios will learn and use the sub-terahertz spectrum. Nokia could become a leader in boosting network capacity in the 6G space.
Pitney Bowes (PBI)
Source: JHVEPhoto / Shutterstock.com
Pitney Bowes (NYSE:PBI) supplies mailing solutions. This includes mail sorting and tracking products like Presort. Presort offers marketing mail and bounding for customers.
Pitney’s SendTech is a digital sending technology that will grow in shipping revenue. In North America, it, along with new products, accounts for 40% of revenue. The company applies the Internet of Things to streamline postal services.
PBI stock is trending lower since its Q4/2022 report. The company posted a 7.6% drop in revenue. In 2023, Pitney Bowes expects revenue growth in the flat to mid-single-digit percentage. Investors are cautious about buying shares in a company that may not grow.
To increase its operating efficiency, the company divested Borderfree recently. Although it could have developed its global business, the sale forces the company to focus on its strengths. It will offset the slowdown in the mail business by expanding its shipping revenue.
SendTech and Presort are hardware products that will turn the company around.
Sirius XM Holdings (SIRI)
Source: Shutterstock
Sirius XM Holdings (NASDAQ:SIRI) is a streaming broadcasting company. SIRI stock lost nearly half its value after failing to hold the $6.00 level.
In an SEC filing, the firm disclosed it cut 8% of its workforce. It cut costs further by lowering its spending on content and marketing. In addition, it reduced its real estate footprint, which will save the company on lease and rental costs.
Sirius XM subscription growth is the biggest revenue opportunity. Chief Executive Officer Jennifer Witz said that it accumulated 32 million paying subscribers. It attracted them through the automotive funnel. Automotive buyers know all too well that their AM/FM radio has a Sirius XM preview channel. As a result, drivers upgrade to a paid, premium version.
CarPlay and Android Auto seek to build from a near-zero market share. Fortunately, Sirius is a dominant provider that can adjust its pricing and content mix to compete effectively.
Estimate a potential adult audience of around 55 million listeners, and Sirius might win their business as its service develops.
Sirius is among the strong buy stocks under $10.
Teva Pharmaceutical (TEVA)
Source: JHVEPhoto / Shutterstock.com
Teva Pharmaceutical (NYSE:TEVA) is one of the strong buy stocks under $10. In just the last month, TEVA stock traded at above $10.
The generic drug manufacturer attracted selling after selling $2.49 billion in sustainability-linked notes. Strong demand for the debt allowed Teva to up-size the offering from $2.25 billion.
The debt will give Teva the finances to deliver on its growth mandate. The U.S. generics are the top priority. CFO Eli Kalif said that generic drug pricing is stabilizing. Outside of this country, ex-U.S. generics revenue is worth around $5 billion. It is a stable business with consistent margins. Teva will build this business by developing complex generics. For example, it will develop inhibitors and injectables.
The more complicated the drug, the higher the drug price and the bigger the profit margin. The market’s skepticism toward Teva is discounting the stock more than it should. Once Teva monetizes its portfolio of 16 assets of biosimilars, revenue will expand for years to come.
On the date of publication, Chris Lau did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.
Chris Lau is a contributing author for InvestorPlace.com and numerous other financial sites. Chris has over 20 years of investing experience in the stock market and runs the Do-It-Yourself Value Investing Marketplace on Seeking Alpha. He shares his stock picks so readers get actionable insight to achieve strong investment returns.
The post 7 Strong Buy Stocks Under $10 to Snap Up Now appeared first on InvestorPlace.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ABEV Ambev $2.64 ERIC Ericsson $5.38 HIMX Himax Technologies $7.86 NOK Nokia $4.64 PBI Pitney Bowes $3.75 SIRI Sirius XM Holdings $3.72 TEVA Teva Pharmaceutical $8.84 Ambev (ABEV) Source: rafapress / Shutterstock.com Ambev (NYSE:ABEV) is a Brazilian brewing company. Chief Financial Officer Lucas Lira said that the industry declined in the last few years, yet Ambev’s market share grew. Demand for in-cell Touch and Display Driver Integration (TDDI) single-chip solutions appear promising. | ABEV Ambev $2.64 ERIC Ericsson $5.38 HIMX Himax Technologies $7.86 NOK Nokia $4.64 PBI Pitney Bowes $3.75 SIRI Sirius XM Holdings $3.72 TEVA Teva Pharmaceutical $8.84 Ambev (ABEV) Source: rafapress / Shutterstock.com Ambev (NYSE:ABEV) is a Brazilian brewing company. Pitney Bowes (PBI) Source: JHVEPhoto / Shutterstock.com Pitney Bowes (NYSE:PBI) supplies mailing solutions. Sirius XM Holdings (SIRI) Source: Shutterstock Sirius XM Holdings (NASDAQ:SIRI) is a streaming broadcasting company. | ABEV Ambev $2.64 ERIC Ericsson $5.38 HIMX Himax Technologies $7.86 NOK Nokia $4.64 PBI Pitney Bowes $3.75 SIRI Sirius XM Holdings $3.72 TEVA Teva Pharmaceutical $8.84 Ambev (ABEV) Source: rafapress / Shutterstock.com Ambev (NYSE:ABEV) is a Brazilian brewing company. InvestorPlace - Stock Market News, Stock Advice & Trading Tips Investors looking for a bargain and potential upside have strong buy stocks under $10 to consider. Teva Pharmaceutical (TEVA) Source: JHVEPhoto / Shutterstock.com Teva Pharmaceutical (NYSE:TEVA) is one of the strong buy stocks under $10. | ABEV Ambev $2.64 ERIC Ericsson $5.38 HIMX Himax Technologies $7.86 NOK Nokia $4.64 PBI Pitney Bowes $3.75 SIRI Sirius XM Holdings $3.72 TEVA Teva Pharmaceutical $8.84 Ambev (ABEV) Source: rafapress / Shutterstock.com Ambev (NYSE:ABEV) is a Brazilian brewing company. In the last quarter, it reported revenue growing by 3.3%. Nokia supplies premium 5G solutions that expand Antina’s coverage and capacity. |
28168.0 | 2023-03-03 00:00:00 UTC | Validea Peter Lynch Strategy Daily Upgrade Report - 3/3/2023 | ABEV | https://www.nasdaq.com/articles/validea-peter-lynch-strategy-daily-upgrade-report-3-3-2023 | nan | nan | The following are today's upgrades for Validea's P/E/Growth Investor model based on the published strategy of Peter Lynch. This strategy looks for stocks trading at a reasonable price relative to earnings growth that also possess strong balance sheets.
DIME COMMUNITY BANCSHARES INC (DCOM) is a small-cap value stock in the Money Center Banks industry. The rating according to our strategy based on Peter Lynch changed from 83% to 93% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Dime Community Bancshares, Inc. is a holding company for Dime Community Bank. It is primarily engaged in commercial banking and financial services. The Bank provides deposit and loan products and financial services to local businesses, consumers, and municipalities. It offers insurance services, financial planning, and investment consultation. It provides business banking solutions, which includes checking and savings, such as business checking and business savings; account services, such as mobile banking, online banking and bill pay, professional services, merchant services, and treasury management, and other services, such as municipal banking, foreign exchange, and business credit cards. Its commercial lending includes commercial term loans, construction loans, commercial lines of credit, letters of credit and commercial property, such as commercial mortgages, and multifamily and mixed-use property loans. It provides safe deposit boxes and consumer credit cards.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: NEUTRAL
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: NEUTRAL
EQUITY/ASSETS RATIO: PASS
RETURN ON ASSETS: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
Detailed Analysis of DIME COMMUNITY BANCSHARES INC
DCOM Guru Analysis
DCOM Fundamental Analysis
CADENCE BANK (CADE) is a mid-cap value stock in the Money Center Banks industry. The rating according to our strategy based on Peter Lynch changed from 0% to 81% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Cadence Bank (the Bank) is a regional banking franchise with approximately 400 branch locations across the South and Texas. The Bank provides consumers, businesses, and corporations with a range of banking and financial solutions. The Bank's services and products include consumer banking, consumer loans, mortgages, home equity lines and loans, credit cards, commercial and business banking, treasury management, specialized lending, asset-based lending, commercial real estate, equipment financing, correspondent banking, small business administration (SBA) lending, foreign exchange, wealth management, investment and trust services, financial planning, retirement plan management, and personal and business insurance. The Bank offers baking solution in checking accounts, savings accounts, mortgages, investment management, credit cards, online and mobile banking, debit cards, treasury management, wealth management, trusts, business loans, business online banking, and merchant services.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
SALES: PASS
YIELD COMPARED TO THE S&P 500: PASS
YIELD ADJUSTED P/E/GROWTH (PEG) RATIO: PASS
TOTAL DEBT/EQUITY RATIO: NEUTRAL
EQUITY/ASSETS RATIO: PASS
RETURN ON ASSETS: FAIL
Detailed Analysis of CADENCE BANK
CADE Guru Analysis
CADE Fundamental Analysis
AMBEV SA (ADR) (ABEV) is a large-cap value stock in the Beverages (Alcoholic) industry. The rating according to our strategy based on Peter Lynch changed from 0% to 91% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Ambev SA, formerly Inbev Participacoes Societarias SA, is a Brazil-based company engaged in the brewing sector. The Company produces, distributes and sells beer, carbonated soft drinks (CSDs) and other non-alcoholic and non-carbonated (NANC) beverages across the Americas. The Company's activities are divided into three segments: Latin America North, including sell of beer, CSD and NANC drinks in Brazil, as well as operations in the Dominican Republic, Saint Vincent, Antigua, Dominica, Cuba, Guatemala, El Salvador, Honduras, Nicaragua, Barbados and Panama; Latin America South, distributing products in Argentina, Bolivia, Paraguay, Uruguay, Chile; and Canada, represented by Labatt's operations, which comprises sales in Canada and some exports to the U.S. market. The Company markets products under various brand names, such as Adriatica, Brahma, Leffe, Budweiser, Corona, PepsiCo and Lipton. It is a subsidiary of Interbrew International BV.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
SALES: PASS
INVENTORY TO SALES: PASS
YIELD COMPARED TO THE S&P 500: PASS
YIELD ADJUSTED P/E/GROWTH (PEG) RATIO: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
Detailed Analysis of AMBEV SA (ADR)
ABEV Guru Analysis
ABEV Fundamental Analysis
BIG 5 SPORTING GOODS CORP (BGFV) is a small-cap value stock in the Retail (Specialty) industry. The rating according to our strategy based on Peter Lynch changed from 74% to 93% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Big 5 Sporting Goods Corporation is a sporting goods retailer in the western United States. The Company conducts its business through its subsidiary, Big 5 Corp. The Company is operating approximately 431 stores and an e-commerce platform under the Big 5 Sporting Goods name. It provides a full-line product offering in a traditional sporting goods store format that averages approximately 11,000 square feet. Its product mix includes athletic shoes, apparel and accessories, as well as a broad selection of outdoor and athletic equipment for team sports, fitness, camping, hunting, fishing, home recreation, tennis, golf, and winter and summer recreation. Its stores include a range of products from various brand name manufacturers, including adidas, Coleman, Columbia, Everlast, New Balance, Timex, Nike, Rawlings, Skechers, Spalding, Under Armour and Wilson. The Company conducts its gift card operations through Big 5 Services Corp., a subsidiary of Big 5 Corp.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
P/E/GROWTH RATIO: PASS
SALES AND P/E RATIO: NEUTRAL
EPS GROWTH RATE: PASS
TOTAL DEBT/EQUITY RATIO: PASS
FREE CASH FLOW: NEUTRAL
NET CASH POSITION: NEUTRAL
Detailed Analysis of BIG 5 SPORTING GOODS CORP
BGFV Guru Analysis
BGFV Fundamental Analysis
BOK FINANCIAL CORP (BOKF) is a mid-cap value stock in the Money Center Banks industry. The rating according to our strategy based on Peter Lynch changed from 72% to 76% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: BOK Financial Corporation is a financial holding company of BOKF, NA (the Bank). The Bank operates TransFund, Cavanal Hill Investment Management and BOK Financial Asset Management, Inc. The Bank operates banking divisions across eight states: Bank of Albuquerque, Bank of Oklahoma, Bank of Texas and BOK Financial in Arizona, Arkansas, Colorado, Kansas and Missouri. It operates three principal businesses: Commercial Banking, Consumer Banking and Wealth Management. Commercial Banking includes lending, treasury and cash management services and customer commodity risk management products for small businesses, middle market and larger commercial customers. Consumer Banking includes retail lending and deposit services, lending and deposit services to small business customers served through the retail branch network and all mortgage loan origination and servicing activities. Wealth Management engages in brokerage and trading activities, related to providing liquidity to the mortgage markets.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
YIELD ADJUSTED P/E TO GROWTH (PEG) RATIO: PASS
EARNINGS PER SHARE: PASS
TOTAL DEBT/EQUITY RATIO: NEUTRAL
EQUITY/ASSETS RATIO: PASS
RETURN ON ASSETS: PASS
FREE CASH FLOW: BONUS PASS
NET CASH POSITION: NEUTRAL
Detailed Analysis of BOK FINANCIAL CORP
BOKF Guru Analysis
BOKF Fundamental Analysis
Peter Lynch Portfolio
Top Peter Lynch Stocks
About Peter Lynch: Perhaps the greatest mutual fund manager of all-time, Lynch guided Fidelity Investment's Magellan Fund to a 29.2 percent average annual return from 1977 until his retirement in 1990, almost doubling the S&P 500's 15.8 percent yearly return over that time. Lynch's common sense approach and quick wit made him one of the most quoted investors on Wall Street. ("Go for a business that any idiot can run -- because sooner or later, any idiot probably is going to run it," is one of his many pearls of wisdom.) Lynch's bestseller One Up on Wall Street is something of a "stocks for the everyman/everywoman", breaking his approach down into easy-to-understand concepts.
About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Detailed Analysis of CADENCE BANK CADE Guru Analysis CADE Fundamental Analysis AMBEV SA (ADR) (ABEV) is a large-cap value stock in the Beverages (Alcoholic) industry. Detailed Analysis of AMBEV SA (ADR) ABEV Guru Analysis ABEV Fundamental Analysis BIG 5 SPORTING GOODS CORP (BGFV) is a small-cap value stock in the Retail (Specialty) industry. The Company produces, distributes and sells beer, carbonated soft drinks (CSDs) and other non-alcoholic and non-carbonated (NANC) beverages across the Americas. | Detailed Analysis of CADENCE BANK CADE Guru Analysis CADE Fundamental Analysis AMBEV SA (ADR) (ABEV) is a large-cap value stock in the Beverages (Alcoholic) industry. Detailed Analysis of AMBEV SA (ADR) ABEV Guru Analysis ABEV Fundamental Analysis BIG 5 SPORTING GOODS CORP (BGFV) is a small-cap value stock in the Retail (Specialty) industry. The Bank's services and products include consumer banking, consumer loans, mortgages, home equity lines and loans, credit cards, commercial and business banking, treasury management, specialized lending, asset-based lending, commercial real estate, equipment financing, correspondent banking, small business administration (SBA) lending, foreign exchange, wealth management, investment and trust services, financial planning, retirement plan management, and personal and business insurance. | Detailed Analysis of CADENCE BANK CADE Guru Analysis CADE Fundamental Analysis AMBEV SA (ADR) (ABEV) is a large-cap value stock in the Beverages (Alcoholic) industry. Detailed Analysis of AMBEV SA (ADR) ABEV Guru Analysis ABEV Fundamental Analysis BIG 5 SPORTING GOODS CORP (BGFV) is a small-cap value stock in the Retail (Specialty) industry. It provides business banking solutions, which includes checking and savings, such as business checking and business savings; account services, such as mobile banking, online banking and bill pay, professional services, merchant services, and treasury management, and other services, such as municipal banking, foreign exchange, and business credit cards. | Detailed Analysis of CADENCE BANK CADE Guru Analysis CADE Fundamental Analysis AMBEV SA (ADR) (ABEV) is a large-cap value stock in the Beverages (Alcoholic) industry. Detailed Analysis of AMBEV SA (ADR) ABEV Guru Analysis ABEV Fundamental Analysis BIG 5 SPORTING GOODS CORP (BGFV) is a small-cap value stock in the Retail (Specialty) industry. The following are today's upgrades for Validea's P/E/Growth Investor model based on the published strategy of Peter Lynch. |
28169.0 | 2023-02-14 00:00:00 UTC | After Hours Most Active for Feb 14, 2023 : ITUB, EQRX, ABNB, CSCO, AAPL, FOLD, ABEV, CSX, NU, C, SM, HPQ | ABEV | https://www.nasdaq.com/articles/after-hours-most-active-for-feb-14-2023-%3A-itub-eqrx-abnb-csco-aapl-fold-abev-csx-nu-c-sm | nan | nan | The NASDAQ 100 After Hours Indicator is down -11.5 to 12,579.39. The total After hours volume is currently 97,460,979 shares traded.
The following are the most active stocks for the after hours session:
Itau Unibanco Banco Holding SA (ITUB) is unchanged at $5.05, with 11,024,880 shares traded. As reported by Zacks, the current mean recommendation for ITUB is in the "buy range".
EQRx, Inc. (EQRX) is unchanged at $2.28, with 3,863,981 shares traded. EQRX's current last sale is 55.61% of the target price of $4.1.
Airbnb, Inc. (ABNB) is +10.94 at $131.81, with 3,491,515 shares traded. ABNB's current last sale is 100.62% of the target price of $131.
Cisco Systems, Inc. (CSCO) is -0.11 at $47.59, with 2,533,635 shares traded.CSCO is scheduled to provide an earnings report on 2/15/2023, for the fiscal quarter ending Jan2023. The consensus earnings per share forecast is 0.76 per share, which represents a 77 percent increase over the EPS one Year Ago
Apple Inc. (AAPL) is -0.07 at $153.13, with 2,529,702 shares traded. Over the last four weeks they have had 3 up revisions for the earnings forecast, for the fiscal quarter ending Sep 2023. The consensus EPS forecast is $1.43. As reported by Zacks, the current mean recommendation for AAPL is in the "buy range".
Amicus Therapeutics, Inc. (FOLD) is +0.01 at $12.50, with 2,448,729 shares traded. As reported in the last short interest update the days to cover for FOLD is 8.355472; this calculation is based on the average trading volume of the stock.
Ambev S.A. (ABEV) is +0.005 at $2.49, with 2,221,820 shares traded. As reported by Zacks, the current mean recommendation for ABEV is in the "buy range".
CSX Corporation (CSX) is -0.01 at $31.43, with 2,123,916 shares traded. CSX's current last sale is 89.8% of the target price of $35.
Nu Holdings Ltd. (NU) is +0.39 at $5.39, with 2,069,424 shares traded. As reported by Zacks, the current mean recommendation for NU is in the "buy range".
Citigroup Inc. (C) is unchanged at $51.61, with 1,983,253 shares traded. Over the last four weeks they have had 5 up revisions for the earnings forecast, for the fiscal quarter ending Mar 2023. The consensus EPS forecast is $1.68. C's current last sale is 97.38% of the target price of $53.
SM Energy Company (SM) is +0.01 at $33.43, with 1,235,965 shares traded. SM's current last sale is 65.55% of the target price of $51.
HP Inc. (HPQ) is unchanged at $30.40, with 1,223,576 shares traded. HPQ's current last sale is 104.83% of the target price of $29.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Ambev S.A. (ABEV) is +0.005 at $2.49, with 2,221,820 shares traded. As reported by Zacks, the current mean recommendation for ABEV is in the "buy range". Itau Unibanco Banco Holding SA (ITUB) is unchanged at $5.05, with 11,024,880 shares traded. | Ambev S.A. (ABEV) is +0.005 at $2.49, with 2,221,820 shares traded. As reported by Zacks, the current mean recommendation for ABEV is in the "buy range". The total After hours volume is currently 97,460,979 shares traded. | Ambev S.A. (ABEV) is +0.005 at $2.49, with 2,221,820 shares traded. As reported by Zacks, the current mean recommendation for ABEV is in the "buy range". The total After hours volume is currently 97,460,979 shares traded. | Ambev S.A. (ABEV) is +0.005 at $2.49, with 2,221,820 shares traded. As reported by Zacks, the current mean recommendation for ABEV is in the "buy range". ABNB's current last sale is 100.62% of the target price of $131. |
28170.0 | 2023-02-14 00:00:00 UTC | 1 Stock That Could Be Weighing Down Your Portfolio | ABEV | https://www.nasdaq.com/articles/1-stock-that-could-be-weighing-down-your-portfolio | nan | nan | There's no denying its long history as a blue chip name. Its products are sold all over the world and have been for the past several decades. Right now and for the foreseeable future though, Ambev S.A. (NYSE: ABEV) -- you may know it better as the parent to beer company Anheuser-Busch -- could prove a tough stock to stick with.
That's the takeaway from recent and forward-looking data regarding the beer industry anyway, underscored by Ambev's slowing growth and increasing pressure on its profit margins.
Beer headwinds are blowing
Don't misunderstand: The beer business is hardly dying. It's not exactly thriving at this time, either. The Brewers Association reports beer sales (revenue but not necessarily volume) in the United States were up a modest 1% in 2022.
And that was before price hikes went into effect late in the year. Nielsen and Bump Williams Consulting report the nation's beer headwinds turned more brisk in the final weeks of 2022 with sales volumes falling after prices finally pushed many consumers to explore other beverage options. Let's presume the rest of the world is feeling similar pain.
Things should start improving this year but only slightly. Most outlooks for the beer business call for forward-looking sales growth rates in the low single digits, though that still doesn't guarantee earnings growth. As Just Drinks' deputy editor James Beeson predicts, the industry should see "spot prices peak" in 2023 while "inflationary headwinds" are likely to persist.
The ultimate end result? The continued waning of brand loyalty and/or trading down due to price.
To its credit, Ambev is responding to the new dynamic. During its third-quarter conference call, management made repeated mention of ensuring "great price execution with the right SKUs at the right price."
There aren't too many details about what that exactly means, however, nor does it ensure the brewer's measures will prove effective. Anheuser-Busch is the biggest beer company in the world, and it got that way by brewing in bulk and bottling (or canning) the same product in the same way over and over again. Even merely tweaking this approach is no easy task when an operation is as enormous as this one.
The analyst community isn't exactly optimistic, either. Although these professionals do rate its stock at a little better than a hold and collectively deem shares are worth roughly 40% more than their present prices, these same analysts don't believe Ambev S.A. is apt to restore and then start growing its bottom line again until well into next year. Some of the beer giant's current customers may find a competing product they like better before then, prompting new and unexpected pressures on profit margins.
Data source: Thomson Reuters. Chart by author. All data is in Brazilian real. Revenue figures are in millions.
And of course, this rekindled profit growth is also predicated on the assumption that revenue will grow as expected and brewing costs will be contained. That may not be the way things pan out, though. Again, as Just Drinks' Beeson notes, brewing costs are still high, and consumers are still looking to lower their bar tabs.
Not enough reward (compared to risk) for newcomers
Does this make Ambev a holding you absolutely must sell if you currently own it? No. Much of the prospective damage has already been done. Shares are already back to multiyear lows, and while the beer market itself isn't firing on all cylinders, it's a highly cyclical one. Beer drinkers are apt to come back around again as tastes and the economic backdrop change.
This company's a solid, dividend-paying cash cow in the meantime, sporting a current yield of 5.9%. Not bad.
If you're on the fence about holding it or buying it, though, the foreseeable future could be tough. The stock's recent decline is the market's way of saying it sees more headwinds on the horizon. Even if dividend income is your goal, there are better options out there right now.
10 stocks we like better than Ambev
When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now... and Ambev wasn't one of them! That's right -- they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of February 8, 2023
James Brumley has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Right now and for the foreseeable future though, Ambev S.A. (NYSE: ABEV) -- you may know it better as the parent to beer company Anheuser-Busch -- could prove a tough stock to stick with. That's the takeaway from recent and forward-looking data regarding the beer industry anyway, underscored by Ambev's slowing growth and increasing pressure on its profit margins. As Just Drinks' deputy editor James Beeson predicts, the industry should see "spot prices peak" in 2023 while "inflationary headwinds" are likely to persist. | Right now and for the foreseeable future though, Ambev S.A. (NYSE: ABEV) -- you may know it better as the parent to beer company Anheuser-Busch -- could prove a tough stock to stick with. That's the takeaway from recent and forward-looking data regarding the beer industry anyway, underscored by Ambev's slowing growth and increasing pressure on its profit margins. The Brewers Association reports beer sales (revenue but not necessarily volume) in the United States were up a modest 1% in 2022. | Right now and for the foreseeable future though, Ambev S.A. (NYSE: ABEV) -- you may know it better as the parent to beer company Anheuser-Busch -- could prove a tough stock to stick with. Although these professionals do rate its stock at a little better than a hold and collectively deem shares are worth roughly 40% more than their present prices, these same analysts don't believe Ambev S.A. is apt to restore and then start growing its bottom line again until well into next year. See the 10 stocks *Stock Advisor returns as of February 8, 2023 James Brumley has no position in any of the stocks mentioned. | Right now and for the foreseeable future though, Ambev S.A. (NYSE: ABEV) -- you may know it better as the parent to beer company Anheuser-Busch -- could prove a tough stock to stick with. That's the takeaway from recent and forward-looking data regarding the beer industry anyway, underscored by Ambev's slowing growth and increasing pressure on its profit margins. The Brewers Association reports beer sales (revenue but not necessarily volume) in the United States were up a modest 1% in 2022. |
28171.0 | 2023-02-09 00:00:00 UTC | After Hours Most Active for Feb 9, 2023 : ABEV, PBR, LYFT, INTC, CLVT, MSFT, SNAP, AAPL, GOOGL, AMZN, GMED, T | ABEV | https://www.nasdaq.com/articles/after-hours-most-active-for-feb-9-2023-%3A-abev-pbr-lyft-intc-clvt-msft-snap-aapl-googl-amzn | nan | nan | The NASDAQ 100 After Hours Indicator is up 8.2 to 12,389.37. The total After hours volume is currently 94,068,895 shares traded.
The following are the most active stocks for the after hours session:
Ambev S.A. (ABEV) is unchanged at $2.45, with 8,453,049 shares traded. As reported by Zacks, the current mean recommendation for ABEV is in the "buy range".
Petroleo Brasileiro S.A.- Petrobras (PBR) is +0.07 at $11.12, with 7,285,611 shares traded. PBR's current last sale is 92.67% of the target price of $12.
Lyft, Inc. (LYFT) is -3.88 at $12.34, with 5,895,349 shares traded. Smarter Analyst Reports: Elastic Continues to Dip Despite Excellent Q2 Results
Intel Corporation (INTC) is unchanged at $27.73, with 4,431,891 shares traded. INTC's current last sale is 99.04% of the target price of $28.
Clarivate Plc (CLVT) is +0.015 at $10.92, with 3,771,434 shares traded. As reported by Zacks, the current mean recommendation for CLVT is in the "buy range".
Microsoft Corporation (MSFT) is -0.12 at $263.50, with 3,664,704 shares traded. Over the last four weeks they have had 3 up revisions for the earnings forecast, for the fiscal quarter ending Sep 2023. The consensus EPS forecast is $2.55. As reported by Zacks, the current mean recommendation for MSFT is in the "buy range".
Snap Inc. (SNAP) is +0.03 at $11.01, with 3,081,104 shares traded. SNAP's current last sale is 110.1% of the target price of $10.
Apple Inc. (AAPL) is -0.08 at $150.79, with 2,982,691 shares traded. Over the last four weeks they have had 3 up revisions for the earnings forecast, for the fiscal quarter ending Sep 2023. The consensus EPS forecast is $1.43. As reported by Zacks, the current mean recommendation for AAPL is in the "buy range".
Alphabet Inc. (GOOGL) is +0.27 at $95.28, with 2,435,692 shares traded. Over the last four weeks they have had 4 up revisions for the earnings forecast, for the fiscal quarter ending Jun 2023. The consensus EPS forecast is $1.25. As reported by Zacks, the current mean recommendation for GOOGL is in the "buy range".
Amazon.com, Inc. (AMZN) is -0.05 at $98.19, with 2,200,623 shares traded. Over the last four weeks they have had 4 up revisions for the earnings forecast, for the fiscal quarter ending Jun 2023. The consensus EPS forecast is $0.29. As reported by Zacks, the current mean recommendation for AMZN is in the "buy range".
Globus Medical, Inc. (GMED) is +0.03 at $63.00, with 1,822,029 shares traded. As reported by Zacks, the current mean recommendation for GMED is in the "buy range".
AT&T Inc. (T) is +0.02 at $18.99, with 1,319,421 shares traded. T's current last sale is 84.4% of the target price of $22.5.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Over the last four weeks they have had 3 up revisions for the earnings forecast, for the fiscal quarter ending Sep 2023. Ambev S.A. (ABEV) is unchanged at $2.45, with 8,453,049 shares traded. As reported by Zacks, the current mean recommendation for ABEV is in the "buy range". | Over the last four weeks they have had 3 up revisions for the earnings forecast, for the fiscal quarter ending Sep 2023. Ambev S.A. (ABEV) is unchanged at $2.45, with 8,453,049 shares traded. As reported by Zacks, the current mean recommendation for ABEV is in the "buy range". | Ambev S.A. (ABEV) is unchanged at $2.45, with 8,453,049 shares traded. As reported by Zacks, the current mean recommendation for ABEV is in the "buy range". As reported by Zacks, the current mean recommendation for AAPL is in the "buy range". | Ambev S.A. (ABEV) is unchanged at $2.45, with 8,453,049 shares traded. As reported by Zacks, the current mean recommendation for ABEV is in the "buy range". The NASDAQ 100 After Hours Indicator is up 8.2 to 12,389.37. |
28172.0 | 2023-02-02 00:00:00 UTC | After Hours Most Active for Feb 2, 2023 : AMZN, F, QQQ, AAPL, SQQQ, TQQQ, GOOGL, ABEV, ITUB, IBN, C, WFC | ABEV | https://www.nasdaq.com/articles/after-hours-most-active-for-feb-2-2023-%3A-amzn-f-qqq-aapl-sqqq-tqqq-googl-abev-itub-ibn-c | nan | nan | The NASDAQ 100 After Hours Indicator is down -223.51 to 12,579.63. The total After hours volume is currently 129,275,042 shares traded.
The following are the most active stocks for the after hours session:
Amazon.com, Inc. (AMZN) is -4.09 at $108.82, with 12,401,708 shares traded. Over the last four weeks they have had 3 up revisions for the earnings forecast, for the fiscal quarter ending Jun 2023. The consensus EPS forecast is $0.35. Smarter Analyst Reports: Amazon Expects FTC’s Verdict on MGM Acquisition by Mid-March: Report
Ford Motor Company (F) is -0.93 at $13.39, with 7,155,507 shares traded. Smarter Analyst Reports: Ford Plans Reorganization into EV and ICE Business Units – Report
Invesco QQQ Trust, Series 1 (QQQ) is -2.84 at $308.88, with 6,635,527 shares traded. This represents a 21.48% increase from its 52 Week Low.
Apple Inc. (AAPL) is +0.18 at $151.00, with 6,289,753 shares traded. Over the last four weeks they have had 3 up revisions for the earnings forecast, for the fiscal quarter ending Dec 2022. The consensus EPS forecast is $1.93. Smarter Analyst Reports: Wednesday’s Pre-Market: Here’s What You Need to Know Before the Market Opens
ProShares UltraPro Short QQQ (SQQQ) is +0.81 at $33.82, with 5,196,677 shares traded. This represents a 8.5% increase from its 52 Week Low.
ProShares UltraPro QQQ (TQQQ) is -0.671 at $26.24, with 5,040,577 shares traded. This represents a 62.98% increase from its 52 Week Low.
Alphabet Inc. (GOOGL) is -3.7 at $104.04, with 4,722,223 shares traded. As reported by Zacks, the current mean recommendation for GOOGL is in the "buy range".
Ambev S.A. (ABEV) is -0.01 at $2.57, with 4,627,819 shares traded. As reported by Zacks, the current mean recommendation for ABEV is in the "buy range".
Itau Unibanco Banco Holding SA (ITUB) is -0.04 at $4.94, with 2,430,565 shares traded.ITUB is scheduled to provide an earnings report on 2/9/2023, for the fiscal quarter ending Dec2022. The consensus earnings per share forecast is 0.16 per share, which represents a 12 percent increase over the EPS one Year Ago
ICICI Bank Limited (IBN) is -0.06 at $20.87, with 2,020,031 shares traded. As reported by Zacks, the current mean recommendation for IBN is in the "strong buy range".
Citigroup Inc. (C) is -0.01 at $52.21, with 1,449,977 shares traded. Over the last four weeks they have had 5 up revisions for the earnings forecast, for the fiscal quarter ending Mar 2023. The consensus EPS forecast is $1.7. C's current last sale is 87.02% of the target price of $60.
Wells Fargo & Company (WFC) is -0.12 at $47.11, with 1,098,834 shares traded. Over the last four weeks they have had 6 up revisions for the earnings forecast, for the fiscal quarter ending Mar 2023. The consensus EPS forecast is $1.19. As reported by Zacks, the current mean recommendation for WFC is in the "buy range".
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Ambev S.A. (ABEV) is -0.01 at $2.57, with 4,627,819 shares traded. As reported by Zacks, the current mean recommendation for ABEV is in the "buy range". Over the last four weeks they have had 3 up revisions for the earnings forecast, for the fiscal quarter ending Jun 2023. | Ambev S.A. (ABEV) is -0.01 at $2.57, with 4,627,819 shares traded. As reported by Zacks, the current mean recommendation for ABEV is in the "buy range". Smarter Analyst Reports: Ford Plans Reorganization into EV and ICE Business Units – Report | Ambev S.A. (ABEV) is -0.01 at $2.57, with 4,627,819 shares traded. As reported by Zacks, the current mean recommendation for ABEV is in the "buy range". The total After hours volume is currently 129,275,042 shares traded. | Ambev S.A. (ABEV) is -0.01 at $2.57, with 4,627,819 shares traded. As reported by Zacks, the current mean recommendation for ABEV is in the "buy range". Amazon.com, Inc. (AMZN) is -4.09 at $108.82, with 12,401,708 shares traded. |
28173.0 | 2023-02-01 00:00:00 UTC | After Hours Most Active for Feb 1, 2023 : META, ABEV, NOG, QQQ, TQQQ, AAPL, AMZN, F, SQQQ, ITUB, TFC, SNAP | ABEV | https://www.nasdaq.com/articles/after-hours-most-active-for-feb-1-2023-%3A-meta-abev-nog-qqq-tqqq-aapl-amzn-f-sqqq-itub-tfc | nan | nan | The NASDAQ 100 After Hours Indicator is up 108.66 to 12,471.76. The total After hours volume is currently 102,668,208 shares traded.
The following are the most active stocks for the after hours session:
Meta Platforms, Inc. (META) is +27.19 at $180.31, with 10,719,344 shares traded. Over the last four weeks they have had 3 up revisions for the earnings forecast, for the fiscal quarter ending Dec 2022. The consensus EPS forecast is $2.12. As reported by Zacks, the current mean recommendation for META is in the "buy range".
Ambev S.A. (ABEV) is -0.01 at $2.58, with 4,754,377 shares traded. As reported by Zacks, the current mean recommendation for ABEV is in the "buy range".
Northern Oil and Gas, Inc. (NOG) is -0.12 at $32.81, with 4,429,412 shares traded. As reported by Zacks, the current mean recommendation for NOG is in the "buy range".
Invesco QQQ Trust, Series 1 (QQQ) is +1.98 at $302.90, with 3,830,353 shares traded. This represents a 19.13% increase from its 52 Week Low.
ProShares UltraPro QQQ (TQQQ) is +0.441 at $24.83, with 3,729,942 shares traded. This represents a 54.23% increase from its 52 Week Low.
Apple Inc. (AAPL) is -0.1 at $145.33, with 3,421,861 shares traded. Over the last four weeks they have had 3 up revisions for the earnings forecast, for the fiscal quarter ending Dec 2022. The consensus EPS forecast is $1.93. AAPL is scheduled to provide an earnings report on 2/2/2023, for the fiscal quarter ending Dec2022. The consensus earnings per share forecast is 1.93 per share, which represents a 210 percent increase over the EPS one Year Ago
Amazon.com, Inc. (AMZN) is +1.9 at $107.05, with 2,768,053 shares traded. Over the last four weeks they have had 3 up revisions for the earnings forecast, for the fiscal quarter ending Jun 2023. The consensus EPS forecast is $0.35. AMZN is scheduled to provide an earnings report on 2/2/2023, for the fiscal quarter ending Dec2022. The consensus earnings per share forecast is 0.15 per share, which represents a 139 percent increase over the EPS one Year Ago
Ford Motor Company (F) is +0.07 at $13.86, with 2,431,095 shares traded.F is scheduled to provide an earnings report on 2/2/2023, for the fiscal quarter ending Dec2022. The consensus earnings per share forecast is 0.6 per share, which represents a 26 percent increase over the EPS one Year Ago
ProShares UltraPro Short QQQ (SQQQ) is -0.73 at $36.11, with 2,351,027 shares traded. This represents a 15.84% increase from its 52 Week Low.
Itau Unibanco Banco Holding SA (ITUB) is -0.015 at $4.91, with 2,303,008 shares traded. As reported by Zacks, the current mean recommendation for ITUB is in the "buy range".
Truist Financial Corporation (TFC) is +0.3699 at $50.00, with 2,225,566 shares traded. TFC's current last sale is 95.24% of the target price of $52.5.
Snap Inc. (SNAP) is +0.13 at $10.50, with 1,997,956 shares traded. SNAP's current last sale is 105% of the target price of $10.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Ambev S.A. (ABEV) is -0.01 at $2.58, with 4,754,377 shares traded. As reported by Zacks, the current mean recommendation for ABEV is in the "buy range". AMZN is scheduled to provide an earnings report on 2/2/2023, for the fiscal quarter ending Dec2022. | Ambev S.A. (ABEV) is -0.01 at $2.58, with 4,754,377 shares traded. As reported by Zacks, the current mean recommendation for ABEV is in the "buy range". The consensus earnings per share forecast is 1.93 per share, which represents a 210 percent increase over the EPS one Year Ago | Ambev S.A. (ABEV) is -0.01 at $2.58, with 4,754,377 shares traded. As reported by Zacks, the current mean recommendation for ABEV is in the "buy range". The consensus earnings per share forecast is 1.93 per share, which represents a 210 percent increase over the EPS one Year Ago | Over the last four weeks they have had 3 up revisions for the earnings forecast, for the fiscal quarter ending Dec 2022. Ambev S.A. (ABEV) is -0.01 at $2.58, with 4,754,377 shares traded. As reported by Zacks, the current mean recommendation for ABEV is in the "buy range". |
28174.0 | 2023-01-25 00:00:00 UTC | Wednesday's ETF Movers: ILF, TAN | ABEV | https://www.nasdaq.com/articles/wednesdays-etf-movers%3A-ilf-tan | nan | nan | In trading on Wednesday, the iShares Latin America 40 ETF is outperforming other ETFs, up about 1.1% on the day. Components of that ETF showing particular strength include shares of Ambev, up about 2.3% and shares of Itau Unibanco Banco Holding, up about 2.2% on the day.
And underperforming other ETFs today is the Invesco Solar ETF, off about 3.1% in Wednesday afternoon trading. Among components of that ETF with the weakest showing on Wednesday were shares of Sunrun, lower by about 10.6%, and shares of Sunnova Energy International, lower by about 9.8% on the day.
VIDEO: Wednesday's ETF Movers: ILF, TAN
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Components of that ETF showing particular strength include shares of Ambev, up about 2.3% and shares of Itau Unibanco Banco Holding, up about 2.2% on the day. Among components of that ETF with the weakest showing on Wednesday were shares of Sunrun, lower by about 10.6%, and shares of Sunnova Energy International, lower by about 9.8% on the day. VIDEO: Wednesday's ETF Movers: ILF, TAN The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Components of that ETF showing particular strength include shares of Ambev, up about 2.3% and shares of Itau Unibanco Banco Holding, up about 2.2% on the day. Among components of that ETF with the weakest showing on Wednesday were shares of Sunrun, lower by about 10.6%, and shares of Sunnova Energy International, lower by about 9.8% on the day. VIDEO: Wednesday's ETF Movers: ILF, TAN The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In trading on Wednesday, the iShares Latin America 40 ETF is outperforming other ETFs, up about 1.1% on the day. Components of that ETF showing particular strength include shares of Ambev, up about 2.3% and shares of Itau Unibanco Banco Holding, up about 2.2% on the day. Among components of that ETF with the weakest showing on Wednesday were shares of Sunrun, lower by about 10.6%, and shares of Sunnova Energy International, lower by about 9.8% on the day. | In trading on Wednesday, the iShares Latin America 40 ETF is outperforming other ETFs, up about 1.1% on the day. Components of that ETF showing particular strength include shares of Ambev, up about 2.3% and shares of Itau Unibanco Banco Holding, up about 2.2% on the day. And underperforming other ETFs today is the Invesco Solar ETF, off about 3.1% in Wednesday afternoon trading. |
28175.0 | 2023-01-12 00:00:00 UTC | Pre-Market Most Active for Jan 12, 2023 : BBBY, TQQQ, BBAI, AAL, MMV, SQQQ, TSLA, ABEV, TSM, AMC, NIO, BBD | ABEV | https://www.nasdaq.com/articles/pre-market-most-active-for-jan-12-2023-%3A-bbby-tqqq-bbai-aal-mmv-sqqq-tsla-abev-tsm-amc-nio | nan | nan | The NASDAQ 100 Pre-Market Indicator is down -30.62 to 11,371.9. The total Pre-Market volume is currently 56,781,766 shares traded.
The following are the most active stocks for the pre-market session:
Bed Bath & Beyond Inc. (BBBY) is +0.65 at $4.14, with 13,530,741 shares traded. BBBY's current last sale is 207% of the target price of $2.
ProShares UltraPro QQQ (TQQQ) is +0.29 at $19.70, with 7,548,630 shares traded. This represents a 22.36% increase from its 52 Week Low.
BigBear.ai, Inc. (BBAI) is +1.6439 at $2.49, with 5,412,060 shares traded. BBAI's current last sale is 49.8% of the target price of $5.
American Airlines Group, Inc. (AAL) is +0.92 at $16.26, with 4,293,809 shares traded. Over the last four weeks they have had 3 up revisions for the earnings forecast, for the fiscal quarter ending Dec 2022. The consensus EPS forecast is $0.6. AAL is scheduled to provide an earnings report on 1/19/2023, for the fiscal quarter ending Dec2022. The consensus earnings per share forecast is 0.6 per share, which represents a -142 percent increase over the EPS one Year Ago
MultiMetaVerse Holdings Limited (MMV) is +0.715 at $3.35, with 3,156,403 shares traded.
ProShares UltraPro Short QQQ (SQQQ) is -0.6199 at $46.84, with 2,730,006 shares traded. This represents a 50.85% increase from its 52 Week Low.
Tesla, Inc. (TSLA) is +0.08 at $123.30, with 2,669,222 shares traded. TSLA's current last sale is 53.61% of the target price of $230.
Ambev S.A. (ABEV) is -0.08 at $2.64, with 1,272,311 shares traded. ABEV's current last sale is 88% of the target price of $3.
Taiwan Semiconductor Manufacturing Company Ltd. (TSM) is +2.77 at $84.55, with 792,127 shares traded. As reported by Zacks, the current mean recommendation for TSM is in the "buy range".
AMC Entertainment Holdings, Inc. (AMC) is -0.07 at $4.85, with 727,460 shares traded. AMC's current last sale is 242.5% of the target price of $2.
NIO Inc. (NIO) is -0.01 at $11.50, with 624,048 shares traded. As reported by Zacks, the current mean recommendation for NIO is in the "buy range".
Banco Bradesco Sa (BBD) is -0.07 at $2.89, with 610,519 shares traded. As reported by Zacks, the current mean recommendation for BBD is in the "buy range".
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Ambev S.A. (ABEV) is -0.08 at $2.64, with 1,272,311 shares traded. ABEV's current last sale is 88% of the target price of $3. Over the last four weeks they have had 3 up revisions for the earnings forecast, for the fiscal quarter ending Dec 2022. | Ambev S.A. (ABEV) is -0.08 at $2.64, with 1,272,311 shares traded. ABEV's current last sale is 88% of the target price of $3. Over the last four weeks they have had 3 up revisions for the earnings forecast, for the fiscal quarter ending Dec 2022. | Ambev S.A. (ABEV) is -0.08 at $2.64, with 1,272,311 shares traded. ABEV's current last sale is 88% of the target price of $3. The total Pre-Market volume is currently 56,781,766 shares traded. | Ambev S.A. (ABEV) is -0.08 at $2.64, with 1,272,311 shares traded. ABEV's current last sale is 88% of the target price of $3. The NASDAQ 100 Pre-Market Indicator is down -30.62 to 11,371.9. |
28176.0 | 2023-01-05 00:00:00 UTC | 7 Must-Buy Penny Stocks for Your January Buy List | ABEV | https://www.nasdaq.com/articles/7-must-buy-penny-stocks-for-your-january-buy-list | nan | nan | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Whenever a discussion of penny stocks to buy materializes, chances are, you are better off staying away than staying not-away. Here’s the deal. I’m not entirely sure if anybody quantified the average risk of this sector, considering how many such “opportunities” exist. Suffice to say, though, that most of these trades end up losing money. It’s the nature of the beast.
That said, every once in a while, you may come across penny stocks to buy that align with a few positive attributes. These could include an undervalued fiscal profile or relevant business or even sentiment based on technical analysis indicators. To be 100% clear, speculative assets commanding these characteristics don’t provide any guarantees. They just might improve your odds slightly – maybe.
To further guide the speculative portion of your portfolio toward the best course possible (relatively speaking of course), I have one major ground rule: none of these market ideas trade over the counter (yet). So, if you’re ready to roll the dice on penny stocks to buy for January, read on.
ABEV Ambev $2.64
FSI Flexible Solutions $3.18
JRSH Jerash Holdings $4.01
WIT Wipro $4.59
UGP Ultrapar $2.27
BTG B2Gold $3.79
WAFU Wah Fu Education $2.43
Ambev (ABEV)
Source: John Brueske / Shutterstock
To be upfront from the get-go, Ambev (NYSE:ABEV) only ranks among penny stocks to buy because of its current share price. At $2.61 at time of writing, ABEV appears to be a wildly speculative asset. However, you must look at the bigger picture. Commanding a market capitalization of slightly over $41 billion, this Brazilian brewery actually represents a large-cap enterprise.
However, I’m grateful that the per-share price allows me to put ABEV on this list of penny stocks to buy. At least, we can start this discussion with a reasonable market idea. For starters, ABEV outperformed countless securities in 2022. During the trailing year, Ambev shares lost less than 1% of equity value. In contrast, the U.S. equities benchmark S&P 500 fell 18% during the same period.
Currently, no analyst covers ABEV, which isn’t completely surprising given its non-U.S. background. However, hedge fund sentiment for Ambev pings as “strong” according to TipRanks. In part, that’s probably because since the fourth quarter of 2020, the company mostly beat its per-share profitability target.
Flexible Solutions (FSI)
Source: Billion Photos / Shutterstock.com
Based in Victoria, British Columbia, Flexible Solutions (NYSEAMERICAN:FSI) develops, manufactures and markets specialty chemicals which slow the evaporation of water. At time of writing, Flexible Solutions commands a market capitalization of $39 million, a more emblematic valuation for penny stocks to buy. In the trailing year, FSI lost nearly 18% of equity value.
If that didn’t scare you off, perhaps you might have the stomach for wagering on Flexible Solutions. To be fair, the company enjoys surprisingly robust financial metrics. For instance, Simplywall.st reports that FSI’s price-earnings ratio of 9.5 times sits below the U.S. market PE (14.3 times). Also, in terms of profitability, earnings grew 21.7% annually over the past five years.
Adding onto that note, the investment resource projects that earnings may grow 36.73% per year. That’s not necessarily a figure that’s pulled out of somewhere dark and cavernous. Per TipRanks’ data, in the last three quarters, Flexible Solutions conspicuously beat its per-share earnings estimates. Thus, it’s one of the penny stocks to buy or at least worth considering.
Jerash (JRSH)
Source: John Brueske / Shutterstock.com
A relatively unknown enterprise for many investors, Jerash (NASDAQ:JRSH) manufactures and exports custom, ready-made sport and outerwear from Jordan. Interestingly, Jerash underlines the manufacturing of the products that most people would know such as New Balance. Unfortunately, consumer sentiment fell badly in 2022 because of skyrocketing inflation. In the trailing year, JRSH shed over 40% of market value.
For conservative investors, that might be the end of the discussion. And to be sure, weakness in the consumer economy – particularly record-breaking credit card debt – might keep shoppers on the sidelines. Nevertheless, if you want to go contrarian, JRSH may be an intriguing idea among penny stocks to buy. Objectively, Wall Street prices shares at 0.35-times sales. In contrast, the underlying industry median is 0.83 times.
Notably, of the one analyst that covers Jerash, it enjoys a moderate buy rating. The price target stands at $8, representing upside potential of 104.6% at time of writing. Also, Jerash beat earnings-per-share targets on several occasions in the past two years.
Wipro (WIT)
Source: Shutterstock
An Indian multinational corporation, Wipro (NYSE:WIT) provides information technology, consulting and business process services. Per its public profile, the company’s capabilities cover cloud computing, cyber security, digital transformation, artificial intelligence, robotics, data analytics and other technology consulting services. Currently, Wipro features a value of $26.2 billion, another big cap with a price tag ($4.69) emblematic of penny stocks to buy.
Still, its massive footprint failed to spare the enterprise from volatility. In the trailing year, WIT hemorrhaged almost 51% of market value. Still, those with the mindset of owning penny stocks to buy might want to roll the dice here. I’ve said this before but fundamentally, Wipro entices because of its exposure to India’s tech market. Notably, India’s IT market contributes a little over 9% to its national GDP.
Financially, prospective investors may also appreciate the underlying discount. At the moment, Wall Street prices WIT at 15.6-times forward earnings. For comparison, the industry median forward PE pings at nearly 24 times.
Ultrapar (UGP)
Source: InvestorPlace unless otherwise noted
Headquartered in Sao Paolo, Brazil, Ultrapar (NYSE:UGP) focuses mainly on the energy and chemicals market. Through its various subsidiaries, Ultrapar operates businesses involved in fuel distribution, specialty chemical production, bulk liquid storage and also pharmacies. Perhaps not surprisingly because of its wide and diverse footprint, UGP lost only 4.3% in the trailing year.
As a larger-sized enterprise, investors enjoy more room to work with than its $2.24 price tag would imply. For one thing, UGP enjoys decent (though not great) stability in the balance sheet. In particular, Ultrapar’s Altman Z-Score stands at just under 5, reflecting low bankruptcy risk.
In terms of value, Gurufocus.com rates UGP as significantly undervalued based on its proprietary calculations. Objectively, Ultrapar offers a discount based on its price-sales ratio of 0.09 times. In contrast, the sector median value stands at a lofty 1.05 times.
Finally, the company put on a decent showing since Q4 2020, mostly beating EPS estimates. Only two glaring bum notes appear on Q1 and Q2 of 2021. Thus, UGP may be worth a shot among penny stocks to buy.
B2Gold (BTG)
Source: Shutterstock
A Canadian mining firm, B2Gold (NYSEAMERICAN:BTG) owns and operates gold mines in Mali, Namibia and the Philippines. Currently, the Federal Reserve’s efforts to unwind the monetary excesses of the coronavirus pandemic theoretically poses deflationary pressures on B2Gold. However, the market now smiles on BTG. In the trailing year, shares gained over 2%.
Granted, it’s a tricky situation. The unexpectedly robust November jobs report suggests that the Fed may tighten money supply more aggressively. But that raises the specter of global recession risks, which then would bolster the fear trade angle.
While penny stocks to buy always present risks, both analysts and the smart money love BTG. Per TipRanks, B2Gold commands a consensus view of strong buy. This breaks down to six individual buy ratings and one hold.
Regarding the smart money (i.e. hedge funds), these institutional investors have been bidding up shares since Q3 2021. According to TipRanks, hedge fund sentiment pings as “very positive.”
Wah Fu Education (WAFU)
Source: Shutterstock
One of the less-appreciated penny stocks to buy listed on a major exchange, Wah Fu Education (NASDAQ:WAFU) is a China-based holding company principally engaged in the provision of online education services and technology research. It also specializes in development services. While relevant, vagaries of China’s economy based on its government’s draconian zero-Covid policy hurt Chinese securities.
As evidence, WAFU itself gave up over 35% of equity value in the trailing year. As a less-discussed enterprise (no analyst covers WAFU), the underlying investment carries significant risks, even compared to other penny stocks to buy. However, the company does enjoy some redeeming qualities.
Perhaps most notably, Wah Fu commands a solid balance sheet, particularly with a cash-to-debt ratio of nearly 83 times. In comparison, the sector median value sits at a lowly 1.29 times. As well, its return on asset is 4.17%, ranking above nearly 61% of the competition.
On Penny Stocks and Low-Volume Stocks: With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That’s because these “penny stocks” are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com’s writers disclose this fact and warn readers of the risks.
Read More: Penny Stocks — How to Profit Without Getting Scammed
On the date of publication, Josh Enomoto did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.
A former senior business analyst for Sony Electronics, Josh Enomoto has helped broker major contracts with Fortune Global 500 companies. Over the past several years, he has delivered unique, critical insights for the investment markets, as well as various other industries including legal, construction management, and healthcare.
The post 7 Must-Buy Penny Stocks for Your January Buy List appeared first on InvestorPlace.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | ABEV Ambev $2.64 FSI Flexible Solutions $3.18 JRSH Jerash Holdings $4.01 WIT Wipro $4.59 UGP Ultrapar $2.27 BTG B2Gold $3.79 WAFU Wah Fu Education $2.43 Ambev (ABEV) Source: John Brueske / Shutterstock To be upfront from the get-go, Ambev (NYSE:ABEV) only ranks among penny stocks to buy because of its current share price. At $2.61 at time of writing, ABEV appears to be a wildly speculative asset. However, I’m grateful that the per-share price allows me to put ABEV on this list of penny stocks to buy. | ABEV Ambev $2.64 FSI Flexible Solutions $3.18 JRSH Jerash Holdings $4.01 WIT Wipro $4.59 UGP Ultrapar $2.27 BTG B2Gold $3.79 WAFU Wah Fu Education $2.43 Ambev (ABEV) Source: John Brueske / Shutterstock To be upfront from the get-go, Ambev (NYSE:ABEV) only ranks among penny stocks to buy because of its current share price. At $2.61 at time of writing, ABEV appears to be a wildly speculative asset. However, I’m grateful that the per-share price allows me to put ABEV on this list of penny stocks to buy. | ABEV Ambev $2.64 FSI Flexible Solutions $3.18 JRSH Jerash Holdings $4.01 WIT Wipro $4.59 UGP Ultrapar $2.27 BTG B2Gold $3.79 WAFU Wah Fu Education $2.43 Ambev (ABEV) Source: John Brueske / Shutterstock To be upfront from the get-go, Ambev (NYSE:ABEV) only ranks among penny stocks to buy because of its current share price. At $2.61 at time of writing, ABEV appears to be a wildly speculative asset. However, I’m grateful that the per-share price allows me to put ABEV on this list of penny stocks to buy. | ABEV Ambev $2.64 FSI Flexible Solutions $3.18 JRSH Jerash Holdings $4.01 WIT Wipro $4.59 UGP Ultrapar $2.27 BTG B2Gold $3.79 WAFU Wah Fu Education $2.43 Ambev (ABEV) Source: John Brueske / Shutterstock To be upfront from the get-go, Ambev (NYSE:ABEV) only ranks among penny stocks to buy because of its current share price. At $2.61 at time of writing, ABEV appears to be a wildly speculative asset. However, I’m grateful that the per-share price allows me to put ABEV on this list of penny stocks to buy. |
28177.0 | 2023-01-03 00:00:00 UTC | Pre-Market Most Active for Jan 3, 2023 : TQQQ, TSLA, SQQQ, TSLL, PBR, BBBY, BABA, NIO, QQQ, ABEV, XPEV, CCL | ABEV | https://www.nasdaq.com/articles/pre-market-most-active-for-jan-3-2023-%3A-tqqq-tsla-sqqq-tsll-pbr-bbby-baba-nio-qqq-abev | nan | nan | The NASDAQ 100 Pre-Market Indicator is up 66.05 to 11,005.81. The total Pre-Market volume is currently 57,597,617 shares traded.
The following are the most active stocks for the pre-market session:
ProShares UltraPro QQQ (TQQQ) is +0.3 at $17.60, with 7,476,206 shares traded. This represents a 9.32% increase from its 52 Week Low.
Tesla, Inc. (TSLA) is -4.98 at $118.20, with 5,589,543 shares traded. TSLA's current last sale is 46.9% of the target price of $252.
ProShares UltraPro Short QQQ (SQQQ) is -1 at $53.01, with 2,911,524 shares traded. This represents a 85.35% increase from its 52 Week Low.
Direxion Daily TSLA Bull 1.5X Shares (TSLL) is -0.37 at $5.88, with 1,808,306 shares traded. This represents a 13.73% increase from its 52 Week Low.
Petroleo Brasileiro S.A.- Petrobras (PBR) is -1.03 at $9.62, with 1,593,752 shares traded. PBR's current last sale is 68.71% of the target price of $14.
Bed Bath & Beyond Inc. (BBBY) is +0.06 at $2.57, with 1,374,701 shares traded.BBBY is scheduled to provide an earnings report on 1/5/2023, for the fiscal quarter ending Nov2022. The consensus earnings per share forecast is -1.93 per share, which represents a -25 percent increase over the EPS one Year Ago
Alibaba Group Holding Limited (BABA) is +2.61 at $90.70, with 1,292,352 shares traded. BABA's current last sale is 64.79% of the target price of $140.
NIO Inc. (NIO) is +0.35 at $10.10, with 1,226,695 shares traded. As reported by Zacks, the current mean recommendation for NIO is in the "buy range".
Invesco QQQ Trust, Series 1 (QQQ) is +1.7 at $267.98, with 1,101,024 shares traded. This represents a 5.4% increase from its 52 Week Low.
Ambev S.A. (ABEV) is -0.08 at $2.64, with 714,228 shares traded. ABEV's current last sale is 88% of the target price of $3.
XPeng Inc. (XPEV) is +0.61 at $10.55, with 490,875 shares traded. XPEV's current last sale is 87.92% of the target price of $12.
Carnival Corporation (CCL) is +0.14 at $8.20, with 450,899 shares traded. CCL's current last sale is 82% of the target price of $10.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Ambev S.A. (ABEV) is -0.08 at $2.64, with 714,228 shares traded. ABEV's current last sale is 88% of the target price of $3. ProShares UltraPro Short QQQ (SQQQ) is -1 at $53.01, with 2,911,524 shares traded. | Ambev S.A. (ABEV) is -0.08 at $2.64, with 714,228 shares traded. ABEV's current last sale is 88% of the target price of $3. ProShares UltraPro QQQ (TQQQ) is +0.3 at $17.60, with 7,476,206 shares traded. | Ambev S.A. (ABEV) is -0.08 at $2.64, with 714,228 shares traded. ABEV's current last sale is 88% of the target price of $3. The total Pre-Market volume is currently 57,597,617 shares traded. | Ambev S.A. (ABEV) is -0.08 at $2.64, with 714,228 shares traded. ABEV's current last sale is 88% of the target price of $3. The NASDAQ 100 Pre-Market Indicator is up 66.05 to 11,005.81. |
28178.0 | 2022-12-27 00:00:00 UTC | Will Boston Beer's (SAM) Growth Strategies Aid Amid Cost Woes? | ABEV | https://www.nasdaq.com/articles/will-boston-beers-sam-growth-strategies-aid-amid-cost-woes | nan | nan | The Boston Beer Company, Inc. SAM looks well-poised for long-term growth, owing to innovation and product portfolio expansion. Its advancement in the non-beer categories, including ciders and hard seltzer, should continue to drive progress. We expect its intensified concentration on pricing, product innovation, growth of non-beer categories, and brand-building efforts to reinforce its position in the market. Its focus on improving Truly brand trends through a renewed focus on the core business, smart brand innovation, and strong distributor support and retail execution bode well.
Boston Beer has been witnessing momentum on strong shipment and depletion growth, excluding the Truly brand. The company reported better-than-expected earnings and sales results for third-quarter 2022. Additionally, the top and bottom lines improved on a year-over-year basis.
Better-than-expected earnings mainly resulted from top-line growth, an improved gross margin and lower operating expenses. The increase in the top line was mainly driven by a strong pricing performance across the portfolio, continued growth in depletions and shipments for the Twisted Tea brand, and positive early progress in Hard Mountain Dew.
However, depletions continue to be hurt by the slowdown in the hard seltzer business and supply-chain woes. Higher material and packaging costs and elevated inventory obsolescence costs have been threats to gross margin.
Shares of Boston Beer have gained 0.5% in the past three months compared with the industry’s rise of 6.5%. The Zacks Consensus Estimate for the Zacks Rank #3 (Hold) company’s current financial year’s sales and earnings suggests declines of 0.8% and 44.8%, respectively, from the year-ago period’s reported numbers.
Image Source: Zacks Investment Research
Factors to Drive Growth
SAM's focus on innovation to revive the Truly brand and expand Twisted Tea’s potential bodes well. Boston Beer is keen on bringing excitement to the Truly brand’s core flavors through innovation. The company’s innovation for the Truly brand — Truly flavored bottle Vodka — sold by Beam Suntory from the latter part of the first quarter of 2022, has been well-received by consumers. The company is optimistic about the Truly Vodka Seltzer launched in October 2022. With regard to revisiting the core flavors, the company announced the reformulation and improvement of core Truly flavors, including the addition of real fruit juice for an even smoother, easy-to-drink and refreshing taste.
Coming to Twisted Tea, the brand drove most of the improvements of Boston Beer in the third quarter. Being one of the top 20 fastest-growing brands in all beer for the past 12 months, Twisted Tea grew in double digits and emerged as the number one in FMB in the third quarter by growing 4.3 share points. The rise was driven by the improved distribution of 12 packs, and a unique product and brand positioning that resonates with more consumers.
We note that Boston Beer has made successful innovations in craft beer, and hard cider and iced tea categories over the years. The company is on track with growth of its Beyond Beer category, wherein it currently holds the 2nd position. Beyond Beer is growing faster than the traditional beer market, and the company expects the trend to continue for the next several years.
The company is also focused on accelerated cost savings and efficiency projects to aid margins. The company’s gross margin expanded 1,250 basis points (bps) year over year to 43.2%. The rise mainly resulted from increased costs in third-quarter 2021 related to the slowdown in hard seltzer and gains from pricing in third-quarter 2022. Going forward, the company expects to offset the impacts of higher commodity costs through price increases.
In third-quarter 2022, SAM’s operating expenses declined 11.7% year over year on lower advertising, promotional and selling expenses, partially offset by higher general and administrative expenses. Advertising, promotional and selling expenses declined on lower brand investments, particularly media costs, and reduced freight to distributors due to lower freight rates. Consequently, the company’s operating income of $38.4 million improved from an operating loss of $75.8 million reported in the year-ago quarter.
For 2022, the company expects investments in advertising, promotional and selling to decline $35-$45 million compared with a decrease of $30-$50 million mentioned earlier. The advertising, promotional and selling guidance does not assume any changes in freight costs for the shipment of products to its distributors.
Headwinds to Overcome
Boston Beer has been witnessing a slowdown in the hard seltzer category and the demand for the Truly brand in recent quarters. The slowing hard seltzer trends hurt the company’s depletions in third-quarter 2022. The Hard seltzer volume declined 17% in the third quarter and 15% for the nine months of 2022, in the measured off-premise channels. The hard seltzer category’s decelerating trend has mainly been attributed to the losing of novelty among consumers due to the entry of several beyond-beer products in the marketplace.
Additionally, the decline has resulted from the ongoing dismal macroeconomic environment, which has caused a volume shift from hard seltzers to premium light beers due to their lower pricing. The slowed hard seltzer sales mainly impacted the company’s Truly hard seltzer performance, which is expected to continue through the rest of 2022.
Boston Beer has been sensitive to changes in volume projections, mostly related to the hard seltzer category, supply-chain performance and inflationary impacts. It narrowed its 2022 view. For 2022, the company envisions adjusted earnings per share of $7.00-$10.00 compared with the $6.00-$11.00 mentioned earlier. Depletions and shipments are expected to decline 4-7% compared with a decrease of 2-8% stated earlier. The narrowed view mainly reflects expectations for continued gains in Twisted Tea and Hard Mountain Dew.
The company expects the 53rd week to aid depletion and shipment growth rates for 2022 by 1-1.5 percentage points. Depletion and shipment growth rates for the fourth quarter are expected to record gains of 4-6 percentage points from the 53rd week.
Boston Beer anticipates a gross margin of 42-43.5% for 2022 compared with the 43-45% mentioned earlier. The lowered guidance is a result of the impacts of higher inventory obsolescence, as well as lower brewery efficiencies due to the slowed ramp-up of the newly integrated variety pack lines. The company expects to offset the impacts of higher commodity costs through price increases.
Stocks to Consider
We highlighted some better-ranked stocks from the broader Consumer Staples space, namely Coca-Cola FEMSA KOF, PepsiCo PEP and Ambev ABEV.
Coca-Cola FEMSA produces, markets and distributes soft drinks throughout the metropolitan area of Mexico City in Southeastern Mexico and the metropolitan region in Buenos Aires, Argentina. KOF has a trailing four-quarter earnings surprise of 33.6%, on average. It currently has a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Shares of Coca-Cola FEMSA have risen 21.9% in the past three months. The Zacks Consensus Estimate for Coca-Cola FEMSA’s current financial-year sales and earnings suggests growth of 15.6% and 6.2%, respectively, from the year-ago period's reported figures. KOF has an expected EPS growth rate of 10.3% for three to five years.
PepsiCo is one of the leading global food and beverage companies. It currently has a Zacks Rank #2. The company has an expected EPS growth rate of 7.7% for three to five years. Shares of PEP have gained 8% in the past three months.
The Zacks Consensus Estimate for PepsiCo’s current financial-year sales and earnings per share suggests growth of 7.1% and 8%, respectively, from the year-ago period’s reported figures. PEP has a trailing four-quarter earnings surprise of 4.5%, on average.
Ambev is engaged in producing, distributing and selling beer, carbonated soft drinks, and other non-alcoholic and non-carbonated products in many countries across the Americas. ABEV currently has a Zacks Rank #2. Ambev has a trailing four-quarter earnings surprise of 4.4%, on average. Shares of ABEV have declined 3.1% in the past three months.
The Zacks Consensus Estimate for Ambev’s current financial-year sales and earnings suggests growth of 19.4% and 6.7%, respectively, from the year-ago period’s reported figures. ABEV has an expected EPS growth rate of 9.1% for three to five years.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."
Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.8% per year. So be sure to give these hand-picked 7 your immediate attention.
See them now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
PepsiCo, Inc. (PEP) : Free Stock Analysis Report
Coca Cola Femsa S.A.B. de C.V. (KOF) : Free Stock Analysis Report
The Boston Beer Company, Inc. (SAM) : Free Stock Analysis Report
Ambev S.A. (ABEV) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Stocks to Consider We highlighted some better-ranked stocks from the broader Consumer Staples space, namely Coca-Cola FEMSA KOF, PepsiCo PEP and Ambev ABEV. ABEV currently has a Zacks Rank #2. Shares of ABEV have declined 3.1% in the past three months. | de C.V. (KOF) : Free Stock Analysis Report The Boston Beer Company, Inc. (SAM) : Free Stock Analysis Report Ambev S.A. (ABEV) : Free Stock Analysis Report To read this article on Zacks.com click here. Stocks to Consider We highlighted some better-ranked stocks from the broader Consumer Staples space, namely Coca-Cola FEMSA KOF, PepsiCo PEP and Ambev ABEV. ABEV currently has a Zacks Rank #2. | de C.V. (KOF) : Free Stock Analysis Report The Boston Beer Company, Inc. (SAM) : Free Stock Analysis Report Ambev S.A. (ABEV) : Free Stock Analysis Report To read this article on Zacks.com click here. Stocks to Consider We highlighted some better-ranked stocks from the broader Consumer Staples space, namely Coca-Cola FEMSA KOF, PepsiCo PEP and Ambev ABEV. ABEV currently has a Zacks Rank #2. | Stocks to Consider We highlighted some better-ranked stocks from the broader Consumer Staples space, namely Coca-Cola FEMSA KOF, PepsiCo PEP and Ambev ABEV. ABEV currently has a Zacks Rank #2. Shares of ABEV have declined 3.1% in the past three months. |
28179.0 | 2022-12-20 00:00:00 UTC | ABEV vs. DEO: Which Stock Is the Better Value Option? | ABEV | https://www.nasdaq.com/articles/abev-vs.-deo%3A-which-stock-is-the-better-value-option-0 | nan | nan | Investors with an interest in Beverages - Alcohol stocks have likely encountered both Ambev (ABEV) and Diageo (DEO). But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look.
We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The proven Zacks Rank puts an emphasis on earnings estimates and estimate revisions, while our Style Scores work to identify stocks with specific traits.
Currently, Ambev has a Zacks Rank of #2 (Buy), while Diageo has a Zacks Rank of #3 (Hold). This system places an emphasis on companies that have seen positive earnings estimate revisions, so investors should feel comfortable knowing that ABEV is likely seeing its earnings outlook improve to a greater extent. But this is just one factor that value investors are interested in.
Value investors are also interested in a number of tried-and-true valuation metrics that help show when a company is undervalued at its current share price levels.
The Style Score Value grade factors in a variety of key fundamental metrics, including the popular P/E ratio, P/S ratio, earnings yield, cash flow per share, and a number of other key stats that are commonly used by value investors.
ABEV currently has a forward P/E ratio of 18.39, while DEO has a forward P/E of 21.67. We also note that ABEV has a PEG ratio of 2.02. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. DEO currently has a PEG ratio of 2.51.
Another notable valuation metric for ABEV is its P/B ratio of 2.57. The P/B ratio is used to compare a stock's market value with its book value, which is defined as total assets minus total liabilities. For comparison, DEO has a P/B of 8.87.
These metrics, and several others, help ABEV earn a Value grade of B, while DEO has been given a Value grade of C.
ABEV is currently sporting an improving earnings outlook, which makes it stick out in our Zacks Rank model. And, based on the above valuation metrics, we feel that ABEV is likely the superior value option right now.
Zacks Top 10 Stocks for 2023
In addition to the investment ideas discussed above, would you like to know about our 10 top picks for the entirety of 2023? From inception in 2012 through November, the Zacks Top 10 Stocks portfolio has tripled the market, gaining an impressive +884.5% versus the S&P 500’s +287.4%.
Now our Director of Research is combing through 4,000 companies covered by the Zacks Rank to handpick the best 10 tickers to buy and hold. Don’t miss your chance to get in on these stocks when they’re released on January 3.
Be First to New Top 10 Stocks >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Ambev S.A. (ABEV) : Free Stock Analysis Report
Diageo plc (DEO) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Investors with an interest in Beverages - Alcohol stocks have likely encountered both Ambev (ABEV) and Diageo (DEO). This system places an emphasis on companies that have seen positive earnings estimate revisions, so investors should feel comfortable knowing that ABEV is likely seeing its earnings outlook improve to a greater extent. ABEV currently has a forward P/E ratio of 18.39, while DEO has a forward P/E of 21.67. | Click to get this free report Ambev S.A. (ABEV) : Free Stock Analysis Report Diageo plc (DEO) : Free Stock Analysis Report To read this article on Zacks.com click here. Investors with an interest in Beverages - Alcohol stocks have likely encountered both Ambev (ABEV) and Diageo (DEO). This system places an emphasis on companies that have seen positive earnings estimate revisions, so investors should feel comfortable knowing that ABEV is likely seeing its earnings outlook improve to a greater extent. | These metrics, and several others, help ABEV earn a Value grade of B, while DEO has been given a Value grade of C. ABEV is currently sporting an improving earnings outlook, which makes it stick out in our Zacks Rank model. Click to get this free report Ambev S.A. (ABEV) : Free Stock Analysis Report Diageo plc (DEO) : Free Stock Analysis Report To read this article on Zacks.com click here. Investors with an interest in Beverages - Alcohol stocks have likely encountered both Ambev (ABEV) and Diageo (DEO). | Investors with an interest in Beverages - Alcohol stocks have likely encountered both Ambev (ABEV) and Diageo (DEO). Another notable valuation metric for ABEV is its P/B ratio of 2.57. This system places an emphasis on companies that have seen positive earnings estimate revisions, so investors should feel comfortable knowing that ABEV is likely seeing its earnings outlook improve to a greater extent. |
28180.0 | 2022-12-20 00:00:00 UTC | International Flavors (IFF) to Sell Savory Solutions Group | ABEV | https://www.nasdaq.com/articles/international-flavors-iff-to-sell-savory-solutions-group | nan | nan | International Flavors & Fragrances IFF announced it has entered into an agreement to divest the Savory Solutions Group to PAI Partners. The deal values the business at around $900 million. IFF intends to use the cash proceeds (net of taxes and expenses) to repay its debt. The sale aligns with IFF’s strategy to focus on highest-return businesses, improve capital structure and enhance its growth profile.
The Savory Solutions Group primarily focuses on ingredients for prepared foods and foodservice and includes products for butchers, and plant-based solutions for the vegan and vegetarian markets. The business generated revenues of around $475 million over the last 12 months. It has units across Austria, Germany, Italy, Ireland, Poland, Canada, Mexico and Thailand and employs around 1,800 people.
PAI Partners is a leading global private equity firm with a strong focus on the food and consumer industry. IFF and PAI Partners expect to close the deal in the second quarter of 2023, subject to customary closing conditions.
Earlier this month, International Flavors provided details of its updated strategic plan and new operating model. The financial and strategic initiatives that the company elaborated on were - growth-focused strategy, enhanced cost & productivity initiatives, financial guidance, redesigning operating model, portfolio optimization, and governance and leadership.
IFF intends to transform its operating model into a more customer-centric and market-backed approach. To this end, it will conduct business in three core end markets — Food and Beverage, Home and Personal Care, and Health. IFF anticipates the new operating model to be completely operational by the end of 2023.
International Flavors & Fragrances also stated that it aims to continue to optimize its portfolio to improve its capital structure. The company had identified Savory Solutions, Texturants, Emulsifiers & Sweeteners and Protein Solutions as underperformers, which it intends to either exit or take initiatives to improve their results. The company had stated that by the end of the first quarter of 2023, it will announce the sale of three non-core assets. The proceeds from these are projected at $1.2 billion and will be utilized to lower debt levels. The current announcement of the Savory Solutions Group is in sync with this.
To drive growth, IFF plans to step up its investment in high-return businesses such as Cosmetic Ingredients, Fine Fragrance, Flavors, Cultures & Food Enzymes, Health, Food Design (excluding the Savory Solutions unit that is being divested), Fragrance Ingredients and Consumer Fragrance.
Price Performance
Image Source: Zacks Investment Research
In the past year, International Flavors’ shares have lost 28.6% compared with the industry’s 33% decline.
Zacks Rank & Key Picks
International Flavors currently carries a Zacks Rank #4 (Sell).
Some better-ranked stocks in the Consumer Staples sector are Archer Daniels Midland ADM, Ambev ABEV, and Coca-Cola Europacific Partners CCEP. ADM sports a Zacks Rank #1 (Strong Buy), while ABEV and CCEP hold a Zacks Rank #2 (Buy) at present.
You can see the complete list of today’s Zacks #1 Rank stocks here.
Archer Daniels Midland’s earnings surprise in the last four quarters was 26.2%, on average. In the past 60 days, its earnings estimates have gone up 8% for 2022. For the ongoing year, the bottom line is estimated to be $7.47, suggesting growth of 44% from the previous year’s level. ADM stock has gained 44% in the past year.
Ambev has an estimated year-over-year earnings growth rate of 6.7% for the current fiscal year. The earnings per share estimate is currently pegged at 16 cents. The estimates have been revised by 7% north in the past 60 days. ABEV has an average trailing four-quarter earnings surprise of 4.4%. Its shares have gained 7% over the past year.
Coca-Cola Europacific Partners has an estimated year-over-year earnings growth rate of 1.5% for the current fiscal year. The earnings estimate is currently pegged at $3.40 per share. The estimates have been revised 3.3% north in the past 60 days. CCEP shares have gained 3% over the past year.
Zacks Top 10 Stocks for 2023
In addition to the investment ideas discussed above, would you like to know about our 10 top picks for the entirety of 2023? From inception in 2012 through November, the Zacks Top 10 Stocks portfolio has tripled the market, gaining an impressive +884.5% versus the S&P 500’s +287.4%.
Now our Director of Research is combing through 4,000 companies covered by the Zacks Rank to handpick the best 10 tickers to buy and hold. Don’t miss your chance to get in on these stocks when they’re released on January 3.
Be First to New Top 10 Stocks >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Archer Daniels Midland Company (ADM) : Free Stock Analysis Report
International Flavors & Fragrances Inc. (IFF) : Free Stock Analysis Report
Ambev S.A. (ABEV) : Free Stock Analysis Report
CocaCola Europacific Partners (CCEP) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Some better-ranked stocks in the Consumer Staples sector are Archer Daniels Midland ADM, Ambev ABEV, and Coca-Cola Europacific Partners CCEP. ADM sports a Zacks Rank #1 (Strong Buy), while ABEV and CCEP hold a Zacks Rank #2 (Buy) at present. ABEV has an average trailing four-quarter earnings surprise of 4.4%. | Some better-ranked stocks in the Consumer Staples sector are Archer Daniels Midland ADM, Ambev ABEV, and Coca-Cola Europacific Partners CCEP. Click to get this free report Archer Daniels Midland Company (ADM) : Free Stock Analysis Report International Flavors & Fragrances Inc. (IFF) : Free Stock Analysis Report Ambev S.A. (ABEV) : Free Stock Analysis Report CocaCola Europacific Partners (CCEP) : Free Stock Analysis Report To read this article on Zacks.com click here. ADM sports a Zacks Rank #1 (Strong Buy), while ABEV and CCEP hold a Zacks Rank #2 (Buy) at present. | Click to get this free report Archer Daniels Midland Company (ADM) : Free Stock Analysis Report International Flavors & Fragrances Inc. (IFF) : Free Stock Analysis Report Ambev S.A. (ABEV) : Free Stock Analysis Report CocaCola Europacific Partners (CCEP) : Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the Consumer Staples sector are Archer Daniels Midland ADM, Ambev ABEV, and Coca-Cola Europacific Partners CCEP. ADM sports a Zacks Rank #1 (Strong Buy), while ABEV and CCEP hold a Zacks Rank #2 (Buy) at present. | Some better-ranked stocks in the Consumer Staples sector are Archer Daniels Midland ADM, Ambev ABEV, and Coca-Cola Europacific Partners CCEP. ADM sports a Zacks Rank #1 (Strong Buy), while ABEV and CCEP hold a Zacks Rank #2 (Buy) at present. ABEV has an average trailing four-quarter earnings surprise of 4.4%. |
28181.0 | 2022-12-19 00:00:00 UTC | Monday's ETF Movers: ILF, PBW | ABEV | https://www.nasdaq.com/articles/mondays-etf-movers%3A-ilf-pbw | nan | nan | In trading on Monday, the iShares Latin America 40 ETF is outperforming other ETFs, up about 1.2% on the day. Components of that ETF showing particular strength include shares of Ambev, up about 4% and shares of Banco Bradesco, up about 2.5% on the day.
And underperforming other ETFs today is the Invesco WilderHill Clean Energy ETF, off about 5% in Monday afternoon trading. Among components of that ETF with the weakest showing on Monday were shares of Gevo, lower by about 10.4%, and shares of VIEW, lower by about 10.1% on the day.
VIDEO: Monday's ETF Movers: ILF, PBW
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | And underperforming other ETFs today is the Invesco WilderHill Clean Energy ETF, off about 5% in Monday afternoon trading. Among components of that ETF with the weakest showing on Monday were shares of Gevo, lower by about 10.4%, and shares of VIEW, lower by about 10.1% on the day. VIDEO: Monday's ETF Movers: ILF, PBW The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Components of that ETF showing particular strength include shares of Ambev, up about 4% and shares of Banco Bradesco, up about 2.5% on the day. Among components of that ETF with the weakest showing on Monday were shares of Gevo, lower by about 10.4%, and shares of VIEW, lower by about 10.1% on the day. VIDEO: Monday's ETF Movers: ILF, PBW The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In trading on Monday, the iShares Latin America 40 ETF is outperforming other ETFs, up about 1.2% on the day. Among components of that ETF with the weakest showing on Monday were shares of Gevo, lower by about 10.4%, and shares of VIEW, lower by about 10.1% on the day. VIDEO: Monday's ETF Movers: ILF, PBW The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | In trading on Monday, the iShares Latin America 40 ETF is outperforming other ETFs, up about 1.2% on the day. Components of that ETF showing particular strength include shares of Ambev, up about 4% and shares of Banco Bradesco, up about 2.5% on the day. And underperforming other ETFs today is the Invesco WilderHill Clean Energy ETF, off about 5% in Monday afternoon trading. |
28182.0 | 2022-12-12 00:00:00 UTC | Is Ambev (ABEV) Stock Outpacing Its Consumer Staples Peers This Year? | ABEV | https://www.nasdaq.com/articles/is-ambev-abev-stock-outpacing-its-consumer-staples-peers-this-year-0 | nan | nan | The Consumer Staples group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Ambev (ABEV) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Consumer Staples sector should help us answer this question.
Ambev is a member of our Consumer Staples group, which includes 200 different companies and currently sits at #2 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Ambev is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for ABEV's full-year earnings has moved 3.3% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Our latest available data shows that ABEV has returned about 4.3% since the start of the calendar year. Meanwhile, stocks in the Consumer Staples group have lost about 2% on average. This shows that Ambev is outperforming its peers so far this year.
Campbell Soup (CPB) is another Consumer Staples stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 28.1%.
For Campbell Soup, the consensus EPS estimate for the current year has increased 3.4% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Ambev belongs to the Beverages - Alcohol industry, a group that includes 18 individual stocks and currently sits at #53 in the Zacks Industry Rank. On average, this group has lost an average of 5.8% so far this year, meaning that ABEV is performing better in terms of year-to-date returns.
On the other hand, Campbell Soup belongs to the Food - Miscellaneous industry. This 50-stock industry is currently ranked #45. The industry has moved +5.8% year to date.
Ambev and Campbell Soup could continue their solid performance, so investors interested in Consumer Staples stocks should continue to pay close attention to these stocks.
Zacks Top 10 Stocks for 2023
In addition to the investment ideas discussed above, would you like to know about our 10 top picks for the entirety of 2023? From inception in 2012 through November, the Zacks Top 10 Stocks portfolio has tripled the market, gaining an impressive +884.5% versus the S&P 500’s +287.4%.
Now our Director of Research is combing through 4,000 companies covered by the Zacks Rank to handpick the best 10 tickers to buy and hold. Don’t miss your chance to get in on these stocks when they’re released on January 3.
Be First to New Top 10 Stocks >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Ambev S.A. (ABEV) : Free Stock Analysis Report
Campbell Soup Company (CPB) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Is Ambev (ABEV) one of those stocks right now? Within the past quarter, the Zacks Consensus Estimate for ABEV's full-year earnings has moved 3.3% higher. Our latest available data shows that ABEV has returned about 4.3% since the start of the calendar year. | Click to get this free report Ambev S.A. (ABEV) : Free Stock Analysis Report Campbell Soup Company (CPB) : Free Stock Analysis Report To read this article on Zacks.com click here. Is Ambev (ABEV) one of those stocks right now? Within the past quarter, the Zacks Consensus Estimate for ABEV's full-year earnings has moved 3.3% higher. | Click to get this free report Ambev S.A. (ABEV) : Free Stock Analysis Report Campbell Soup Company (CPB) : Free Stock Analysis Report To read this article on Zacks.com click here. Is Ambev (ABEV) one of those stocks right now? Within the past quarter, the Zacks Consensus Estimate for ABEV's full-year earnings has moved 3.3% higher. | Is Ambev (ABEV) one of those stocks right now? Within the past quarter, the Zacks Consensus Estimate for ABEV's full-year earnings has moved 3.3% higher. Our latest available data shows that ABEV has returned about 4.3% since the start of the calendar year. |
28183.0 | 2022-12-09 00:00:00 UTC | International Flavors (IFF) Gains From New Strategy Reveal | ABEV | https://www.nasdaq.com/articles/international-flavors-iff-gains-from-new-strategy-reveal | nan | nan | Shares of International Flavors & Fragrances IFF have increased 2.6% since the company provided details of its updated strategic plan and new operating model on Dec 7. These strategic actions will enable IFF to sharpen its customer focus and better align with the market, setting it up to maximize its growth potential.
The financial and strategic initiatives that the company elaborated on are growth-focused strategy, enhanced cost & productivity initiatives, financial guidance, redesigned operating model, portfolio optimization, and governance and leadership.
With the help of this new strategic framework, the company will focus on customer excellence and continued profitable growth. IFF will be better positioned to meet consumer demand and achieve its goal of applying science and creativity for a better world with this updated strategy framework. It will help IFF advance the possibilities with the highest potential returns through controlled investments, consistent execution, and incremental cost reductions. Moreover, it will implant Environmental, Social and Governance (ESG+) priorities across the company’s entire enterprise.
The company will continue to take pricing actions to counter the impact of cost inflation while improving productivity and delivering cost reductions. IFF expects to achieve mid-single-digit adjusted operating EBITDA growth on a comparable currency-neutral basis in fiscal 2023. As part of the company’s long-term financial objectives, IFF outlined that it expects to increase sales by 4% to 6% and adjusted operating EBITDA by 8% to 10% on a comparable currency-neutral basis over the 2024, 2025 and 2026 period.
IFF expects a further $100 million in annual savings through headcount reduction that can be reinvested and boost earnings. From 2023 to 2025, the company anticipates achieving net yearly savings of between $350 and $400 million.
IFF intends to transform its operating model into a more customer-centric and market-backed approach. To this end, it will conduct business in three core end markets — Food and Beverage, Home and Personal Care, and Health. IFF anticipates the new operating model to be completely operational by the end of 2023.
International Flavors & Fragrances aims to continue to optimize its portfolio to improve the capital structure and step up its investment in high-return businesses. By the end of the first quarter of 2023, the company plans to announce the sale of three non-core assets, with the projected proceeds of $1.2 billion to be utilized to lower debt levels.
The next action plan is to modify the board of directors in accordance with ideal corporate governance principles. This will provide the company with the best assistance and monitoring possible for the advancement of its growth and transformation strategy. The board intends to lower its size to 10 directors from the current 14 by the annual shareholder meeting in May 2023.
For the third quarter of 2022, the company reported adjusted earnings of $1.36 per share, beating the Zacks Consensus Estimate of $1.30. The bottom line declined 7% from the year-ago quarter. IFF’s total revenues came in at $3,063 million, beating the Zacks Consensus Estimate of $3,026 million. The top line remained flat year over year.
Price Performance
In the past year, International Flavors’ shares have lost 27% compared with the industry’s decline of 32%.
Image Source: Zacks Investment Research
Zacks Rank & Key Picks
International Flavors currently carries a Zacks Rank #4 (Sell).
Some better-ranked stocks in the Consumer Staples sector are Archer Daniels Midland ADM, Ambev ABEV, and Coca-Cola Europacific Partners CCEP. ADM flaunts a Zacks Rank #1 (Strong Buy), while ABEV and CCEP hold a Zacks Rank #2 (Buy) at present.
You can see the complete list of today’s Zacks #1 Rank stocks here.
Archer Daniels Midland’s earnings surprise in the last four quarters was 26.2%, on average. In the past 60 days, its earnings estimates have increased 9.5% for 2022. For the ongoing year, the bottom line is estimated to be $7.49, suggesting growth of 44.3% from the previous-year’s level. ADM stock has gained 46% in the past year.
Ambev has an estimated year-over-year earnings growth rate of 6.7% for the current fiscal year. The earnings per share estimate is currently pegged at 16 cents. The estimates have been revised by 6.7% north in the past 60 days. ABEV has an average trailing four-quarter earnings surprise of 4.4%. Its shares have gained 6.9% over the past year.
Coca-Cola Europacific Partners has an estimated year-over-year earnings growth rate of 1.5% for the current fiscal year. The earnings estimate is currently pegged at $3.40 per share. The estimates have been revised 3.3% north in the past 60 days. CCEP shares have gained 0.3% over the past year.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Archer Daniels Midland Company (ADM) : Free Stock Analysis Report
International Flavors & Fragrances Inc. (IFF) : Free Stock Analysis Report
Ambev S.A. (ABEV) : Free Stock Analysis Report
CocaCola Europacific Partners (CCEP) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Some better-ranked stocks in the Consumer Staples sector are Archer Daniels Midland ADM, Ambev ABEV, and Coca-Cola Europacific Partners CCEP. ADM flaunts a Zacks Rank #1 (Strong Buy), while ABEV and CCEP hold a Zacks Rank #2 (Buy) at present. ABEV has an average trailing four-quarter earnings surprise of 4.4%. | Some better-ranked stocks in the Consumer Staples sector are Archer Daniels Midland ADM, Ambev ABEV, and Coca-Cola Europacific Partners CCEP. Click to get this free report Archer Daniels Midland Company (ADM) : Free Stock Analysis Report International Flavors & Fragrances Inc. (IFF) : Free Stock Analysis Report Ambev S.A. (ABEV) : Free Stock Analysis Report CocaCola Europacific Partners (CCEP) : Free Stock Analysis Report To read this article on Zacks.com click here. ADM flaunts a Zacks Rank #1 (Strong Buy), while ABEV and CCEP hold a Zacks Rank #2 (Buy) at present. | Click to get this free report Archer Daniels Midland Company (ADM) : Free Stock Analysis Report International Flavors & Fragrances Inc. (IFF) : Free Stock Analysis Report Ambev S.A. (ABEV) : Free Stock Analysis Report CocaCola Europacific Partners (CCEP) : Free Stock Analysis Report To read this article on Zacks.com click here. Some better-ranked stocks in the Consumer Staples sector are Archer Daniels Midland ADM, Ambev ABEV, and Coca-Cola Europacific Partners CCEP. ADM flaunts a Zacks Rank #1 (Strong Buy), while ABEV and CCEP hold a Zacks Rank #2 (Buy) at present. | Some better-ranked stocks in the Consumer Staples sector are Archer Daniels Midland ADM, Ambev ABEV, and Coca-Cola Europacific Partners CCEP. ADM flaunts a Zacks Rank #1 (Strong Buy), while ABEV and CCEP hold a Zacks Rank #2 (Buy) at present. ABEV has an average trailing four-quarter earnings surprise of 4.4%. |
28184.0 | 2022-12-07 00:00:00 UTC | Our 7 Top Penny Stock Picks for 2023 | ABEV | https://www.nasdaq.com/articles/our-7-top-penny-stock-picks-for-2023 | nan | nan | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Despite a myriad of warnings to avoid the sector, speculative investments rank highly among search queries, practically necessitating a conversation about top penny stock picks for 2023. To be clear, whenever you dive into this space, you’re on your own. With low price tags and often unpredictable trading dynamics, these market ideas can quickly go wrong.
On the other hand, if you’re willing to exercise strict money management – that is, using only funds you can afford to lose – the top penny stock picks for 2023 could be relatively intriguing. For a small expenditure, it’s possible (though not likely) that you can enjoy massive gains. If you’re ready to take the plunge, below are (somewhat) fundamentally sensible penny stock picks for 2023.
WIT Wipro $4.90
ABEV Ambev $3.03
SPRS Surge Components $3.26
MNDO MIND C.T.I. $2.16
FEEXF Ferrexpo $1.98
BTG B2Gold $3.35
ALKEF Alkane Resources $0.42
Wipro (WIT)
Source: John Brueske / Shutterstock
An Indian multinational corporation, Wipro (NYSE:WIT) provides information technology, consulting, and business process services. Per its public profile, the company’s capabilities cover cloud computing, cyber security, digital transformation, artificial intelligence, robotics, data analytics, and other technology consulting services. Currently, Wipro features a market capitalization of $27.1 billion and a price tag of $4.92.
Since the start of this year, WIT dropped over 49% of equity value, which is not uncommon for speculative trades, even those regarded as the top penny stock picks for 2023. However, WIT may be gaining nearer-term momentum, with shares up 2% in the trailing month.
Fundamentally, Wipro entices because of its exposure to India’s tech market. Notably, India’s IT market contributes a little over 9% to its national GDP.
From the financial angle, Wipro delivers goods in myriad ways. Perhaps most conspicuously, the company features excellent profitability metrics, ranking among the sector’s elite. As well, Gurufocus.com notes that WIT is priced conspicuously under the investment resource’s proprietary calculation for fair market value (FMV).
Ambev (ABEV)
Source: Billion Photos / Shutterstock.com
A Brazilian brewing company, Ambev (NYSE:ABEV) currently trades hands for three bucks a share. It’s almost not fair to characterize ABEV as one of the top penny stock picks for 2023 because it lacks this sector’s poor attributes. For instance, it features a market capitalization of $47.6 billion. You’re not going to find too many speculative ideas with that kind of market value.
Fundamentally, ABEV aligns with certain cynical realities. While the assumption that imbibing increases during recessions remains a debatable topic, what appears to be relatively established is that, per a Forbes article, “alcoholic beverage consumption should be resilient even during a future economic recession.” It’s not a dinner table conversation but it is a relatively predictable social phenomenon.
Also, unlike garbage speculative trades, Ambev commands robust financials. It features a highly stable balance sheet, solid growth trends and excellent profitability metrics. An above-sector-average return on equity of 15.4% also reflects Ambev’s high-quality business.
Surge Components (SPRS)
Source: Shutterstock
Headquartered in Deer Park, New York, Surge Components (OTCMKTS:SPRS) is a world-class supplier of capacitors and discrete semiconductors. Per its website, the company’s current product portfolio includes aluminum electrolytic capacitors, film capacitors, MLCC [multilayer ceramic capacitors], discrete semiconductors, and switches. Currently, Surge Components features a market cap of $18.1 million.
To be fair, Surge presents risks based on its nano-cap profile. Also, the company’s stock trades over the counter, which may present liquidity concerns among other administrative challenges. At the time of writing, SPRS trades hands at $3.26. On a year-to-date basis, SPRS dipped slightly over 14%.
Despite obvious obstacles, SPRS could make a case for top penny stock picks for 2023 due to its infrastructural relevance. Thanks to the Biden administration’s various initiatives to boost American infrastructure and technology, Surge may enjoy a demand upswing.
Financially, one of Surge’s strong points centers on its all-around solid financials. One of the rarities of securities listed on Gurufocus.com, SPRS enjoys six green flags and no major points of concern. As an added bonus, SPRS rates as modestly undervalued based on the investment resource’s calculation for FMV.
Mind C.T.I. (MNDO)
Source: Shutterstock
Headquartered in Israel, Mind C.T.I. (NASDAQ:MNDO) is a global provider of billing and customer care solutions for voice, data, video, and content services. Presently, Mind carries a market cap of $43.7 million. At the time of writing, shares trade hands for $2.17. As well, the average volume is quite high for a speculative investment at 22,000 shares. Since the start of the year, MNDO slipped 31%.
Fundamentally, Mind brings fiscal stability and strong margins to the table, making it an intriguing idea among top penny stock picks for 2023. Primarily, the company enjoys a strong cash position, evidenced by its cash-to-debt ratio of 17.7 times. In contrast, the industry median is 3.2 times. Additionally, its Altman Z-Score is 5.2, reflecting low bankruptcy risk.
Even better for those seeking bargains among the top penny stock picks for 2023, MNDO rates as undervalued based on traditional metrics. For instance, the market prices Mind at 8 times trailing earnings. In contrast, the sector median value is 25.7 times.
Ferrexpo (FEEXF)
Source: Shutterstock
To be clear, Ferrexpo (OTCMKTS:FEEXF) may represent the riskiest idea on this list of top penny stock picks for 2023. A Swiss-based commodity trading and mining firm, Ferrexpo specializes in iron ore pellets. However, its operating base is located in central Ukraine, which brings up major concerns for obvious reasons.
Indeed, Ferrexpo is one of the largest employers of Ukrainian workers. Currently, the company prioritizes the safety of its employees, along with supporting humanitarian initiatives. For those that are interested in high-risk ventures with feel-good narratives, Ferrexpo might appeal to certain investors.
Should you decide to buy FEEXF, you should know that it’s not all about the feels with this company. Rather, Ferrexpo enjoys excellent strengths in the balance sheet. As well, its revenue growth rate and profit margins rank among the sector’s upper echelon. Finally, the market prices FEEXF at only 3.8 times trailing earnings, making it significantly undervalued.
B2Gold (BTG)
Source: InvestorPlace unless otherwise noted
A Canadian mining firm, B2Gold (NYSEAMERICAN:BTG) owns and operates gold mines in Mali, Namibia, and the Philippines. Currently, the Federal Reserve’s efforts to unwind the monetary excesses of the coronavirus pandemic pose deflationary pressures on B2Gold. Since the beginning of this year, BTG fell almost 14%. However, circumstances appear to be stabilizing, with shares gaining over 4% in the trailing month.
Still, it’s a tricky situation. Earlier, rumors suggested the Fed would be less aggressive with its rate hikes. However, the unexpectedly robust November jobs report probably threw this narrative out the window. Nevertheless, the fear of trade associated with global recession risks could cynically blossom.
Either way, B2Gold enjoys surprisingly robust financials. In terms of key growth and profitability metrics, B2Gold ranks noticeably above sector averages. As well, prospective investors should check out the company’s balance sheet. With an Altman Z-Score of 5.5 reflecting low bankruptcy risk, BTG could rank among the intriguing penny stock picks for 2023.
Alkane Resources (ALKEF)
Source: Shutterstock
Founded in 1969, Alkane Resources (OTCMKTS:ALKEF) calls the Land Down Under home. According to its website, Alkane is poised to become Australia’s next multi-mine gold producer. Although it features projects throughout the country, management focuses predominantly on the New South Wales region.
As of this writing, Alkane carries a market cap of 371.5 million AUD or about $248.7 million. ALKEF trades hands for 45 cents a share. Against the January opener, the stock dropped almost 32% in equity value. However, in the trailing five days, ALKEF popped up nearly 5%, reflecting a possible bullish resurgence.
On the financials, Alkane is arguably best known for its revenue trend. Its three-year sales growth rate stands at 20.8%, beating out 79% of its competitors. Also, the company delivers on the bottom line, particularly with a net margin of 42.6%. This stat ranks above 93% of the industry.
Finally, Alkane enjoys a return on equity of nearly 30%, reflecting a very high-quality business. So, don’t let the cheap price fool you. ALKEF may be one of the best-hidden gems among top penny stock picks for 2023.
On Penny Stocks and Low-Volume Stocks: With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That’s because these “penny stocks” are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com’s writers disclose this fact and warn readers of the risks.
Read More: Penny Stocks — How to Profit Without Getting Scammed
On the date of publication, Josh Enomoto did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.
A former senior business analyst for Sony Electronics, Josh Enomoto has helped broker major contracts with Fortune Global 500 companies. Over the past several years, he has delivered unique, critical insights for the investment markets, as well as various other industries including legal, construction management, and healthcare.
The post Our 7 Top Penny Stock Picks for 2023 appeared first on InvestorPlace.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | WIT Wipro $4.90 ABEV Ambev $3.03 SPRS Surge Components $3.26 Ambev (ABEV) Source: Billion Photos / Shutterstock.com A Brazilian brewing company, Ambev (NYSE:ABEV) currently trades hands for three bucks a share. It’s almost not fair to characterize ABEV as one of the top penny stock picks for 2023 because it lacks this sector’s poor attributes. | WIT Wipro $4.90 ABEV Ambev $3.03 SPRS Surge Components $3.26 Ambev (ABEV) Source: Billion Photos / Shutterstock.com A Brazilian brewing company, Ambev (NYSE:ABEV) currently trades hands for three bucks a share. It’s almost not fair to characterize ABEV as one of the top penny stock picks for 2023 because it lacks this sector’s poor attributes. | WIT Wipro $4.90 ABEV Ambev $3.03 SPRS Surge Components $3.26 Ambev (ABEV) Source: Billion Photos / Shutterstock.com A Brazilian brewing company, Ambev (NYSE:ABEV) currently trades hands for three bucks a share. It’s almost not fair to characterize ABEV as one of the top penny stock picks for 2023 because it lacks this sector’s poor attributes. | WIT Wipro $4.90 ABEV Ambev $3.03 SPRS Surge Components $3.26 Ambev (ABEV) Source: Billion Photos / Shutterstock.com A Brazilian brewing company, Ambev (NYSE:ABEV) currently trades hands for three bucks a share. It’s almost not fair to characterize ABEV as one of the top penny stock picks for 2023 because it lacks this sector’s poor attributes. |
28185.0 | 2022-12-07 00:00:00 UTC | Brown-Forman (BF.B) Q2 Earnings Miss Estimates, Sales Beat | ABEV | https://www.nasdaq.com/articles/brown-forman-bf.b-q2-earnings-miss-estimates-sales-beat | nan | nan | Brown-Forman Corporation (BF.B) reported second-quarter fiscal 2023 results, wherein earnings missed the Zacks Consensus Estimate, while sales beat the same.
Sales also improved year over year, backed by the increased demand for its brands, mainly the resurgence of Jack Daniel’s Tennessee Whiskey, and growth across all geographic clusters. Meanwhile, earnings were affected by soft margin trends resulting from input cost inflation, higher supply-chain costs, and increased compensation and advertising expenses.
For the fiscal second quarter, earnings per share (EPS) of 47 cents declined 4% year over year and lagged the Zacks Consensus Estimate of 55 cents. The decline can be attributed to soft margins due to higher input costs, supply-chain headwinds, and increased compensation and advertising expenses, partly offset by sales growth and a lower effective tax rate.
Net sales of $1,094 million beat the Zacks Consensus Estimate of $1,089 million. The top line increased 10% year over year on a reported basis. On an organic basis, net sales were up 16% from the prior-year level. Sales benefited from strong consumer demand for its brands and sustained brand investments. BF.B is benefiting from recent acquisitions, product innovation and strategic relationships.
For the second quarter of fiscal 2023, Brown-Forman’s gross profit amounted to $613 million, improving 4% year over year. On an organic basis, the gross profit rose 13%.
Meanwhile, the gross margin contracted 330 basis points (bps) to 56%. The gross margin decline can be attributed to the impact of input cost inflation, elevated costs resulting from supply-chain disruptions and adverse currency rates. These were partly negated by a favorable price/mix and the removal of the EU and the U.K. tariffs on American whiskey.
SG&A expenses rose 9% year over year to $180 million and 15% on an organic basis, mainly on higher compensation-related expenses. Advertising expenses increased 16% year over year to $121 million for the fiscal second quarter.
On an organic basis, advertising expenses advanced 22%. This was driven by elevated marketing spends in the United States to back the growth of Jack Daniel’s Tennessee Whiskey, Herradura, the launch of the Jack Daniel’s Bonded series and Woodford Reserve.
The operating income declined 2% year over year to $313 million on a reported basis. The organic operating income increased 8%. The operating margin contracted 360 bps to 28.7% in the fiscal second quarter.
This Zacks Rank #3 (Hold) company’s shares have risen 1.2% in the past three months compared with the industry’s growth of 6.1%.
Image Source: Zacks Investment Research
Category-Wise & Channel-Wise Performance
For the first half of fiscal 2023, net sales increased 11% year over year to $2.1 billion and 17% on an organic basis. The rise was mainly driven by broad-based growth across all geographic regions and the Travel Retail channel on strong volume growth and rebuilding of distributor inventories.
Net sales for Jack Daniel’s family of brands were up 9% on a reported basis and 17% on an organic basis in the first half of fiscal 2023. The brand’s sales were driven by solid demand and increased prices in emerging markets, developed international markets and the Travel Retail channel.
The upside in sales was also driven by the resurgence of Jack Daniel’s Tennessee Whiskey, which reported sales growth of 9% and organic growth of 18%. Higher pricing and the estimated increase in distributor inventories also aided sales.
Further, sales benefited from the continued consumer interest in flavor and convenience, which boosted the performance of Jack Daniel’s Ready-to-Drink (RTD), Jack Daniel’s Tennessee Honey and Jack Daniel’s Tennessee Fire. Innovation contributed to sales growth through the launch of Jack Daniel’s Bonded series.
Premium bourbon brands reported sales growth of 39% and organic sales growth of 40% in the fiscal first half, driven by growth in Woodford Reserve and Old Forester, supported by higher volumes in the United States. An estimated rise in distributor inventories due to the easing of glass supply constraints also boosted sales for Woodford Reserve and Old Forester.
BF.B’s RTD category reported double-digit sales growth of 14% and organic sales growth of 20%. This was mainly driven by Jack Daniel’s RTDs and New Mix.
Jack Daniel’s RTDs/Ready-to-Pours benefited from gains in Australia and Germany, resulting in year-over-year sales growth of 9% and 15% on an organic basis. New Mix reported sales growth of 48% and organic sales growth of 46%, driven by market share gains in the RTD category in Mexico.
Brown-Forman’s tequila portfolio reported sales growth of 10% year over year and 11% on an organic basis. This was driven by volume growth in the United States for the el Jimador and Herradura brands.
Sales increased 9% on both reported and organic basis for the Herradura brand due to the positive impacts of an estimated increase in distributor inventories as supply constraints eased. el Jimador reported sales growth of 16% year over year and 18% on an organic basis.
The company’s overall sales in the United States advanced 11% on a reported and organic basis. The rise was driven by volume gains, a favorable mix and improved pricing across the portfolio. Higher volumes and pricing for Woodford Reserve and Jack Daniel’s Tennessee Whiskey were key drivers. These were partly negated by Korbel California Champagne, which witnessed higher pricing and lower volumes.
Meanwhile, the developed international market reported sales growth of 3%, with organic sales rising 14%. The improvement can be attributed to strong consumer demand. Volume gains from Jack Daniel’s Tennessee Whiskey and Jack Daniel’s RTDs mainly aided the results.
The emerging markets registered 14% net sales growth, whereas organic sales improved 27%. This was backed by the growth of Jack Daniel’s Tennessee Whiskey in Sub-Saharan Africa and Brazil, as well as New Mix in Mexico.
Net sales in the Travel Retail channel advanced 60% on a reported basis and 67% on an organic basis due to higher volumes for the majority of the portfolio as travel trends continued to rebound.
Balance Sheet & Cash Flow
The company ended the first half of fiscal 2023 with cash and cash equivalents of $1,087 million and long-term debt of $1,974 million. Its total shareholders’ equity was $3,040 million. As of Oct 31, 2022, BF.B generated $316 million in cash from operating activities.
Outlook
Despite the ongoing macroeconomic and geopolitical challenges, management anticipates continued growth for fiscal 2023. Brown-Forman expects strength in its brand portfolio and strong consumer demand and easing supply constraints to aid organic sales growth in fiscal 2023.
It anticipates organic sales growth in the high single digits for fiscal 2023 compared with the mid-single-digit growth expected earlier. The company expects the gross margin for fiscal 2023 to be consistent with the first half of fiscal 2023, wherein it reported a decline due to the effects of inflation, supply-chain disruption costs and currency headwinds.
Based on the aforementioned assumptions, Brown-Forman expects the organic operating income to increase in the high single digits. The effective tax rate is expected to be 22-23% for fiscal 2023. Capital expenditure is anticipated in the band of $190-$210 million.
Stocks to Consider
We have highlighted three better-ranked stocks from the Consumer Staples sector, namely Coca-Cola FEMSA KOF, PepsiCo Inc. PEP and Ambev ABEV.
Coca-Cola FEMSA produces, markets and distributes soft drinks throughout the metropolitan area of Mexico City in Southeastern Mexico and the metropolitan region in Buenos Aires, Argentina. KOF has a trailing four-quarter earnings surprise of 33.6%, on average. It currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here.
Shares of Coca-Cola FEMSA have risen 8.4% in the past three months. The Zacks Consensus Estimate for Coca-Cola FEMSA’s current financial-year sales and earnings suggests growth of 15.6% and 6.2%, respectively, from the year-ago period's reported figures. KOF has an expected EPS growth rate of 10.3% for three to five years.
PepsiCo is one of the leading global food and beverage companies. It currently has a Zacks Rank #2 (Buy). The company has an expected EPS growth rate of 7.6% for three to five years. Shares of PEP have increased 5.2% in the past three months.
The Zacks Consensus Estimate for PepsiCo’s current financial-year sales and earnings per share suggests growth of 7.1% and 8%, respectively, from the year-ago period’s reported figures. PEP has a trailing four-quarter earnings surprise of 4.5%, on average.
Ambev is engaged in producing, distributing and selling beer, carbonated soft drinks, and other non-alcoholic and non-carbonated products in many countries across the Americas. ABEV currently has a Zacks Rank #2. Ambev has a trailing four-quarter earnings surprise of 4.4%, on average. Shares of ABEV have risen 2.7% in the past three months.
The Zacks Consensus Estimate for Ambev’s current financial-year sales and earnings suggests growth of 19.4% and 6.7%, respectively, from the year-ago period’s reported figures. ABEV has an expected EPS growth rate of 9.1% for three to five years.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock And 4 Runners Up
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
BrownForman Corporation (BF.B) : Free Stock Analysis Report
PepsiCo, Inc. (PEP) : Free Stock Analysis Report
Coca Cola Femsa S.A.B. de C.V. (KOF) : Free Stock Analysis Report
Ambev S.A. (ABEV) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | PEP and Ambev ABEV. ABEV currently has a Zacks Rank #2. Shares of ABEV have risen 2.7% in the past three months. | de C.V. (KOF) : Free Stock Analysis Report Ambev S.A. (ABEV) : Free Stock Analysis Report To read this article on Zacks.com click here. PEP and Ambev ABEV. ABEV currently has a Zacks Rank #2. | PEP and Ambev ABEV. ABEV currently has a Zacks Rank #2. Shares of ABEV have risen 2.7% in the past three months. | PEP and Ambev ABEV. ABEV currently has a Zacks Rank #2. Shares of ABEV have risen 2.7% in the past three months. |
28186.0 | 2022-12-05 00:00:00 UTC | After Hours Most Active for Dec 5, 2022 : ITUB, BBD, ABEV, VALE, CMCSA, CSX, V, ABCL, QQQ, EW, AMZN, EXC | ABEV | https://www.nasdaq.com/articles/after-hours-most-active-for-dec-5-2022-%3A-itub-bbd-abev-vale-cmcsa-csx-v-abcl-qqq-ew-amzn | nan | nan | The NASDAQ 100 After Hours Indicator is down -1.61 to 11,785.19. The total After hours volume is currently 89,034,034 shares traded.
The following are the most active stocks for the after hours session:
Itau Unibanco Banco Holding SA (ITUB) is unchanged at $4.80, with 14,707,561 shares traded. As reported by Zacks, the current mean recommendation for ITUB is in the "buy range".
Banco Bradesco Sa (BBD) is +0.01 at $2.79, with 7,421,763 shares traded. As reported by Zacks, the current mean recommendation for BBD is in the "buy range".
Ambev S.A. (ABEV) is +0.015 at $3.03, with 5,298,306 shares traded. ABEV's current last sale is 100.83% of the target price of $3.
VALE S.A. (VALE) is -0.01 at $16.45, with 5,251,778 shares traded. As reported by Zacks, the current mean recommendation for VALE is in the "buy range".
Comcast Corporation (CMCSA) is unchanged at $35.15, with 4,576,633 shares traded. CMCSA's current last sale is 78.99% of the target price of $44.5.
CSX Corporation (CSX) is -0.04 at $31.31, with 4,451,258 shares traded. CSX's current last sale is 94.88% of the target price of $33.
Visa Inc. (V) is unchanged at $213.68, with 4,139,350 shares traded. As reported by Zacks, the current mean recommendation for V is in the "buy range".
AbCellera Biologics Inc. (ABCL) is unchanged at $11.91, with 3,795,913 shares traded. As reported by Zacks, the current mean recommendation for ABCL is in the "strong buy range".
Invesco QQQ Trust, Series 1 (QQQ) is -0.14 at $287.50, with 3,264,257 shares traded. This represents a 13.07% increase from its 52 Week Low.
Edwards Lifesciences Corporation (EW) is unchanged at $73.85, with 3,224,006 shares traded. As reported by Zacks, the current mean recommendation for EW is in the "buy range".
Amazon.com, Inc. (AMZN) is -0.05 at $90.96, with 3,148,094 shares traded. As reported by Zacks, the current mean recommendation for AMZN is in the "buy range".
Exelon Corporation (EXC) is unchanged at $41.75, with 2,470,809 shares traded. EXC's current last sale is 93.82% of the target price of $44.5.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Ambev S.A. (ABEV) is +0.015 at $3.03, with 5,298,306 shares traded. ABEV's current last sale is 100.83% of the target price of $3. Itau Unibanco Banco Holding SA (ITUB) is unchanged at $4.80, with 14,707,561 shares traded. | Ambev S.A. (ABEV) is +0.015 at $3.03, with 5,298,306 shares traded. ABEV's current last sale is 100.83% of the target price of $3. Itau Unibanco Banco Holding SA (ITUB) is unchanged at $4.80, with 14,707,561 shares traded. | Ambev S.A. (ABEV) is +0.015 at $3.03, with 5,298,306 shares traded. ABEV's current last sale is 100.83% of the target price of $3. As reported by Zacks, the current mean recommendation for BBD is in the "buy range". | Ambev S.A. (ABEV) is +0.015 at $3.03, with 5,298,306 shares traded. ABEV's current last sale is 100.83% of the target price of $3. The NASDAQ 100 After Hours Indicator is down -1.61 to 11,785.19. |
28187.0 | 2022-12-02 00:00:00 UTC | After Hours Most Active for Dec 2, 2022 : ITUB, BBD, VALE, ABEV, AMZN, AAPL, QQQ, GOOGL, GRAB, CMCSA, F, T | ABEV | https://www.nasdaq.com/articles/after-hours-most-active-for-dec-2-2022-%3A-itub-bbd-vale-abev-amzn-aapl-qqq-googl-grab-cmcsa | nan | nan | The NASDAQ 100 After Hours Indicator is down -18.89 to 11,975.37. The total After hours volume is currently 87,716,413 shares traded.
The following are the most active stocks for the after hours session:
Itau Unibanco Banco Holding SA (ITUB) is -0.01 at $5.03, with 9,965,329 shares traded. As reported by Zacks, the current mean recommendation for ITUB is in the "buy range".
Banco Bradesco Sa (BBD) is unchanged at $2.95, with 8,294,821 shares traded. As reported by Zacks, the current mean recommendation for BBD is in the "buy range".
VALE S.A. (VALE) is unchanged at $16.72, with 5,294,305 shares traded. As reported by Zacks, the current mean recommendation for VALE is in the "buy range".
Ambev S.A. (ABEV) is +0.01 at $3.11, with 4,827,876 shares traded. ABEV's current last sale is 103.67% of the target price of $3.
Amazon.com, Inc. (AMZN) is -0.05 at $94.08, with 3,540,743 shares traded. As reported by Zacks, the current mean recommendation for AMZN is in the "buy range".
Apple Inc. (AAPL) is -0.18 at $147.63, with 3,213,878 shares traded. Over the last four weeks they have had 3 up revisions for the earnings forecast, for the fiscal quarter ending Mar 2023. The consensus EPS forecast is $1.5. As reported by Zacks, the current mean recommendation for AAPL is in the "buy range".
Invesco QQQ Trust, Series 1 (QQQ) is -0.43 at $292.12, with 3,048,084 shares traded. This represents a 14.89% increase from its 52 Week Low.
Alphabet Inc. (GOOGL) is -0.24 at $100.20, with 2,430,664 shares traded. As reported by Zacks, the current mean recommendation for GOOGL is in the "buy range".
Grab Holdings Limited (GRAB) is unchanged at $3.16, with 2,231,961 shares traded. As reported by Zacks, the current mean recommendation for GRAB is in the "buy range".
Comcast Corporation (CMCSA) is -0.11 at $35.75, with 1,869,824 shares traded. CMCSA's current last sale is 80.34% of the target price of $44.5.
Ford Motor Company (F) is -0.01 at $13.85, with 1,666,059 shares traded. F's current last sale is 92.33% of the target price of $15.
AT&T Inc. (T) is -0.02 at $19.00, with 1,578,497 shares traded. T's current last sale is 84.44% of the target price of $22.5.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Ambev S.A. (ABEV) is +0.01 at $3.11, with 4,827,876 shares traded. ABEV's current last sale is 103.67% of the target price of $3. Itau Unibanco Banco Holding SA (ITUB) is -0.01 at $5.03, with 9,965,329 shares traded. | Ambev S.A. (ABEV) is +0.01 at $3.11, with 4,827,876 shares traded. ABEV's current last sale is 103.67% of the target price of $3. Itau Unibanco Banco Holding SA (ITUB) is -0.01 at $5.03, with 9,965,329 shares traded. | Ambev S.A. (ABEV) is +0.01 at $3.11, with 4,827,876 shares traded. ABEV's current last sale is 103.67% of the target price of $3. As reported by Zacks, the current mean recommendation for VALE is in the "buy range". | Ambev S.A. (ABEV) is +0.01 at $3.11, with 4,827,876 shares traded. ABEV's current last sale is 103.67% of the target price of $3. Amazon.com, Inc. (AMZN) is -0.05 at $94.08, with 3,540,743 shares traded. |
28188.0 | 2022-12-01 00:00:00 UTC | After Hours Most Active for Dec 1, 2022 : ITUB, TLT, BBD, BEKE, VALE, ABEV, NYCB, AAPL, PDD, Z, AMZN, WBD | ABEV | https://www.nasdaq.com/articles/after-hours-most-active-for-dec-1-2022-%3A-itub-tlt-bbd-beke-vale-abev-nycb-aapl-pdd-z-amzn | nan | nan | The NASDAQ 100 After Hours Indicator is down -20.5 to 12,021.4. The total After hours volume is currently 132,556,279 shares traded.
The following are the most active stocks for the after hours session:
Itau Unibanco Banco Holding SA (ITUB) is unchanged at $4.97, with 9,735,215 shares traded. As reported by Zacks, the current mean recommendation for ITUB is in the "buy range".
iShares 20+ Year Treasury Bond ETF (TLT) is -0.02 at $105.74, with 9,318,267 shares traded. This represents a 15.12% increase from its 52 Week Low.
Banco Bradesco Sa (BBD) is -0.005 at $2.94, with 8,321,525 shares traded. As reported by Zacks, the current mean recommendation for BBD is in the "buy range".
KE Holdings Inc (BEKE) is unchanged at $16.70, with 7,663,534 shares traded. As reported by Zacks, the current mean recommendation for BEKE is in the "buy range".
VALE S.A. (VALE) is -0.03 at $16.61, with 4,925,547 shares traded. As reported by Zacks, the current mean recommendation for VALE is in the "buy range".
Ambev S.A. (ABEV) is unchanged at $3.08, with 4,607,666 shares traded. ABEV's current last sale is 102.67% of the target price of $3.
New York Community Bancorp, Inc. (NYCB) is +0.06 at $9.25, with 3,392,337 shares traded. NYCB's current last sale is 92.5% of the target price of $10.
Apple Inc. (AAPL) is -0.17 at $148.14, with 2,997,532 shares traded. Over the last four weeks they have had 3 up revisions for the earnings forecast, for the fiscal quarter ending Mar 2023. The consensus EPS forecast is $1.5. As reported by Zacks, the current mean recommendation for AAPL is in the "buy range".
Pinduoduo Inc. (PDD) is -0.24 at $83.50, with 2,808,508 shares traded. As reported by Zacks, the current mean recommendation for PDD is in the "buy range".
Zillow Group, Inc. (Z) is unchanged at $38.32, with 2,692,754 shares traded.
Amazon.com, Inc. (AMZN) is -0.17 at $95.33, with 2,448,139 shares traded. As reported by Zacks, the current mean recommendation for AMZN is in the "buy range".
Warner Bros. Discovery, Inc. (WBD) is unchanged at $11.63, with 2,146,757 shares traded. WBD's current last sale is 58.15% of the target price of $20.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Ambev S.A. (ABEV) is unchanged at $3.08, with 4,607,666 shares traded. ABEV's current last sale is 102.67% of the target price of $3. Itau Unibanco Banco Holding SA (ITUB) is unchanged at $4.97, with 9,735,215 shares traded. | Ambev S.A. (ABEV) is unchanged at $3.08, with 4,607,666 shares traded. ABEV's current last sale is 102.67% of the target price of $3. Itau Unibanco Banco Holding SA (ITUB) is unchanged at $4.97, with 9,735,215 shares traded. | Ambev S.A. (ABEV) is unchanged at $3.08, with 4,607,666 shares traded. ABEV's current last sale is 102.67% of the target price of $3. The total After hours volume is currently 132,556,279 shares traded. | Ambev S.A. (ABEV) is unchanged at $3.08, with 4,607,666 shares traded. ABEV's current last sale is 102.67% of the target price of $3. The NASDAQ 100 After Hours Indicator is down -20.5 to 12,021.4. |
28189.0 | 2022-11-30 00:00:00 UTC | Why Monster Beverage (MNST) Continues to Outpace Its Industry | ABEV | https://www.nasdaq.com/articles/why-monster-beverage-mnst-continues-to-outpace-its-industry | nan | nan | Monster Beverage Corporation MNST is trending up the charts, thanks to the continued strong demand for energy drinks. Product innovation plays a significant role in MNST's success. Its actions, including price increases, reducing reliance on imported cans and moving production closer to markets to mitigate the ongoing cost pressures, bode well.
Backed by the aforementioned tailwinds, MNST posted better-than-expected earnings in the quarter, while its top line lagged the Zacks Consensus Estimate. Meanwhile, sales improved 15.2% year over year, driven by continued strong demand for the energy drinks category. On a currency-adjusted basis, net sales rose 20.2%. Net sales to customers outside the United States rose 15.8% to $610.6 million, representing about 38% of the total net sales. On a currency-adjusted basis, sales to customers outside the United States improved 29.3%.
The Zacks Rank #3 (Hold) stock has gained 12.3% in the past three months, outperforming the industry and the Consumer Staples sector’s growth of 5.3% and 2.9%, respectively. The stock performance also compared favorably against the S&P 500’s fall of 0.4% in the same period.
The Zacks Consensus Estimate for Monster Beverage’s 2022 sales suggests growth of 15.2% from the year-ago period’s reported number, while earnings estimates indicate a decline of 11.3%.
Image Source: Zacks Investment Research
Factors to Aid Growth
Monster Beverage, which primarily markets and distributes energy drinks and alternative beverages, is a key beneficiary of the recent consumer awareness of health drinks. This has led to strength in its energy drink category, particularly the Monster Energy brand. We note that MNST offers a wide range of energy drinks brands such as Monster Energy, Java Monster, Cafe Monster, Espresso Monster, Monster Energy Mule, Juice Monster Pipeline Punch, Juice Monster Pacific Punch, Juice Monster Mango Loco, Monster Ultra Paradise and Monster Hydra Sport.
Management is optimistic about the strength in the global energy drinks category. It remains poised to gain from growth in the Monster Energy family of brands, and strength in Strategic and Affordable energy brands in the long run.
Monster Beverage also remains committed to product launches and innovation to boost growth. In third-quarter 2022, the company launched several products and expanded distribution in international markets.
The company is on track to launch Monster Energy Zero Sugar in fourth-quarter 2022, initially in the United States. Monster Energy Zero Sugar is developed to provide a zero-sugar variant of its original Monster Energy Green flavor. Monster Energy Lewis Hamilton Zero Sugar Energy Drink is likely to enter select EMEA markets in the fourth quarter of 2022, with a rollout to 20 additional markets in the first quarter of 2023.
In the first half of 2023, MNST plans to launch pure unflavored water, namely Monster Tour Water, in the United States in still and sparkling variants. The company intends to launch Rainstorm in 4 flavors in the first half of 2023. The company is optimistic about the launch of its first flavored malt beverage alcohol product, known as ‘The Beast Unleashed.’
Gains from the CANarchy acquisition, and a robust line-up of product launches for alcoholic and non-alcoholic drinks make it well-placed for long-term growth.
Monster Beverage continues to stand by its strategy to ensure product availability and solidify the continued long-term growth of its brands despite the ongoing supply-chain challenges. Some of the actions taken to navigate through the challenges are decreasing the company’s reliance on imported cans.
The company is currently purchasing aluminum cans from local sources in both the United States and EMEA. It expects the increased use of domestic cans to result in a reduction in the cost of sales over the next few quarters.
Additionally, Monster Beverage is implementing pricing actions to overcome the ongoing cost pressures. In third-quarter 2022, the company remained on track with the mitigation of higher production and distribution costs through pricing actions and lower promotional expenses. It implemented price increases for its products in the United States on Sep 1, 2022. The company also brought effective price increases in certain international markets in the third quarter. Some of these will be in addition to price increases already implemented earlier this year in order to mitigate inflationary cost pressures.
Hurdles to Overcome
Higher freight rates and fuel costs have been hurting Monster Beverage’s gross and operating margins for a while, which persisted in the third quarter as well. Inflationary operational costs for aluminum cans, shipping, freight and other inputs dented the company’s bottom line in the third quarter of 2022. In the quarter, the company continued to experience additional global supply-chain challenges, including the lack of adequate shipping containers, which resulted in shortages of certain ingredients and finished products.
Monster Beverage has been witnessing significant increases in the cost of sales, which have been majorly impacting the gross profit and the gross margin rate. Higher logistics costs, increased aluminum-can costs, unfavorable geographical and product sales, elevated ingredients, and other input costs, comprising secondary packaging materials and increased co-packing fees, hurt the cost of sales in the third quarter.
In addition to the aforementioned factors, Monster Beverage experienced a significant rise in distribution expenses, including increased fuel, freight and warehousing costs. This hurt operating expenses.
Stocks to Consider
We highlighted some better-ranked stocks from the broader Consumer Staples space, namely Coca-Cola FEMSA KOF, Ambev ABEV and General Mills Inc. GIS.
Coca-Cola FEMSA produces, markets and distributes soft drinks throughout the metropolitan area of Mexico City, in Southeastern Mexico, and the metropolitan region in Buenos Aires, Argentina. It currently sports a Zacks Rank #1 (Strong Buy). KOF has a trailing four-quarter earnings surprise of 33.6%, on average. Shares of KOF have risen 9.7% in the past three months.
You can see the complete list of today's Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for Coca-Cola FEMSA’s current financial-year sales and earnings suggests growth of 15.6% and 6.2%, respectively, from the year-ago period's reported figures. KOF has an expected EPS growth rate of 10.3% for three-five years.
Ambev is engaged in producing, distributing and selling beer, carbonated soft drinks, and other non-alcoholic and non-carbonated products in many countries across the Americas. ABEV currently has a Zacks Rank #2 (Buy). ABEV has a trailing four-quarter earnings surprise of 4.4%, on average. Shares of ABEV have risen 0.6% in the past three months.
The Zacks Consensus Estimate for Ambev’s current financial-year sales and earnings suggests growth of 19.4% and 6.7%, respectively, from the year-ago period’s reported figures. ABEV has an expected EPS growth rate of 9.1% for three-five years.
General Mills is a global manufacturer and marketer of branded consumer foods sold through retail stores. It currently has a Zacks Rank of 2. GIS has an expected EPS growth rate of 7.5% for three-five years. Shares of GIS have rallied 7.8% in the past three months.
The Zacks Consensus Estimate for General Mills’ current financial-year sales and earnings per share suggests growth of 2.7% and 3.8%, respectively, from the year-ago period’s reported figures. GIS has a trailing four-quarter earnings surprise of 6.1%, on average.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
General Mills, Inc. (GIS) : Free Stock Analysis Report
Coca Cola Femsa S.A.B. de C.V. (KOF) : Free Stock Analysis Report
Monster Beverage Corporation (MNST) : Free Stock Analysis Report
Ambev S.A. (ABEV) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Stocks to Consider We highlighted some better-ranked stocks from the broader Consumer Staples space, namely Coca-Cola FEMSA KOF, Ambev ABEV and General Mills Inc. GIS. ABEV currently has a Zacks Rank #2 (Buy). ABEV has a trailing four-quarter earnings surprise of 4.4%, on average. | de C.V. (KOF) : Free Stock Analysis Report Monster Beverage Corporation (MNST) : Free Stock Analysis Report Ambev S.A. (ABEV) : Free Stock Analysis Report To read this article on Zacks.com click here. Stocks to Consider We highlighted some better-ranked stocks from the broader Consumer Staples space, namely Coca-Cola FEMSA KOF, Ambev ABEV and General Mills Inc. GIS. ABEV currently has a Zacks Rank #2 (Buy). | de C.V. (KOF) : Free Stock Analysis Report Monster Beverage Corporation (MNST) : Free Stock Analysis Report Ambev S.A. (ABEV) : Free Stock Analysis Report To read this article on Zacks.com click here. Stocks to Consider We highlighted some better-ranked stocks from the broader Consumer Staples space, namely Coca-Cola FEMSA KOF, Ambev ABEV and General Mills Inc. GIS. ABEV currently has a Zacks Rank #2 (Buy). | Stocks to Consider We highlighted some better-ranked stocks from the broader Consumer Staples space, namely Coca-Cola FEMSA KOF, Ambev ABEV and General Mills Inc. GIS. ABEV currently has a Zacks Rank #2 (Buy). ABEV has a trailing four-quarter earnings surprise of 4.4%, on average. |
28190.0 | 2022-11-25 00:00:00 UTC | Here's Why Diageo (DEO) Stock is Worth a Watch at This Time | ABEV | https://www.nasdaq.com/articles/heres-why-diageo-deo-stock-is-worth-a-watch-at-this-time | nan | nan | Diageo Plc DEO is a stock to watch, given its business momentum on continued recovery in the on-trade channel, strong consumer demand in the off-trade and market share gains. DEO is anticipated to retain the strength in its business on constant premiumization efforts and favorable industry trends, particularly in the spirits category. Its organic net sales were up 21.4% year over year in fiscal 2022.
Recovery in the on-trade channel in North America and Europe, and the partial recovery in Travel Retail have been aiding the price/mix for a while. Diageo’s positive mix also resulted from the robust performance of its super-premium-plus brands, particularly scotch, tequila and Chinese white spirits.
Shares of the Zacks Rank #3 (Hold) company have gained 2% in the past three months compared with the industry’s growth of 1.1%. DEO also compared favorably with the Consumer Staples sector’s growth of 1% and against the S&P 500’s decline of 1.3%.
Image Source: Zacks Investment Research
Factors Aiding Growth
Diageo is well-poised for growth from effective marketing and exceptional commercial execution. It is likely to invest strongly in marketing and innovation, and leverage its revenue growth management capabilities, including strategic pricing actions. This is likely to support DEO in the near and the long term.
DEO’s margin trends were favorable in fiscal 2022 owing to its premiumization efforts, rebound in markets, pricing actions and supply productivity savings, which mostly offset the cost inflation. Diageo delivered £380 million of productivity savings in fiscal 2022, driven by COGS productivity and marketing effectiveness. Its operating profit improved 18.2% in fiscal 2022, led by robust organic operating profit growth.
Although Diageo expects the operating environment to be challenging in fiscal 2023, it remains confident about its business resilience and its ability to navigate the headwinds. DEO is confident about the long-term growth potential of the total beverage alcohol sector and expects to expand its value share by 50% in the sector to 6% within 2030.
Diageo is on track to deliver on its medium-term guidance for fiscal 2023-2025, wherein it targets organic sales growth of 5-7% and an organic operating profit rise of 6-9%.
For fiscal 2023, Diageo expects net sales growth across North America, Europe and the Asia Pacific. However, the growth rate is likely to moderate from the fiscal 2022 level due to the robust on-trade recovery witnessed in fiscal 2022. It anticipates continued organic operating margin growth in fiscal 2023, aided by strong premiumization trends and operating leverage despite constant investment in marketing. DEO expects an effective interest rate of 3.5% for fiscal 2023.
Hurdles to Overcome
Diageo suffers persistent inflationary pressures, induced by higher commodity costs, particularly agave, energy expenses and supply disruptions. As a substantial portion of Diageo’s business comes from international operations, exchange rate fluctuations have been hampering its sales for a while.
In fiscal 2023, Diageo expects to invest continually in marketing and innovation, particularly in North America. Moreover, it expects continued impacts of rising inflationary pressures to partly hurt margins.
DEO also remains susceptible to adverse currency rates. While the weakening of sterling against the U.S. dollar and some impacts of emerging market currencies look favorable, Diageo expects adverse currency impacts from hyperinflationary economies, primarily Turkey.
Stocks to Consider
We highlighted some better-ranked stocks from the broader Consumer Staples space, namely Coca-Cola FEMSA KOF, Ambev ABEV and General Mills Inc. GIS.
Coca-Cola FEMSA produces, markets and distributes soft drinks throughout the metropolitan area of Mexico City, in Southeastern Mexico, and the metropolitan region in Buenos Aires, Argentina. It currently sports a Zacks Rank #1 (Strong Buy). KOF has a trailing four-quarter earnings surprise of 33.6%, on average. Shares of KOF have risen 9.9% in the past three months.
You can see the complete list of today's Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for Coca-Cola FEMSA’s current financial-year sales and earnings suggests growth of 15.6% and 6.2%, respectively, from the year-ago period's reported figures. KOF has an expected EPS growth rate of 10.3% for three-five years.
Ambev is engaged in producing, distributing and selling beer, carbonated soft drinks, and other non-alcoholic and non-carbonated products in many countries across the Americas. ABEV currently has a Zacks Rank #2 (Buy). Shares of ABEV have declined 3.6% in the past three months.
The Zacks Consensus Estimate for Ambev’s current financial-year sales and earnings suggests growth of 19.4% and 6.7%, respectively, from the year-ago period’s reported figures. ABEV has an expected EPS growth rate of 9.1% for three-five years.
General Mills is a global manufacturer and marketer of branded consumer foods sold through retail stores. It currently has a Zacks Rank of 2. GIS has an expected EPS growth rate of 7.5% for three-five years. Shares of GIS have rallied 8.5% in the past three months.
The Zacks Consensus Estimate for General Mills’ current financial-year sales and earnings per share suggests growth of 2.7% and 3.8%, respectively, from the year-ago period’s reported figures.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
General Mills, Inc. (GIS) : Free Stock Analysis Report
Diageo plc (DEO) : Free Stock Analysis Report
Coca Cola Femsa S.A.B. de C.V. (KOF) : Free Stock Analysis Report
Ambev S.A. (ABEV) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Stocks to Consider We highlighted some better-ranked stocks from the broader Consumer Staples space, namely Coca-Cola FEMSA KOF, Ambev ABEV and General Mills Inc. GIS. ABEV currently has a Zacks Rank #2 (Buy). Shares of ABEV have declined 3.6% in the past three months. | de C.V. (KOF) : Free Stock Analysis Report Ambev S.A. (ABEV) : Free Stock Analysis Report To read this article on Zacks.com click here. Stocks to Consider We highlighted some better-ranked stocks from the broader Consumer Staples space, namely Coca-Cola FEMSA KOF, Ambev ABEV and General Mills Inc. GIS. ABEV currently has a Zacks Rank #2 (Buy). | Stocks to Consider We highlighted some better-ranked stocks from the broader Consumer Staples space, namely Coca-Cola FEMSA KOF, Ambev ABEV and General Mills Inc. GIS. ABEV currently has a Zacks Rank #2 (Buy). Shares of ABEV have declined 3.6% in the past three months. | Stocks to Consider We highlighted some better-ranked stocks from the broader Consumer Staples space, namely Coca-Cola FEMSA KOF, Ambev ABEV and General Mills Inc. GIS. ABEV currently has a Zacks Rank #2 (Buy). Shares of ABEV have declined 3.6% in the past three months. |
28191.0 | 2022-11-24 00:00:00 UTC | Is Ambev (ABEV) Outperforming Other Consumer Staples Stocks This Year? | ABEV | https://www.nasdaq.com/articles/is-ambev-abev-outperforming-other-consumer-staples-stocks-this-year | nan | nan | Investors interested in Consumer Staples stocks should always be looking to find the best-performing companies in the group. Is Ambev (ABEV) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Consumer Staples peers, we might be able to answer that question.
Ambev is a member of our Consumer Staples group, which includes 201 different companies and currently sits at #7 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Ambev is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for ABEV's full-year earnings has moved 3.3% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
According to our latest data, ABEV has moved about 4.3% on a year-to-date basis. Meanwhile, stocks in the Consumer Staples group have lost about 2.8% on average. As we can see, Ambev is performing better than its sector in the calendar year.
General Mills (GIS) is another Consumer Staples stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 22.9%.
Over the past three months, General Mills' consensus EPS estimate for the current year has increased 2.2%. The stock currently has a Zacks Rank #2 (Buy).
To break things down more, Ambev belongs to the Beverages - Alcohol industry, a group that includes 18 individual companies and currently sits at #81 in the Zacks Industry Rank. On average, stocks in this group have lost 5.8% this year, meaning that ABEV is performing better in terms of year-to-date returns.
On the other hand, General Mills belongs to the Food - Miscellaneous industry. This 51-stock industry is currently ranked #64. The industry has moved +5.9% year to date.
Going forward, investors interested in Consumer Staples stocks should continue to pay close attention to Ambev and General Mills as they could maintain their solid performance.
Free Report Reveals How You Could Profit from the Growing Electric Vehicle Industry
Globally, electric car sales continue their remarkable growth even after breaking records in 2021. High gas prices have fueled his demand, but so has evolving EV comfort, features and technology. So, the fervor for EVs will be around long after gas prices normalize. Not only are manufacturers seeing record-high profits, but producers of EV-related technology are raking in the dough as well. Do you know how to cash in? If not, we have the perfect report for you – and it’s FREE! Today, don't miss your chance to download Zacks' top 5 stocks for the electric vehicle revolution at no cost and with no obligation.
>>Send me my free report on the top 5 EV stocks
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Ambev S.A. (ABEV) : Free Stock Analysis Report
General Mills, Inc. (GIS) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Is Ambev (ABEV) one of those stocks right now? Within the past quarter, the Zacks Consensus Estimate for ABEV's full-year earnings has moved 3.3% higher. According to our latest data, ABEV has moved about 4.3% on a year-to-date basis. | Click to get this free report Ambev S.A. (ABEV) : Free Stock Analysis Report General Mills, Inc. (GIS) : Free Stock Analysis Report To read this article on Zacks.com click here. Is Ambev (ABEV) one of those stocks right now? Within the past quarter, the Zacks Consensus Estimate for ABEV's full-year earnings has moved 3.3% higher. | Click to get this free report Ambev S.A. (ABEV) : Free Stock Analysis Report General Mills, Inc. (GIS) : Free Stock Analysis Report To read this article on Zacks.com click here. Is Ambev (ABEV) one of those stocks right now? Within the past quarter, the Zacks Consensus Estimate for ABEV's full-year earnings has moved 3.3% higher. | Is Ambev (ABEV) one of those stocks right now? Within the past quarter, the Zacks Consensus Estimate for ABEV's full-year earnings has moved 3.3% higher. According to our latest data, ABEV has moved about 4.3% on a year-to-date basis. |
28192.0 | 2022-11-22 00:00:00 UTC | After Hours Most Active for Nov 22, 2022 : BBD, ITUB, VALE, PBR, ABEV, BHC, AMZN, PLYA, SABR, LAUR, DLO, LYFT | ABEV | https://www.nasdaq.com/articles/after-hours-most-active-for-nov-22-2022-%3A-bbd-itub-vale-pbr-abev-bhc-amzn-plya-sabr-laur | nan | nan | The NASDAQ 100 After Hours Indicator is down -15.46 to 11,709.38. The total After hours volume is currently 101,724,161 shares traded.
The following are the most active stocks for the after hours session:
Banco Bradesco Sa (BBD) is -0.02 at $2.83, with 13,009,027 shares traded. As reported by Zacks, the current mean recommendation for BBD is in the "buy range".
Itau Unibanco Banco Holding SA (ITUB) is -0.02 at $4.84, with 10,312,335 shares traded. As reported by Zacks, the current mean recommendation for ITUB is in the "buy range".
VALE S.A. (VALE) is -0.04 at $14.85, with 6,147,949 shares traded. VALE's current last sale is 92.81% of the target price of $16.
Petroleo Brasileiro S.A.- Petrobras (PBR) is unchanged at $10.16, with 5,844,211 shares traded. PBR's current last sale is 72.57% of the target price of $14.
Ambev S.A. (ABEV) is -0.01 at $2.87, with 5,100,114 shares traded. ABEV's current last sale is 95.67% of the target price of $3.
Bausch Health Companies Inc. (BHC) is -0.0074 at $6.93, with 5,016,077 shares traded. BHC's current last sale is 92.43% of the target price of $7.5.
Amazon.com, Inc. (AMZN) is -0.03 at $93.17, with 3,042,900 shares traded. As reported by Zacks, the current mean recommendation for AMZN is in the "buy range".
Playa Hotels & Resorts N.V. (PLYA) is +0.005 at $6.10, with 2,898,366 shares traded. As reported by Zacks, the current mean recommendation for PLYA is in the "strong buy range".
Sabre Corporation (SABR) is +0.1999 at $5.03, with 2,505,585 shares traded. As reported in the last short interest update the days to cover for SABR is 8.758018; this calculation is based on the average trading volume of the stock.
Laureate Education, Inc. (LAUR) is unchanged at $10.49, with 1,979,839 shares traded. As reported by Zacks, the current mean recommendation for LAUR is in the "buy range".
DLocal Limited (DLO) is unchanged at $13.14, with 1,929,689 shares traded. As reported in the last short interest update the days to cover for DLO is 13.316535; this calculation is based on the average trading volume of the stock.
Lyft, Inc. (LYFT) is -0.03 at $11.02, with 1,844,769 shares traded. LYFT's current last sale is 47.91% of the target price of $23.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Ambev S.A. (ABEV) is -0.01 at $2.87, with 5,100,114 shares traded. ABEV's current last sale is 95.67% of the target price of $3. Itau Unibanco Banco Holding SA (ITUB) is -0.02 at $4.84, with 10,312,335 shares traded. | Ambev S.A. (ABEV) is -0.01 at $2.87, with 5,100,114 shares traded. ABEV's current last sale is 95.67% of the target price of $3. The total After hours volume is currently 101,724,161 shares traded. | Ambev S.A. (ABEV) is -0.01 at $2.87, with 5,100,114 shares traded. ABEV's current last sale is 95.67% of the target price of $3. The total After hours volume is currently 101,724,161 shares traded. | ABEV's current last sale is 95.67% of the target price of $3. Ambev S.A. (ABEV) is -0.01 at $2.87, with 5,100,114 shares traded. VALE's current last sale is 92.81% of the target price of $16. |
28193.0 | 2022-11-18 00:00:00 UTC | After Hours Most Active for Nov 18, 2022 : BBD, ITUB, PBR, VALE, ABEV, VCSH, BEKE, MSFT, AAPL, FTAI, ICLN, QQQ | ABEV | https://www.nasdaq.com/articles/after-hours-most-active-for-nov-18-2022-%3A-bbd-itub-pbr-vale-abev-vcsh-beke-msft-aapl-ftai | nan | nan | The NASDAQ 100 After Hours Indicator is down -4.73 to 11,672.29. The total After hours volume is currently 136,332,480 shares traded.
The following are the most active stocks for the after hours session:
Banco Bradesco Sa (BBD) is unchanged at $2.90, with 12,674,335 shares traded. As reported by Zacks, the current mean recommendation for BBD is in the "buy range".
Itau Unibanco Banco Holding SA (ITUB) is -0.01 at $4.93, with 9,730,752 shares traded. As reported by Zacks, the current mean recommendation for ITUB is in the "buy range".
Petroleo Brasileiro S.A.- Petrobras (PBR) is +0.09 at $11.44, with 7,616,013 shares traded. PBR's current last sale is 81.71% of the target price of $14.
VALE S.A. (VALE) is unchanged at $15.07, with 7,043,531 shares traded. VALE's current last sale is 94.19% of the target price of $16.
Ambev S.A. (ABEV) is -0.005 at $2.87, with 5,634,086 shares traded. ABEV's current last sale is 95.67% of the target price of $3.
Vanguard Short-Term Corporate Bond ETF (VCSH) is unchanged at $75.01, with 5,035,500 shares traded. This represents a 2.39% increase from its 52 Week Low.
KE Holdings Inc (BEKE) is unchanged at $14.81, with 4,500,715 shares traded. As reported by Zacks, the current mean recommendation for BEKE is in the "buy range".
Microsoft Corporation (MSFT) is +0.035 at $241.26, with 3,867,283 shares traded. As reported by Zacks, the current mean recommendation for MSFT is in the "buy range".
Apple Inc. (AAPL) is -0.21 at $151.08, with 3,706,305 shares traded. Over the last four weeks they have had 4 up revisions for the earnings forecast, for the fiscal quarter ending Mar 2023. The consensus EPS forecast is $1.5. As reported by Zacks, the current mean recommendation for AAPL is in the "buy range".
FTAI Aviation Ltd. (FTAI) is unchanged at $16.93, with 3,250,164 shares traded. Over the last four weeks they have had 3 up revisions for the earnings forecast, for the fiscal quarter ending Mar 2023. The consensus EPS forecast is $0.46. As reported in the last short interest update the days to cover for FTAI is 12.567487; this calculation is based on the average trading volume of the stock.
iShares S&P Global Clean Energy Index Fund (ICLN) is -0.1 at $20.39, with 3,203,287 shares traded. This represents a 24.75% increase from its 52 Week Low.
Invesco QQQ Trust, Series 1 (QQQ) is +0.01 at $284.83, with 3,058,956 shares traded. This represents a 12.02% increase from its 52 Week Low.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Ambev S.A. (ABEV) is -0.005 at $2.87, with 5,634,086 shares traded. ABEV's current last sale is 95.67% of the target price of $3. Vanguard Short-Term Corporate Bond ETF (VCSH) is unchanged at $75.01, with 5,035,500 shares traded. | Ambev S.A. (ABEV) is -0.005 at $2.87, with 5,634,086 shares traded. ABEV's current last sale is 95.67% of the target price of $3. The total After hours volume is currently 136,332,480 shares traded. | Ambev S.A. (ABEV) is -0.005 at $2.87, with 5,634,086 shares traded. ABEV's current last sale is 95.67% of the target price of $3. The total After hours volume is currently 136,332,480 shares traded. | Ambev S.A. (ABEV) is -0.005 at $2.87, with 5,634,086 shares traded. ABEV's current last sale is 95.67% of the target price of $3. Over the last four weeks they have had 4 up revisions for the earnings forecast, for the fiscal quarter ending Mar 2023. |
28194.0 | 2022-11-18 00:00:00 UTC | Interesting ABEV Put Options For July 2023 | ABEV | https://www.nasdaq.com/articles/interesting-abev-put-options-for-july-2023 | nan | nan | Investors in Ambev SA (Symbol: ABEV) saw new options begin trading today, for the July 2023 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 245 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABEV options chain for the new July 2023 contracts and identified the following put contract of particular interest.
The put contract at the $2.50 strike price has a current bid of 10 cents. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $2.50, but will also collect the premium, putting the cost basis of the shares at $2.40 (before broker commissions). To an investor already interested in purchasing shares of ABEV, that could represent an attractive alternative to paying $2.92/share today.
Because the $2.50 strike represents an approximate 14% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 76%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract. Should the contract expire worthless, the premium would represent a 4.00% return on the cash commitment, or 5.96% annualized — at Stock Options Channel we call this the YieldBoost.
Below is a chart showing the trailing twelve month trading history for Ambev SA, and highlighting in green where the $2.50 strike is located relative to that history:
The implied volatility in the put contract example above is 66%.
Meanwhile, we calculate the actual trailing twelve month volatility (considering the last 252 trading day closing values as well as today's price of $2.92) to be 37%. For more put and call options contract ideas worth looking at, visit StockOptionsChannel.com.
Top YieldBoost Puts of the S&P 500 »
Also see:
Top Ten Hedge Funds Holding RPG
DTM Videos
Institutional Holders of NAV
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Investors in Ambev SA (Symbol: ABEV) saw new options begin trading today, for the July 2023 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABEV options chain for the new July 2023 contracts and identified the following put contract of particular interest. To an investor already interested in purchasing shares of ABEV, that could represent an attractive alternative to paying $2.92/share today. | Investors in Ambev SA (Symbol: ABEV) saw new options begin trading today, for the July 2023 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABEV options chain for the new July 2023 contracts and identified the following put contract of particular interest. To an investor already interested in purchasing shares of ABEV, that could represent an attractive alternative to paying $2.92/share today. | At Stock Options Channel, our YieldBoost formula has looked up and down the ABEV options chain for the new July 2023 contracts and identified the following put contract of particular interest. Investors in Ambev SA (Symbol: ABEV) saw new options begin trading today, for the July 2023 expiration. To an investor already interested in purchasing shares of ABEV, that could represent an attractive alternative to paying $2.92/share today. | At Stock Options Channel, our YieldBoost formula has looked up and down the ABEV options chain for the new July 2023 contracts and identified the following put contract of particular interest. Investors in Ambev SA (Symbol: ABEV) saw new options begin trading today, for the July 2023 expiration. To an investor already interested in purchasing shares of ABEV, that could represent an attractive alternative to paying $2.92/share today. |
28195.0 | 2022-11-15 00:00:00 UTC | ABEV or DEO: Which Is the Better Value Stock Right Now? | ABEV | https://www.nasdaq.com/articles/abev-or-deo%3A-which-is-the-better-value-stock-right-now-1 | nan | nan | Investors with an interest in Beverages - Alcohol stocks have likely encountered both Ambev (ABEV) and Diageo (DEO). But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out.
We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The proven Zacks Rank puts an emphasis on earnings estimates and estimate revisions, while our Style Scores work to identify stocks with specific traits.
Right now, Ambev is sporting a Zacks Rank of #2 (Buy), while Diageo has a Zacks Rank of #3 (Hold). Investors should feel comfortable knowing that ABEV likely has seen a stronger improvement to its earnings outlook than DEO has recently. However, value investors will care about much more than just this.
Value investors also tend to look at a number of traditional, tried-and-true figures to help them find stocks that they believe are undervalued at their current share price levels.
Our Value category grades stocks based on a number of key metrics, including the tried-and-true P/E ratio, the P/S ratio, earnings yield, and cash flow per share, as well as a variety of other fundamentals that value investors frequently use.
ABEV currently has a forward P/E ratio of 19.16, while DEO has a forward P/E of 21.49. We also note that ABEV has a PEG ratio of 2.11. This popular figure is similar to the widely-used P/E ratio, but the PEG ratio also considers a company's expected EPS growth rate. DEO currently has a PEG ratio of 2.27.
Another notable valuation metric for ABEV is its P/B ratio of 2.68. The P/B is a method of comparing a stock's market value to its book value, which is defined as total assets minus total liabilities. By comparison, DEO has a P/B of 8.54.
Based on these metrics and many more, ABEV holds a Value grade of B, while DEO has a Value grade of C.
ABEV stands above DEO thanks to its solid earnings outlook, and based on these valuation figures, we also feel that ABEV is the superior value option right now.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Ambev S.A. (ABEV): Free Stock Analysis Report
Diageo plc (DEO): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Investors should feel comfortable knowing that ABEV likely has seen a stronger improvement to its earnings outlook than DEO has recently. Investors with an interest in Beverages - Alcohol stocks have likely encountered both Ambev (ABEV) and Diageo (DEO). ABEV currently has a forward P/E ratio of 19.16, while DEO has a forward P/E of 21.49. | Ambev S.A. (ABEV): Free Stock Analysis Report Investors with an interest in Beverages - Alcohol stocks have likely encountered both Ambev (ABEV) and Diageo (DEO). Investors should feel comfortable knowing that ABEV likely has seen a stronger improvement to its earnings outlook than DEO has recently. | Investors with an interest in Beverages - Alcohol stocks have likely encountered both Ambev (ABEV) and Diageo (DEO). Based on these metrics and many more, ABEV holds a Value grade of B, while DEO has a Value grade of C. ABEV stands above DEO thanks to its solid earnings outlook, and based on these valuation figures, we also feel that ABEV is the superior value option right now. Investors should feel comfortable knowing that ABEV likely has seen a stronger improvement to its earnings outlook than DEO has recently. | Based on these metrics and many more, ABEV holds a Value grade of B, while DEO has a Value grade of C. ABEV stands above DEO thanks to its solid earnings outlook, and based on these valuation figures, we also feel that ABEV is the superior value option right now. Investors with an interest in Beverages - Alcohol stocks have likely encountered both Ambev (ABEV) and Diageo (DEO). Investors should feel comfortable knowing that ABEV likely has seen a stronger improvement to its earnings outlook than DEO has recently. |
28196.0 | 2022-11-11 00:00:00 UTC | Rethink What's Working and Snag 15%+ Annually | ABEV | https://www.nasdaq.com/articles/rethink-whats-working-and-snag-15-annually | nan | nan | Every Thanksgiving, I get together with my in-laws. They're nice enough people ... but if I'm being honest, some of them aren't particularly interesting.
Conversations are invariably limited to just two or three topics. In fact, some people just have two or three particular stories they trot out.
I just sit there and nurse my second or third glass of wine, and try to look interested.
The stock market is kind of like that in 2022. There simply aren't a lot of things to say about the stock market - rising rates and inflation have gutted Big Tech and other growth-oriented names, while commodity stocks and defensive plays reign supreme.
You surely don't need to hear that story again. So here's one you may not have heard before: There are a few stocks out there that are doing quite well ... but don't fit the mold of the typical bear market plays you've been hearing about lately.
Thinking Outside the Box Isn't Easy
While low-risk dividend stocks have fared better as a group this year, the bottom line is that most assets in this category have simply done "less bad."
Consider the following list that shows the top 7 performers on U.S. stock exchanges that feature a trailing dividend of more than 3% and a market valuation of $10 billion or greater.
If you want to go all-in on energy, then I suppose this list is useful. But for those of us who care about diversification or are concerned that the sector's recent outperformance can't persist in the long term, this screen is about as useful as a hole in the head.
There's more to life than just domestic energy stocks, and if you have any inclinations towards diversification you should consider a different approach.
Take one of my favorite outside-of-the-box picks right now, AmBev (ABEV). It's a consumer staples stock, but it also happens to be an emerging market company based in Brazil.
That's certainly not the familiar kind of utility stock or MLP. And many investors may be leery of investing in a more aggressive market like South America when even some staples stocks in Western market have had a rough go of it this year.
But AmBev illustrates the power of thinking like a contrarian to unlock outperformance - in any market.
Here are the highlights:
AmBev is rallying in November after strong Q3 earnings, with positive momentum in its local markets and expectations of more than 15% revenue growth this fiscal year.
It has a wide moat thanks to lucrative licensing deals with megabrands including Busch, Michelob and Budweiser as well as soft drinks like Gatorade, Lipton and Pepsi.
Year to date ABEV stock is up 15% from a total return perspective when you add up dividends and price performance.
Sure, Brazil was hit hard by a one-two punch with the pandemic and with political troubles that created uncertainty for businesses.
And it's also worth noting that ABEV is a bit of a leap of faith. It only pays dividends once per year - but that dividend dropped in December of 2021, and the yield is calculated based on that roughly 11 cent payday at the time.
But this stock actually exited recession in 2022 even as the "R" word is being thrown about elsewhere. So by virtue of having already priced in the mayhem, stocks like ABEV are able to stand on their own merit.
You just have to be willing to think differently to see the opportunity.
Snag 15%+ Like Clockwork in Low-Risk Stocks
A year ago, it may have been wise to build a portfolio out of 10 high-yield MLPs. But there's a risk that these old dogs won't be able to learn any new tricks as we enter 2023.
It's time for investors to start looking to the future, instead of the past. And that means rethinking what's working on Wall Street.
We are in the midst of a "Great American Reset," as my colleague Brett Owens likes to say. It's a megatrend that's obliterating Big Tech stocks, vanilla index funds and the conventional portfolio of blue chip dividend stocks.
But it's also unlocking big-time potential for the investors who see this Great American Reset at work - and then adapt.
That includes rethinking domestic stocks like popular Blue Chips, but also taking a hard look at international dividend payers like AmBev.
Let us show you how to change course and reallocate your portfolio to the right stocks, at the right time.
We've just updated two important reports that will show you the way -- 8 "Old Guard" stocks to SELL immediately, and 7 American Reset stocks to BUY for predictable and consistent returns of 15%+ per year, just like AmBev.
You can't afford to keep looking backwards, wringing your hands over poor performers or wishing you got into trades that are now 12 months too late.
It's time to take control of your portfolio, and enter 2023 on the right foot. Tap into the power of the "Great American Reset" and start seizing 15%+ annual returns in these top stocks offering hidden yields.
Also see:
Warren Buffett Dividend Stocks
Dividend Growth Stocks: 25 Aristocrats
Future Dividend Aristocrats: Close Contenders
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Take one of my favorite outside-of-the-box picks right now, AmBev (ABEV). Year to date ABEV stock is up 15% from a total return perspective when you add up dividends and price performance. And it's also worth noting that ABEV is a bit of a leap of faith. | Take one of my favorite outside-of-the-box picks right now, AmBev (ABEV). Year to date ABEV stock is up 15% from a total return perspective when you add up dividends and price performance. And it's also worth noting that ABEV is a bit of a leap of faith. | Take one of my favorite outside-of-the-box picks right now, AmBev (ABEV). Year to date ABEV stock is up 15% from a total return perspective when you add up dividends and price performance. And it's also worth noting that ABEV is a bit of a leap of faith. | Take one of my favorite outside-of-the-box picks right now, AmBev (ABEV). Year to date ABEV stock is up 15% from a total return perspective when you add up dividends and price performance. And it's also worth noting that ABEV is a bit of a leap of faith. |
28197.0 | 2022-11-09 00:00:00 UTC | 7 Cheap Stocks to Buy Now if You Have $100 to Spend | ABEV | https://www.nasdaq.com/articles/7-cheap-stocks-to-buy-now-if-you-have-%24100-to-spend-0 | nan | nan | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
As the market continues to drop, there are still plenty of cheap stocks for investors to load up on. These low-priced shares are trading at record lows, and you could pick a bunch of them for just a $100 bill. Investors are always on the lookout for a good deal, and with so many cheap stocks available in the current bear market, it’s an ideal time to build a robust long-term portfolio. With stocks at multi-year lows, you can find a fair number of cheap stocks to buy for $100.
Multiple stocks have shed a ton of value due to their weakening fundamentals and future outlooks. On the flip side, we have a fair few stocks that have been swept away by the bear market despite boasting incredible fundamentals. Doing your due diligence on which cheap stocks are best seems daunting, but don’t worry; we have you covered! Without further ado, let’s look at seven of the top cheap stocks to buy for $100.
Cheap Stocks to Buy for $100: AvePoint (AVPT)
Source: rafapress / Shutterstock.com
AvePoint (NASDAQ:AVPT) is a software-as-a-service business offering various services such as data management, protection, and migration in Microsoft Office 365. It went public last year following a merger with shell Apex Technology Acquisition. Like other SPAC companies, its stock has been pummeled at the market this year, and it trades at just three times forward sales.
AvePoint facilitates the ease of use and user experience of Microsoft’s (NASDAQ:MSFT) products. Though Microsoft could produce these services in-house, it’s been more profitable for the business to outsource these services to firms such as AvePoint. This is evidenced in stellar late results for AvePoint, where it’s generated double-digit revenue growth with over a 100% net retention rate. Microsoft sees AvePoint as a firm that has helped expand its overall addressable market, which bodes well for AVPT stock over the long term.
Nokia (NOK)
Source: rafapress / Shutterstock.com
Nokia (NYSE:NOK) has come a long way from a struggling smartphone marker to a leading telecommunications player. It continues to execute its turnaround plans effectively, reporting stellar top-line expansion across its core business segments. Its network infrastructure and cloud segments have demonstrated spectacular growth in the past several quarters and continue to push Nokia ahead in the 5G race.
It recently reported its third-quarter results, where its sales increased by 16% from the prior-year period and a comparable earnings growth of 19%. Moreover, it’s making a habit of beating analyst estimates, with the third quarter being the eighth consecutive time it’s beaten analyst estimates. Moreover, the firm has done remarkably well in diversifying its customer base and growing its enterprise sales. Revenues from the enterprise segment have soared roughly 50% since 2018. Overall, NOK stock is considerably cheap relative to its immense growth potential and is poised for long-term success.
Cheap Stocks to Buy for $100: Ambev (ABEV)
Source: Anton Garin / Shutterstock.com
Ambev (NYSE:ABEV) is the South American arm of the world’s top brewing giant Anheuser-Busch InBev SA (NYSE:BUD). It’s been sluggish in bouncing back from the pandemic-led headwinds; however, recent results point to a resurgence. The beer market in Brazil has been resilient and has helped Ambev post strong results of late. Moreover, with the FIFA World Cup coming up, its brands will likely witness strong momentum.
It is imperative, though, for Ambev to improve its sales volume to take pressure off prices. As we advance, its core markets will remain robust, resulting in incredible sales for the foreseeable future. Its cash flows need to protect its dividend, though, but it is unlikely to be cut given its incredible liquidity positioning.
American Airlines (AAL)
Source: GagliardiPhotography / Shutterstock.com
American Airlines (NASDAQ:AAL) is among the top legacy carriers in the U.S. that were on the brink of bankruptcy during the height of the pandemic. However, the tables have turned completely, with AAL benefitting from the massive pent-up demand for travel in the post-pandemic world. Its recent quarterly results have been tremendous and point to more upside ahead for the business.
AAL recently reported its third-quarter results, where its revenues soared over 50%. Moreover, its occupancy levels nearly matched pre-pandemic levels, showing that the pandemic no longer impacts travel plans. Additionally, the company is executing its plans to pay down $15 billion of its debt by the conclusion of 2025. AAL is excellently growing sales, limiting costs, and executing well in the Latin American region. All the while, its stock still trades at just 0.2 times forward sales.
Cheap Stocks to Buy for $100: SoFi Technologies (SOFI)
Source: shutterstock.com/Michael Vi
SoFi Technologies (NASDAQ:SOFI) operates as a personal finance business that has made amazing strides in expanding its burgeoning ecosystem. It has seen incredible momentum in its customer and lending segment, and the resumption of student loans will be a major catalyst for EBITDA expansion. Despite a phenomenal outlook, its shares have taken a major haircut and now boast a significantly better risk/reward trade-off.
Its third-quarter results show a 50% bump in its top line, and the rock-solid growth was due to product innovation and the increase in its products and services. It wrapped up the third quarter with 4.7 million customer accounts, a 424,000 increase on a sequential basis. Based on its results, it should speed past five million accounts by the end of the year, leading to meaningful improvement in its stock price.
Nio (NIO)
Source: Andy Feng / Shutterstock.com
Nio (NYSE:NIO) has been the most popular Chinese electric vehicle (EV) stock, soaring to record heights over the past few years. It has grown its deliveries by triple-digit margins in a short amount of time and has now become an EV juggernaut. Macroeconomic troubles and its Covid-19-led disruptions have weighed down its business this year, resulting in its stock plummeting over 70%.
It would appear that Nio was past its supply-chain woes delivering record deliveries in the past couple of months. However, another production disruption has likely ended investors’ hopes of seeing a record fourth quarter. Nevertheless, I feel investors focus too much on the short-term and ignore its incredible long-term potential in the sphere. There’s plenty to look forward to with Nio, including new models and its foray into Europe to ignore the stock at current price levels.
Cheap Stocks to Buy for $100: The Original Bark Company (BARK)
Source: IgorGolovniov / Shutterstock.com
The Original Bark Company (NYSE:BARK) sells its popular branded product line to dog owners. The budding pet business generates the bulk of its sales through direct-to-consumer subscription boxes, a model that has proven to be profitable and consistent. It’s moving towards profitability briskly, with its management cutting operational expenses by healthy margins each quarter.
BARK’s subscription business is generating incredible fundamentals, and its management reports that customer acquisition costs haven’t increased much in recent quarters. Moreover, it operates in a typically stable sector through recessions, which suggests it won’t have much of a problem navigating the current economic climate. Moreover, cross-selling opportunities through new and existing products will further expand its revenue base and improve profitability.
On Penny Stocks and Low-Volume Stocks: With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That’s because these “penny stocks” are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com’s writers disclose this fact and warn readers of the risks.
Read More: Penny Stocks — How to Profit Without Getting Scammed
On the date of publication, Muslim Farooque did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.
Muslim Farooque is a keen investor and an optimist at heart. A life-long gamer and tech enthusiast, he has a particular affinity for analyzing technology stocks. Muslim holds a bachelor’s of science degree in applied accounting from Oxford Brookes University.
The post 7 Cheap Stocks to Buy Now if You Have $100 to Spend appeared first on InvestorPlace.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Cheap Stocks to Buy for $100: Ambev (ABEV) Source: Anton Garin / Shutterstock.com Ambev (NYSE:ABEV) is the South American arm of the world’s top brewing giant Anheuser-Busch InBev SA (NYSE:BUD). Investors are always on the lookout for a good deal, and with so many cheap stocks available in the current bear market, it’s an ideal time to build a robust long-term portfolio. BARK’s subscription business is generating incredible fundamentals, and its management reports that customer acquisition costs haven’t increased much in recent quarters. | Cheap Stocks to Buy for $100: Ambev (ABEV) Source: Anton Garin / Shutterstock.com Ambev (NYSE:ABEV) is the South American arm of the world’s top brewing giant Anheuser-Busch InBev SA (NYSE:BUD). Cheap Stocks to Buy for $100: SoFi Technologies (SOFI) Source: shutterstock.com/Michael Vi SoFi Technologies (NASDAQ:SOFI) operates as a personal finance business that has made amazing strides in expanding its burgeoning ecosystem. Cheap Stocks to Buy for $100: The Original Bark Company (BARK) Source: IgorGolovniov / Shutterstock.com The Original Bark Company (NYSE:BARK) sells its popular branded product line to dog owners. | Cheap Stocks to Buy for $100: Ambev (ABEV) Source: Anton Garin / Shutterstock.com Ambev (NYSE:ABEV) is the South American arm of the world’s top brewing giant Anheuser-Busch InBev SA (NYSE:BUD). InvestorPlace - Stock Market News, Stock Advice & Trading Tips As the market continues to drop, there are still plenty of cheap stocks for investors to load up on. Cheap Stocks to Buy for $100: AvePoint (AVPT) Source: rafapress / Shutterstock.com AvePoint (NASDAQ:AVPT) is a software-as-a-service business offering various services such as data management, protection, and migration in Microsoft Office 365. | Cheap Stocks to Buy for $100: Ambev (ABEV) Source: Anton Garin / Shutterstock.com Ambev (NYSE:ABEV) is the South American arm of the world’s top brewing giant Anheuser-Busch InBev SA (NYSE:BUD). The beer market in Brazil has been resilient and has helped Ambev post strong results of late. AAL recently reported its third-quarter results, where its revenues soared over 50%. |
28198.0 | 2022-11-08 00:00:00 UTC | Is General Mills (GIS) Stock Outpacing Its Consumer Staples Peers This Year? | ABEV | https://www.nasdaq.com/articles/is-general-mills-gis-stock-outpacing-its-consumer-staples-peers-this-year | nan | nan | Investors interested in Consumer Staples stocks should always be looking to find the best-performing companies in the group. Is General Mills (GIS) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Consumer Staples sector should help us answer this question.
General Mills is a member of our Consumer Staples group, which includes 201 different companies and currently sits at #6 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. General Mills is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for GIS' full-year earnings has moved 1.9% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
According to our latest data, GIS has moved about 17.5% on a year-to-date basis. At the same time, Consumer Staples stocks have lost an average of 6.7%. This means that General Mills is performing better than its sector in terms of year-to-date returns.
Another stock in the Consumer Staples sector, Ambev (ABEV), has outperformed the sector so far this year. The stock's year-to-date return is 11.8%.
In Ambev's case, the consensus EPS estimate for the current year increased 3.3% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, General Mills belongs to the Food - Miscellaneous industry, a group that includes 51 individual stocks and currently sits at #140 in the Zacks Industry Rank. On average, stocks in this group have gained 2.2% this year, meaning that GIS is performing better in terms of year-to-date returns.
On the other hand, Ambev belongs to the Beverages - Alcohol industry. This 18-stock industry is currently ranked #140. The industry has moved -7.3% year to date.
General Mills and Ambev could continue their solid performance, so investors interested in Consumer Staples stocks should continue to pay close attention to these stocks.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
General Mills, Inc. (GIS): Free Stock Analysis Report
Ambev S.A. (ABEV): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Another stock in the Consumer Staples sector, Ambev (ABEV), has outperformed the sector so far this year. Ambev S.A. (ABEV): Free Stock Analysis Report A quick glance at the company's year-to-date performance in comparison to the rest of the Consumer Staples sector should help us answer this question. | Ambev S.A. (ABEV): Free Stock Analysis Report Another stock in the Consumer Staples sector, Ambev (ABEV), has outperformed the sector so far this year. General Mills and Ambev could continue their solid performance, so investors interested in Consumer Staples stocks should continue to pay close attention to these stocks. | Another stock in the Consumer Staples sector, Ambev (ABEV), has outperformed the sector so far this year. Ambev S.A. (ABEV): Free Stock Analysis Report The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group. | Another stock in the Consumer Staples sector, Ambev (ABEV), has outperformed the sector so far this year. Ambev S.A. (ABEV): Free Stock Analysis Report General Mills is a member of our Consumer Staples group, which includes 201 different companies and currently sits at #6 in the Zacks Sector Rank. |
28199.0 | 2022-11-04 00:00:00 UTC | After Hours Most Active for Nov 4, 2022 : PBR, VALE, ITUB, ABEV, U, T | ABEV | https://www.nasdaq.com/articles/after-hours-most-active-for-nov-4-2022-%3A-pbr-vale-itub-abev-u-t | nan | nan | The NASDAQ 100 After Hours Indicator is down -9.38 to 10,847.65. The total After hours volume is currently 92,093,959 shares traded.
The following are the most active stocks for the after hours session:
Petroleo Brasileiro S.A.- Petrobras (PBR) is -0.07 at $12.58, with 6,277,896 shares traded.PBR is scheduled to provide an earnings report on 11/10/2022, for the fiscal quarter ending Sep2022. The consensus earnings per share forecast is 1.32 per share, which represents a 52 percent increase over the EPS one Year Ago
VALE S.A. (VALE) is unchanged at $14.39, with 5,373,483 shares traded. VALE's current last sale is 89.94% of the target price of $16.
Itau Unibanco Banco Holding SA (ITUB) is unchanged at $5.97, with 5,012,691 shares traded. As reported by Zacks, the current mean recommendation for ITUB is in the "buy range".
Ambev S.A. (ABEV) is unchanged at $3.24, with 4,703,824 shares traded. ABEV's current last sale is 108% of the target price of $3.
Unity Software Inc. (U) is +0.07 at $25.33, with 3,348,290 shares traded.U is scheduled to provide an earnings report on 11/9/2022, for the fiscal quarter ending Sep2022. The consensus earnings per share forecast is -0.5 per share, which represents a -39 percent increase over the EPS one Year Ago
AT&T Inc. (T) is -0.01 at $18.31, with 2,751,851 shares traded. Over the last four weeks they have had 5 up revisions for the earnings forecast, for the fiscal quarter ending Dec 2022. The consensus EPS forecast is $0.58. T's current last sale is 81.38% of the target price of $22.5.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. | Ambev S.A. (ABEV) is unchanged at $3.24, with 4,703,824 shares traded. ABEV's current last sale is 108% of the target price of $3. Petroleo Brasileiro S.A.- Petrobras (PBR) is -0.07 at $12.58, with 6,277,896 shares traded.PBR is scheduled to provide an earnings report on 11/10/2022, for the fiscal quarter ending Sep2022. | Ambev S.A. (ABEV) is unchanged at $3.24, with 4,703,824 shares traded. ABEV's current last sale is 108% of the target price of $3. Petroleo Brasileiro S.A.- Petrobras (PBR) is -0.07 at $12.58, with 6,277,896 shares traded.PBR is scheduled to provide an earnings report on 11/10/2022, for the fiscal quarter ending Sep2022. | Ambev S.A. (ABEV) is unchanged at $3.24, with 4,703,824 shares traded. ABEV's current last sale is 108% of the target price of $3. The consensus earnings per share forecast is 1.32 per share, which represents a 52 percent increase over the EPS one Year Ago | Ambev S.A. (ABEV) is unchanged at $3.24, with 4,703,824 shares traded. ABEV's current last sale is 108% of the target price of $3. The NASDAQ 100 After Hours Indicator is down -9.38 to 10,847.65. |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.